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Abstract 
 
Mitochondria are essential organelles of nucleated cells that have the ability to 
conduct intra-organellar protein synthesis. Many aspects of this process are 
poorly understood especially the quality control and the rescue of stalled 
mitoribosomes. 
My project was focused on investigating potential candidates involved in quality 
control and ribosome rescue, including the release factor protein C12orf65. The 
importance of this protein in mt-translation was confirmed in a patient 
harbouring a mutation in C12orf65 gene, which displayed a general decrease in 
de novo mt-translation with subsequent disruption in assembly of OXPHOS 
complexes I, IV and V. I investigated the consequences on mitochondrial 
homeostasis in such a cell line. However, for a molecular understanding of the 
mechanism of this protein’s function a different, more focused approach was 
needed. To this end I applied ribosome profiling to mitochondria. 
Ribosome profiling provides a genome-wide analysis of protein synthesis by 
deep-sequencing of the mRNA fragments protected by ribosomes. It allows 
monitoring of progression of translation in vivo and can be used to identify 
contributions by regulating factors. I optimized the protocol for use in human 
mitochondria, initially on a cell line with a mutation in mt-tRNAVal. The decrease 
in stability of the uncharged tRNAVal resulted in an increase in mitoribosomal 
density over the valine codons, consistent with ribosomal stalling. I then used 
the final protocol, proven effective to study defects in mitoribosome progression, 
on cells with siRNA depleted C12orf65. Reducing transcript levels to 30% of 
control gave modest differences in mitoribosomal profiles. The control profiles, 
however, allowed normal features of mitochondrial translation to be identified. 
Although the exact function of C12orf65 remains unknown its involvement in 
mitochondrial protein translation is clear. Further applications of mitoribosome 
profiling to depleted or mutant cell lines should elucidate mechanisms that 
rescue stalled mitoribosomes and the potential role of C12orf65. 
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rRNA – ribosomal RNA 
s – seconds 
SD – standard deviation 
SDH – succinate dehydrogenase 
SDS – sodium-dodecyl-sulphate 
siRNA – silencing RNA, small interfering RNA 
SLIRP – stem-loop interacting RNA binding protein  
SM – silent mutation 
sprcRNAs – short polycistronic ribosome-associated coding RNAs 
SSC – saline-sodium citrate 
ssDNA – single stranded DNA 
SSPE – saline sodium phosphate EDTA buffer  
SSU – small subunit of the ribosome 
TAE – tris-acetate EDTA  
Taq – DNA polymerase from Thermus aquaticus  
TBS – tris buffered saline  
TBS-T – tris buffered saline, containing Tween-20 (0.1%) 
TE – tris EDTA buffer 
TE (ratio) – translational efficiency 
TEMED – N, N, N’, N’-tetramethylethylene-diamine 
Tet – tetracycline 
TFAM – transcription factor A 
TFB1M and TFB2M – mitochondrial transcription factor B1 or 2 (synonym 
mtTFB1/2)  
Tm – melting temperature 
tmRNA – transfer messanger tRNA 
TO – tetracycline operator 
Tris – 2-Amino-2-hydroxymethyl-propane-1,3-diol 
Triton X-100 – polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether  
tRNA – transfer RNA  
T. thermophilus - Thermus thermophilus 
Tween-20 – polyoxyethylene sorbitanmonolaurate  
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U – unit (enzyme activity; 1U = 1µmol/ min) 
U2OS – human osteosarcoma cell line 
uORFs – upstream open reading frames 
UTR(s) – untranslated region(s) 
UV – ultra-violet 
V, Val – valine 
VARS2/ VARS2L – mitochondrial valyl-tRNA synthetase 
v/v – volume/ volume WT – wild type 
w/v – weight/ volume 
WT – wild type 
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1.1. Mitochondria – an overview 
1.1.1. Origin and evolution 
Mitochondria, specialized energy-converting organelles, are present in all 
known eukaryotic nucleated cells. Studies based on one of their specific 
features, the presence of an intraorganellar unique genome and its expression, 
suggested the eubacterial origin of mitochondria. The sequencing and 
phylogenetic analysis of mitochondrial DNA from a broad range of organisms 
resulted in proposing a single ancestor related to α-proteobacteria (Gray et al., 
1999). According to the wildly accepted endosymbiotic hypothesis, this original 
bacteria was engulfed by another cell, the identification of which has proven 
controversial (Embley and Martin, 2006), forming a symbiotic relationship. This 
endosymbiont would, with time, evolve into the mitochondrion. One piece of 
evidence that strongly supports this course of action was provided by 
sequencing the genome of Rickettsia prowazekii, an α-proteobacteria and 
intracellular parasite. Phylogenic analysis of this organism’s DNA showed that it 
is very closely related to mitochondria and that this similarity is greater than for 
any other microbe studied so far (Andersson et al., 1998). Although 
mitochondria may have originated from bacteria their genomes are much 
smaller than these found in their respective ancestors. Over time many of the 
organellar genomes have decreased their size due to the transfer of genes from 
mitochondria to nucleus. Many of these genes have become functional nuclear 
copies and their products are re-imported into the mitochondrion to perform 
their functions (Timmis et al., 2004). 
 
1.1.2. Mitochondrial structure and functions 
Similar to bacteria that they presumably originated from, mitochondria are 
surrounded by a double membrane (Fig. 1.1 A). The inner membrane (IMM) is 
highly infolded and forms specific structures called cristae. Parts between the 
cristae where the inner membrane runs parallel to the outer membrane (OM) 
are known as the inner boundary membrane. The gap between the OM and 
inner boundary membrane is called intermembrane space (approx. 20 nm 
width). The cristae membrane, protruding deep into the inside space of the 
organellum (matrix) is mainly tubular but can take many different forms. The 
parts of matrix enclosed by cristae membrane are called intermembrane space 
(IMS) or intercristal space and the points were the membrane joins with the 
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inner boundary membrane are called cristae junctions (Fig. 1.1 B) (Frey and 
Mannella, 2000). Mitochondria occupy up to 25% of the cytoplasmic volume 
(Ballard and Whitlock, 2004) and in most organisms they form a dynamic 
reticulum often in contact with other cellular compartments (Rizzuto et al., 
1998). The mitochondrial network, as well as isolated organelles, are subject to 
constant rearrangements resulting from fusion, fission and motility events. 
These processes require constant membrane remodelling that is regulated by a 
number of proteins (Chan, 2006). 
 
 
Figure 1.1 Organisation of the mitochondrial structures 
A. Schematic representing internal structure of mitochondria. B. Electron microscopic 
image with details and measured dimensions of membrane structures inside 
mitochondria. Adapted from (Frey and Mannella, 2000).  
 
Mitochondria perform many functions but synthesis of ATP by oxidative 
phosphorylation (OXPHOS) is a crucial and probably the most recognized role. 
This process is conducted via the transport of electrons through the series of 
protein complexes (respiratory chain, RC) embedded in the inner mitochondrial 
membrane. The electrons are transferred through the respiratory chain until 
finally they are transferred to the molecular oxygen. The passage of electrons is 
linked to the production of a proton gradient across the IMM, which is necessary 
for the FOF1 ATP synthase to produce ATP from ADP. The respiratory chain 
comprises of 4 protein complexes: complex I (NADH:CoQ oxidoreductase), 
complex II (succinate: ubiquinone reductase), complex III (cytochrome bc1) and 
complex IV (cytochrome c oxidase). All complexes (except for complex II) have 
A. B.
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components encoded in mitochondrial DNA as well as the nuclear genome. The 
electrons that are transferred across the RC are provided by reduced cofactors 
NADH and FADH2, produced during enzymatic reactions of glycolysis and 
tricarboxylic acid cycle (TCA). Complex I (reviewed in (Vogel et al., 2007) 
catalyzes the oxidation of NADH during which 2 electrons are released and 
passed through a flavin mononucleotide, iron-sulfur clusters and finally to 
ubiquinone (Q), which is reduced to ubiquinol (QH2). During the transfer of 
these two electrons four protons are released to the intermembrane space 
across the IMM. Complex II (reviewed in (Cecchini, 2003) is a part of the Krebs 
cycle but it contributes to the respiratory chain by transferring electrons from 
succinate to the ubiquinone. During this process there is no proton translocation 
only supplying of the electrons to the electron transport chain (ETC). After the 
electrons are passed through complex I and II, QH2 is reoxidised by complex III 
(reviewed in (Crofts, 2004). This reaction, called the Q-cycle, carries 2 electrons 
to the cytochrome c while releasing 2 protons across the membrane. The 
electron transfer is a 2-step process. First, one of the electrons from ubiquinol is 
carried to the cytochrome c on the membrane surface and the second electron 
passes to the ubiquinone at the matrix site of the complex. The uptake of the 
electron reduces ubiquinone to ubisemiquinone. When the second molecule of 
ubiquinol binds to the complex (again releasing 2 electrons and 2 protons) one 
of its electrons binds to another cytochrome c molecule while the second 
completes the reduction of the ubisemiquinone to ubiquinol. The final member 
of the electron transfer machinery is complex IV (reviewed (Yoshikawa et al., 
2006), which receives electrons from the cytochrome c. These electrons are 
next passed on to the molecular oxygen (O2), which is converted to water. For 
that reaction to fully occur 4 electrons are necessary but the cytochrome c can 
only transfer one at a time. Binding of just 1 electron to O2 forms a dangerous 
reactive superoxide radical anion (O2•-), which, if not contained, can damage 
the surrounding environment. Therefore the O2 molecules are stored inside the 
complex in a bimetallic centre until it receives all 4 electrons. Only then it can be 
released as 2 molecules of water. The electrons pass through a chain of copper 
ions and hemes groups, which results in pumping protons across the 
membrane. For each O2 molecule that is converted into water 4 protons are 
transferred through the membrane. The protons that are transferred to the IMM 
during the electron transfer form the electrochemical gradient, which is then 
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utilized by the last of the OXPHOS complexes, F1FO ATP synthase (Abrahams 
et al., 1994). The synthesis of ATP, which is assembled from ADP and Pi, is 
driven by proton flow back into the matrix. The production of ATP through 
oxidative phosphorylation is, therefore, more efficient than via anaerobic 
glucose metabolism, namely glycolysis. 
 
 
Figure 1.2. The schematic of oxidative phosphorylation 
The schematic overview of OXPHOS with the simplified chemical reaction that is 
catalyzed by each of the complexes, adapted from (Dudkina et al., 2010). The electron 
transfer path is marked (red arrows) as well as the places where electron pumping 
occurs (black arrows). Positions of mitochondrial matrix (M), inner membrane (IM) and 
intermembrane space (IMS) are marked with black lines. Complex I (NADH:CoQ 
oxidoreductase) consists of 45 subunits, out of which 7 are encoded in mtDNA.  
Complex II (succinate: ubiquinone reductase), the smallest of all complexes is build of 
4 subunits, all encoded in nuclear DNA. The products of redox reactions catalyzed by 
CI and CII is coenzyme Q (ubiquinone). Complex III (cytochrome bc1) consists of 10 
nuclear- and 1-mitochondrally encoded subunits. Cytochrome C shuttles electrons 
between CIII and Complex IV. CIV (cytochrome c oxidase), with 3 mitochondrial and 10 
nuclear encoded subunits. The final complex, CV is a F0F1 ATP synthase is a 
multisubunit complex encoded in nuclear DNA except for 2 subunits.  
 
However, ATP synthesis through OXPHOS is not the only function of 
mitochondria. These organelles take part in various processes within the cell 
including apoptosis (Martinou and Youle, 2011), calcium homeostasis (Celsi et 
al., 2009), and transduction of intra-cellular signals (Hüttemann et al., 2007). 
The only common function mitochondria of all species share is production of 
iron-sulphur clusters, crucial components of many essential enzymes (Lill, 
2009). 
 
1.1.3. Characteristics of mitochondrial genomes and mtDNA 
replication  
The presence of the genome separate to the nucleus is one of the most 
profound characteristics of mitochondria. Mitochondrial genomes, 
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depending on the organism, vary in size from <6 kb in Plasmodium falciparum 
to ∼ 367 kb in Arabidopsis thaliana (Gray et al., 1999; Unseld et al., 1997) and 
contents from 5 genes in Plasmodium to 97 in Reclinomonas Americana (Gray, 
1999; Lang et al., 1997). They can also differ in shape, which in the majority of 
cases is circular but in some organisms linear genomes can be found (Nosek et 
al., 1998). Features of the human mtDNA are as follows: it is a small (16569 
nucleotides), circular and double stranded DNA molecule, which encodes 13 
polypeptides, 2 rRNAs and 22 tRNAs. The polypeptides are all subunits of the 
OXPHOS complexes. Coding sequences are placed on both strands of mtDNA, 
named H (heavy) and L (light) historically based on their buoyant densities in 
alkaline CsCl gradients (Clayton, 1991). The genetic information in humans and 
other mammals is very compact. There are no introns and the noncoding 
elements, including the regulatory sequences, are grouped in one place 
commonly named the displacement loop (D-loop), as it maintains a short 
nascent DNA sequence at the origin of leading strand replication (Clayton, 
1991). D-loop contains promoters of transcription and replication (Anderson et 
al., 1981). In comparison, mitochondrial genomes of plants, which are much 
bigger than the mammalian ones, contain 80-90% non-coding sequences such 
as 5’ and 3’ untranslated regions introns, intronic and undefined ORFs, 
pseudogenes, and pieces of foreign DNA (chloroplast and nuclear) (Lang et al., 
1999). 
Often mitochondrial genome is characterized by having a higher mutation rate 
than the nuclear one (9-25 times) (Lynch et al., 2006). Mammalian 
mitochondrial DNA is maternally inherited, therefore the mutations in mtDNA 
can only be transmitted from mother to child but deletions seem to escape this 
and generally are not passed on. There are multiple copies of mtDNA in one 
cell (in somatic cell ~1000-10,000 per cell) and they can all be identical, a 
phenomenon called homoplasmy, where all copies are either wild type or 
harbouring a single specific mutation. If the mutation is present in only a subset 
of molecules it is termed heteroplasmy (Smeitink et al., 2001). The replication 
and turnover of the mtDNA was thought to be constant during the cell cycle with 
no specific connection to any of the phases (Bogenhagen and Clayton, 1977). 
However, this concept has recently been challenged when a link between the 
mitochondrial form and properties and the cell cycle was found in rat NRK cell 
line. (Mitra et al., 2009).  
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The replication of the mitochondrial genome is carried out by a set of proteins, 
the most important of them being the DNA polymerase γ, a helicase named 
Twinkle and mtSSB, which coats single stranded mtDNA (Graziewicz et al., 
2006; Korhonen et al., 2003). The 2 main mechanisms that were proposed to 
describe the replication process are the strand-asymmetric / asynchronous and 
the bidirectional model. In the first one the replication is unidirectional and the 
synthesis of the lagging strand is delayed (Clayton, 1991; Robberson et al., 
1972). The second model, describes the processes as bidirectional where a 
strand-coupled DNA synthesis occurs (Berk and Clayton, 1974; Holt et al., 
2000). It is suggested that both mechanism coexist in mitochondria and the 
physiological conditions determine which one is utilized (Berk and Clayton, 
1974; Bogenhagen and Clayton, 2003; Holt et al., 2000). However, there is a 
growing body of evidence that a third mtDNA replication mechanism named 
RITOLS (ribonucleotide incorporation throughout lagged strand) exists. In this 
model, replication is unidirectional and synthesis of lagging DNA strand involves 
a ‘bootlace’ mechanism during which RNA sequences are hybridized with it 
(Pohjoismäki et al., 2010; Reyes et al., 2013; Yasukawa et al., 2005). 
 
1.1.4. Mitochondrial transcription, mtRNA processing and 
maturation 
Even though mitochondria contain their own genome, its expression inside the 
organelle is not entirely independent of the rest of the cell. The polypeptides 
that are encoded in the human mtDNA are the subunits of the OXPHOS 
complexes (CI - MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, 
MT-ND6; CIII - MT-CYB; CIV - MT-CO1, MT-CO2, MT-CO3; CV - MT-ATP6, 
MT-ATP8). The rest of the genes encode both of the ribosomal RNAs and a 
complete set of tRNAs. All of the remaining ~1500 proteins (Nunnari and 
Suomalainen, 2012) required to generate and maintain a functional organelle 
are encoded in nuclear genome. Therefore more than 99% of all the necessary 
factors for replication, transcription (mt-transcription) and translation (mt-
translation) and mitochondrial homeostasis, need to be imported from  the 
cytosol (Glick and Schatz, 1991; Smits et al., 2010b). The transcription of 
human mtDNA is initiated from different sites on each strand. The L strand 
harbours only one promoter (LSP, position on the mtDNA marked on Fig. 1.3), 
whereas there are 2 promoters on the H strand (HSP1 and HSP2, also 
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referred to as H1 and H2, Fig. 1.3) (Montoya et al., 1982) located within 87 bp 
of each other. Transcription from all mentioned above promoters results in 
synthesis of polycistronic transcripts that are later processed by RNase P and Z 
(R. J. Temperley et al., 2010)  to generate discreet coding sequences. Which 
transcripts originate from which promoter is presented on Fig. 1.3. 
 
Figure 1.3. A schematic of transcription initiation of human mtDNA 
The human mitochondrial genome is depicted as a circle with all the genes and 
initiation sites marked. The transcription of the L strand from the LSP promoter is 
presented as proceeding in the anticlockwise direction and the genes that are included 
in the polycistronic transcript that results from it are marked on the inside of the circle 
(tRNA genes depicted as black bars, MT-ND6 in green). The genes transcribed from 
the H strand are marked at the outside of the circle and the process progresses in the 
clockwise direction. The polycistronic transcript originating from the HSP1 contains the 
two rRNA genes (12S and 16S rRNA in purple) and tRNAs F and V (black bars). The 
initiation from the HSP2 covers almost all of the H strand, including: 2 rRNAs, 13 
tRNAs V, L1, I, M, W, D, K, G, R, H, S2, L2, and T (black) as well as 12 mRNAs: MT-
ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-NG5 (in green), MT-CO1, MT-CO2, 
MT-CO3 (orange), MT-CYB (blue), MT-ATP6 and MT- ATP8 (yellow). Adapted from 
(Bonawitz et al., 2006).  
 
The most important components of the mt-transcription machinery are: RNA 
polymerase (POLRMT), transcription factor A (TFAM) and transcription factor B 
paralogues (TFB1M or TFB2M) (Bonawitz et al., 2006; Falkenberg et al., 2007). 
The polymerase consists of one unit and it contains 2 PPR motives (35 amino 
acid motifs) characteristic of RNA binding and processing functions. There is 
also a series of conserved motifs in the C-terminus that are found in 
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bacteriophage RNA polymerases (Masters et al., 1987) to which POLRMT has 
similarity. The proposed role of TFAM involves introducing conformational 
changes to mtDNA to facilitate binding of the RNA polymerase in the promoter 
region. This activity is sequence independent and allows binding, bending and 
unwinding of the DNA (Fisher et al., 1992). The direct interactions between 
TFAM and POLRMT result in formation of pre-initiation complex (pre-IC) in the 
promoter region. In order to initiate transcription pre-IC requires recruitment of 
TFB2M, that results in forming of the initiation complex (IC). The N-terminus of 
TFB2M reaches the active site of POLRMT, so that the later can bind an 
recognized the promoter (Morozov et al., 2015).  
In addition to transcription activation, TFAM has another role in mitochondrial 
gene expression, namely it organizes mtDNA into the nucleoids. Within these 
protein complexes mtDNA is shaped into a U-turn via interaction with TFAM. 
Thus TFAM performs a dual role in transcription and organisation and 
maintenance of mtDNA (Ngo et al., 2011).  
As for the remaining two transcription factors (TFB1M and TFB2M), the 
molecular mechanism of their action has not yet been fully defined (Sologub et 
al., 2009). However, the results in human mitochondria suggests that TFB2M 
plays a more important role in transcription than TFB1M, as it is involved in 
melting of the promoter and binding of a priming substrate (Sologub et al., 
2009; Litonin et al., 2010).  Although initially TFB1M demonstrated an ability to 
stimulate transcription initiation in in vitro studies (Falkenberg et al., 2002), it 
was not validated in vivo. Metodiev et al. showed that this protein is an essential 
methyltransferase of 12S rRNA and has no role in transcription (Metodiev et al., 
2009). 
After the polycistronic transcripts are generated from both mtDNA strands they 
are processed to produce individual transcripts. Since each protein coding or 
rRNA fragments is flanked by at least one tRNA gene, the formation of their 
characteristic cloverleaf structures was proposed as marker for endonucleolytic 
cleavage. This mechanism was termed the tRNA punctuation model (Ojala et 
al., 1981). Even though it does not explain all cleavage that occurs during 
mitochondrial tRNA processing it accounts for most of it (R. J. Temperley et al., 
2010). There are 2 main enzymes involved in this process. RNase P that 
catalyses the cleavage at the 5’ ends of tRNAs (Holzmann et al., 2008). The 
processing of the 3’ ends is handled by RNase Z-like protein, ELAC2 
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(Dubrovsky, 2004). For the complete maturation, the resulting tRNA molecules 
require addition of the CCA nucleotides on the 3’ terminus and aminoacylation 
by the correct aminoacyl-tRNA synthetase (Smits et al., 2010b).  
The maturation of the mitochondrial mRNAs requires addition of a poly(A) tail. 
In human mitochondria all protein coding transcripts, except MT-ND6, are 
constitutively polyadenylated by addition of approximately 50 A residues (R. J. 
Temperley et al., 2010). For the majority of these transcripts, polyadenylation is 
necessary to complete the stop codon sequence as 7 of the 13 ORFs terminate 
with single U or UA nucleotides (Gagliardi et al., 2004). The poly(A) tail can also 
influence stability of mt-mRNAs, but its effect on each transcript differs (Chang 
and Tong, 2011; Nagaike, 2005; Tomecki et al., 2004). Recently published work 
of Wilson et al. provided additional insight into mechanisms regulated by the 
poly(A) modification through mutations that affect the activity of the 
mitochondrial poly(A) polymerase (mtPAP). Their results showed that changes 
to the length of the poly(A) tail can disrupt the post-transcriptional gene 
expression of mt-mRNAs and assembly of the respiratory chain complexes 
(Wilson et al., 2014).  
In addition, the activity of the mtPAP was enhanced by the presence of the 
LRPPRC/SLIRP complex, which caused the poly(A) tail elongation. LRPPRC 
and SLIRP are two mitochondrial RNA binding proteins (RBP). They form a 
complex that binds the majority of the mt-mRNAs and is involved in 
maintenance of the poly(A) tails (Chujo et al., 2012; Ruzzenente et al., 2012; 
Sasarman et al., 2010). MtPAP was also found colocalizing with mt-RNA in 
discreet foci (Wilson et al., 2014), termed mitochondrial RNA granules (MRGs), 
which were first described by (Jourdain et al., 2013). MtPAP showed the same 
pattern of distribution as the marker of MRGs, GRSF1 protein. This protein 
belongs to a family of RNA processing proteins. Its role and presence in MRGs, 
where it colocalizes with RNase P and nascent mtRNAs, was investigated by 
(Jourdain et al., 2013) and (Antonicka et al., 2013). Integrity of these granules 
influenced the mtRNA maintenance and generation of the functional RNAs. 
GRSF1 was identified as an important factor in processing of the precursor 
RNA species (containing or lacking the tRNAs transcripts). It was suggested 
that these precursor species accumulate in the MRGs and are then released 
after the appropriate processing (Jourdain et al., 2013). Another study focusing 
on GRSF1 and its role in mitochondrial RNA processing granules proposed 
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an additional function for this protein. In the work by Antonicka et al. GRSF1 
was found binding long non-coding RNAs (lcnRNAs) that originated from the 
mtDNA L-strand. In addition, the knockdown of GRSF1 resulted in disruption of 
the ribosome function and biogenesis (Antonicka et al., 2013). The 
mitochondrial RNA granules are most likely the place where processing and 
maturation of mt-transcripts occurs, which is necessary to prepare transcripts 
for the subsequent step in gene expression, namely, translation. 
 
1.2. Translation 
The protein synthesis system that operates in mitochondria, despite the 
presence of unique features, resembles more closely prokaryotic type of 
translation than the one from eukaryotic cytosol (Smits et al., 2010b). Many 
aspects of this process are still ucharacterised but those that are well described 
reveal features distinguishing mitochondrial translation from other systems. The 
necessary components for mitochondrial protein synthesis, apart from the 
mRNA template, include mitoribosome, 22 tRNAs with the enzymes required for 
their aminoacetylation, as well as various protein factors that facilitate mRNA 
recognition, translation initiation, elongation, termination and mitoribosome 
recycling (described in detail in the following subsections). All 13 polypeptides 
that are synthesised in human mitochondria are subunits of the OXPHOS 
complexes. However, the mitochondrially encoded proteins constitute only a 
small portion of all OXPHOS complexes subunits. The remaining proteins are 
encoded in nuclear genome and they are transported to mitochondria through 
the import system (Harbauer et al., 2014).  
Therefore generation of the fully assembled OXPHOS complexes requires 
coordination of protein synthesis in both mitochondrial and cytosolic 
compartments. The mitochondrially-encoded proteins are highly hydrophobic 
and they are inserted into the inner mitochondrial membrane. The protein called 
Oxa1L (Oxa1 in yeast) plays the major part in the insertion process and it binds 
the nascent polypeptides at an early stage (Hell et al., 2001). Oxa1L is binding 
the mitoribosome via its C-terminus (Haque et al., 2010). This interaction is 
thought to facilitate the insertion of the proteins to the IMM (Szyrach et al., 
2003). Although, Oxa1 is crucial for protein insertion, other factors’ involvement 
is also highly likely (Ott and Herrmann, 2010). In addition, a significant 
proportion of mammalian mitochondrial ribosomes was found bound to the 
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inner mitochondrial membrane (Liu and Spremulli, 2000). Such positioning 
could enable delivery of mt-encoded proteins to their place in OXPHOS 
complexes. 
 
1.2.1. Mitoribosomes - architecture and functions 
Mitoribosomes are unique multi RNA-protein complexes that differ in structure 
from both prokaryotic and eukaryotic counterparts. In addition, there is also a 
significant variation between mitoribosomes from different organisms, which 
sets the mammalian mitoribosomes apart from others (O’Brien, 2003). They are 
composed of two subunits; small (28S; mt-SSU) and large (39S; mt-LSU) that 
together form a 55S monosome (O’Brien, 1971). Even though the 
sedimentation coefficient of a mitochondrial monosome is lower than that of 
bacterial one (55S as opposed to 70S) due to more porous structure, 
mitoribosomes’ molecular weight is higher (Sharma et al., 2003). They also 
have a different rRNA/protein ratio (O’Brien, 2002). Mitoribosomes contain more 
proteins but two times less rRNA making the ratio 69% protein to 31% rRNA, 
whereas in bacterial ribosomes it is 33% protein and 67% rRNA (O’Brien, 2002; 
Sharma et al., 2003). In addition, human and other mammalian mitoribosomes 
lack the 5S rRNA that is present in large subunits of bacterial and cytosolic 
ribosomes (O’Brien, 2003). The small subunit of the mammalian mitoribosome 
is compose of 29 proteins and 12S rRNA, which is 950 nucleotides long, whilst 
the mt-LSU is made up of 52 proteins and 16S rRNA (1560 nucleotides) (Mears 
et al., 2006; Sharma et al., 2003). Almost half of these 81 proteins are specific 
to the mitochondrial ribosome, the rest have bacterial homologues (Sharma et 
al., 2003).  The recent cryo-electron microscopy (cryo-EM) images of 
mammalian LSU gave near atomic resolution and so allowed very detailed 
reconstruction of its structure. This combined with cross-linking experiments 
revealed the exact positions of many mt-specific proteins (Greber et al., 2014, 
2013). The following cryo-EM reconstruction of the human mt-LSU with the 3.4 
Å resolution showed new, specific features (Brown et al., 2014) and confirmed 
the reduction in rRNA, which is evenly distributed throughout the whole 
structure, not specified to one particular place or randomly distributed losses. 
As a result of the loss of parts of rRNA, mitoribosomes have much more porous 
structure in comparison to the bacterial and cytosolic counterparts. Small 
portions of the missing 16S domains are compensated by the presence of 
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the mt-specific proteins that stabilize the structure in the absence of rRNA. 
However, the majority of mt-specific proteins are placed in new positions 
(Brown et al., 2014). In mammalian mitoribosomes the solvent exposed side 
tends to contain more of these proteins (Fig. 1.4 A), whereas the core is more 
conserved (Fig. 1.4 B) and is formed with homologues of bacterial proteins 
(Greber et al., 2013). The mitochondrial specific changes were also found in the 
part of the LSU called the central protuberance (CP), which contains mt-
exclusive proteins. One of these proteins is ICT1, which was previously 
characterised as a mitoribosomal protein (Richter et al., 2010b) but only 
recently its exact position in CP was revealed (Greber et al., 2013). In bacterial 
ribosomes 5S rRNA is a part of central protuberance. However, since the 5S is 
not present in mammalian mitoribosomes, its place in CP is taken by a different 
RNA species, namely tRNA (Fig. 1.4 C) (Brown et al., 2014; Greber et al., 
2014). The exact type of the tRNA, which functions as a scaffold for CP, is not 
yet clear. The porcine mt-LSU reconstruction identified it to be tRNAPhe (Greber 
et al., 2014), the human mt-LSU, however, was shown to contain the tRNAVal 
instead (Brown et al., 2014). The latter could be easily explained by the 
composition of the genes encoded in the mt-transcripts. The mt-tRNAVal gene is 
flanked by the 16S rRNA gene at the 3’ end of the tRNA gene (Fig. 1.3). The 
tRNAPhe is flanked by the 12S rRNA gene at the 5’ end of the tRNA gene but 
the whole fragment of mtDNA containing both of the mention tRNAs and rRNAs 
is proposed to be transcribed from the additional H strand transcription 
promoter (Fig. 1.3 HSP1). The general structure of the CP is remodelled due to 
the lack of the 5S and its binding partners as well as the presence of the tRNA 
(Brown et al., 2014; Greber et al., 2014). 
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Figure 1.4. Overall structure of the 39S large subunit (A, B) and 55S 
mammalian mitoribosome (C) 
A. The structure of the large mitoribosome subunit viewed from the solvent side with 
depiction of conserved (in blue) mitochondrial specific elements (red). The positions of 
central protuberance (CP), polypeptide accessible site (PAS), polypeptide exit site 
(PES), L1 and L7/L12 stalk. Adapted from (Greber et al., 2013). B. The interface site 
view of mt-LSU with the same color code as in A. C. A complete 55S mitoribosome 
structure divided in large 39S and small 28S subunits. Proteins of the 39S subunit are 
presented in blue, 16S rRNA in orange and tRNA in CP in brown. In small subunit 
proteins are visualized in pale yellow, 12S rRNA in light green, A-site tRNA in yellow 
and P-site tRNA in purple. Adapted from (Greber et al., 2015). 
 
Another part of the mitoribosome that was identified to contain very 
characteristic features is the polypeptide exit tunnel, where the nascent 
polypeptide leaves the ribosome.  In human mitoribosomes the overall path of 
this tunnel is similar to the bacterial/cytosolic ones. However, inside is much 
more hydrophobic and it is possible that there are strong interactions with also 
hydrophobic nascent polypeptides. The exit tunnel can also be a place where 
the helical tertiary structures of the mt-peptide start to form as observed in 
cytosolic ribosomes (Brown et al., 2014). As for the exact protein composition of 
A. B.
C.
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the mammalian mitoribosomal polypeptide exit tunnel, the ring that surrounds it 
is conserved and has corresponding bacterial homologues. However, there is a 
second layer of proteins that is specific to mitochondria only (MRPL44 and 
MRPL45) (Greber et al., 2013). The remodelling and mt-specific proteins 
present at the exit site may be a result of adaptation to the unique mitochondria 
translation system. It seems that these changes allow binding of the maturation 
factors and docking of the mitoribosomes to IMM (Brown et al., 2014; Greber et 
al., 2013).  
The recently presented cryo-EM structure of the small subunit of the 
mitoribosome in 7-Å resolution (Kaushal et al., 2014) revealed the importance 
of the mitochondrial-specific extensions of homologous MRPs. These protein 
parts are involved in forming contacts with fully mt-specific MRPs. A lot of 
elements interacting with mRNA and tRNA are lined with the mt-specific 
proteins, which confirms the adaptation of the mitoribosome to the specific of 
mt-translation. Also there was a higher number of proteins involved in the 
formation of intersubunit connections (Kaushal et al., 2014). These 
observations were confirmed with proceeding publication of the higher 
resolution (3.6 Å) cryo-EM structures of SSU, in a context of a fully assembled 
monosome (Greber et al., 2015). An additional structure of an intact monosome 
(3.5 Å) presented even more details of mt-SSU consistent with aforementioned 
publications (Amunts et al., 2015). As in case of the mt-LSU, large pieces of 
small subunit rRNA were lost in mitoribosome in comparison to the bacterial 
one (Amunts et al., 2015; Greber et al., 2015). Many helices of rRNA that are 
involved in interaction with tRNA (P and A sites) in bacterial and cytosolic 
ribosomes are lost in mitoribosomes. The most recent structures of 
mitoribosomes shed light on the highly flexible nature of the mt-SSU that 
facilitates taking different conformations necessary for its function. In addition, 
the structure of the mRNA channel was resolved, which identified mitoribosome 
specific remodelling of both entry and exit sites. The most important element in 
the channel was protein uS5m (MRPS5) that seemed to be in contact with 
mRNA (Amunts et al., 2015; Greber et al., 2015). In contrast to mRNA channel, 
the tRNA decoding centre appeared to be well conserved between 
mitoribosomes and bacterial counter parts (Greber et al., 2015). 
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1.2.2. Translation initiation 
The first step of the protein synthesis is called translation initiation and it 
requires recognition of the start codon in mRNA by the ribosome. This codon is 
then placed in the ribosomal P site where it is bound by the initiator tRNAMet 
carrying methione in its formylated form. This action, as well as the following 
steps of the initiation in mitochondria, is still poorly understood. Distinctive 
features of the 5’ ends of mammalian mt-transcripts such as short (≤ 3) 
unstructured 5’ sequences (Montoya et al., 1981), the absence of a prokaryotic 
Shine-Dalgarno sequence or eukaryotic 7-methylguanylate cap (Grohmann et 
al., 1978) makes the comparison with any known model impossible. In 
prokaryotic and cytosolic translation in eukaryotes, these special features serve 
as the markers for the binding of the small ribosomal subunit and forming of the 
preinitiation complex. With such short 5’ untranslated region, and no 
modifications it is difficult to identify what attracts mitoribosomes to the start 
codons of mt-transcripts. There is a hypothesis that the very lack of specific 
features or long 5’ UTRs is the signal, which gets recognized by the small 
mitoribosomal subunit (Haque et al., 2008; Jones et al., 2008) and that the 
process is facilitated by one of the initiation factors, mtIF3. This factor has an 
ability to induce dissociation of the mitoribosomal into large and small subunits 
in order to facilitate binding of the mRNA and initiator tRNA (Koc and Spremulli, 
2002). Recently published structures of small subunit of the mitoribosome 
suggest the possible mechanism of how the mRNA is connected to the mt-SSU 
during initiation. Based on the architecture of the mRNA entry channel it was 
proposed that the 5’ end of the transcript is threaded through the entry with 
assistance of mt-specific MRPs MRPS5 and MRPS39 (Greber et al., 2015)  
Mitochondria utilize the formylated methionine for the initiation of translation but 
it is carried by the same tRNA species that facilitates incorporation of the 
methionine during elongation. When initiation codon AUG is position in 
ribosomal P site, fMet-tRNAMet is incorporated into the ribosome with the help 
from GTP-dependant second initiation factor, mtIF2 (Christian and Spremulli, 
2010). In any characterized mitochondrial translational systems there are no 
equivalents of IF1, which is considered a universal initiation factors for both 
bacterial and eukaryotic cytoplasmic systems (Christian and Spremulli, 2012). 
In E. coli IF1 blocks the A site of the small ribosomal subunit during the initiation 
(Allen et al., 2005). In mitochondrial system, the mtIF2 is thought to perform 
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this function as well as the previously described facilitating of the initiator tRNA 
binding (Christian and Spremulli, 2012). The mRNA binding is directed through 
the mRNA entry gate in mt-SSU (Sharma et al., 2003) and is though to occur 
prior to the fMet-tRNAMet recognition (Christian and Spremulli, 2010). The 
mRNA with AUG codon in mitoribosomal P site, fMet-tRNAMet and factors mtIF2 
and mtIF3 form an initiation complex, which is additionally stabilized by the 
interactions of codon:anticodon binding between tRNA and start codon 
(Christian and Spremulli, 2010). In the next step the mt-LSU joins the small 
subunit to form the 55S monosome, the GTP from mtIF2 is hydrolysed to GDP 
and both initiation factors are released, which marks the end of the initiation 
process (Haque et al., 2008; Smits et al., 2010b).  
 
1.2.3. Translation elongation 
After the initiation step is over the mitoribosome proceeds to the elongation 
phase when new amino acids are added to the growing polypeptide chain. For 
each incorporated residue the following reactions have to take place: 
aminoacyl-tRNA binding, peptide bond formation and ribosome translocation, 
which moves it 3 nt along the mRNA (towards 3’ end) to a position ready for the 
next cycle. With a few exceptions, the elongation phase of mitochondrial 
translation is similar to the bacterial model from E. coli (Cai et al., 2000). In 
general this step of protein synthesis is more conserved than the initiation or 
termination (Christian and Spremulli, 2012). The first factor engaged in this 
process in mitochondria, mtEF-Tu, is the homologue of the main bacterial 
elongation factor. Its active, GTP-bound form captures the aminoacyl–tRNA 
(aa-tRNA) creating a ternary complex. This complex enters the mitoribosomal A 
site where the fidelity of the codon-anticodon binding is assured in a process 
named tRNA decoding. In bacterial ribosomes the correct pairing of codon and 
anticodon is recognised by specific bases of ribosomal 16S rRNA. These bases 
(G530, A1492 and A1493) make contact with the minor groove of codon-
anticodon helix and recognise the correct geometry of the Watson-Crick 
binding. Only the geometry at first two positions is closely monitored, allowing 
for the non-canonical (wobble) base pairing at the third (Ogle and 
Ramakrishnan, 2005). The correctly selected tRNA causes conformational 
changes of the ribosomal decoding centre that closes tightly around it 
(Demeshkina et al., 2012). This induces the hydrolysis of the GTP and 
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GDP-bound mtEF-Tu is released from the ribosome. MtEF-Tu goes through 
cyclic changes between active (bound with GTP) and inactive forms (containing 
GDP) that are regulated by another factor, mtEF-Ts (Sprinzl, 1994; Woriax et 
al., 1997). Mt-EF-Ts induces the exchange of the GDP in inactive mtEF-Tu to 
GTP, thus activating the protein and preparing it to bind another aa-tRNA. 
When a codon in the A site is correctly decoded by a corresponding aa-tRNA, a 
new peptide bond is formed. The C-terminus of the peptide is released from the 
P site tRNA and joined with the N-terminus of the A site tRNA in reaction called 
transpeptidation. The catalysis of this reaction is performed by the ribosome 
itself, in a part of the large subunit called the peptidyl transferase centre (PTC). 
In mammalian mitoribosome the PTC is built with 16S rRNA and is highly 
conserved between mitochondria, prokaryotes and eukaryotic cytosol. The 
modelled structures that contained tRNA in P and A site showed that 
interactions between them and 16S rRNA in PTC are also conserved (Greber et 
al., 2014).  After the polypeptide bond is formed and the protein chain is 
attached to the A site tRNA, another elongation factor, mtEF-G1 catalyses the 
translocation of the ribosome 3 nucleotides toward the 3’ end of mRNA. During 
this step the peptidyl-tRNA moves from the A site to the P site and the 
deacylated tRNA from the P site is removed (Smits et al., 2010b). In bacterial 
and cytosolic translation, the deacylated tRNA is moved from P to E site. 
However, the exact mechanism behind the release of the deacylated tRNA in 
mammalian mitoribosome is not clear (Sharma et al., 2003). Most important 
rRNA domains, that in bacterial ribosome are responsible for interactions with 
tRNAs in the E site are missing from the mammalian ribosome. The only one 
part of the E site that is conserved is the tRNA’s CCA-3’ terminus binding 
pocket (Greber et al., 2014). In the model of human mt-LSU the same 3’ part of 
the tRNA was shown bound to the ribosome, which confirms that a vestigial E 
site may be present but the interactions between it and tRNAs are much weaker 
than in bacteria (Brown et al., 2014). 
 
1.2.4. Translation termination and mitoribosome recycling 
The elongation cycles continue until one of the stop codons UAA, UAG and 
UGA (in prokaryota and eukaryotic cytosol) reaches the ribosomal A site 
(Nakamura et al., 1996; Tate and Brown, 1992). There is no tRNA that would 
recognize a stop codon, hence a special type of protein factor is required 
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that would bind the A site of the ribosome instead. These proteins belong to the 
class I release factors (RF). In bacteria the 2 types of release factors are 
distinguished: RF1, which recognizes UAA and UAG codons and RF2 that 
interacts with UAA and UGA stop codons (Müller et al., 2012). Eukaryota and 
archaebacteria require only one class I release factor named eRF1 and aRF1 
respectively (Dontsova et al., 2000; Frolova et al., 1999; Konecki et al., 1977). 
The specific, codon recognition function of RF in bacteria is determined by the 
characteristic motifs in domain 2 (Laurberg et al., 2008), namely PXT in RF1 
and SPF in RF2 (Ito et al., 2000). Upon stop codon recognition release factors 
undergo structural rearrangements resulting in the conformation that places the 
loop between domains 3 and 4 in the ribosomal peptidyl transferase centre (Fig. 
1.5 A and B) (Laurberg et al., 2008). This loop contains another motif unique to 
release factors, a tri-peptide GGQ (glycine-glycine-glutamine). The GGQ motif 
is highly conserved, present in all class I release factors and is indicative of their 
function, which is ribosome dependent peptidyl-tRNA hydrolase activity (Frolova 
et al., 1999). Placing of the GGQ in the PTC triggers structural changes to the 
ribosome, which then result in the hydrolysis of the bond between the nascent 
peptide and the P site tRNA that is docking it to the ribosome (Laurberg et al., 
2008; Trobro and Åqvist, 2007). After the peptide is released the class II 
release factor help to dissociate the class I RF from the ribosome. In bacteria 
the class II release factor is a small, G-protein named RF3 that facilitates the 
removal of the RF1/RF2 after the completed peptidyl-tRNA hydrolysis 
(Freistroffer et al., 1997). Then the ribosome recycling (RRF) factor with the 
elongation factor EF-G promote dissociation of the ribosome to separate 
subunits (Zavialov et al., 2005). Eukaryotic cells utilize a different mechanism of 
recycling of the ribosome. The homologue of RF3, eRF3, stimulates the eRF1 
release activity in a GTP-dependent manner but not its dissociation (Alkalaeva 
et al., 2006; Jackson et al., 2012; Kisselev and Buckingham, 2000). The 
eukaryotic homologue of RF3, eRF3, stimulates the eRF1 release activity in a 
GTP-dependent manner. (Alkalaeva et al., 2006; Jackson et al., 2012; Kisselev 
and Buckingham, 2000). These two protein factors form a stable ternary 
complex with GTP (eRF1-eRF3-GTP). Hydrolysis of GTP results in release of 
eRF3 and allows eRF1 to assume the conformation necessary for peptidyl-
tRNA hydrolysis (des Georges et al., 2014). After eRF3 dissociates an ABC-
type ATPase ABCE1 binds the ribosome and stimulates the peptide release 
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by eRF1 (Preis et al., 2014). Finally, ABCE1 cooperates with eRF1 to dissociate 
ribosomal subunit, thus there is a functional coupling of the translation 
termination and ribosome recycling (Jackson et al., 2012; Pisarev et al., 2010).
 
Figure 1.5. Structures of release factors RF2 and mtRF1a  
A. Overview of the bacterial ribosome (50S in grey, 30S in yellow) with release factor 
(RF2) bound to the A-site, E-site tRNA (red), P-site tRNA (green) and mRNA template 
in purple. Adapted from (Weixlbaumer et al., 2008). B. Structure of bacterial RF2 free 
form (in grey) and bound to ribosome (each domain in different color) aligned together 
to show differences in conformation. Black arrows demonstrate the movement of 
domains after binding to ribosome. C. Structure of mitochondrial release factor mtRF1a 
modeled on bacterial RF2. Conformation of the protein is representing the ribosome-
bound state with relative positions of LSU, SSU and peptidyl transferase centre (PTC). 
The position of GGQ motif in domain 3 (red) and sequence recognition elements (α-5 
helix, PKT, purple) are detailed. Adapted from (Chrzanowska-Lightowlers et al., 2011). 
 
The process of translation termination in mitochondria differs from that 
described above. Most species’ mitochondria utilize only two out of three 
canonical stop codons, namely UAA and UAG (Soleimanpour-Lichaei et al., 
2007), whereas UGA encodes tryptophan (Lee et al., 1987).  However, in 
human mitochondria 2 of the transcripts (MT-CO1 and MT-ND6) have either 
AGA or AGG following the open reading frame instead. This resulted in the 
assumption that human mitochondria were characterised by a set of four stop 
codons. The first candidate for the mitochondrial release factor that 
A. B.
C.
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emerged from the bioinformatics survey, was a protein called mtRF1 (Zhang 
and Spremulli, 1998). However, it failed to present the release factor activity 
with any of the canonical stop codons. Thus a new candidate protein was 
proposed, mtRF1a (Fig. 1.5 C), which displayed the peptide release activity 
both in vitro and in vivo but only for the canonical UAA and UAG codons 
(Soleimanpour-Lichaei et al., 2007). Termination of the translation of MT-CO1 
and MT-ND6 is achieved through a -1 single nucleotide frameshift, which 
changes codon in mitoribosomal A-site from the AGA/AGG into canonical UAG. 
This frameshift allows for the canonical mechanism of termination facilitated by 
mtRF1a to occur. (R. Temperley et al., 2010). Therefore mtRF1a operates as a 
universal mitochondrial release factor and terminates translation of all 13 
polypeptides. 
A candidate for the mitochondrial ribosome recycling factor, class II factor, has 
been proposed from bioinformatics data (Zhang and Spremulli, 1998), namely 
mtRRF, which displayed necessary in vitro and in vivo activity (Rorbach et al., 
2008a). In contrast to bacterial translational system where both translocation of 
the ribosome and disassembly of its subunits are carried by one protein EF-G, 
in mitochondria these two functions are divided between 2 proteins: mt-EFG1 
and mtEFG2 (Tsuboi et al., 2009). As discussed in section 1.2.3 mtEFG1 is 
involved in translocation. Therefore, the role of mtEFG2 is to assist mtRRF in 
recycling of the mitoribosomal units during post-termination step. The GTPase 
activity displayed by mtEFG2 is required after the subunits are separated in 
order to release mtRRF and mtEFG2 (Tsuboi et al., 2009). The subunits remain 
separated due to binding of the initiation factor mtIF3 to the mt-SSU (Christian 
and Spremulli, 2012). 
 
1.3. Stalling of ribosomes - rescue mechanisms in bacteria  
Not every translational event results in complete protein synthesis. Some 
ribosomes can be arrested at various points of translation and fail to undergo 
the canonical process of termination and subunit recycling, a phenomenon 
known as ribosome stalling (Garza-Sánchez et al., 2008). When ribosomes are 
arrested and unable to resume translation it poses a threat to cell viability as it 
reduces available pool of ribosomes and therefore affects translation efficiency 
(Chadani et al., 2010; Jørgensen and Kurland, 1990). Such stalled ribosomes 
have to be either degraded or recycled with a help of external factors. As a 
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consequence of ribosome rescue the mRNA template as well as the nascent 
polypeptide (in most cases unfinished) are also removed and often degraded 
(Guydosh and Green, 2014). Stalling can occur either at the 3’ end of the 
transcript, when there is a lack of functional stop codon (non-stop mRNA) or 
during elongation. In both cases it leaves the ribosome with an empty A-site 
(Keiler et al., 1996; Vivanco-Domínguez et al., 2012). The non-stop RNA 
species can be caused by premature termination of transcription or by nuclease 
cleavage (Keiler et al., 1996). The stalling of the elongating ribosomes is 
triggered by the features of tRNAs, mRNAs or the nascent polypeptide. The 
shortage of the particular aminoacyl-tRNA can result in stalling over the 
corresponding codon (Vivanco-Domínguez et al., 2012) as well as the presence 
of rare codons (Gouy and Gautier, 1982). The forming of the secondary 
structures as hairpins and pseudoknots (Somogyi et al., 1993; Wen et al., 2008) 
is also thought to impede the progression of ribosomes. Finally, the features of 
the nascent polypeptide, such as accumulation of positive charges that could 
interact with the exit tunnel, are other possible stalling factors (Charneski and 
Hurst, 2013). !
1.3.1. tmRNA- mediated ribosome rescue 
Mechanisms able to rescue stalled ribosomes thereby maintaining translation 
efficiency have been developed in many bacterial species. The most common 
system, trans-translation, utilizes a specific RNA molecule, named tmRNA that 
has functions of both tRNA as it is shaped to resemble tRNA structure, charged 
with alanine and mRNA as it encodes a short ORF (SsrA) (Hayes and Keiler, 
2010). This molecule recognizes and enters the A-site of the stalled ribosome 
(Fig. 1.6 A) and accepts the nascent polypeptide on the alanine residue 
attached to the tRNA-like component (Fig. 1.6 B). Next, it resumes the 
translation of that peptide using the short ORF in mRNA part as a template (Fig. 
1.6 C) (Hayes and Keiler, 2010; Keiler et al., 1996; Withey and Friedman, 
2003). As a result the polypeptide with an added SsrA tag is released from the 
ribosome by canonical termination at the SsrA ORF stop codon and the 
ribosome is recycled (Fig. 1.6 D). The tagged protein, which most likely is 
truncated as its translation was interrupted, is recognized and degraded by 
proteases (Janssen and Hayes, 2009). Factors essential for the trans-
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translation to occur are EF-Tu and small protein SmpB (Barends et al., 2000; 
Kurita et al., 2007; Moore and Sauer, 2007). When the ribosome is stalled by 
reasons other than the non-stop mRNA, the cleavage of the transcript is 
necessary prior to the tmRNA-mediated action (Roche and Sauer, 1999), 
(Garza-Sánchez et al., 2008). One of the identified factors that is involved in 
this process is a RelE toxin, which catalyses the cleavage of the 3’ end side of 
the mRNA, close to the stalled ribosome. As a result, the substrate for 
tmRNA/SmpB is created (Pedersen et al., 2003). However, the participation of 
toxins in trans-translation occurs only upon strong amino acid starvation. 
Moderate conditions invoke toxin-independent cleavage of the 3’ mRNA (Li et 
al., 2008). 
 
Figure 1.6. Overview of tmRNA-mediated rescue of stalled ribosomes  
Mechanism of tmRNA function presented in separate steps. A. Recognition of the 
stalled complex by the aminoacylated-tmRNA facilitated by SmpB and EF-Tu. B. 
Change of the template for the ORF-part of tmRNA. C. Addition of the SsrA tag as a 
result of translation of tmRNA ORF. D. Release of the tagged-protein followed by 
proteolysis. Image adapted from (Shimizu, 2014). 
 
 
A.
B.
C. D.
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1.3.2. ArfA and YaeJ - alternative rescue strategies  
Although tmRNA is present in all sequenced eubacterial genomes, it is not the 
exclusive rescue system for many species. For example E. coli harbour an 
alternative rescue mechanism of stalled ribosomes on non-stop mRNA that 
involves protein called ArfA (Alternative release factor A) (Chadani et al., 2010). 
This protein lacks the GGQ motif, therefore in order to hydrolyse the peptidyl-
tRNA bond in the stalled complex it recruits the release factor RF2. ArfA binds 
the large subunit of the ribosome and directs RF2 to the ribosomal A-site 
resulting in the process similar to the canonical translation termination (Chadani 
et al., 2012; Shimizu, 2012). However, the exact molecular mechanism of the 
rescue conducted by ArfA and RF2 is still unknown (Abo and Chadani, 2014). 
A second identified alternative mechanisms involved in rescue of stalled 
ribosomes is based on protein factor called YaeJ (or ArfB), which was utilized in 
non-stop mRNA and in case of rare-codon clusters (Y. Handa et al., 2010). 
Contrary to ArfA, YaeJ contains the GGQ motif (Fig. 1.7 A), which it utilizes to 
catalyse the peptidyl-tRNA hydrolysis in stalled ribosomes and enable the 
recycling of the ribosomal subunits (Y. Handa et al., 2010). Despite the 
similarities between the catalytic domain of YaeJ and class I release factors, the 
former differs in structure from the RFs. YaeJ lacks the codon-recognition 
domain which results in much shorter amino acid sequence (approximately 140 
aa instead of 360). Therefore the function of this protein can be described as a 
codon-independent but ribosome depending peptidyl-tRNA hydrolase (Chadani 
et al., 2011; Y. Handa et al., 2010). Studies on the crystal structure show that it 
utilizes its basic-residue rich C-terminal tail as a sensor to detect the presence 
of mRNA in entry channel downstream of ribosomal A-site. When the entry 
channel is empty YaeJ binds to large subunit, which results in placing GGQ-
containing domain in ribosome PTC and hydrolysis of peptidyl-tRNA (Fig. 1.7 
B). This process utilizes the same mechanism as the canonical translation 
termination (Gagnon et al., 2012). Mutational analysis of the C-terminal tail 
amino acid sequence identified the residues important for the binding of the 
stalled ribosome (Kogure et al., 2014). 
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Figure 1.7. Structure of YaeJ bound to the 70S ribosome 
A. Conformation of YaeJ in a ribosome bound-state with labeled domains. B. Position 
of YaeJ (red) in an empty A-site of a stalled 70S ribosome. Large subunit (50S) 
presented in light blue, small (30S) in pale yellow, P-site tRNA in green and mRNA in 
purple. N-terminal domain is placed in the A-site of the large subunit, C-terminal 
domain placed in empty mRNA entry channel of small subunit. Adapted from (Gagnon 
et al., 2012) 
 
In conclusion, E. coli cells were identified with at least 3 different ribosome 
rescue mechanisms, which supports the prediction that ribosome stalling is 
detrimental for the cell. According to the present model, the tmRNA remains the 
primary rescue strategy with ArfA and YaeJ-mediated mechanism acting as a 
fail-safe (Abo and Chadani, 2014). 
 
1.4. Stalling of ribosomes - rescue mechanisms in eukaryotes 
The mechanisms of mRNA and protein synthesis quality control are also 
present in eukaryotic cells, although no homologues of tmRNA have been 
found. Instead, a few different translation-dependent mechanisms have been 
characterized that are triggered by the ribosome stalled during elongation or 
termination (Isken and Maquat, 2007). One of the common stalling-inducing 
features is an absence of the stop codon. Lack of an in frame stop codon (non-
stop mRNA) can be caused by an error in transcription or accidental cleavage 
at the 3’ end of the mRNA. There are even genes identified to produce such 
transcripts as a result of a natural expression (Sparks and Dieckmann, 1998). 
A. B.
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Other reasons for the presence of non-stop mRNAs are endonucleolytic 
cleavage or chemical damage (Meaux and Van Hoof, 2006). Non-stop mRNAs 
are likely to cause ribosome stalling at their 3’ end with the polypeptide-tRNA 
still covalently bound to the P site. These mRNAs are rapidly degraded in 
mammalian and yeast cytosol by the mechanism called non-stop mediated 
degradation (NSD) (Graille and Séraphin, 2012). The process utilizes 
nucleolytic activity of the exosome as well as the SKI complex with Ski7 
associated factors (Fig. 1.8 B) (Schaeffer and van Hoof, 2011; van Hoof et al., 
2002). 
A second mRNA quality control mechanism, named nonsense mediated decay 
(NMD), induces the degradation of the transcripts with a premature stop codon. 
The stalled translation complex recruits exoribonucleases as well as the 
cytoplasmic exosome that degrade the aberrant transcript (Cole et al., 2009). 
When ribosome stalling is triggered by other than defective stop codons, 
transcripts are degraded with a mechanism called no-go decay (NGD). The 
substrates for the NGD are usually mRNAs that cause stalling at positions other 
than the 3’ end. Hence the system requires an endonucleolytic cleavage of the 
mRNA close to the stalled ribosome, which is followed by exonuclease 
degradation of the remaining mRNA by Xrn1 and exosome (Fig. 1.8 C). 
Transcripts with internal poly(A) sequences, as well as those chemically 
damaged mRNAs are also potential targets of NGD (Graille and Séraphin, 
2012). Finally, there is an indication that NGD also targets transcripts containing 
strong secondary structures within the open reading frame (Doma and Parker, 
2006). 
Defective mRNAs are not the only cause of the disruption of the translational 
progression. Ribosomal defects, including mutations, chemical damage and 
errors at biogenesis can also result in stalling, as these dysfunctional ribosomes 
fail to conduct translation efficiently (Fig. 1.8 D) (Graille and Séraphin, 2012). In 
yeast these defective ribosomes are stalled at sense codons during elongation 
and are removed with the mechanism called non-functional 18S-rRNA decay 
(NRD) (Cole et al., 2009; LaRiviere et al., 2006). 
In yeast, all surveillance pathways described above have a common feature, 
namely the involvement of Dom34:Hbs1 complex (Graille and Séraphin, 2012). 
The orthologues of the first component, Dom34 are found in many eukaryotic 
species, in humans is called Pelota (Atkinson et al., 2008). Both Dom34 and 
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Pelota share similarities in both structure and sequence with termination factor 
eRF1 (Graille et al., 2008). Dom34 structure mimics tRNA in the way eRF1 
does. However, it does not contain the GGQ motif responsible for the peptidyl-
tRNA hydrolysis and unlike eRF1 its N-terminal domain folding suggests an 
ability to bind RNA (Graille and Séraphin, 2012). The second component of the 
complex is a GTPase related to the eRF3 (Carr-Schmid et al., 2002). The 
Dom34-Hbs1 complex, when bound to the ribosome, resembles the ribosome-
bound eRF1–eRF3 complex (Becker et al., 2011). Through their interaction with 
the ribosomal A site, Dom34-Hbs1 triggers dissociation of the subunits and 
peptidyl-tRNA drop-off from stalled ribosomes (Shoemaker et al., 2010)(Becker 
et al., 2011). The subsequent GTP hydrolysis results in Hbs1 dissociation and 
conformational changes in Dom34. These actions lead to the recruitment of the 
Rli1 (in mammals ABC1), which triggers ATP-dependent ribosomal subunit 
dissociation and recycling (Pisareva et al., 2011; Shoemaker et al., 2010). 
Rescue of ribosomes is also linked to degradation of nascent proteins that were 
translated by the stalled complex. This process involves recruitment of the 
ribosome dependent quality control complex (RQC) that includes ubiquitin 
ligase Ltn1 and other factor facilitating recognition and removal of the 
polypeptide (Brandman et al., 2012; Defenouillère et al., 2013; Verma et al., 
2013).  
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Figure 1.8. Mechanisms of quality control of translation in eukaryota 
A. Termination of translation of a canonical template by release factor 1 (eRF1), 
followed by eRF3-GTP. B. Overview of the non-stop mRNA decay pathway. In the 
absence of stop codon ribosome is stalled during translating the poly(A) tail, 
synthesizing a polylysine extension to the nascent polypeptide. The stalled complex is 
resolved by Ski7- exosome and Dom34-Hbs1.The ribosome recycling is coupled with 
degradation of the peptide and mRNA. C. Ribosomes stalled within an ORF are rescue 
as a part of no-go decay pathway. The mechanism involves endonucleolytic cleavage 
followed by 5’-3’ degradation with Xrn1. The proteins that carry the release of the 
nascent polypeptide and recycling of the ribosome are Dom34 and Hbs1. D. 
Ribosomes that are unable to carry translation due to defects of small subunit (40S) 
are bound by Dom34, Hbs1 and Ski7, which result in 18S rRNA degradation. Adapted 
from (Graille and Séraphin, 2012). 
 
A. Canonical termination B. Non-stop decay
C. No-go decay D. 18 rRNA decay
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1.5. Translational recoding 
Ribosome stalling is not the only non-canonical event that can occur during 
protein synthesis. There are programmed mechanisms, collectively known as 
translational recoding, that affect the progression of the ribosome, resulting in 
the change in the linearity of the genetic information readout or decoding of a 
particular codon (Gesteland and Atkins, 1996). These alternative ways of 
decoding mRNA compete with standard translation and result in 2 or more 
different polypeptides from one transcript. Although, there are many 
mechanisms of translational recoding this section will focus on 3 major types: 1) 
-1 or +1 frameshifting, 2) ribosome hopping and 3) stop codon readthrough 
(Namy et al., 2004). During the frameshift ribosome slides over one nt 
(upstream or downstream), which results in translation of an overlapping ORF. 
The frameshift is usually triggered by the presence of a slippery sequence in 
mRNA that favours the misalignment of the tRNA and a stimulator element, 
often decreasing the speed of translation, such as pseudoknot (Kontos et al., 
2001). An example of such frameshift in Prokaryotes is prfB gene that encodes 
the RF2 protein and harbours -1 signal necessary for the expression of the 
functional protein (Craigen and Caskey, 1986).  
A second type of recoding, ribosome hopping (or bypassing) involves 
detachment of the ribosome from the mRNA and continuing of translation at a 
different spot on template. So far the only one well-characterized example of 
this phenomenon is a bypass of 50 nt sequence in gene 60 of T4 bacteriophage 
(Herr et al., 2000; Huang et al., 1988). However, recently a number of 
programmed bypassing sites were identified in mitochondria of yeast 
Magnusiomyces capitatus (Lang et al., 2014; Nosek et al., 2015). 
Finally, the last form of translational recoding is a readthrough of the stop 
codon. It requires a specific sequence context near the termination site that 
allows recognition by tRNA and carrying of the translation beyond it (Namy et 
al., 2004). The context can be interpret as: 1) the base immediately 
downstream from the stop codon, 2) last 2 amino acid residues of the nascent 
polypeptide, 3) presence of the stimulating elements downstream from the stop 
codon as secondary structures (Bertram et al., 2001). The readthrough of the 
stop codon allows synthesis of a protein of extended length and alternative 
biochemical features. The most common form of the programmed suppression 
of the stop codon is decoding of UGA triplet with selenocysteine identified in 
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both prokaryotes and eukaryotes (Namy et al., 2004). However, the 
readthrough can also involve decoding with canonical amino acid (Jungreis et 
al., 2011; Namy et al., 2004). Many examples of genes that undergo the 
suppression of the stop codon were recently identified in Drosophila 
melanogaster (Jungreis et al., 2011). 
 
1.6. Stalling of ribosomes and mammalian mitochondria 
1.6.1. What do we know ? 
So far no mechanism accountable for the rescue of stalled mitoribosomes has 
been identified. However, there is no evidence for mitochondrial protein 
synthesis to be error-free. On the contrary, mitoribosomes are anticipated to 
encounter issues with progression, such as stalling, but the cause and the ways 
to overcome it are yet to be determined. As discussed in section 1.2, given the 
presumed α-proteobacterial origin of mitochondria (Gray et al., 1999) many 
processes involved in mt-genes expression are modelled on the bacterial 
system (Smits et al., 2010b). However, so far no tmRNA-like apparatus was 
found in mitochondrial genomes. There was a tRNA species that resembled 
upstream part of the tmRNA identified in the mt-genome of a primitive species 
Reclinomonas americana (Keiler et al., 2000). The tRNA fragment, however, 
was not coupled with an open reading frame, which suggested lack of function. 
Therefore it is unlikely that the mechanisms of ribosome rescue similar to 
tmRNA would be present in any mitochondrial genome. The unique features of 
the mitochondrial genome and protein synthesis apparatus suggest that various 
aspects of these processes including quality control would exhibit 
mitochondrial-specific characteristics. Especially distinctive features of 
mitoribosome architecture (1.2.1) would most likely determine the special 
quality control pathways. Despite the uniqueness of the mitochondrial 
translational system, the analysis of mt-proteins with bacterial homologues of 
known function in quality control may still be the best way to commence the 
search for potential rescue factors. This approach can be enforced with 
additional identification of factors transiently interacting with mitoribosome. The 
only candidates for the rescue of mitoribosomes proposed so far are members 
of so called mitochondrial release factor family. The family was identified 
through bioinformatics screening based on the shared feature: presence of the 
GGQ motif (Richter et al., 2010a; Rorbach et al., 2008a). As presented in 
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section 1.2.4, the highly conserved GGQ motif is characteristic to all class I 
release factors (Frolova et al., 1999). Human mitochondrial release factor family 
consists of 4 proteins but only one of them, mtRF1a, is a bona fide release 
factor that operates during termination of all mt-polypeptides translation 
(Soleimanpour-Lichaei et al., 2007; R. Temperley et al., 2010). However the 
function of the remaining 3 members: mtRF1, ICT1 and C12orf65 is still 
unknown. Each member of this family will be characterised and discussed in 
details in the following subsection. 
 
1.6.2. Mammalian mitochondrial release factor family 
mtRF1 
The first member of the mitochondrial release factor family is protein mtRF1, 
which is exclusively present in vertebrates and originated from mtRF1a gene 
duplication (Soleimanpour-Lichaei et al., 2007; Young et al., 2010). As 
discussed in 1.2.4, this protein was primarily a candidate for a canonical release 
factor but eventually failed to display the peptidyl-tRNA hydrolysis activity both 
in vitro and in vivo (Soleimanpour-Lichaei et al., 2007). The structure of mtRF1 
resemble the bacterial class 1 RFs, as well as the mtRF1a, with which it shares 
39% of sequence similarity (Huynen et al., 2012). It contains both of the 
functionally important domains: the GGQ domain and stop codon recognition 
domain. The latter, however, varies from the prokaryotic recognition sequence 
(hexapeptide PEVGLS instead of tripeptide PXT) (Duarte et al., 2012; Huynen 
et al., 2012). The 3D modelling of mtRF1 predicted that it could bind to the 
empty A-site of the mitoribosome in the absence of mRNA. Based on this 
observation an involvement of mtRF1 in the rescue of the stalled mitoribosomes 
with an empty A-site was proposed (Huynen et al., 2012). However, the exact 
role, especially in the context of mt-translation quality control is yet to be 
uncovered (Chrzanowska-Lightowlers et al., 2011; Huynen et al., 2012). 
 
ICT1 
Of all members of mitochondrial release factor family ICT1 (Immature Colon 
Carcinoma Transcript-1), has been the most successfully characterised so far. It 
was first identified as a downregulated transcript in colon carcinoma cell line 
during in vitro differentiation and at that point no connection to mitochondria 
was made (van Belzen et al., 1998, 1995). The following experiments 
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conducted in my host lab characterised ICT1 as a protein associated with 
mtRRF (Rorbach et al., 2008a). Further analysis of ICT1 structure showed that 
the mature protein (175 aa) lacks the codon recognition sequences but contains 
functional GGQ domain. ICT1 retained the peptidyl-tRNA hydrolysis activity but 
it is codon-independent (Richter et al., 2010b). Interestingly this protein was 
also identified as an integral part of the mitoribosome, which was recently 
confirmed in the cryo-EM structures of the mt-LSU supported by the cross-
linking proteomic analysis (Fig. 1.9) (Greber et al., 2013) as discussed in 1.2.1. 
The presence of ICT1 in mitoribosome was consistent with observed disruption 
of ribosome structure and decrease in de novo mt-protein synthesis due to ICT1 
depletion (Richter et al., 2010b). The solution structure analysis of ICT1 showed 
3 main parts of the protein namely: 1) N-terminal mt-targeting signal, 2) 
structured domain containing GGQ motif and 3) unstructured C-terminal tail 
enriched with positively charged amino acids (Yoshihiro Handa et al., 2010). 
The GGQ-containing domain topology, β1-β2-α1-β3- α2 resembles the one in 
bacterial RF2, except for the additional α-helix inserted between β2 and β3 in 
ICT1.  
ICT1 has a bacterial homologue, which is a previously described protein YaeJ 
(1.3.2). Comparison of structures between ICT1 and YaeJ showed high level of 
similarity but not complete (Gagnon et al., 2012; Yoshihiro Handa et al., 2010; 
Kogure et al., 2014). The main difference is present in the N-termini, as ICT1 is 
a mitochondrial protein with targeting sequence. Although both proteins contain 
an additional insertion in the GGQ-domain, in case of YaeJ it is a β-strand not a 
α-helix (Kogure et al., 2014). The C-terminal tail of YaeJ, which structure and 
composition were important for the ribosome binding function and PTH activity 
are conserved in ICT1 (Kogure et al., 2014). All shared features between ICT1 
and YaeJ that also distinguish these 2 proteins from canonical RFs suggest a 
similar, potentially conserved function. YaeJ, as ICT1, was characterized with 
codon-independent peptide release activity (Kogure et al., 2014; Wesolowska et 
al., 2014). However, YaeJ is not an integral part of a ribosome, nor can it 
substitute for ICT1 and stably interact with the mitoribosome (Wesolowska et 
al., 2014). This result clearly distinguishes the mechanism of action of these 
proteins. YaeJ is expected to transiently interact with an empty A-site of the 
ribosome, where it is able to catalyze the release of the peptide from the stalled 
complex (Gagnon et al., 2012; Kogure et al., 2014).  
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Figure 1.9. Position of ICT1 in the mt-LSU 
Structure of the large mitoribosomal subunit (subunit interface side). Ribosomal 16S 
RNA is depicted in orange, mitoribosomal proteins in cyan. The position of ICT1 in the 
central protuberance (CP) is boxed in red, A-site and P-site tRNAs are presented in 
purple and yellow respectively. Adapted from (Greber et al., 2014). 
 
ICT1 is placed in the mitoribosomal central protuberance far from the peptidyl 
transferase centre (Fig. 1.9), which prevents the unrestricted PTH activity 
(Greber et al., 2013). Therefore, in order for ICT1 to utilize the GGQ motif, the 
mitoribosome would require significant conformational changes to the structure. 
Despite the growing evidence and similarities to known ribosome rescue 
factors, the involvement of ICT1 in relieving of stalling, as well as the exact 
mechanism of action are yet to be confirmed.  
 
C12orf65 
The last member of the mitochondrial release factor family, a protein called 
C12orf65, was first characterised in case of 2 unrelated patients with Leigh 
syndrome (Antonicka et al., 2010). Both patients harboured frameshift 
mutations (210delA and 248delT) in C12orf65 gene resulting in a premature 
stop codon. In each case patients’ skin fibroblasts showed impairment of mt-
protein synthesis, lower CIV activity and defects in CI, IV and V assembly. 
Since then a number of different patient reports have been published (Buchert 
et al., 2013; Haruo Shimazaki et al., 2012; Spiegel et al., 2014; Tucci et al., 
2013) confirming the importance of this protein for proper mitochondrial 
translation (discussed more thoroughly in chapter 4). 
ICT1
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Figure 1.10. Comparison of the GGQ domain structures from C12orf65, 
ICT1 and bacterial class I release factor. 
Individual structures of GGQ domains of C12orf65 (A) bacterial RF (B) and ICT1 (C). 
The exact position of the GGQ motif is depicted by brackets in all 3 structures. The 
additional α-helix insertion in ICT1 (C) also presented by brackets. Alignment of the all 
3 structures (D), C12orf65 and RF (E) and C12orf65 and ICT1 (F) in order to facilitate 
comparison of topological features. Adapted from (Kogure et al., 2012) 
 
The solution structure of C12orf65 was resolved and showed high similarity to 
ICT1. As ICT1, C12orf65 consists of 3 major parts (N-terminal part with 
targeting sequence, GGQ domain and C-terminal tail). It also lacks the codon 
recognition domain, hence it is much smaller than canonical release factors 
(~190 residues instead of ~360) (Kogure et al., 2012). The structure of the GGQ 
domain displays the following topology: 310-β1−β2−β3−α1 with the GGQ motif is 
located in a loop between β1 and β2 (Fig. 1.10 A). As the GGQ domain of 
C12orf65 lacks the insertion between β2 and β3, it resembles the bacterial 
RF2’s domain 3 more closely than the GGQ domain in ICT1 (Fig. 1.10 D). 
Differences between C12orf65 and ICT1 are also visible in their mitochondrial 
localization as C12orf65 was identified as a free matrix protein, not a part of 
mitoribosome (Antonicka et al., 2010). Finally, unlike ICT1, C12orf65 did not 
display PTH activity in vitro (with or without the presence of a stop codon) 
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(Antonicka et al., 2010). However, the in vitro experiments were performed on 
bacterial 70S ribosomes, hence it is possible that the lack of 55S mitoribosome 
or some mitochondrial specific factors was impeding the C12orf65 function. 
Interestingly, overexpression of ICT1 in patient fibroblasts was able to partially 
rescue the pathological phenotype (Antonicka et al., 2010). This result 
suggested that these proteins may share some functions or take part in similar 
processes. 
Apart from the patient case, the potential function of C12orf65 was also studied 
in HeLa cells with siRNA-mediated knockdown (Kogure et al., 2012). Lack of 
C12orf65 caused a decrease in cell growth as well as lower complex IV activity. 
It therefore, confirmed that C12orf65 is necessary for cell viability and proper 
mitochondrial function (Kogure et al., 2012). The same experiments were 
performed on ICT1-depleted cells and they also displayed cell and 
mitochondrial function defects. However, the lack of ICT1 had more detrimental 
effect than the lack of C12orf65 (Kogure et al., 2012). These results together 
with the partial-rescue with ICT1 overexpression in C12orf65 patient fibroblasts 
(Antonicka et al., 2010) suggest the possibility that both proteins may have 
overlapping but not identical functions. As observed in E. coli, where at least 3 
different ribosome rescue mechanisms exist it is possible that mitochondria are 
also equipped with multiple tools to alleviate stalling. 
 
1.7. Aims of this study   
The main goal of the first part of my PhD project was to characterise the 
function of C12orf65 and explore its role in mitochondrial translation. The strong 
indication that C12orf65 is essential for synthesis of mitochondrial proteins was 
based on patient reports, mainly (Antonicka et al., 2010). As presented in my 
introduction (1.6) there are a number of pieces of evidence that suggest the 
potential involvement of C12orf65 in quality control of mt-translation. The 
investigation of C12orf65 function in relation to this hypothesis was commenced 
by Dr. Aleksandra Pajak. Thus my objective was to carry on experiments in 
order to broaden the knowledge on the role of C12orf65. 
Main goals for experiments included in this part of my project were as follows: 
• Complete characterisation of C12orf65 mitochondrial distribution. 
• Establish if the C12orf65 GGQ motif is functional and necessary for the 
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cell viability utilizing cell lines expressing mutated forms of this protein 
(AGQ and GSQ mutations). 
• Investigate the effect of C12orf65 depletion on mt-translation (de novo 
protein synthesis and steady state levels of mt-proteins). 
• Investigate how mitochondrial transcripts are affected in C12orf65 
depleted cells. 
 
In order to expand characterisation of C12orf65 function an additional set of 
experiments was performed utilizing immortalized skin fibroblast of a patient 
who was diagnosed with 210delA mutation in C12orf65. This mutation was 
predicted to cause a frameshift change to the gene sequence that would result 
in premature stop codon. A patient harbouring the exact same mutation was 
described in the report by (Antonicka et al., 2010). The initial biochemical 
analysis of patient fibroblasts (carried in Mitochondrial NCG Diagnostic Service) 
showed decrease in complex IV activity. The clinical presentation varied from 
the original report, so I performed a series of experiments focused on 
identification of changes to mitochondrial gene expression in this patient’s cells 
at the molecular level. 
Experimental aims for the analysis of patient cell line in the second part of my 
project included: 
• Comparison of the growth rate between patient and control cell lines. 
• Assessment of the mitochondrial protein synthesis levels (de novo 
translation and steady state levels of mt-proteins). 
• Investigation of the changes to the levels of mitochondrial transcripts. 
 
The third and last part of my project was focused on addressing the challenges 
involved in investigation translation quality control in mitochondria. Given the 
hypothesis that C12orf65 is a potential candidate to rescue stalled 
mitoribosomes it was necessary to develop an appropriate tool to study 
changes to ribosome progression. A method called ribosome profiling was 
selected for this purpose. Ribosome profiling was developed to combine 
advantages of nuclease protection assay with deep sequencing (Ingolia et al., 
2009). Fragments of mRNA that are protected by ribosomes from RNase 
digestion are sequenced and aligned to reference genome. Results represent 
the map of ribosome distribution across transcripts (ribosome profiles) and 
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allow genome-wide analysis of translation in vivo. Differences in ribosome 
densities within particular transcript can be used to infer variation in ribosome 
progression: high number of ribosomes at specific region is likely to be a result 
of slower ribosome movement within it (Ingolia, 2014). At the beginning of my 
project there were no published cases of ribosome profiling conducted on 
mitochondria. Therefore, my first aim was to adjust the present protocols 
(Ingolia, 2010; Ingolia et al., 2012) in order to apply them on mitoribosome 
protected fragments. The new protocol was designed for sequencing using 
IonTorrentTM. This approach was later adjusted for Illumina platform according 
to the first published results of ribosome profiling in human mitochondria 
(Rooijers et al., 2013). The objective of this part of my project was to apply 
optimized protocol to analyse mitoribosome profiles from wild type cell lines. 
 
These experiments were aimed to provide the following information:  
• Identify a general pattern for the mitoribosome distribution across mt-
transcripts. 
• Identify naturally occurring regions were there is a higher accumulation of 
mitoribosomes. 
• Test for specific mRNA sequences that would cause stalling (such as 
overlapping sequences in bicistronic transcripts). 
Finally the mitoribosome profiling experiments were applied to cell lines where 
stalling of mitoribosomes was expected. First of the cell lines carried a C25U 
mutation in mt-tRNAVal that reduced levels of its aminoacylated form (Hornig-Do 
et al., 2014; Rorbach et al., 2008b). Due to deficiency of mt-tRNAVal 
mitoribosomes were expected to stall during translation of valine codons. In 
addition, the cell line version selected for these experiments was stably 
transfected with valyl-tRNA synthetase (VARS2) which was shown to partially 
rescue the tRNAVal deficiency (Hornig-Do et al., 2014).  
 
The experiments on mt-tRNAVal mutant cell line aimed to establish: 
• If mitoribosomes stall on valine codon in the mutant cell line 
• Is the stalling prevented by overexpression of VARS2? 
• Develop data analysis approach for identification of stalling sites in 
mitoribosome profiles. 
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The second cell line used in the final part of my PhD project was depleted of 
C12orf65 via siRNA treatment. The analysis of mitoribosome profiles from this 
cell line was compared to non-targeting control in order to answer: 
• Is there more evidence of mitoribosome stalling in the absence of 
C12orf65 than in control cells? 
• Can involvement of C12orf65 in the rescue of stalled mitoribosomes be 
confirmed based on these experiments? 
 
The following chapters will describe results of experiments performed to 
address the presented questions for each part of my PhD project. !  
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Chapter 2 
 
Materials and methods 
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2.1. Mammalian cell culture 
2.1.1. Culturing and storage of cells  
Cell lines used in this study: 
• HEK293T FLP-IN TRex (Invitrogen) 
• U2OS wild type 
• 143B.206 
• T1V1 trans-mitochondrial cybrid with m.1624C>T mutation in mt-tRNAVal, 
stably expressing mitochondrial valyl-tRNA synthetase (VARS2) 
• HEK293T inducibly expressing FLAG tagged C12orf65 wild type with 
silent mutation in C12orf65 
• HEK293T inducibly expressing FLAG tagged C12orf65 AGQ mutant with 
silent mutation in C12orf65 
• HEK293T inducibly expressing FLAG tagged C12orf65 GSQ mutant with 
silent mutation in C12orf65 
• Immortalised patient fibroblasts with c.210delA, p.(Gly72Alafs*13) 
mutation in C12orf65!
• Immortalised Control fibroblasts 
 
HEK293 WT, U2OS WT, 143B cell lines used in this study were grown as 
monolayer cultures in Dulbecco’s Modified Eagle’s Medium (SIGMA 6429) 
supplemented with 10% foetal calf serum (FCS), 1x nonessential amino acids 
(NEAA) and 50 µg/ml uridine. The basic culture was performed in 75 cm2 
vented flasks under standard conditions (37°C, 5% CO2, humidified 
atmosphere) with 15 ml of DMEM. Growth medium was changed every 3 days 
and when cells reached 80% of confluency they were split and reseeded in new 
flasks. Cells were stripped by incubation in PBS / 1 mM EDTA and pelleted by 
centrifugation at 220x g for 4 min. Pellets were then resuspended in growth 
media and 1/2 -1/10 (depending on initial confluency) was reseeded in new 
flasks.  
Stable transfection cell lines expressing FLAG tagged variants of C12orf65 
were grown as untransfected cell lines with addition of BlasticidinS (10 µg/ml 
final concentration, in order to retain the tetracycline repressor) and 
HygromycinB (100 µg/ml final concentration, to repress growth of cells devoid of 
expression construct) every third passage. During culturing of T1V1 cell lines 
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addition of HygromycinB was omitted. Immortalised patient and Control 
fibroblasts were also grown in DMEM (SIGMA 6429, supplemented with 10% 
FCS, 1x NEAA and 50 µg/ml uridine). For passage of these cell lines 1x Trypsin 
(Sigma) in PBS/EDTA solution was used. Cells were split maximum 1:5. 
In order to store cell lines, cells grown in 75 cm2 flasks to ~ 80% confluence, 
were stripped, pelleted and resuspended in ice-cold FCS with 10% DMSO. Cell 
suspensions were kept on ice for ~5 min and then transferred to 
cryopreservation tubes, placed in polystyrene container, overnight at -80°C. 
Afterwards they were transferred to liquid nitrogen.  
 
2.1.2. Mycoplasma testing 
Mycoplasma test were kindly performed by Mrs. Debra Jones using MycoAlert® 
Mycoplasma Detection Kit (Lonza) following the manufacturer’s instruction. In 
case of an infection, cells were treated with Plasmocin (1:1000) for minimum 2 
weeks and the Mycoplasma test was repeated. 
 
2.1.3. Cell counting 
For the experiments comparing fibroblast cell growth on different carbon 
sources, cells cultured in a standard way (2.1.1) were seeded in 6-well plates (2 
ml of media per well). To investigate the growth on galactose, medium after one 
day was replaced with DMEM lacking glucose, supplemented with 0.9 mg/ml 
galactose and dialyzed FCS. For testing the growth on glucose, cells were 
cultured in the standard DMEM. At chosen time points cells were counted by 
adding 10 µl of cell suspension mixed with 0.4% Trypan blue solution (Sigma, in 
order to distinguish between live and dead cells) to haemocytometer (Hawksley, 
depth 0.1 mm, 1/400 mm2). Mean values of the counts taken from 8 peripheral 
squares were calculated and the count was multiplied by 10,000, giving the 
amount of cells/ml.  
 
2.1.4. siRNA transfection to mediate transcript depletion 
siRNA mediated depletion was performed in 6-well or in 24-well plates on wild 
type HEK293-Flp-InTM cells or on stable transfected cell lines named: HEK-
C12orf65-WT, HEK-C12orf65-AGQ or HEK-C12orf65-GSQ cell lines. For the 6-
well plates 100,000 of cells were seeded per well (in 1.25 ml DMEM) on the day 
of transfection. For the experiments in 24-well plates 30,000 cells in 400 µl 
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of DMEM per well were seeded a day before transfection. For each transfected 
well a tube was prepared containing a mixture of Opti-MEM® + GlutatmaxTM 
(Gibco 51985-026), siRNA (siC12orf65 or non-targeting, 20 µM stock) and 
Lipofectamine RNAiMAX (Invitrogen) in proportions as described in Table 2.1. 
The mix was incubated at room temperature for 10-20 min and then added to 
cells. The siRNA treatment for the ribosome profiling experiments was 
performed in 15 cm diameter dishes on wild type HEK293-Flp-InTM. The siRNA 
mixture (Table 2.1) was incubated in plates for 20 min at room temperature, 
after which the cells (in 20 ml DMEM) were added.  
In each case, after 3 days cells were harvested or re-transfected for another 3 
days. The re-transfection was carried by removing the old media and adding the 
same volume of the fresh one with the same amount of siRNA and transfections 
reagents.  
 
Table 2.1. Proportions of siRNA treatment mixture 
Reagent 24-well plate 6-well plate 15 cm diam. dish  
Opti-MEM 100 µl 250 µl 4.5 ml 
siRNA (20 µM) 1.5 µl 3.75 µl 66.6 µl 
Lipofectamine 0.8 µl 2 µl 36 µl 
 
Each siRNA was custom synthesised by Eurogentec (Table 2.2) and stored at 
 -20 °C as 20 µM or 100 µM stocks in RNase free water. 
 
Table 2.2. Sequences of all siRNAs used in this project 
Name Sequence 
siRNA- C12orf65 5’-GGG AGA AGC UGA CGU UGU U dTdT 
siRNA NT siRNA non-targeting negative control duplex OR-0030- 
NEG05 
 
2.1.5. Transient transfection and generation of stable cell lines 
(HEK293, U2OS) 
Stable cell lines were generated by integration of the sequences from 
pcDNA5/FRT/TO, tetracycline inducible expression vector (Invitrogen) with the 
gene of interest (GoI). Two types of cell lines, HEK293-Flp-InTM T-RexTM and 
U2OS-Flp-InTM T-RexTM, were transfected with pcDNA5/FRT/TO/GoI and 
pOG44 vectors (Ampicillin and HygromycinB resistant) using the 1:5 or 1:7.5 
ratio, following the protocol from Superfect Transfection Reagent Handbook 
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(Qiagen). Stable transfection reactions were carried in 6-well plates seeding 
100000 cells/well. 
Transient transfection of U2OS cells was performed only with pcDNA5/FRT/TO 
vector containing the gene of interest (2 µg DNA) and Superfect Transfection 
Reagent using 1:7.5 ratio according to the manufacturer’s instructions. 
Transient transfection reactions were carried in the 24-well plates seeding 
25000 cell per well.  
 
2.2.  Bacterial cell manipulation 
2.2.1. Bacterial culture 
All bacterial strains were grown in LB media or on LB agar plates (detailed 
below). For plasmid amplification, bacteria were grown at 37°C, overnight in 
suspension, with aeration in the presence of appropriate antibiotics. For the 
long term storage at -80°C, bacteria were suspended in LB media with 15% 
glycerol (v/v). 
 
Lysogeny Broth (LB) medium, pH 7.5:  
1% Bacto-tryptone 
0.5% Yeast extract 
1% NaCl 
    for plates : 2% agar  
 
2.2.2. Bacterial transformation 
The α-select chemically competent cells (BIO-85025, Bioline) were transformed 
with pcDNA5/FRT/TO/FLAG-tagged protein GoI expression vector according to 
the manufacturer’s instructions. Selection of the transformants was performed 
overnight on the LB plates (2.2) with 100 µg/ml ampicillin. Transformed strains 
with the plasmid of interest were stored at -80°C (as in 2.2). 
 
2.2.3. Plasmid DNA purification 
Positively transformed cells were grown in 5 ml LB with ampicillin overnight at 
37°C. The plasmids were isolated using GeneJET Plasmid Miniprep Kit 
(Thermo Scientific) according to the manufacturer’s instructions and eluted with 
50 µl of elution buffer. 
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2.3. Cloning and DNA manipulation 
2.3.1. PCR 
PCR reactions that required proofreading polymerase activity (in order to 
amplify fragments for cloning) were performed with KOD hotstart polymerase 
(Novagen) in 50 µl of volume (Table 2.3 A and B). Other amplification reactions 
were carried with DreamTaq polymerase (Thermo Scientific, FEREP0701) in 20 
µl of volume (Table 2.4 A and B). Primers used in this study are listed in the 
specific subsection. 
 
Table 2.3. Components and conditions for PCR with KOD hotstart 
polymerase 
A.  
Components [stock] Volume 
KOD buffer [10x] 5 µl 
dNTPs [2 mM] 5 µl 
MgSO4 [25 mM] 3 µl 
Forward primer [10 µM]  1.5 µl 
Reverse primer [10 µM] 1.5 µl 
H2O 30 µl 
KOD Polymerase [1U/ µl] 1.5 µl 
Template (cDNA) 3 µl 
 
B. 
Stage Temperature Time 
Hold 94˚C 5 min 
30 
cycles 
95˚C 1 min 
54˚C 1.5 min 
72˚C 2.5 min 
Hold 72˚C 7 min 
Hold 4˚C ∞ 
 
Table 2.4. Components and conditions for PCR with DreamTaq 
polymerase. 
A. 
Components [stock] Volume 
DreamTaq buffer [10x] 2 µl 
dNTPs [2 mM] 2 µl 
Forward primer [10 µM]  0.15 µl 
Reverse primer [10 µM] 0.15 µl 
H2O 14.5 µl 
Dream Taq polymerase [5 U/ µl] 0.125 µl 
Template (15 ng DNA) 1 µl 
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B. 
Stage Temperature Time 
Hold 95˚C 3 min 
35 
cycles 
95˚C 1 min 
52˚C 1 min 
72˚C 1 min 
 72˚C 8 min 
Hold 4˚C ∞ 
 
2.3.2. Electrophoresis 
Regular 1% agarose and low-melt 1% agarose gels were prepared as follows: 
agarose was dissolved in the 1x TAE buffer (40 mM Tris acetate, 1 mM EDTA 
pH 8.0) in a microwave. After cooling, either ethidium bromide (0.5 µg/ml final 
concentration) or GelRed (Biotium, 1:10000 dilution) was added in order to 
visualize DNA by UV light. Samples, mixed with loading dye (1 µl of 10x buffer 
per sample, as described below) were loaded on the gel along the 1 kb ladder 
(molecular weight marker). The gel electrophoresis was carried at constant 
voltage (60- 80V) in 1x TAE buffer. 
 
10x loading buffer:  
-  0.25% bromophenol blue   
-  0.25% xylene cyanol FF   
-  30% (v/v) glycerol   
 
2.3.3. Purification of PCR products 
PCR products were size selected via electrophoresis in 1% low melting agarose 
gel. Next, they were extracted from gels and purified using the QIAquick Gel 
extraction kit (Qiagen) according to the manufacturer’s instructions.  
 
2.3.4. Digestion with restriction enzymes 
The restriction digestion with both XhoI (1U per reaction, NEB) and HindIII 
(0.5U per reaction, Roche) was performed in the 20 µl final volume using buffer 
2 (B7002S, New England Biolabs), following the manufacturers’ protocol. 
Samples were incubated at 37°C for 3 h. 
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2.3.5. Dephosphorylation 
Vectors subjected to dephosphorylation were treated with alkaline phosphatase 
(Roche) for 30 min at 37°C supplemented with 0.5 % SDS in 100 mM Tris- HCl 
pH 9.0. The enzyme was denatured by incubation at 50°C for 30 min. 
 
2.3.6. Phenol/chloroform purification 
The volume of each sample was increased to 100 µl with dH2O and then 100 µl 
of phenol pH 7.9 was added. Samples were mixed by vortexing and centrifuged 
for 2 min at 14,000 x g. The aqueous, upper phase was removed, transferred to 
a new tube and an equal volume of chloroform was added. Samples were 
vortexed and centrifuged again. DNA from the aqueous phase was precipitated 
with 0.3 M sodium acetate (final concentration), 96% ethanol (2.5x sample 
volume) and 1 µl of linear acrylamide by incubation at -80°C for at least 1h. The 
samples were then centrifuged at 20,000 g, 4°C for 30 min. After ethanol was 
removed, the DNA pellets were resuspended in 10 µl of sterile dH2O. 
 
2.3.7. Ligation 
The ligation of the digested PCR product and the linear vector (molar ratio of 
insert to vector 1:3) was conducted using Rapid DNA Ligation kit (Thermo 
Scientific) according to the manufacturer’s protocol. Samples (20 µl final 
volume) were incubated for 5 min at 22°C. 
 
2.3.8. Measurement of DNA concentration 
DNA concentration of samples diluted in either dH2O or TE buffer was 
measured using NanoDrop Spectrophotometer ND-1100. For double stranded 
DNA a millimolar extinction coefficient of 50 was used and 40 for RNA, 30 for 
ssDNA. 
 
2.3.9. Sequencing 
Sequencing was kindly performed by Mrs. Charlotte Alston using 3130xl 
Genetic Analyzer (Applied Biosystems) and BigDye® Terminator v3.1 kit 
according to the manufacturer’s instructions. Sequencing of PCR reactions 
were conducted as follows: 1 µl sequencing primer (5 µM stock, listed in Table 
2.5), 500 ng DNA, 1.5 µl 5x Sequencing Buffer v3.11 and 3 µl BigDye 
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Terminator v3.1 were made up to the final volume of 20 µl. The PCR reaction 
conditions are described in Table 2.6.  
 
Table 2.5. Sequencing primers 
Name Sequence (5’-3’) 
CMV Forward CGCAAATGGGCGGTAGGCGTG 
BGH Reverse TTAGAAGGCACAGTCGAGG 
 
Table 2.6. Sequencing PCR conditions 
Stage Temperature Time 
Hold 95˚C 5 min 
30 
cycles 
95˚C 30 s 
50˚C 10 s 
60˚C 4 min 
Hold 4˚C ∞ 
 
PCR products were precipitated in 96 well plate. To each sample 10 µl Hi-Di 
was added then they were incubation at 95°C for 2 min and loaded on the 
analyser. SeqScape v2.6 software (Applied Biosystems) to analyse data. 
 
2.4. RNA manipulation 
All experiments involving RNA were performed using DEPC-treated water. 
DEPC was added to dH2O at the final concentration of 0.1% and then 
autoclaved. 
 
2.4.1. RNA isolation  
RNA isolation from human cells was conducted using Trizol Reagent 
(Invitrogen) following manufacturer’s instruction. The pellet of harvested cells 
was resuspended in 0.5 ml (or 1 ml, depending on pellet volume) of Trizol and 
the solution was incubated for 5 min at room temperature. Then 0.1 ml (0.2 ml) 
of chloroform was added and each sample was vortexed for 15 s and 
centrifuged at 12000 x g at 4°C. The clear supernatant was collected and 
transferred into a new tube with 0.25 ml (0.5 ml) of isopropanol. Samples were 
mixed and then incubated at room temperature for 10 min. RNA was pelleted by 
centrifugation for 15 min, 12000 x g at 4°C. Pellets were washed with 0.5 ml (1 
ml) 75% ethanol, centrifuged for 5 min, 7500 x g at 4°C. Final pellets were 
resuspended in 10-30 µl of DEPC-H2O. 
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2.4.2. Northern blotting 
RNA samples (20 µl final sample volume) containing 1-4 µg of RNA in 8 µl of 
DEPC-H2O, 1x MOPS, 35% (v/v) formamide and 5.5% (v/v) formaldehyde. First 
samples were incubated at 55°C for 15 min, then cooled down and 1x RNA 
loading buffer and ethidium bromide (0.1 µg/ µl final concentration) were added. 
Samples were electrophoresed in the 1.2% (w/v) denaturing agarose gel (1x 
MOPS pH 7.2, 0.9% formaldehyde). The separation of the samples was 
performed in 1x MOPS buffer pH 7.2 (50 V) for approximately 6 h. The samples 
were transferred onto the GeneScreen Plus membrane overnight in 10x SSPE 
buffer. After transfer, the membrane was vacuum dried at 80°C for 2h followed 
by incubation with prehybridisation buffer (50% v/v formamide, 5x SSPE, 1% 
w/v SDS and 5x Denhardt’s solution) for minimum 2 h at 42°C.  
The probes for labeling specific mt-transcripts were prepared as follows: DNA 
fragment in DEPC-H2O (9 µl volume) was denatured at 95°C for 4 min, then 
placed on ice and mixed with 3 µl random hexamer mix (containing dGTP, 
dATP, TTP and 5x buffer), 5 U Klenow DNA polymerase I and 2 µl of [32P]- 
dCTP (~ 10-20 µCi, PerkinElmer NEG513H). Reactions were incubated at 37°C 
for 1 h.  
The volume of samples was increased to 50 µl with DEPC-treated water and 
purification was conducted using illustra Microspin G-25 spin columns (GE 
Healthcare) according to the manufacturer’s instructions. The activity of purified 
probes was measured with a Cerenkov counter and minimum of 500000 cps 
was added 10 ml hybridisation buffer. Membranes were incubated with the 
probe in hybridization buffer overnight at 42°C, then washed twice with 2x 
SSPE for 15 min at room temperature. The final wash was performed for 15 min 
at 65°C with 2x SSPE / 2% SDS buffer. Next membranes were exposed to a 
Phosphor-Imager screen. The visualisation and analysis of the signal form 
radiolabelled RNA species was conducted using TyphoonTM PhosphoImager 
and ImageQuant software (GE Healthcare). For the purpose of reprobing of 
membranes they were washed twice with boiling 0.1x SSC and once with 0.1x 
SSC/ 0.1% (w/v) SDS in order to strip previous signals. Next, membranes were 
prehybridised as described above prior to adding a new probe. 
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10x MOPS-buffer (pH 7.2)      20x SSPE (pH 7.4)  
0.4 M Morpholinopropanesulfonic acid (MOPS)  3 M NaCl  
0.1 M NaOAc       0.2 M NaH2PO4 
10 mM EDTA        20 mM EDTA  
 
10x RNA loading buffer     5x random hexamer mix 
50% (v/v) glycerol     250 mM Tris/ HCl (pH 7.5)  
1 mM EDTA      50 mM MgCl2 
0.25% (w/v) bromophenol blue   5mM DTT  
0.25% (w/v) xylene cyanol     0.5 mM dATP 
       0.5 mM dGTP 
20x SSC      0.5 mM dTTP 
3M NaCl  
0.3 M Na-citrate 
 
2.4.3. Reverse transcription 
Reverse transcription reactions on total RNA were carried using either Super 
Script® VILOTM Mastermix (Life Technologies, 11755050) or SuperScript® III 
First-Strand Synthesis System (Life Technologies 18080-051). In both cases 
reactions were performed according to the manufacturer’s instructions in 20 µl 
volumes, using 300 ng of total RNA template and random hexamers (for 
SuperScript® III First-Strand Synthesis System only). 
 
2.4.4. Quantitative real time PCR  
The qPCR reactions were carried on cDNA templates. A list of all primers used 
is presented in Table 2.7. Dilution of template depended on the primers used 
(C12orf65: undiluted; VARS2L 1:10; 18S rRNA 1:100). Fast start essential DNA 
green Master kit (Roche, 06 402 712 001) was used. Each reaction was made 
up to 20 µl in the following way: 2 µl of cDNA template, 1 µl forward primer (10 
µM stock), 1 µl reverse primer (10 µM stock), 6 µl dH2O and 10 µl Fast start 
essential DNA green Master reagent (2x concentrated stock). LightCycler® 
Nano (Roche) was used with the reaction conditions as in Table 2.8. 
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Table 2.7. List of primers for qPCR 
 
Table 2.8. Profile and analysis condition for LightCycler®  Nano software 
Stage Temperature Ramp Time 
Hold 95˚C 5 600 s 
45 cycles 95˚C 5 10 s 
60˚C 4 10 s 
72˚C 5 15 s  ! 
Melting: initiation 65˚C 4 50 s 
Melting: final 95˚C 0.1 1 
Hold 4˚C - - 
! data generated after this step 
Analysis: automatic quantification, Tm calling 
 
2.5. Protein manipulation 
2.5.1. Preparation of cell lysate 
Pellets of harvested cells were washed once with PBS and resuspended in cold 
lysis buffer (50 mM Tris pH 7.4, 130 mM NaCl, 2 mM MgCl2, 1 mM PMSF, 
Protease Inhibitor Cocktail EDTA-free (Roche), 1% Nonidet P-40). Samples 
were incubated on ice for 15 min, vortexed 30 s and centrifuged at 1100 x g, 2 
min 4°C. In order to digest nucleic acids approximately 1 U of Benzonase® 
Nuclease (70746) was added per 100 µl. Supernatant was collected to a 
separate tube and stored at -80°C (longer than a few weeks) or -20°C (more 
immediate use). 
 
2.5.2. Mitochondrial isolation and lysis 
Mitochondria were isolated from cells grown in 75 or 225 cm2 flasks and 
harvested at ~80% confluency. Pellets were washed with Dulbecco’s PBS and 
Type  Name Sequence (5’-3’) Tm 
C12orf65 
Forward 
C12RTFor GTTTCTCGCATGCGCAGTCAGT 51.6°C 
C12orf65 
Reverse 
C12RTRev TCAGCGGAGGATTCGCAA 53.4°C 
VARS2L 
Forward 
VARS2LqPCRFor CTGATGCAGAGGTTGTGGTAG 49.2°C 
VARS2L 
Reverse 
VARS2LqPCRRev GCCCGTGTAGATGTGTGTATC 49.2°C 
18S rRNA 
Forward 
18S For GTAACCCGTTGAACCCAATT 60°C 
18S rRNA 
Reverse 
18S Rev CAATCCAATCGGTAGTAGCG 62°C 
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resuspended in homogenisation buffer (0.6 M Mannitol, 10 mM Tris pH 7.4, 1 
mM EGTA) supplemented with 0.1% BSA and 1 mM PMSF. The 
homogenisation was carried in Glass Col Homogeniser (15 passes) and the 
suspension was centrifuged at 400 x g, 10 min, 4°C in order to separate 
mitochondria (in supernatant) from unbroken cells (pellets). These two steps 
were repeated 3 times and the supernatants collected after each repeat were 
centrifuged at 11000 x g, 10 min, 4°C. Pelleted mitochondria were washed in 1 
ml homogenisation buffer (lacking BSA). Where required mitochondria were 
lysed using lysis buffer from the Sigma FLAG-IP kit (50 mM Tris pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with Protease Inhibitor 
Cocktail EDTA-free (Roche), 1 mM PMSF and 10 mM MgCl2. Lysis conditions 
were as follows: 30 min lysis with agitation at 4°C and centrifugation 12000 x g, 
10 min 4°C.  
 
2.5.3. Bradford measurement of protein concentration 
Measurement of protein concentration was carried using Bradford Assay. Cell 
or mitochondrial lysate (1 µl) were diluted in dH2O (800 µl final volume). In 
parallel a series of BSA standard dilutions (in 800 µl H2O) was prepared with 
following concentrations: 0, 2, 5, 10, 15 and 20 mg/ml. To each sample 
(experimental and standard) 200 µl of Bradford reagent (BioRad) was added, 
and voretxed. Next, 200 µl of each solution was loaded on the 96-well plate 
(experimental samples 4 times, standard in duplicates) and analysed in 
Microplate Reader (Elx800) measuring the absorbance of 595 nm. 
 
2.5.4. Blue native PAGE 
Mitochondria isolated from patient and control fibroblasts grown in 1x 300 cm2 
flasks (2.5.2) were resuspended in solubilisation buffer (50 mM NaCl, 50 mM 
imidazole-HCl, 2 mM 6-aminohexanoic acid, 1 mM EDTA, 1 mM PMSF). Next, 
protein concentration was measured (2.5.3) and the detergent, 
dodecylmaltoside (DDM, Sigma), was added at concentration 3.2 g/ g of 
protein. Solubilisation was carried on ice for 20 min, then samples were 
centrifuged at 20000 x g, 20 min, 4°C and the supernatant was transferred to a 
new tube. Protein concentration was measured again and samples containing 
equal amount of protein (25 µg) were prepared by adding Coomassie G250 
solution in solubilization buffer at detergent/dye ratio of 10 g/g. Samples 
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were separated on a 4.5  - 16 % gradient BN-PAGE (Table 2.9) under following 
conditions: 150 V, 4°C, approximately 4 h. The gel chamber was filled with deep 
blue cathode buffer (50 mM tricine, 7.5 mM imidazole, 0.02% Coomassie blue 
G-250, pH 7), which after approximately 20 min of electrophoresis was changed 
into slightly blue cathode buffer (50 mM tricine, 7.5 mM imidazole, 0.002% 
Coomassie blue G-250, pH 7). The bottom chamber was filled with anode buffer 
(25 mM imidazole-HCl pH 7.0). Gels were transferred to PVDF membranes 
(activated with 100% methanol) in Mini Trans-Blot (Bio-Rad, 1.5 h, 4°C 150mA 
with constant stirring) using transfer buffer (25 mM Tris, 200 mM glycine, 10% 
methanol). After transfer the blot was fixed in 8% acetic acid for 15 min in room 
temperature and immunostained (2.5.6) with antibodies specific to each 
complex (Table 2.10). 
 
Table 2.9. BN-PAGE gels composition (3.5 ml final volume) 
Stock solutions 4.5% 16%  
ReadySol IEF 40% T, 3% C 
Acrylamide solution (GE Healthcare) 
1.7 ml 6 ml 
100% glycerol  - 3 ml 
3x gel buffer (75 mM Imidazole-HCl, pH 
7.0 and 1.5M 6-aminohexanoic acid 
5 ml 5 ml 
dH2O 8.243 ml 0.935 ml 
TEMED 27 µl 19 µl 
10% APS 2.7 µl 1.9 µl 
  
Table 2.10. Primary antibodies used in Western blotting analysis of BN-
PAGE 
Name  Complex Company Cat.  No. Dilution Secondary Conditions 
NDUFB9 CI Abcam AB11928 1:1000 mouse O/N 4°C 
70kDa CII Mitosciences MS204 1:1000 mouse O/N 4°C 
Core2 CIII Abcam Ab14745 1:1000 mouse O/N 4°C 
COX4 CIV Abcam Ab14744 1:1000 mouse O/N 4°C 
ATP5 A CV Abcam Ab14748 1:1000 mouse O/N 4°C 
 
2.5.5. SDS-PAGE 
Proteins from samples (lysates from cell and mitochondria, sucrose gradient 
fractions) were separated on 12 or 14% Tris-glycine SDS-PAGE (Table 2.11). 
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Prior to loading samples were denatured in 1x (final concentration) loading 
buffer at 95°C for 3 min. Electrophoresis was carried in 1x running buffer at 15 
mA per 1 gel, alongside Spectra Multicolour Broad Range Protein Ladder 
(Thermo Scientific). 
 
Table 2.11. SDS-PAGE gels composition (5 ml final volume) 
Stock solutions 12%  
resolving gel 
14%  
resolving gel 
3.75% 
stacking gel 
30% acrylamide: 
bisacrylamide (29:1) 
2 ml 2.333 ml 0.625 ml 
3.75 M Tris-HCl (pH 8.5) 0.5 ml 0.5 ml - 
0.5 M Tris-HCl (pH 6.2) - - 1.25 ml 
dH2O 2.395 ml 2.062 ml 3.02 ml 
10% SDS 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 
10% APS 50 µl 50 µl 50 µl 
 
5x SDS-PAGE loading dye:             1x running buffer: 
312.5 mM Tris-HCl pH 6.8    192 mM glycine 
10% SDS      25 mM Tris 
50% glycerol      0.1 % SDS 
0.05% bromophenol blue 
0.25 M DTT  
 
2.5.6. Western blot 
Samples resolved on gels were immobilised on PVDF membrane (Immobilion-
P, Milipore, activated with 100% methanol) using Mini Trans-Blot (Bio-Rad) for 
wet transfer under following conditions: 1 h, 100 V, 4°C with constant stirring. 
After transfer, membranes were blocked with 5% milk in T-TBS buffer for 1 h at 
room temperature. 
 
1x Transfer buffer    T-TBS 
25 mM Tris     20 mM Tris-HCl pH 7 
192 mM glycine    0.5 M NaCl 
0.02% SDS     0.1% Tween 20 
15% methanol 
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The blocked membranes were incubated with primary antibodies (Table 2.12 A) 
overnight at 4°C and then washed 3x for 10 min with T-TBS. Incubation with 
secondary antibodies (Table 2.12 B) proceeded for 1 h at room temperature 
followed by the same washing procedure. Signals were detected with a use of 
ECL Plus reagent (Amersham) when visualised on X-ray films or 
Phosphoimager, or with ECL Prime kit (Amersham) for visualisation with 
ChemiDoc-MP (Bio-Rad), protocol according to manufacturer’s instruction. 
 
Table 2.12. Primary antibodies used in this study 
A. 
Protein  Size 
[kDa] 
Company Cat. 
number 
Dilution Secondary 
C12orf65 15 Eurogentec custom 1:500 rabbit 
C12orf65 15 Santa Cruz Sc-6024 1:200 goat 
C12orf65 15 Abnova FLJ386663 1:500 mouse 
CII 70kDa 70 MitoSciences MS204 1:1000 mouse 
ClpX 65 Abcam Ab68338 1:1000 rabbit 
Core2/UQCRC2 42 Abcam Ab14745 1:1000 mouse 
COX2 20 Molecular 
Probes 
A6404 1:1000 mouse 
DAP3 45 Abcam AB11928 1:1000 mouse 
FLAG M2 1 Sigma F1804 1:1000 mouse 
HSP60 60 BD 
Biosciences 
611562 1:1000 mouse 
ICT1 20 ProteinTech 10403-1-AP 1:1000 rabbit 
Lon-P 110 Sigma HPA002192 1:1000 rabbit 
MRPL3 39 Abcam AB39268 1:2000 goat 
MRPL45 35 ProteinTech 15682-1-AP 1:1000 rabbit 
MRPS26 25 ProteinTech 15989-1-AP 1:1000 rabbit 
MRSP27 45 ProteinTech 17280-1-AP 1:1000 rabbit 
mtRF1 48 Eurogentec custom 1:2000 rabbit 
NDUFB8 20 MitoSciences MS105 1:1000 mouse 
Porin/VDAC1 39 Abcam Ab14734 1:10000 mouse 
SLIRP 12 Abcam Ab51523 1:1000 rabbit 
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B. 
Name Raised 
in 
Company Cat. 
number 
Dilution 
Anti-Mouse/HRP rabbit Daco P0260  1:2000 
Anti-goat/HRP rabbit Daco P0449 1:2000 
Anti-Rabbit/HRP swine Daco P0339 1:3000 
 
2.6. Affinity purification of antibodies 
2.6.1. Expression and purification of GST-tagged fusion protein 
Liquid LB medium (1 l, supplemented with 100 µg/ml ampicillin) was inoculated 
with Rosetta cell culture (4x 5 ml) carrying pGEX vector with recombinant 
C12orf65 N-terminal GST fusion protein (generated by Dr. Pajak). Bacteria 
were grown at 37°C in a orbital shaker (200 rpm) until the culture reached 
OD600 = 0.4-0.6. At that point bacteria were induced with 1 mM (final 
concentration) IPTG (isopropyl-1-thio-b-D-galactopyranoside) overnight at 
16°C. Cells were then harvested by centrifugation at 5000 rpm (GST rotor), 4°C 
15 min. Pellets were washed with PBS (with 1x protease inhibitor cocktail 
(Roche), 1 mM PMSF, 1 µl Benzonase® Nuclease (70746)), resuspended by 
vortexing and incubated on ice for 20 min. The cell suspension was then 
sonicated with 15x 10 s pulses (Soniprep 150, 18 microns amplitude) and 
centrifuged at 30,000 x g in 4°C for 30 min. Collected supernatants were filtered 
(0.45 µm) and added to a column with 0.6 ml Glutathione Sepharose 4B beads. 
The column was then washed with sterile PBS and dH2O, prior to the overnight 
incubation at 4°C with agitation. This was followed by another series of 
washings: 5 times with 10 ml PBS (with proteinase inhibitor cocktail and 1 mM 
PMSF) and 5 times with 10 ml PBS. In order to elute the protein from the 
column, 600 µl of PBS containing 25 µl PreScission Protease, 1 mM EDTA and 
1mM DTT was added and the elution fractions were collected to separate 
tubes. 
2.6.2. Purification of antibodies using NHS-activated sepharose 
After the purification of the C12orf65 protein, a column with NHS-Activated 
Sepharose 4 Fast Flow (GE Healthcare) was prepared. Beads (1 ml) were 
added to 10 ml BioRad column and washed 3 times with cold 1 mM HCl. Next, 
the purified protein in elution buffer (4 mg of protein) was incubated on the 
column overnight at 4°C. After the incubation the flowthrough was saved and 
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the column was incubated with 0.1 M Tris-HCl pH 7.4 overnight, 4°C. Prior to 
application of the final bleed from the immunisation (generated by Eurogentec, 
Speedy protocol for Custom Anti-protein Polyclonal Antibody Production), the 
column was incubated with 8 M urea in PBS (3 h, 4°C with agitation) and 
washed twice with 10 ml PBS. The serum (7 ml) was added on the column and 
incubated overnight at 4°C with agitation. The flowthrough was saved and the 
incubation with 7 ml of serum was repeated. Finally, after the second 
flowthrough was collected, beads were washed 2 times with PBS, once with 
Tris-buffer/pH 8.0 (50 mM Tris-HCl pH8.0, 0.1% Triton X-100, 0.5 M NaCl), 
once with Tris-buffer/pH 9.0 (50 mM Tris-HCl pH 9.0, 0.1 % Triton X-100, 0.5 M 
NaCl) and once with sodium-phosphate-buffer/pH 6.3 (50 mM sodium 
phosphate pH 6.3, 0.1% Triton X-100, 0.5 M NaCl). The final elution of the 
antibodies was carried with 5 ml of Glycine-buffer/pH 2.5 (50 mM glycine pH 
2.5, 0.1% Triton X-100 and 0.15 M NaCl) that was added to the column, 
followed by immediate neutralization with 1ml of 1 M Tris-HCl pH 9.0. The 
eluted antibodies were then dialyzed twice against 1L of PBS at 4°C, overnight 
with stirring. In order to reduce the volume of dialysed antibodies Aquacide II 
(Calbiochem) was used. The reduced antibodies sample (1.250 ml) was 
supplemented with 10% glycerol and 0.02% of sodium azide for long term 
storage at -20°C. 
 
2.7. Isokinetic sucrose gradients 
Sucrose gradients were prepared in Ultra Clear open top tubes in 1 ml volume. 
Two different sucrose solutions (10% and 30% w/v) were prepared in 1x 
sucrose gradient buffer (see below). 0.5 ml of 10% solution was added to each 
tube. Then, with a use of a syringe, 0.5 ml of 30% solution was loaded carefully 
on the bottom of tube so that both solutions formed separate layers. Gradient 
was obtained in tilted tube rotation using 55 s programme (Biocomp Gradient 
Maker instrument). Tubes with gradients were incubated for 1 h at 4 °C prior to 
loading. Samples (cell or mitochondrial lysates, maximum of 700 µg of protein) 
were loaded carefully on top of gradients and separated by centrifugation in 
Optima TLX Ultracentrifuge (BECKMAN) using TLS55 rotor under following 
conditions:  39000 rpm (100000 xg), 2 h 15 min at 4 °C (accel.= 1, decel.=4). 
After centrifugation from each gradient sample 10 fractions of 100 µl (the 
volume of the 11th fraction depended on the volume of lysate input) were 
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taken, stored in separate tubes and labelled: 1-11 starting from the top of 
gradient. If the gradient centrifugation was followed by SDS-PAGE, 12 µl of 
each fraction was taken, mixed with 3 µl of 5x SDS-PAGE loading dye (2.5.5) 
and stored at -20°C. 
 
1x sucrose buffer: 
625 mM  Tris-HCl (pH 7.2) 
500 mM  NH4Cl 
125 mM  MgOAc 
100 mM  KCl 
1 mM   PMSF 
 
2.8. Immunocytochemistry 
U2OS cell were grown on glass cover slips placed on the bottom of 24-well 
plates. First, cells were fixed with formaldehyde solution in PBS (4% final 
concentration) for 10 min at room temperature. Then the cells were 
permeabilized with “Abdil” buffer (0.1% v/v Triton-100, 3% w/v BSA final 
concentration in PBS) for 30 min at room temperature. The primary antibodies 
diluted in the “Abdil’ buffer were added to the samples on cover slips and 
incubated for 1 h at room temperature. Next samples were washed with PBS 
with 0.1% Triton X-100, 3 times for 5 min at room temperature and incubated 
with secondary antibodies diluted in “Abdil” buffer for 1 h. Finally samples were 
washed again 3x 5 min with PBS and 0.1% Triton X-100 and mounted on the 
glass slide using Vectashield Mounting medium with DAPI (hard set, H-1500, 
Vector). Cells were visualised on Axiovert 200M (Zeiss) microscope under 
bright field and using appropriate filters. 
 
2.9. [35S]-methionine/cysteine metabolic labelling 
patient and control fibroblasts were grown in 25 cm2 flasks to ~70% confluence. 
Prior to the metabolic labeling, cells were incubated with methionine/cysteine 
free DMEM twice for 10 min at 37°C. Next, they were incubated with the same 
medium supplemented with 10% dialyzed FCS, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 50 µg/ml uridine and 100 µg/ml final emetine dihydrochloride 
for 30 min at 37°C. From each flask 0.5 ml of medium was removed and 20 µl 
of [35S]-methionine/cysteine mix added (PerkinElmer; 125 µCi/ml EasyTagTM 
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express [35S] protein labeling mix NEG-772, 73% L-met, 22% L-cys). Incubation 
was carried for 1 h at 37°C, after which the metabolic labeling medium was 
removed. Cells were harvested with PBS/1 mM EDTA and centrifuged at 250 x 
g, 4 min, 4°C. Pellets were washed once and resuspended in ice-cold PBS with 
Protease Inhibitor Cocktail (EDTA-free, Roche) and 1 mM PMSF. Cell 
suspensions were snap frozen and stored at -80°C, until SDS-PAGE 
separation.  
Prior to electrophoresis, samples were thawed on ice, protein concentration was 
measured and aliquots of equal protein content (50 µg) were mixed with loading 
buffer (1x final concentration, 2.5.5). Next, samples were incubated 1 h at room 
temperature with 12 U Benzonase® Nuclease (Novagen) and separated on 
15% (w/v) SDS-PAGE. Unless stated otherwise in the subsection, after 
electrophoresis gels were fixed overnight with fixing buffer (3% v/v glycerol, 
10% v/v glacial acetic acid, 30% v/v methanol). Visualisation of nascent 
proteins was carried with PhosphorImager and analysed using Image-Quant 
software (GE Healthcare). In order to asses equality of samples’ loading, after 
the visualisation gels were rehydrated and stained with Coomassie Brilliant Blue 
(CBB) using 0.2% (w/v) Coomassie Blue R solution in 45% (v/v) methanol, 10% 
(v/v) and glacial acetic acid. Staining was carried out for 15 min at room 
temperature. Next, gels were destained twice for 10 min in CBB destaining 
solution (45% (v/v) methanol and 10% (v/v) acetic Acid). Images were taken 
with CCD camera system.  
 
2.10. Statistics analysis 
Calculation of standard deviation of all the mean values obtained from the data 
in this project were carried using t-test available at: 
http://www.graphpad.com/quickcalcs/ttest1.cfm.  
The significance of the difference between results were specified as:  
p > 0.05 as not statistically significant 
p = 0.01 to 0.05 as significant (*) 
p = 0.001 to 0.01 as very significant (**)  
p < 0.001 extremely significant (***).  !  
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Chapter 3 
 
Characterisation of C12orf65 !  
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3.1.  Introduction 
One of the primary questions underlying my project was to define the function of 
C12orf65. The attempts to characterize this protein function were included in 
patient reports (Antonicka et al., 2010) (Haruo Shimazaki et al., 2012) and in 
the study on the solution of the C12orf65 crystal structure (Kogure et al., 2012). 
The former two publications (especially (Antonicka et al., 2010) included a 
detailed analysis of the effect of mutations in C12orf65 on the mitochondrial 
gene expression. The mutations, namely homozygous 1 bp deletions different 
in both patients (246delA and 210delA), resulted in premature stop codons but 
did not affect the levels of the C12orf65 transcript. However, the effect on the 
stability of the protein was unknown (Antonicka et al., 2010). In the second 
study a homozygous nonsense mutation (C394T, (Haruo Shimazaki et al., 
2012) resulted in a truncated, stable form of the protein (Haruo Shimazaki et al., 
2012). The most outstanding changes to the mitochondrial gene expression 
were observed in de novo mitochondrial protein synthesis (where a generalized 
decrease was seen in patient samples), assembly and activity of the OXPHOS 
complexes (disruption of CI, IV and V formation, decrease of complex IV 
activity) (Antonicka et al., 2010; Haruo Shimazaki et al., 2012). Further 
functional studies were performed on cells following C12orf65 depletion using 
siRNA (Kogure et al., 2012). The described effects of the lack of C12orf65 
included increase in cell death (65%) and lower complex IV activity compared to 
controls (decreased by 52% in isolated mitochondria). These results clearly 
show the importance of C12orf65 for the cell and mitochondrial function but 
what is the exact role of this protein? 
Investigation of the C12orf65 function was started by a former member of my 
host laboratory Dr. Aleksandra Pajak as a part of her PhD thesis. She was able 
to establish that the depletion of the C12orf65 caused a growth defect of 
HEK293 or HeLa cells when cultured in media containing galactose. These 
conditions, forcing cells to respire, are known to be a very sensitive test of 
potential mitochondrial defects. Both cell lines presented slower growth rate and 
unusual morphology after 3 days of C12orf65 depletion, although the effect was 
more profound in HeLa cells than in HEK293T. These cells also displayed 
changes to the mitochondrial network as assessed by non-quench mode 
fluorescent staining using the membrane potential dye, TMRM. Mitochondrial 
distribution was more compact and clustered around the nucleus after the 
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depletion. However, the observed changes to the cell morphology were not 
caused by the decrease in the steady state levels of mitochondrially encoded 
proteins. The steady state levels of COXII, a subunit of complex IV, was not 
affected by the C12orf65 depletion, neither was the nuclear NDUFB8. The latter 
protein, even though it is imported from the cytosol, is a surrogate marker for 
the assembly of the complex I. No changes to the levels of these two proteins 
suggested that there may be correct assembly of the complex I and IV. The 
detrimental result of the C12orf65 depletion could not be attributed to a 
decrease in the levels of MRPs, which remained stable even after 6 days of the 
treatment. However, the changes to the mitochondrial gene expression were 
visible when the steady state levels of mitochondrial transcripts were tested. 
Northern blot analysis showed an accumulation of the mt-mRNAs (RNA14, MT-
ND1, MT-CO1, RNA15) and mt-rRNA. This increase became more profound 
after 6 days of depletion. The accumulated mitochondrial mRNAs were not 
associated with the monosome, but rather with separate mitoribosomal large 
subunit. Further, the lack of C12orf65 did not affect the composition of the 
mitoribosome, or caused the accumulation of the free ribosomal subunits, which 
might have been suggested by the upregulation of the rRNAs. There was also 
no evidence of the C12orf65 being a part of the mitoribosome, but a transient 
interaction cannot be ruled out.  
This work, especially when put in the context with already published data 
(Antonicka et al., 2010; Kogure et al., 2012; Haruo Shimazaki et al., 2012) 
strongly suggests the involvement of the C12orf65 in mitochondrial gene 
expression. The objective of my experiments on the C12orf65 was to carry on 
the characterization of the protein function in the cells depleted of it. 
 
3.2. C12orf65 colocalizes with mitochondria 
The patient reports and resolving of the crystal structure are not the only 
context in which C12orf65 was noticed. In the study by (Antonicka et al., 2013) 
a novel mitochondrial function of the protein GRSF1 was identified and it co-
immunoprecipitated with C12orf65. This former protein is involved in 
posttranscriptional processing and storage of mt-mRNAs as a part of RNA 
processing granules in mitochondria. The possibility of C12orf65 being a part of 
these granules could not be verified due to the lack of sufficiently specific and 
sensitive antibodies that would be suitable for immunocytochemistry (ICC). 
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Therefore, to test this hypothesis I performed ICC on C12orf65-FLAG 
expressing cells, which allowed me to use FLAG antibodies instead of those 
recognizing C12orf65. The objective of this experiment was to confirm the 
mitochondrial localization of C12orf65 and investigate the pattern of this protein 
distribution. There was a possibility that if the distribution was highly discreet, 
further ICC co-staining with GRSF1 antibodies would give the potential to 
identify any colocalization of the two proteins, indicating that C12orf65 may be 
sequestered in RNA processing granules. Even though a stable HEK293 cell 
line with the potential to inducibly express C12orf65-FLAG was available, it was 
not used because of the issues with imaging of HEK cells. For this type of 
experiments it is advised to use more flat cells, like U2OS, where the 
intracellular features are more clearly visualised. Since there was no stable 
U2OS cell line that could inducibly express C12orf65-FLAG, I made a transient 
transfection with the plasmid pcDNA5/FRT/TO/C12orf65-FLAG that contained a 
wild type FLAG tagged copy of C12orf65 (generated by Dr. Aleksandra Pajak; 
detailed protocol for transfection is described in 2.1.5). Briefly, U2OS cells were 
seeded on glass cover slips (round, dim. 13 mm) put inside the 24-well plate, at 
a density of 25000 cells per well. On the same day, one set of cells was 
transfected with plasmid (2 µg), the other was left as an untreated control. The 
ICC was performed the next day, based on the protocol (2.8) kindly delivered by 
Dr. Alexis Jourdain (University of Geneva). The procedure and the following 
imaging were performed with supervision from Dr Jorge Oliveira (University of 
Porto).  
First the live cells were incubated with MitoTracker Red (CM-H2XRos, Molecular 
Probes; final conc. 400 nM, 30 min) in order to stain the mitochondrial network. 
The trial epifluorescent images were taken and confirmed sufficient intensity of 
the signal to proceed with the procedure. Next, cells were fixed and 
immunostained (2.8). Detection of FLAG tag was performed with monoclonal 
anti-FLAG antibodies (1:200, Sigma F1804) and secondary goat anti-mouse 
antibodies conjugated with fluorescent dye (Alexa 488; Invitrogen, A11001). 
These cover slips were next mounted on glass slides using hard set mounting 
medium with DAPI (to stain the nuclei). The fluorescent signal from different 
dyes (red MitoTracker stained mitochondria, green C12orf65-FLAG and blue 
DAPI-labelled nuclei) was detected through epifluorescence microscopy 
(Axiovert 200M, Zeiss). Z stack Images were taken (with help from Dr. 
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Oliveira, Fig. 3.1) using appropriate filters independently (for Alexa488: 
excitation λ=493 nm, emission λ=520 nm; for DAPI ex. λ=359 nm, em. λ=461 
nm; for MitoTracker Red CM-H2XRos ex. λ=579 nm, em. λ=599 nm). These 
images could be superimposed to a ‘Merged’ image (Fig. 3.1). The successfully 
transfected cells were visualized through the signal from the green channel 
(coming from C12orf65-FLAG). On the merged images this signal fully 
colocalized with the signal derived from mitochondria. Untransfected cells 
displayed only the blue DAPI staining of nuclei and MitoTracker red 
mitochondria.  
 
 
Figure 3.1. C12orf65 is localized to mitochondria 
Fixed U2OS cells transiently expressing C12orf65-FLAG were analyzed via 
immunocytochemistry using antibodies against FLAG and visualized with fluorescent 
Alexa 488 conjugated secondary antibodies (green). The nuclei were stained with 
DAPI (blue) and the mitochondrial network was labeled with MitoTracker Red (red). 
Presented data comes from sigle Z-stack images.  
 
The signal detected from FLAG antibodies was very intense due to the strong 
expression of the C12orf65 and it exceeded the strength of the mitochondrial 
labeling. Due to the strong promoter and a transient unregulated expression 
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the amount of C12orf65 protein significantly exceeded the physiological 
amount, which is undetectable using the antibodies available (that can detect 
20 ng by western). Since the signal was saturated it was not possible to 
determine if the distribution of this protein was in discreet foci, which could 
resemble the pattern displayed by proteins associated with RNA processing 
granules. To answer this question in the future it will be necessary to create a 
stable cell line with morphology that is suitable for microscopy and that would 
allow titration of induced C12orf65-FLAG expression. Also the use of confocal 
microscopy instead of just the epifluorescent would be advised because it 
allows collecting serial optical sections and eliminate background information 
away from focal plane. As a result, images come from thin sections and the out 
of focus fluorescent light is rejected. Scanning a number of sections within one 
sample can be used to build a sharp 3D image. In addition, it allows special 
discrimination between full co-localization and signals from separate sources in 
close proximity. In order to address these issues I then created a stable U2OS 
cell line with inducible expression of the C12orf65-FLAG that could be used in 
the future to help determine whether C12orf65 colocalises with the RNA 
processing granules.  
The stable transfection was performed (2.1.5) with the C12orf65-WT-FLAG 
construct in pcDNA5/FRT/TO vector together with pOG44 plasmid (encoding 
the Flp recombinase). U2OS-Flp-in cells in 6-well plates (seeded 60000 cells/ 
well) were transfected and selection of successful transformants achieved with 
hygromycinB (100 µg /ml). Clones of the cells that survived selection were 
isolated, propagated separately in 25 cm2 flasks and tested for the expression 
of the gene of interest. Induction of the C12orf65-FLAG expression was 
conducted with 1 µg /ml tetracycline for 3 days. Total cell lysate was prepared 
from induced cells and uninduced controls and equal amounts (50 µg) were 
separated by SDS-PAGE (2.5.5). After transfer to membranes the proteins of 
interest were immunodetected with antibodies and the results are presented in 
Fig. 3.2.  
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Figure 3.2. C12orf65-FLAG expression in the sable transfection U2OS cell 
line 
The U2OS cell line was stably transfected with C12orf65-FLAG (2.1.5). After 3 days of 
induction with tetracycline the total cell lysate (50 µg per lane) of induced and 
uninduced control cells was analysed via western blot using anti-FLAG antibodies. The 
detection with porin served as a loading control. Visualization of signals was by 
chemiluminescence and CCD camera capture. 
 
Two clones (No 18 and 20) were tested using α-FLAG to confirm expression of 
C12orf65-FLAG and porin as a loading control. Both clones displayed positive 
expression of the C12orf65-FLAG corresponding to the stronger signal from 
FLAG antibodies in induced cells (Fig. 3.2, lanes marked ‘+ Tetracyline’) in 
comparison to the control (- Tetracycline). Although the loading of the samples 
is not perfectly even, as is evident from the porin signal, the fold increase in 
FLAG signal is greater than the difference observed in porin signal, confirming 
that there is inducible expression of C12orf65-FLAG. A faint but detectable 
signal is present in the uninduced control and is the result of the “leaky” 
expression. This is not uncommon and occurs when the Tet operator upstream 
from the promoter controlling the expression of the construct is not completely 
blocked by the Tet repressor. In such cases even without addition of 
tetracycline there is a possibility of uncontrolled expression. This should not, 
however, affect the ICC imaging as the levels of the product are very low. The 
clones presented here were, therefore, suitable be used for these experiments. 
Moreover, the expression levels of C12orf65 could be titrated by applying 
different concentrations of doxycycline. This antibiotic is known to induce 
expression of the gene of interest in a much more controllable way than 
tetracycline, which essentially switches on expression at maximum levels.  
 
3.3. Comparison of purified and commercially available C12orf65 
 antibodies   
One of the difficulties of working on C12orf65 is the lack of good commercially 
available antibodies. In order to address this problem Dr. Aleksandra Pajak 
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PORIN
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generated a fusion C12orf65-GST protein, which after removal of the GST tag 
was sent to be used as an antigen in a rabbit immunization programme 
(Eurogentec). The antibodies were subsequently affinity purified from the 2 
batches of antisera. Affinity and specificity were tested by western blotting using 
recombinant antigen and the following samples of HEK293 mitochondria: wild 
type untransfected, C12orf65 depleted (via siRNA), overexpressing C12orf65-
FLAG. The initial results were very promising. At a dilution of 1:200 the 
antibodies could detect the recombinant protein (20 ng), and endogenous 
C12orf65 in 10 µg of mitochondrial lysate. Although there were a number of 
unspecific bands, the one corresponding to C12orf65 was easily confirmed by a 
comparison with the overexpressing cell line and the one with C12orf65 
depletion. However, these purified antibodies appeared to be very unstable 
during storage both at 4°C as well as -20°C, making reproducibility a problem. I 
continued this work by repeating the affinity purification step making the 
following adjustments to the commonly used protocol (2.6). First, double the 
amount (14 ml) of antiserum was used (#94 that previously gave a better result 
in terms of specificity). Second, the protein was denatured with 8 M urea while 
still attached to NHS-activated beads, in order to better expose the epitopes. 
Finally, in order to increase the concentration of the protein, the eluted 
antibodies were dialyzed and the final volume was reduced using Aquacide. 
Glycerol (10%, final concentration) and sodium azide (0.02% final 
concentration) were added and aliquots of the purified antibody were stored at -
20ºC. 
The specificity of these purified antibodies was tested by western blotting on 
total cell (Fig. 3.3, lane 4) and mitochondrial (Fig. 3.3, lanes 5-8) lysates. 
Different dilutions of the recombinant C12orf65 protein were used as positive 
controls (Fig. 3.3, lanes 1-3).  
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Figure 3.3. Affinity purified antibodies do not recognize the endogenous 
levels of C12orf65 
Samples of wild type HEK293 total cell lysate (lane 4), mitochondrial lysate (lanes 5-8) 
and recombinant C12orf65 protein (lanes 1-3, as positive control) were separated by 
15% SDS PAGE. Purified C12orf65 antibodies (1:200) were used to test their efficacy 
in western blot analysis. 
 
The purified antibodies recognized the recombinant protein with very weak 
recognition of 2 ng but clear signal for 10 and 50 ng (Fig. 3.3 lane 1-3). 
Unfortunately, it was unable to detect the endogenous levels of C12orf65 in cell 
lysate (50 µg) nor when tested against high amounts (70 µg) of mitochondrial 
lysate (Fig. 3.3, lane 8). It seems, therefore, that the purification did not increase 
the sensitivity of the antibodies. In addition, the antibodies specificity was low as 
indicated by the presence of multiple bands. The affinity purified antibodies 
cannot be used in experiments and commercial antibodies became available.  
The antibodies offered by Santa Cruz Biotech (SC-242028) and Abnova 
(FLJ38663) were tested. These antibodies were used at a 1:200 (Santa Cruz) 
and 1:500 (Abnova) dilution on HEK293 cell line inducibly expressing C12orf65-
FLAG. Both types of antibodies were able to detect C12orf65 in mitochondrial 
lysate in induced cells (50 µg) and recognize the recombinant protein (10 ng). 
However, detection in uninduced cell lines was obscured by the abundance of 
unspecific signal, especially close to expected size of the protein (data not 
shown). Addition of the signal enhancing reagent SuperSignal® (Life 
Technologies, 46640) did not improve specificity of the binding. The comparison 
of the 3 types of used antibodies shows that none of them was sufficient to 
detect the endogenous form of the protein. For the following experiments, the 
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levels of the C12orf65 could not be detected with western blot analysis. Instead, 
the transcript levels measurements with qPCR had to be used. 
 
3.4. C12orf65 is not an integral part of mitoribosome   
Of the mitochondrial release factor family of proteins, two have lost the 
sequence recognitions domains, namely C12orf65 and ICT1. The latter has 
become incorporated into the mitoribosome (Richter et al., 2010b), unlike its 
bacterial homologue YaeJ, which interacts transiently with stalled ribosomes 
(Gagnon et al., 2012). The mechanisms of C12orf65 action and its relation to 
mitoribosomes are unknown. The preliminary data from Dr. Pajak thesis 
suggested C12orf65 is not an integral part of mitoribosome and any potential 
interaction is only transient. In order to definitely exclude that, like ICT1, 
C12orf65 is incorporated to the mitoribosome (either monosome or any subunit) 
mitochondrial ribosomes were analyzed on sucrose gradient prior to the 
western blot analysis. In this experiment cell lysate is centrifugated in isokinetic 
sucrose gradient (10-30%, 2.7) and its components (including the content of 
mitochondria) are separated based on their buoyant density. Single 
mitoribosomal subunits or fully assembled monosome binding partners can be 
immunodetected and analysed as they are collected with different fractions of 
the gradient. Since the endogenous levels of C12orf65 were known to be low, 
and the antibodies were not efficient enough to detect these, the experiment 
was done on the stable cell line expressing FLAG tagged version of C12orf65 
(HEK-C12orf65-FLAG). The position of small (mt-SSU, 28S) and large 
mitoribosomal subunit (mt-LSU, 39S) were detected with antibodies for one of 
their components (DAP3 and MRPL3 respectively, Fig. 3.4).  
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Figure 3.4. C12orf65 is not detectable in the separate mitoribosomal 
subunits 
HEK-C12orf65-FLAG cells were induced for 3 days (1 µg/ml tetracycline) and the 
lysate (700 µg) was separated on the isokinetic sucrose gradient (10-30 %, 2.7). 
Fractions (1-11) were taken from the top down and all fractions were electrophoresed 
on 12% PAG followed by western blotting. Immunodetection was performed using 
antibodies specific to proteins from small and large mitoribosome subunit (DAP3 and 
MRPL3 respectively). The presence of the overexpressed C12orf65-FLAG was 
detected with α-FLAG antibodies. 
 
Fractions 3 and 4 (Fig. 3.4), where the highest concentration of DAP3 protein 
was found were also most likely containing small ribosomal subunit (28S, SSU). 
Position of the large subunit (39S, LSU) was determined by the signal from 
MRPL3 to be in fractions 5 and 6. Unfortunately, the presence of the 
monosome could not be detected which is not uncommon when analysing cell 
lysates and observed in my host lab. However, even without the detectable 
levels of monosomes, it was ppossible to determine if there is an interaction of 
C12orf65 with separate subunits. The signal from C12orf65-FLAG was only 
present in fraction 1 and 2 (but much weaker), which correspond to the free 
protein not attached to any ribosomal subunit. Therefore it was concluded that 
C12orf65 is not permanently associated with the free mitoribosomal subunits 
(small or large) and if any such interaction occurs it is only transient. 
 
3.5.  Is the GGQ motif important for C12orf65 function?  
After investigating a possible interaction of C12orf65 with mitoribosomes, 
another feature of the protein was tested, namely the functionality of the GGQ 
motif. The presence of this well conserved and highly specific sequence is the 
reason for characterizing C12orf65 as a member of mitochondrial release factor 
family. The GGQ motif is present in all class I release factors and is 
unambiguously associated with ribosome dependent PTH activity (Frolova 
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et al., 1999). Previous experiments by Dr. Pajak started investigating if the GGQ 
motif in C12orf65 is functional. If it were then the potential ribosome-dependent 
peptidyl-tRNA hydrolysis activity would be another argument for proposing 
C12orf65 as a candidate ribosome rescue factor. It has been previously 
established, by testing AGQ and GSQ E. coli mutants that the first two residues 
are essential for the release activity (Frolova et al., 1999). Therefore, Dr. Pajak 
created two constructs of C12orf65 in pcDNA5/FRT/TO vector, each one 
containing either AGQ or GSQ mutation, to generate stable-transfection cell 
lines. In order to be able to deplete the endogenous protein but not newly 
incorporated mutated form, silent mutations (SM, five single bp mutations) were 
introduced by site directed mutagenesis to the construct sequence. The lack of 
complementarity across this SM sequence protected the mutant C12orf65 from 
the siRNA. In addition, the sequence of FLAG tag was also included to enable 
detection of the expressed proteins on Western blots. Finally, Dr. Pajak 
confirmed the import of the encoded proteins into mitochondria.  
I used these constructs generated by Dr. Pajak and repeated generation of 
stable cells lines as described above (2.1.5). Wild type HEK293-Flp-In TRex 
cells were seeded in the 6-well plates (160000/ well) and on the next day 
transfected with the pOG44 plasmid and either pcDNA5-C12orf65-AGQ-SM-
FLAG or pcDNA5-C12orf65-GSQ-SM-FLAG. Two days later antibiotic selection 
started using Hygromycin B (100 µg/ml). After approximately 3 weeks selection, 
the remaining resistant colonies of cells (clones) were isolated, propagated 
independently and subsequently tested for expression of the transfected 
constructs. For each protein expressing cell line C12orf65-AGQ-FLAG (Fig. 3.5 
A) or –GSQ-FLAG (Fig. 3.5 B) 4 clones were tested. Expression of the proteins 
of interest was induced with tetracycline (1 µg/ml) for 3 days in each cell line. In 
addition, an identical set of uninduced cells was cultivated alongside the 
induced ones. The expression was confirmed with western blotting (50 µg of 
total cell lysate per sample) targeting the FLAG tag. Porin served as a loading 
control. 
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Figure 3.5. Generation of the cell lines expressing C12orf65 mutants  
Western blot analysis was performed on total cell lysates (50 µg) from induced (1 µg/ml 
tetracycline, 3 days) and uninduced HEK-C12orf65-AGQ-FLAG (A) or –GSQ-FLAG (B) 
cell lines. Each cell line originates from an individual clone of transfected cells isolated 
during selection (labelled from 1-1 to 1-4). Expression was confirmed by 
immunodetection of the FLAG tag, equality of the loading was tested with porin 
antibodies. Each sample was run as a duplicate. Only clones positively expressing the 
gene of interest are included.  
 
Each of the tested HEK-C12orf65-AGQ cell lines expressed the protein of 
interest (Fig. 3.5 A). Only in cell line ‘AGQ 1-1’ there is a faint signal from 
C12orf65-FLAG in uninduced control samples lanes. This is an evidence of a 
very subtle “leaky” phenotype. For the GSQ cell lines only 1 failed to express 
the C12orf65-GSQ-FLAG (cell line ‘GSQ 1-3’, data not shown), the rest 
displayed high levels of expression. 
Further experiments involved testing if the overexpression of the mutated forms 
of C12orf65 would have a dominant negative effect on the cell growth. 
However, it was important to first investigate if the excess of wild type C12orf65, 
on its own, would be toxic for the cells. In order to test this, a cell line 
expressing the wild type form of C12orf65 (HEK-C12orf65-WT-SM-FLAG clone 
3-2, produced by Dr. Pajak) was used alongside the newly generated C12orf65-
AGQ (clone 1-1) and GSQ (clone 1-1) mutants. The growth of the induced and 
uninduced cells from the aforementioned cell lines was monitored and 
compared (Fig. 3.6 A). In parallel, 2 sets of all 3 cell lines were cultivated for the 
purpose of confirming the expression by western blot analysis (50 µg cell 
lysate/sample). As described previously, the expression of these 3 C12orf65 
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forms (WT, AGQ and GSQ) was validated by immunodetection via FLAG and 
compared with uninduced cells (Fig. 3.6 B).  
 
Figure 3.6. Cell growth rate is not affected by overexpression of WT or 
mutated forms of C12orf65  
A. Growth of 3 different cell lines was monitored, those overexpressing wild type 
C12orf65 (C12orf65-WT), the AGQ mutant (C12orf65-AGQ) and the GSQ mutant 
(C12orf65-GSQ). Equal numbers of cells (30000, represented by the dashed line) were 
seeded in a 24-well plate. One set of cells was induced with tetracycline (1 µg/ml; 
purple), second identical set was left untreated (uninduced control; lilac). The number 
of cells in each condition (average and standard deviation of 3 wells) after 3 days of 
overexpression is graphically represented. B. Expression of the proteins of interest 
(wild type and GGQ-mutant C12orf65) was confirmed by western blot analysis (50 µg 
cell lysate) via FLAG tag immunodetection. Each sample was loaded as duplicate. 
Porin was used as a loading control.  
 
The expression of all 3 forms of C12orf65, validated with FLAG detection was 
positive (Fig. 3.6 B). The levels of these proteins exceeded any potential traces 
of uninduced expression (as defined by a very faint signal seen in uninduced 
cell lines). The comparison between induced and uninduced C12orf65-WT 
expressing cells (Fig. 3.6 A) showed no difference to the cell growth, which 
suggests that the much higher than physiological levels of C12orf65 is not 
harmful to the cells. The same observation was made in both mutant- 
expressing cell lines, as the doubling time of cells in uninduced and induced cell 
lines was very similar and also comparable to wildtype. These results indicate 
that the presence of high levels of the C12orf65 with mutations in the GGQ 
motif does not have a dominantly negative effect on the cell. However, it is 
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still possible that the GGQ in C12orf65 is functional and necessary for the 
normal cell growth. It is important to remember that in these experiments the 
endogenous, wild type protein is still present and therefore can be sufficient to 
maintain the function suppressing the effect of the mutation. 
In order to better characterize whether the mutation of the GGQ recessively 
affects the cell viability, a further experiment was performed. The same 3 cell 
lines were seeded in 24-well plates (30000/ well) expressing wild type C12orf65 
(‘C12-WT’, clone 3-2), C12orf65 AGQ mutant (‘AGQ’, clone 1-1) and GSQ 
mutant (‘GSQ’, clone 1-1) as before all cell lines were induced to express their 
form of C12orf65 (1 µg/ml, 3 days). This time, one set of cell lines was depleted 
of C12orf65 mediated via siRNA (‘siC12’) and a second parallel set was treated 
with non-targeting control siRNA (‘NT’). As all three cell lines expressed 
C12orf65 containing the silent mutation, the expressed C12orf65 protein was 
immune to the C12-targetted siRNA. The endogenous mRNA, however, would 
still be targeted and depleted. This approach aimed to replace the endogenous 
C12orf65 so that the expressed form would dominate. The overexpression of 
the WT form was included as a control in this experiment to investigate if the 
siRNA transfection procedure together with simultaneous replacement with 
overexpressed C12orf65 is harmful to the cell. This control aimed to identify if 
the exogenous C12orf65 impairs function, potentially due to the presence of a 
C-terminal FLAG-tag. It was important to establish this in order to accurately 
interpret the results derived from the GGQ-mutations. These growth rate 
experiments were performed as those described previously (Fig 3.8). 
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Figure 3.7. Replacement of the WT C12orf65 with GGQ-motif mutants does 
not affect the cell growth. 
Cells were induced to express various forms of C12orf65 (wild type, AGQ mutant and 
GSQ mutant; tetracycline 1 µg/ml, 3 days in plate (30000 cells/15.6 mm diameter well, 
indicated by the dashed line). One set of cells were C12orf65 depleted (siC12) and the 
control cells were treated with non-targeting siRNA (NT). Cell numbers were 
determined after 3 days and are presented graphically (expts performed in triplicate, 
mean +/- SD).  
 
No significant difference between the C12orf65 depleted and control samples 
was observed (Fig. 3.7). This indicated that replacing the endogenous form of 
C12orf65 with either the WT or GGQ mutated forms does not impair the cell 
growth. However, prior to accepting this interpretation, it was necessary to 
confirm both that overexpression of the transfected C12orf65 was successful, 
and that the endogenous version was actually depleted. To answer the first 
question western blotting analysis was performed on cell lysate from each cell 
line (50 µg) either induced or uninduced. FLAG tag immunodetection validated 
the C12orf65-FLAG expression in all tested cell lines (Fig. 3.8). This confirmed 
that the lack of growth defect was not due to unsuccessful production of the 
mutant and WT C12orf65. 
 
 
Figure 3.8. Confirmation of expression of WT and GGQ-mutant C12orf65-
FLAG proteins 
Cell lysates (50µg) from all 3 cell lines (induced and uninduced, each sample was run 
in duplicate) were analysed by western blot.  Antibodies to the FLAG moiety validated 
the overexpression. Porin immunodetection was used as a loading control. 
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Having confirmed the overexpression of the proteins of interest the next step 
was to investigate the level of the endogenous C12orf65 depletion by qPCR 
(2.4.4). The primers used in this analysis were specific to the region upstream 
of the coding sequence (CDS), which was not included in the C12orf65 
construct cloned in pcDNA5 vector used for the stable transfections. Therefore, 
this experiment was designed to detect only the endogenous form of C12orf65 
and was used subsequently to estimate the level of depletion as follows:  2!∆∆!!!! = 2∆!!!!!!"!"#!"2∆!!!!"!!!"#$∗ ! 
Where:  ∆!!!!!"!"#!" = !!!!"#$!! − !!!!!"#!"!"#!" ∆!!!!"!!!"#$ = !!!!"#$!! − !!!!!"#!"!"#!"!
* 18S-rRNA reference gene 
 
 
Figure 3.9. Detection of the endogenous levels of C12orf65 in induced cell 
lines. 
RNA was isolated from each of the cell lines induced to express wild type C12orf65, or 
AGQ and GSQ mutants. qPCR analysis was used to measure the level of depletion of 
endogenous C12orf65 transcript in all samples. C12orf65 levels were calculated based 
on mean value of 3 technical repeats and normalized to 18S rRNA levels. Results were 
represented in relation to the expression in NT cells.  
  
In the C12orf65-WT overexpressing cell line (Fig. 3.9, C12-WT) the level of 
depletion was around 80% (indicating that there was only 20% of the 
endogenous C12orf65 transcript remaining). This result confirms that when the 
endogenous form of the protein is severely depleted and replaced with the 
exogenous form, the cell growth is not impaired (Fig. 3.7).  In the case of the 
GGQ-mutant cell lines (AGQ and GSQ), the depletion was not as effective (only 
35% reduction for the AGQ and 60% for the GSQ, Fig. 3.9). Both of these cell 
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lines did not display any major change to the growth rate (Fig.Fig. 3.7), which 
could be explained by the fact that they still retained a relatively high (especially 
AGQ- 65%) level of the endogenous, wild type C12orf65. This could suggest 
that approximately 40% of wild type C12orf65 is sufficient to sustain the function 
and normal cell growth. 
 
3.6.  Effect of C12orf65 depletion on de novo synthesis of 
mitochondrial  proteins   
Another critical experiment to determine the function of C12orf65 was the effect 
of depletion on de novo mitochondrial protein synthesis. Studies on the patient 
fibroblasts carrying the C12orf65 mutations shows that the resulting phenotype 
often includes a decrease in the levels of newly synthesized mitochondrial 
proteins (Antonicka et al., 2010; Haruo Shimazaki et al., 2012). In order to 
compare the results of a patient mutation and depletion of C12orf65, wild type 
HEK293 were treated with C12orf65 siRNA (2.1.4), followed by [35S]- 
methionine/cysteine metabolic labeling of mitochondrial proteins (standard 
protocol used in my host lab, 2.9). The cells were cultivated and treated in 6-
well plates (90000 cells/ well, 3 wells/ siRNA treated for 6 days, 6 wells for 3-
days treatment). On the final day of the siRNA treatment they were 
metabolically labeled with [35S]-methionine/ cysteine with prior emetine 
inhibition of cytosolic translation. Under these conditions only newly synthesized 
mtDNA-encoded polypeptides would be visualized. Equal amounts of cell lysate 
from each condition were separated by 15% SDS-PAGE. Signals from 
radiolabelled newly-synthesised mt-proteins were detected and visualised by 
PhoshoImager and ImageQuant software (Fig. 3.10). 
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Figure 3.10. De novo protein synthesis in mitochondria following C12orf65 
depletion 
HEK293 wild type cells were treated with C12orf65 siRNA (siC12) or nontargeting 
siRNA (NT) for 3 or 6 days (3d or 6d). They were subsequently metabolically labelled 
with [35S]-methionine/ cysteine with parallel inhibition of cytosolic translation (as 
described in 2.9). Samples (50 µg total cell protein) were separated by 15% SDS-
PAGE. Signals from newly synthesised mt-proteins were detected via PhosphoImaging 
(upper panel). Prior to the imaging, the gel was stained with Coomassie brilliant blue 
(CBB, lower panel) to confirm loading. 
 
Visualisation of the metabolic labeling of the newly-synthesized mt-proteins 
(Fig. 3.10 upper panel) shows no general difference between the depleted and 
control samples. Coomassie staining of the gel (Fig. 3.10, bottom panel) 
indicates the protein levels in each sample. Here it confirmed even loading of 
the samples. To correctly interpret this result, however, a confirmation of the 
depletion must also be made. For this purpose, in parallel to metabolic labeling, 
cells were cultured with siRNA treatment (siC12 and NT, 3 and 6 days) to 
provide material for qPCR analysis of C12orf65 levels. Estimation of the 
depletion level was conducted as described previously (Fig. 3.9 and section 
2.4.4). The comparison of the C12orf65 levels between the depleted (Fig. 3.11, 
siC12) and control cells (NT) shows that after 3 days there was 40% of the 
transcript remaining. The longer siRNA treatment resulted in an increase of 
C12orf65 levels to 60%. This suggested that the re-transfection with siRNA after 
3 days was not as successful and failed to maintain or further decrease the 
level of the transcript. However, even in the sample with higher level of 
depletion (3d, 40% of control) there are no changes in de novo mt-protein 
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synthesis in comparison to the control. This result can be explained in the same 
way as the GGQ mutant experiments. It is possible that 60% depletion is 
insufficient to cause a deleterious phenotype in cells and affect the synthesis of 
mitochondrial proteins. 
 
 
Figure 3.11. Estimation of the level of C12orf65 depletion in the de novo 
mt-translation experiment 
RNA was extracted from cells cultured and treated in parallel to those used in 
metabolic labelling. Depletion of C12orf65 was analysed by qPCR to estimate residual 
C12orf65 levels. C12orf65 levels were calculated based on mean value of 3 technical 
repeats.. Results, normalized to 18S rRNA levels, were represented in relation to the 
expression in NT cells.  
 
3.7. Does depletion of C12orf65 cause accumulation of mitochondrial 
 transcripts?   
It had been observed by Dr. Pajak that the steady state levels of mt-RNAs were 
elevated after C12orf65 was depleted and that this effect was even stronger 
after longer siRNA treatment. In order to confirm this observation, I replicated 
this experiment by depleting wild type HEK293 cells (seeded in 6-well plates at 
100000/ well with siRNA against C12orf65 (siC12, 3 and 6 days). Control cells 
were treated with non-targeting siRNA (NT). At the end of the treatment total 
RNA was isolated from cells, equal amounts (4 µg) were separated on 
denaturing agarose gel and subjected to Northern blot analysis (as described in 
2.4.2).  
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Figure 3.12. Levels of the mitochondrial transcripts are not affected by 
C12orf65 depletion 
A. Total RNA (4 µg) isolated either from C12orf65-depleted (siC12) or control (NT) 
HEK293 cells (3-day and 6-day treatment), was subjected to Northern blot analysis 
with the indicated probes. The probes were targeting mitochondrial-encoded transcripts 
(2.4.2). B. Quantification of mt-mRNA steady state levels after 3 days of siRNA 
treatment (siC12) was calculated using ImageQuant software and presented as the 
percentage of the control sample (NT) sample. Levels of cytosolic 18S RNA, detected 
by retained intercalated ethidium bromide on the membrane after transfer, were used 
as the loading control to normalise intensity of each signal. The graph presents the 
mean and standard deviation of three independent experimental repeats. C. The signal 
quantification and normalisation of the samples treated for 6 days was performed as in 
B. 
 
The mt-mRNAs were visualized with specific probes to compare the steady 
state levels between the depleted samples (Fig.3.12 A, siC12) with non-
targeting control (Fig.3.12 A, NT). Signal from each probe was normalized 
against the loading control: 18S rRNA ethidium bromide signal. The calculated 
relative amounts of mt-mRNA (MT-CO1, MT-ND1, RNA14) are presented as 
histograms (Fig 3.12 B, 3 day depletion; Fig. 3.12 C, 6-days). The histograms 
(Fig. 3.12 B and C) showed a very clear result where, with the exception of MT-
ND1 transcripts, the steady state levels of mt-mRNAs did not differ significantly 
between the depleted (siC12) and control (NT) samples. The lack of significant 
difference between the siC12 and NT samples was unexpected, especially for 
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the 6-days depletion, as they contradicted those of Dr. Pajak. The latter clearly 
showed an increase in the levels of mt-mRNAs that was even more prominent 
after 6 days of C12orf65 depletion. However, as in previous experiments to 
determine GGQ functionality (Fig. 3.8 and 3.9) and de novo mt-protein 
synthesis (Fig. 3.10 and 3.11), the validation of the depletion was essential for 
accurate interpretation of this data. The remaining RNA from the samples used 
for the Northern blot was analysed by qPCR (as in Fig. 3.9 and 2.4.4).  
 
 
Figure 3.13. Estimation of the level of C12orf65 depletion in the samples 
used for Northern blot analysis 
RNA used in the Northern blot analysis (3 and 6 days of C12orf65 depletion) was 
analysed by qPCR to estimate the level of C12orf65 depletion. C12orf65 levels were 
normalized to 18S rRNA levels and represented as the remaining transcript after 
depletion (siC12) in relation to the level in non-targeting control (NT) cells. 
 
Similar to the depletion verification performed on de novo mt-translation 
samples (Fig. 3.11) approximately 40% C12orf65 remained after 3 days of 
siRNA treatment (Fig.3.13, siC12, 3 days). The re-transfection for the 6-days 
sample again did not result in further reduction of the targeted transcript. On the 
contrary, the amount of the C12orf65 transcript elevated (~ 90%) almost to the 
levels in the non-targeting control samples (Fig. 3.13 siC12, 6 days). These 
results suggest that the reduction of the C12orf65 level to 40% of the control is 
not enough to cause the accumulation of the mt-mRNA transcripts as observed 
in previous experiments by Dr. Pajak and (Antonicka et al., 2010). 
 
3.8.  Discussion   
The experiments described above were designed to complement the work of 
Dr. Pajak who started the characterisation of the C12orf65 function in HEK293 
and HeLa cell lines. One of her most striking observations was that upon 
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depletion of C12orf65 the steady state levels of the mt-RNAs were elevated. A 
similar phenotype was then described in the patient report (Antonicka et al., 
2010) as a result of the 248delT and, to much less extent, 210delA C12orf65 
mutations. However, she did not observe the decrease in steady state levels of 
the mitochondrially-encoded proteins that was characteristic to these patients 
(Antonicka et al., 2010).  
In my experiments, I aimed to further characterise the function of this protein. In 
order to identify if there is any association of C12orf65 with the mitochondrial 
RNA processing granules as reported by (Antonicka et al., 2013) I generated a 
stable U2OS cell line that could inducibly express wild type C12orf65-FLAG. A 
good antibody would facilitate investigations, so I performed a comparison of 
our custom synthesised affinity purified antisera (Fig. 3.3) and the commercially 
available C12orf65 antibodies. Unfortunately, none one of these 3 antibodies 
was specific and sensitive enough to recognize the endogenous form of the 
protein in 50 µg of cell lysate or similar amounts of purified mitochondria. In the 
cell lines tested, C12orf65 protein is expressed at a very low level and even 
using the enhancer, immunodetection could not detect the protein. Unless the 
method can be further improved, the levels and specifically changes in levels of 
C12orf65 protein cannot be estimated by western blotting. Potentially a more 
sensitive enhancer than SuperSignal® reagent would solve this problem. The 
reagent reported to be useful with C12orf65 antibodies was Can Get Signal 
immunostain (Toyobo, (Kogure et al., 2012), however this could not be supplied 
to the UK. Further, I generated the 2 stable cell lines that could inducibly 
express the mutated forms of C12orf65 GGQ sequence (AGQ and GSQ, Fig. 
3.5). These cell lines were next used to investigate if the conserved GGQ motif 
had retained functionality. Unfortunately, in order to determine that, it was 
necessary to completely deplete cells of the wild type C12orf65 and replace it 
with the overexpressed, mutated versions. This, however, was not successful 
because the levels of the C12orf65 depletion were approximately 60% of 
control and this was not sufficient to lose activity of the wild type protein (Fig. 
3.9). A similar issue with insufficient depletion of C12orf65 was observed in de 
novo mt-translation assay (Fig. 3.11) and during measurement of the steady 
state levels of mt-transcripts (Fig. 3.13). In all three cases, the remaining 
C12orf65 (not less than 40% of control) could have prevented the development 
of the expected, pathological phenotype. It was, therefore, impossible to 
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determine if the lack of change to the cell viability and mitochondrial function 
was because they do not depend on the presence of C12orf65 or simply 
because depletion did not cross the low threshold required to trigger pathology. 
This hypothesis seems to be supported by the observation by (Kogure et al., 
2012) where the cell and mitochondrial defects were observed with 90% 
depletion of C12orf65. Perhaps, if the level of depletion was as high in my 
experiments, the results would better show the importance of the C12orf65 and 
its motifs for cell and mitochondrial function. In order to achieve this it would be 
critical to refine the siRNA depletion of C12orf65, which was used in my 
experiments (2.1.4). I had already modified the protocol used by Dr. Pajak by 
increasing the final concentration of siRNA from 0.33 µM to 0.5 µM. I have also 
used a newly synthesised batch of siRNA, increased time of incubation to 4 
days and tested a different than lipofectamine transfection reagent 
(INTERFERin® reagent, Polyplus 409-10). None of these changes resulted in 
higher than 70% depletion level. Potentially increasing the amount of siRNA 
even further or changing the siRNA sequence to that used by (Kogure et al., 
2012) would improve the depletion level. The re-transfection for the 6-days 
treatment is another step that needs optimization. In the described protocol 
(2.1.4) the conditions were optimised for the 3-days incubation. For longer 
treatments a fresh siRNA solution was added on the third day. To increase the 
efficiency of this step the concentration of siC12 could be increased and a 
reverse transfection method employed so that cells would be resuspended and 
reseeded again to prevent them from growing in clumps rather than left 
adherent, and this would improve the access of the siRNA to all cells. However, 
if the level of the depletion cannot be improved, an alternative approach could 
be used to perform the experiments on cells (preferably HeLa as they had a 
stronger susceptibility to depletion) grown in galactose containing medium 
rather than glucose. It has been observed by Dr. Pajak, that under these 
conditions the growth defect is visible and potentially the anticipated features of 
a deleterious phenotype would also be observed.  
At this point the function of C12orf65 is still not clear.  Obvious comparisons can 
be drawn between the C12orf65 and ICT1 because of the structural similarities 
(Kogure et al., 2012). In addition, in (Antonicka et al., 2010) the patient 
phenotype was partially rescued by overexpression of the ICT1 construct, which 
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indicates some reciprocity of the two proteins’ functions. However, the 
experiments described in Kogure et al. unambiguously show that the effects of 
ICT1 downregulation are much more severe than in the case of C12orf65 
depletion (Kogure et al., 2012). Unlike ICT1, C12orf65 is not a part of the 
mitoribosome and it seems to be lacking the peptidyl-tRNA hydrolysis activity in 
vitro (Antonicka et al., 2010). Differences between C12orf65 and ICT1 
structures, such as the lack of the additional α-helix in the former or the varying 
distribution of the protein specific residue clusters and electrostatic charges 
(Kogure et al., 2012), could account for the different features of these two 
proteins. However, to better understand the function of C12orf65 it needs to be 
studied in the model that is truly devoid of this protein and would better reflect 
the changes that are caused by its absence. Further experiments to generate 
such a cell line could use for example CRISPR/Cas9 system in order to 
knockout the C12orf65 gene with high efficiency. 
Although the insufficient C12orf65 depletion potentially prevented the 
anticipated changes to mitochondrial translation and transcription, it did, 
however, reveal a very important feature of C12orf65. It seems that presumably 
very low levels of C12orf65 are sufficient to maintain its function. It is also 
possible that C12orf65 protein is highly stable and even if synthesis of its new 
molecules is impaired by siRNA, these produced before the treatment are still 
present and functional. However, considering the former possibility is true it 
could mean that C12orf65 function is highly specialised and it is involved in rare 
occurring events. An example of such event would be a very specific type of 
mitoribosome stalling. Finally, it could also further confirm the possibility of 
C12orf65 and ICT1 having overlapping functions. Therefore, the deficiency of 
one factor can be partially recompensed by the activity of the other, preventing 
the changes to mitochondrial gene expression. 
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Chapter 4 
 
Molecular analysis of the effect of c.210delA C12orf65 mutation 
- patient case !  
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4.1. Introduction 
Due to its classification as a mitochondrial release factor family member, my 
host laboratory was already studying C12orf65 and its role in human mito-
protein synthesis. Further focus on C12orf65 and its potential role in 
mitochondrial protein synthesis was brought by multiple published reports on 
patients harbouring pathogenic mutations in the encoding gene. One example 
described the case of two unrelated patients with Leigh syndrome, optic atrophy 
(loss of optic disc nerve fibres) and ophthalmoplegia (paralysis of the 
extraocular muscles) that were both the result of a 1 bp deletion in C12orf65 
(Antonicka et al., 2010), causing a frameshift and premature termination. 
Another group of patients described by Shimazaki and colleagues (H. 
Shimazaki et al., 2012) displayed a milder phenotype that was dominated by 
optic atrophy and neuropathy. Impairment of motor functions caused by 
peripheral neuropathy and spasticity were observed to develop later. In these 
patients the symptoms were all results of a nonsense mutation (c.394C>T, 
p.R132X) that produced a truncated form of C12orf65. Since these two patient 
reports, three other studies have been published that broaden the knowledge of 
C12orf65 related phenotypes. The first study by Spiegel et al. (Spiegel et al., 
2014) described the case of seven patients from two consanguineous families, 
each carrying a pathogenic C12orf65 mutation. Affected members of family A (3 
males and 1 female) displayed slowly progressing bilateral optic atrophy with 
variability in visual acuity. They developed gait disturbances, spastic 
paraparesis and hyper reflexia in the legs. There were no changes in the brain 
MRI. Patients from family B (one male and two females) showed delayed 
development that progressed into mild-to-moderate intellectual disability. 
Patients were diagnosed with severe optic atrophy resulting in blindness. In 
addition, possibility of peripheral neuropathy was suggested due to progressive 
spastic paraparesis (lower limb spasticity), limitation in walking and foot 
deformations. Brain MRI of two of these patients revealed presence of lesions.  
In the second study (Tucci et al., 2013) two members of a consanguineous 
family were diagnosed with slowly progressing axonal neuropathy, bilateral 
optic atrophy, muscle loss and weakness. These phenotypes were consistent 
with Charcot-Marie Tooth disease type 6 (CMT6) and were the consequence of 
c.346delG, p.V116X mutation introducing premature stop codon in C12orf65 
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gene. The last report (Buchert et al., 2013) compares two cases of patients with 
mild cognitive impairment, spastic paraplegia and feet malformations. As in the 
case of previous reports, the mutation underlying these phenotypes was 
c.415C>T, causing a premature stop codon in C12orf65 gene. 
As an addition to the clinical description of patient conditions, three of these 
reports included molecular characteristics of the phenotypes. The most detailed 
analysis (Antonicka et al., 2010) investigated steady state levels of mtDNA 
encoded proteins and RNAs, as well as activity and structure of OXPHOS 
complexes. The results revealed a decrease in complex IV activity in patients’ 
fibroblasts and severe disruption of complex I, IV and V assembly. There was 
also a decrease in steady state levels of mitochondrially-encoded proteins as a 
result of uniformly affected mt-protein synthesis. Similar observations were 
made in the study by Shimazaki et al. (H. Shimazaki et al., 2012), where a 
general defect of mitochondrial translation was reported. The activity of complex 
IV but also complex I were decreased as well as levels of fully assembled 
complexes I, III and IV. In case of patients with CMT6 phenotype (Tucci et al., 
2013), the complex V defect was reported based on disruption of the complex 
structure and decrease in its activity. The mitochondrial membrane potential in 
one of the patients was reduced without any change to the morphology of the 
organelle.   
During this project an opportunity arose to analyse samples from a previously 
uncharacterized patient with a C12orf65 mutation. The genetic defect in this 
patient samples was primarily analysed in the Mitochondrial Diagnostic Service, 
Newcastle. I carried out the analyses to investigate how dysfunction of 
C12orf65 protein affects patient’s mitochondrial homeostasis, especially 
mitochondrial gene expression. The overarching aim of this investigation was to 
better understand the function of the protein by characterising the patient’s 
molecular phenotype caused by the C12orf65 mutation in skin derived 
fibroblasts. 
 
 
4.2. Clinical and diagnostic presentation (courtesy of the Mitochondrial 
NCG Diagnostic Service and associated clinicians) 
Patient report (courtesy of Dr. Grainne Gorman): 
!
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Presentation 
A 45 year old man presented acutely falling at home, with reduced Glasgow 
coma scale (GCS 6 out of 15). He was found to be in type II respiratory failure 
and warranted ITU admission and intubation and ventilation. He developed 
massive hematemesis and required urgent laparotomy and repair of a 
perforated duodenal ulcer. He was slow to wean from the ventilator and was 
noted to have difficulty swallowing. 
He had a term birth and normal development until aged 2 years at which stage 
he underwent anaesthetic and surgery for hypospadias. He sustained a 
perioperative respiratory arrest and was noted to have a visual defect, 
dysarthria, mild fixed limb spasticity and cognitive developmental delay 
subsequently. He underwent a tendon lengthening procedure at age 14 years 
with no untoward sequelae. He was diagnosed with schizoaffective disorder in 
his second decade of life requiring multiple hospital admissions. 
Six months prior to his acute admission, he was noted to have deteriorated 
physically with shortness of breath on exertion and worsening mobility requiring 
two sticks to mobilise with the need for a wheelchair for longer distances. His 
dysarthria had also progressively worsened. 
On examination, he had bilateral ptosis, nystagmus and bilateral optic atrophy.  
He had mild facial muscle weakness, palatal myoclonus, a reduced gag reflex, 
dysarthria and was unable to protrude his tongue. He had severe muscle 
wasting of upper and lower limbs with marked distal muscle atrophy. Upper and 
lower limb reflexes were pathologically brisk. Ankle and plantar reflexes were 
absent. 
He had a protracted hospital stay and remained ventilator dependent via a 
trachyostomy related to gross disturbance of central respiratory drive 
compounded by respiratory muscle weakness. Bulbar function remained 
profoundly poor, necessitating the placement of a percutaneous endoscopic 
gastrostomy feeding tube. 
 
Initial investigations  
Neurophysiological evaluation was consistent with an axonal neuropathy. 
 Initial neuropathy screen including serum protein electrophoresis, copper, 
caeruloplasmin, acylcarnitines, carnitine, phytanic acid, very long chain fatty 
acids, alpha-fetoprotein and urinary organic acids were normal.  
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MRI of the head showed extensive swelling and abnormal high T2-weighted 
signal changes centrally within the medulla and dorsal pons (Fig. 4.1). 
Additional small foci of restricted diffusion were seen within this and the 
cerebellar hemispheres. Brain MRS showed a lactate peak, with reduced NAA 
and raised choline in a voxel centred over the brain stem consistent with a 
diagnosis of Leigh’s syndrome. 
 
Figure 4.1. Results of the patient’s brain MRI 
MRI of the head shows extensive swelling and abnormal high T2-weighted signal 
changes centrally within the dorsal pons (A, red arrow) and medulla (B, C red arrows).  
Additional small foci of restricted diffusion are seen within this and the cerebellar 
hemispheres (A, yellow arrow).  
 
To investigate the possibility of mitochondrial disease, histochemical and 
biochemical analyses of patient fibroblasts and skeletal muscle samples were 
performed in the Mitochondrial NCG Diagnostic Service. The hematoxylin and 
eosin staining (H&E) revealed normal morphology and integrity of muscle fibers 
(Fig. 4.2 A). Activity of cytochrome c oxidase (COX) was investigated by 
addition of 3,3’-diaminobenzidine (DAB), which would cause dark brown 
staining of the cells with functional COX. Lack off the brown staining in patient 
muscle sample indicates severe complex IV deficiency. Succinate 
dehydrogenase (SDH) activity was visualized by reduction of nitroblue 
A" B"
C"
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tetrazolium (NBT) to blue formazan end product. Sequential double-labeling 
(COX/SDH) allowed for final identification of cells with dysfunctional COX as 
these not saturated by DAB and retaining the blue staining. The complex IV 
deficiency was confirmed by spectrophotometric respiratory chain enzymes 
activity assays (Fig. 4.2 B). Activity of complex IV was reduced to 20% of 
control values in muscle samples and to 50% in fibroblasts. The 
spectrophotometric assay was performed by Dr. Langping He as described in 
(Kirby et al., 2007).  
 
Figure 4.2. Histopathological and biochemical analysis of C12orf65 patient 
fibroblasts and skeletal muscle reveals complex IV defect  
A. Histochemical analysis of cytochrome c oxidase (COX) in patient muscle was 
performed as described in (Old and Johnson, 1989) by Mr. Gavin Falkous. For 
comparison, a panel of images of control samples from a separate experiment was 
included. The morphology and integrity of the muscle tissue was determined by 
hematoxylin and eosin staining (H&E). Cytochrome c oxidase (COX) activity was 
assessed by staining with 3,3’-diaminobenzidine (DAB), whereas the succinate 
dehydrogenase (SDH) activity was visualized by nitroblue tetrazolium (NBT) staining. 
Sequential double-staining (COX/SDH) was performed for final assessment of COX 
activity B. Respiratory chain enzyme activity in skeletal muscles and fibroblasts were 
determined in control (blue) and patient (red). Results, normalised to citrate synthase, 
were based on three independent measurements and are shown as percent of the 
control mean value. The significance was assessed based on reference range. 
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The biochemical analysis of patient muscle and skin samples indicated a 
disruption in mitochondrial function. In order to identify the genetic origin of the 
patient’s pathogenic phenotype molecular genetic diagnostics were performed. 
Sequencing of mtDNA excluded depletion, rearrangements, and no point 
mutations in mtDNA were identified. These experiments were performed in the 
Mitochondrial Diagnostics Service by Dr. Langping-He, Dr. Emma Watson and 
Ms. Anna Butterworth respectively. The next step of analysis, sequencing of the 
SURF1 gene (the most common cause of Leigh syndrome), was performed in 
the laboratory of Prof. Garry Brown in Oxford and its results also showed no 
mutations. Since the genetic cause of the patient’s condition was not in 
mitochondrial DNA, exome capture was performed and the results were 
analysed in the laboratory of Prof. Patrick Chinnery (Wellcome Trust Centre for 
Mitochondrial Research, Institute of Genetic Medicine, Newcastle University), to 
investigate nuclear encoded mitochondrial proteins. The analysis identified a 
mutation in the C12orf65 gene as the most likely factor causing the patient’s 
disorder. It was chosen based on the fact that another case was reported with 
the same genetic defect (Antonicka et al., 2010) resulting in mitochondrial 
disease. As both patient’s parents were unaffected, the pathogenic mutation 
could only be recessive and the identified C12orf65 mutation was homozygous 
which further justified the choice. This left the potentially pathogenic mutation 
being the one in the C12orf65 gene. The mutation singled out by exome 
capture, was confirmed by Sanger sequencing performed by Mrs Charlotte 
Alston in the Mitochondrial Diagnostics Service (Fig. 4.3). 
 
 
Figure 4.3. Sequence analysis of patient DNA samples 
Electropherogram of Sanger sequencing. Sequencing of the C12orf65 gene was 
performed for the patient (upper panel) as well as normal controls (example shown in 
lower panel. The arrow points at the position of the nucleotide (A) in control sample 
that is deleted from the patient’s genome. 
Control 
Patient 
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The mutation was a deletion of 1 bp in position 210 (c.210delA) resulting in a 
frameshift and premature stop codon. The first amino acid affected by the 
frameshift is glycine in position 72 and the stop codon occurs 13 residues 
downstream from the pathogenic deletion (p.Gly72Alafs*13). The resulting 
protein would be predicted to be truncated, consisting of only 84 amino acids, 
not 166 as the full-length form. Additionally this mutation occurs just before the 
well conserved GGQ motif (highlighted in Fig. 4.4 panel A; described in detail in 
1.2.4 and 1.6.2), changing its amino acid sequence to GAR (boxed in Fig. 4.4 B 
below).  
 
 
Figure 4.4. Prediction of c.210delA mutation effect on C12orf65 protein 
A. Effect of c.210delA on C12orf65 protein predicted by Alamut Visual software. The 
red line indicates the place of mutation in the genome and resulting protein sequence. 
Bottom panel represents conserved motifs present in C12orf65 protein sequence, as 
well as the position of the mutation in relation to putatively functional GGQ motif 
(highlighted by the yellow box). B. Prediction of how the C12orf65 amino acid 
sequence is affected by c.210delA mutation. The frameshift caused by the deletion 
changes amino acid composition starting from two residues downstream. The most 
important functional consequences are highlighted (altered GGQ motif with yellow box, 
premature stop codon with red). The analisis was perfomed by Mrs. Charlotte Alston in 
the Mitochondrial Diagnostic Service.  
 
B.#
A.#
 67     68    69      70     71    72       
Gly    His   Gly    Pro   Gly    Gly    Gln   Ala   Thr   Asn  Lys   Thr   Ser   Asn  Cys   Val    Val   Leu   Lys   
GGA CAC GGT CCA GGG GGC CAG GCA ACC AAC AAA ACC AGC AAC TGC GTG GTG CTG AAG 
GGA CAC GGT CCG GGG GCC AGG CAA CCA ACA AAA CCA GCA ACT GCG TGG TGC TGA AG... 
 Gly    His   Gly    Pro   Gly   Ala    Arg    Gln   Pro  Thr   Lys   Pro   Ala   Thr   Ala    Trp   Cys STOP 
                                      +1     +2    +3    +4    +5     +6    +7    +8     +9  +10    +11     +12   +13 
 c.210delA, p.Gly72Alafs*13 
WT 
Patient 
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4.3.  c.210delA mutation in C12orf65 causes an OXPHOS defect and 
impaired growth of patient’s fibroblasts in medium containing 
galactose 
For further investigations, patient skin fibroblasts obtained from biopsies were 
immortalized by the Neuromuscular Biobank, (Institute of Genetic Medicine, 
Newcastle University by Ms. Mojgan Mohammed Reza). The method of 
immortalization utilised a retroviral vector encoding the E6/E7 early region gene 
from HPV and geneticin as a selection agent. This process allows the extended 
divisions when culturing of fibroblast cell lines, which are required to generate 
sufficient amount of material for experiments. In addition to the patient, a control 
skin fibroblast cell line (sample: M08828-12) derived from a non-familial, healthy 
person was immortalized in parallel. After the immortalization, cells from both 
patient and control fibroblasts were transported back from the Institute of 
Genetic Medicine in a 6-well plate to start the selection process. Selection was 
necessary in order to preserve only those cells that were successfully 
immortalized. Wells of unimmortalized cells (1 well of each cell line) were also 
placed in selective media as a control for efficiency of the transfection and to 
identify when selection process was complete as all the untransfected cell 
would be dead. The concentration of the selection agent, geneticin was chosen 
based on the previous experiments by Dr. William C. Wilson. DMEM medium 
containing 400 µg/ml of geneticin was added to all the cells (un- and 
immortalized), which were then cultured until all unimmortilized cells died. 
Throughout the selection process the medium with geneticin was changed 
every two days. The immortalized cell lines were labelled: “C12orf65-MUT 
SW/IMM” for the patient (in this study referred to as “patient”) and “DC/IMM” for 
the control (referred to as “Control 1”). Both cell lines were propagated and 
multiple aliquots were stored in liquid nitrogen for the future experiments. 
In order to answer the question of whether the mutation in C12orf65 affects the 
patient’s cell doubling time, growth curves for both cell lines were produced. 
Parallel experiments were conducted using standard growth medium containing 
either glucose, or galactose as the only source of carbon (as described in 
2.1.3). Galactose-based medium was used to force cells to utilise OXPHOS for 
ATP production. In these conditions defects of mitochondrial functioning and 
their effect on cell growth were enhanced causing impaired growth in 
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comparison to control cells. 
 
Figure 4.5. Comparison of patient’s and control fibroblasts growth on 
different sources of carbon. 
A. Equal number of patient or control fibroblasts were seeded and then counted at the 
same time points (2, 4 and 6 days) in two different growth media (as described in 
2.1.3). Growth curves were produced based on average from 3 experimental repeats. 
B. Differences in density and morphology of the patient and control fibroblasts is 
detectable by bright field light microscopy. Equal number of cells were seeded and the 
panels presented are after 6 days growth in galactose medium. 
 
When grown in standard, glucose-containing medium both cell lines exhibited 
similar growth rates. However, when the source of carbon was changed to 
galactose, the growth of patient cells appeared to be completely inhibited. The 
number of cells at the last time point was lower than the initially seeded 
number, suggesting accelerated cell death. These results show that c.210delA 
mutation in C12orf65 indeed causes mitochondrial OXPHOS defects and 
confirms the role of this protein in normal cell functioning. 
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4.4. c.210delA mutation in C12orf65 causes disruption of complex I, IV 
and V assembly 
After identification of the mitochondrial defect, further investigation was 
conducted to characterize more specifically how OXPHOS is affected by the 
C12orf65 mutation. BN-PAGE analysis was performed to assess respiratory 
chain complexes assembly. Mitochondria were isolated from patient and control 
fibroblasts and solubilised with dodecylmaltoside (as described in 2.5.4). 
Samples (12.5 μg) were separated on a gel 4.5-16% gradient gel in imidazole-
containing buffer under native conditions in order to preserve OXPHOS 
complexes intact. Western blot analysis then allowed for the detection of the 
fully and potentially partially assembled respiratory chain complexes using 
antibodies specific to a single subunit. Any potential disruption of complex 
formation could be identified as decrease in amount of its subunit or aberrant 
migration.  
  
Figure 4.6. BN-PAGE analysis revealed changes in OXPHOS complexes in 
patient fibroblasts with c.210delA C12orf65 mutation 
Equal amounts of mitochondrial lysate (12.5 µg per lane) from patient and control 
fibroblasts were loaded on 4.5-16% gradient polyacrylamide BN gel. After transfer, 
Western blot analysis was used to visualize all OXPHOS complexes with subunit 
specific antibodies as follows: complex I (NDUFA9), complex III (Core 2) and complex 
II (SDHA 70 kDa), complex IV (COX4) and complex V (α-subunit).  
 
Results of BN-PAGE analysis showed visible differences in amounts of protein 
complexes between patient and control samples (Fig. 4.6). The most severely 
affected complexes are complex I, IV and V. In case of complex I and IV, the 
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assembly defect manifests itself as lower amounts of proteins. Impaired 
complex V formation is represented by detection of free F1 subunits detached 
from the rest of the complex. There is also a minor defect of complex III, visible 
also in combination with complex I deficiency, where it results in lower levels of 
supercomplex I+III. As expected, levels of complex II are not affected as it 
consists of exclusively nuclear encoded subunits, in comparison to all other 
OXPHOS complexes that contain components coded by mtDNA. Thus any 
potential disruptions to mitochondrial gene expression can cause defects in 
their formation. 
 
4.5.  C12orf65 mutation causes a decrease in steady state levels of 
complex I and IV subunits. 
To further investigate what defects of OXPHOS and mitochondrial function are 
caused by the C12orf65 mutation, analysis of the steady state levels of 
mitochondrial and mitochondrially encoded proteins was performed. Solubilised 
mitochondria were subjected to SDS-PAGE (2.5.5) and Western blotting (2.5.6) 
using a panel of antibodies (Fig. 4.7 A and C). 
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Figure 4.7. Comparison of steady state levels of mitochondrial proteins 
was assessed in patient and control fibroblasts 
Mitochondrial lysates of patient and control fibroblasts (12.5 µg per lane) were 
separated on 12% SDS-PAGE, each sample was loaded twice as technical repeats 
(lanes 1 and 3 for control, 2 and 4 for patient) A. Levels of subunits of respiratory chain 
complexes were detected with antibodies specific to nuclear encoded NDUFB8 
(complex I), SDHA 70kDa (complex II), Core2 (complex III) and mitochondrially 
encoded COX2 (complex IV) porin and HSP60 were used as loading controls. B. 
Histograms, were generated from the densitometric measurements of the westerns in 
panel A. Mean value of the signals from two repeats was calculated for patient and 
control. Results of patient samples were presented in relation to the signal of the 
control.  C. Levels of mitochondrial release factor family members (mtRF1 and ICT1), 
mitochondrial proteases (Lon-P, ClpX) and mitoribosomal proteins (small subunit: 
MRPS26 and MRPS27 or large subunit: MRPL3 and MRPL45) were investigated. In 
each case porin was used as a loading control. D. Densitometric measurements of the 
signal from panel C. were presented as histograms with the mean value of the signal 
from patient sample represented in relation to the mean signal of the control. 
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Visual inspection, supported by densitometry analysis (Fig 4.7 B), showed a 
severe decrease in levels of mitochondrially encoded COX2 (subunit of 
complex IV), which suggests a disruption in mt-translation in the patient sample. 
Lower levels of NDUFB8 (complex I subunit) support this observation. Although 
NDUFB8 is encoded in the nuclear genome, it is incorporated with all mt-
encoded subunits into the membrane-anchored part of the complex I (Perales-
Clemente et al., 2010) and is  sensitive marker of complex I assembly. Thus a 
decrease in its levels indicates that the levels of mitochondrially encoded 
subunits could also be reduced. In addition the western blot results showed no 
significant reduction in levels of nuclear encoded Core 2 (subunit of complex III) 
or SDHA (70 kDa subunit of complex II). All these results are consistent with the 
defects of OXPHOS complexes identified during BN-PAGE analysis (Fig. 4.6) 
with complex I and IV being the most affected and no observed changes to 
complex II, which is fully encoded by the nuclear genome. These results further 
support the observation that the decrease in steady state levels of respiratory 
chain complexes in the patient samples was due to defects of mitochondrially 
encoded components. The mutation in C12orf65 was most likely causing 
disruption in mitochondrial translation but if it was due to the decrease in de 
novo protein synthesis or the increase in the turnover then this could be 
confirmed by [35S]-Met/Cys metabolic labelling. 
In addition to respiratory chain subunits the following groups of mitochondrial 
proteins were also studied: release factor family, mitochondrial proteases and 
mitoribosomal proteins (MRPs). The steady state levels of release factor family 
members were analysed in order to investigate if the mutation of C12orf65 
would trigger a potential compensation mechanism. However, patient sample 
showed no increase in levels of neither mtRF1 nor ICT1 (Fig 4.7 C, quantified in 
Fig. 4.7 D). On the contrary, there was a moderate decrease in levels of mtRF1. 
Comparison of the levels of mt-proteases (Lon-P, ClpX) was performed to 
detect if in the absence of functional C12orf65 there is an increase in protein 
degradation. Only slight changes in levels of these two proteins were observed 
(increase of Lon-P signal and decrease of ClpX in patient sample, Fig. 4.7 C 
and D) suggesting that there is no additional elevation of proteolytic activity 
caused by C12orf65 mutation. Finally, the steady state levels of MRPs from 
both small and large ribosomal subunits were investigated. With the exception 
of MRPL3 which showed an increase in patient samples, there were no 
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changes between patient and control samples (Fig. 4.7 C and D). These results 
indicated that the C12orf65 mutation did not affect the mitoribosomal biogenesis 
or turnover. 
 
4.6. C12orf65 c.210delA mutation causes a decrease in mitochondrial 
de novo protein synthesis 
The observed detrimental effects on the composition and levels of OXPHOS 
complexes, as well as their subunits described above, suggest that this 
mutation in C12orf65 may result in a disruption of mitochondrial protein 
synthesis. This could be caused either by a defect of de novo synthesis or by 
accelerated mt-protein turn over. To investigate this hypothesis, [35S]-
methionine/ cysteine metabolic labelling was performed under conditions where 
cytosolic protein synthesis was inhibited with emetine to facilitate visualisation 
of only the newly formed 13 mtDNA-encoded polypeptides. The patient and two 
control cell lines were incubated with [35S]-labelled methionine/cysteine (2.9). 
Samples from each labelled cell line, containing equal amounts of protein were 
separated on 15% SDS-PAGE. Signals from radiolabelled newly-synthesised 
mt-proteins were detected by PhoshoImager and ImageQuant software. 
 
Figure 4.8. Decrease of the de novo mitochondrial protein synthesis in 
patient samples with c.210delA C12orf65 mutation 
patient (P) and two control fibroblast cell lines (C1 and C2) were metabolically labelled 
with [35S]-methionine/ cysteine with parallel inhibition of cytosolic translation. Equal 
amounts of radiolabelled samples (50 µg of total cell protein) were separated by 15% 
SDS-PAGE. Signal from newly synthesised mt-proteins was detected via 
phosphoImaging (Phosphoimager, left panel). Prior to the imaging, the gel was stained 
with Coomassie brilliant blue (CBB, right panel) to confirm even loading. 
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Comparison of the results of the [35S]- methionine/ cysteine metabolic labelling 
between the patient sample (Fig. 4.8 ‘P’) and control cell lines (C1 and C2) 
showed the general decrease of the signal in the patient sample. The difference 
was more profound in comparison with C2 sample. However, this was caused 
by overloading of the control 2 sample, confirmed based on the Coomassie blue 
staining of the gel (Fig. 4.8 ‘CBB’). The decrease of the signal in patient sample 
was observed for all mitochondrially encoded proteins with exception of 
COX2/3/ATP6 triad and ATP8/ND4L. In both cases regions of higher signal in 
the patient sample seemed to be of lower motility than the corresponding areas 
in control samples. Hence it was impossible to assess whether they were a 
result of increase in translation or represent truncated/degraded form of 
polypeptide. The result of [35S]- methionine/ cysteine metabolic labelling 
suggested that the C12orf65 mutation impairs the de novo protein synthesis in 
mitochondria with a varying effect on different polypeptides.  
 
4.7. The c.210delA mutation in C12orf65 causes accumulation of 
mitochondrially encoded transcripts 
It is clear that the mutation in C12orf65 causes a defect in translation of 
mitochondrial proteins but is this an indirect effect with the primary defect being 
in the transcription of mt-mRNA? In some other contrary cases, inhibition of 
translation can cause accumulation of transcripts (R. Temperley et al., 2010). 
To investigate whether changes in the steady state levels mitochondrial 
transcripts were responsible for the changes in protein synthesis, mt-RNAs 
were analysed via Northern blot. 
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Figure 4.9.  Steady state levels of mitochondrial transcripts are altered in 
C12orf65 patient. 
A. Total RNA (4 µg) isolated either from patient or control fibroblasts, was subjected to 
Northern blot analysis with the indicated probes. The probes were designed to target 
mitochondrial-encoded transcripts (2.4.2). B. Quantification of mt-RNA steady state 
levels was calculated using ImageQuant software and presented as the percentage of 
the patient sample. Levels of 18S cytosolic RNA, detected by retained intercalated 
ethidium bromide on the membrane after transfer, were used as the loading control to 
normalise intensity of each signal. The graph consists of a mean and standard 
deviation of three independent experimental repeats (*p <0.05, **p<0.01, ***p<0.001). 
 
Visualisation with probes specific to different mt-transcripts allowed comparison 
of their amounts between patient and control samples (Fig 4.9 A). After the 
normalization with 18S as a loading control (signal from the ethidium bromide 
stained samples visible on the membrane after the transfer), relative amounts of 
mt-mRNA (MT-CO1, MT-ND1, RNA14) and mt-rRNA (MT-RNR1, MT-RNR2) 
were calculated and presented as histograms (Fig 4.9 B). The measurement 
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of the signals was performed with ImageQuant software which is only a semi-
quantitative method but the generated histograms clearly showed the difference 
between patient’s and control’s steady state levels of mt-transcripts. In case of 
mitochondrial messenger RNA, levels of both MT-ND1 and RNA14 were 
elevated in patient sample (2.7x  and 1.7x respectively, relative to control 1 
levels). However, increase in levels of MT-CO1 in patient samples was not as 
profound (1.2x in relation to control 1). Similarly to mRNAs, patient sample 
showed increase in levels of mitochondrial ribosomal RNAs (1.4x for MT-RNR1 
and 1.7x for MT-RNR2 in comparison to control 1). These results suggest the 
accumulation of mitochondrial transcripts in patient fibroblast as the result of 
C12orf65 mutation.  
 
4.8. Discussion 
Many cases of patients with C12orf65 mutations have been published so far. 
Interestingly, these reports show a wide variety of clinical presentations. The 
common features for most of these patients’ phenotypes are optic atrophy often 
with ophthalmoplegia, peripheral neuropathy accompanied by muscle 
weakness and spasticity and abnormalities in brain MRI and MRS. The severity 
of phenotypes ranges from mild to acute but with the predominance of the 
former. Out of 15 reported cases only one patient died at a young age 
(Antonicka et al., 2010), the majority of them were diagnosed as adults and 
were still alive at the time of publication of the reports (Buchert et al., 2013; H. 
Shimazaki et al., 2012; Spiegel et al., 2014; Tucci et al., 2013).  
The characterisation of patient samples in my project clearly indicated that the 
c.210delA C12orf65 mutation resulted in an OXPHOS defect. It was manifested 
by a decrease in cytochrome c oxidase (COX) activity in skeletal muscle and 
skin fibroblasts (Fig. 4.2) and confirmed by impaired growth of fibroblasts on 
galactose medium (Fig. 4.5). The observed decrease in COX activity was 
consistent with the defect of complex IV assembly (Fig. 4.6). In addition, BN-
PAGE analysis revealed that respiratory chain complexes I, V and, to a lesser 
extent, complex III were also affected. In case of complex V, immunoblotting 
detected the presence of free F1 subunit, which was the result of severe 
assembly defect (Fig. 4.6). These results were reflected in decreased steady 
state levels of complex I, III, IV and V subunits (Fig. 4.7 A and B). The reduction 
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in steady state levels of these proteins was not, however, coupled with an 
upregulation of mitochondrial proteolytic activity. Levels of mitochondrial 
proteases ClpX and Lon-P were not changed between the patient and control 
(Fig. 4.7 C). The C12orf65 mutation had an effect only on the OXPHOS 
complexes that contain mitochondrially-encoded subunits. Complex II, which is 
composed entirely of subunits synthesised in cytosol, was not affected. These 
observations indicated impairment of mt-translation further confirmed by the 
decrease in de novo mitochondrial protein synthesis (Fig. 4.8). However, the 
reduction in levels of newly synthetises mt-proteins, observed in [35S]-
methionine/cysteine metabolic labelling, was not uniform. There was a visible 
increase in the signal in vicinity of COX3/COX2/ATP6 triplet and ATP8/ND4L. 
This result could be caused by either upregulation of translation or 
accumulation of the truncated form of unidentified polypeptide. A similar 
observation was made during characterisation of the mutation in mitochondrial 
poly(A) polymerase where the same pattern of differences in de novo mt-
translation between patient and control was present (Wilson et al., 2014).  
The final characterised feature of the patient’s phenotype described in this 
section was accumulation of mitochondrial transcripts (Fig. 4.9). This result 
suggested a possible compensation mechanism for defects in mt-translation. 
Another explanation would be a disruption to RNA degradation mechanism. 
Increase in levels of mt-transcripts in patient sample was observed for both 
mRNAs and rRNAs. The surplus of the ribosomal RNAs was not coupled with 
an increase in mitoribosomal biogenesis as the levels of MRPs were not 
changed (Fig. 4.7 C). Increase in steady state levels of mitochondrial transcripts 
was also observed by Dr. Pajak due to depletion of C12orf65 via siRNA. The 
steady state levels of mitoribosomal proteins in that study were also not 
changed. 
The molecular analysis of the patient samples conducted for this project is 
consistent with the published reports, especially with characterisation of patients 
from Antonicka et al. study (Antonicka et al., 2010). In this report the mutation in 
patient 1 is identical with the genetic defect of patient described in my project. 
Both cases displayed the same defects in assembly of OXPHOS complexes, 
with complex I, IV and V most severely affected. Also the characteristic 
detachment of F1 subunit from complex V is consistent between the two reports, 
as well as observed in patients reported by Tucci et al. (Tucci et al., 2013). 
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Number of additional features characterised as a result of C12orf65 mutation in 
my project were also consistent with published patient reports. For example, 
decrease in complex IV activity was present in multiple patient cases (Antonicka 
et al., 2010; H. Shimazaki et al., 2012; Spiegel et al., 2014; Tucci et al., 2013). 
The increase in steady state level of mt-transcripts was among the effects of 
C12orf65 mutation in patients characterised in (Antonicka et al., 2010). The 
results of de novo mt-protein synthesis are also consistent between different 
studies, where mutations in C12orf65 are causing a general decrease in de 
novo mt-translation (Antonicka et al., 2010; H. Shimazaki et al., 2012). The 
specificity of the C12orf65 mutation effect on mt-translation was confirmed in 
(Antonicka et al., 2010) by the successful rescue experiment. Overexpression 
of wild type C12orf65 in patient cell lines resulted in increase in de novo 
translation levels and partial suppression of the other defects. 
The most recent publication characterises mutation in C12orf65 as a new cause 
for Behr syndrome and proposes to re-evaluate classification of the already 
published cases of C12orf65 mutations (Pyle et al., 2014). However, the 
unusual clinical presentation of the patient described in my project varies from 
the definition of Behr syndrome, especially due to lack of early (less than 10 
years) onset of optic atrophy.  
Results of this study, as well as the published data strongly suggest 
involvement of C12orf65 in mitochondrial translation. Mutations in C12orf65 are 
clearly impairing protein synthesis in mitochondria, which is reflected by 
decrease in de novo mt-translation. Resulting deficiencies in mitochondrially-
produced proteins could be the reason for the observed disruption in complex 
assembly, which would then lead to the decrease in their activity. The final 
outcome is the mitochondrial defect manifested by the range of symptoms from 
nervous system and skeletal muscles, two of the most energy-demanding 
tissues. Like in many cases of mitochondrial diseases the consequence of the 
organellar defect can be tissue specific and despite the clear evidence of a role 
for C12orf65 in mitochondrial translation, the nature of its involvement is still 
unknown. !
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Chapter 5 
 
Mitoribosome profiling - preliminary protocol for use with 
IonTorrent sequencing !  
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5.1. Introduction 
The study of cell lines with depleted or mutated C12orf65 allowed 
characterisation of the consequent defect but did not yield sufficiently definitive 
results to explain the function of the protein. The methods used for these 
experiments were not enough to reveal the role of C12orf65 as a potential 
ribosome rescue factor. For this purpose, different methodology needed to be 
used that would provide more insight into the direct interactions of 
mitoribosomes with mt-mRNA and be sensitive enough to detect changes to 
ribosome progression after loss of a protein involved in translation. The chosen 
method that had the potential to answer these questions was ribosome profiling. 
Ribosome profiling is a relatively new technique for studying translation in vivo, 
combined with high throughput Next Generation Sequencing (NGS). Before this 
methodology was pioneered, investigation of the levels of gene expression was 
conducted through assessing the amount of transcribed and translated mRNA 
by northern/qPCR/microarray and westerns respectively. The development of 
Next Generation Sequencing contributed to the advancement of this field and 
provided immeasurable benefits to genomic and transcriptomic analysis. This 
led to the creation of the RNAseq methodology, which replaced microarrays in 
assessment of gene expression levels. However, the measurement of 
transcripts levels is not sufficient to analyse the actual process and levels of 
translation. To study how much of the generated mRNA is actually being 
translated it is necessary to focus only on levels of mRNA bound to ribosomes. 
One of the approaches used to obtain this type of data was polysome profiling. 
More than just one ribosome can translate a single transcript at the same time 
creating what are called polysomes (Mašek et al., 2011). The mRNA translated 
by polysomes can be separated on sucrose gradient based on its differences in 
density. The method allows to distinguish between fractions of free mRNA and 
transcripts occupied by one or multiple ribosomes (Arava et al., 2003; Mašek et 
al., 2011). The number of the ribosomes attached to a given transcript is a 
reflection of the efficiency of its translation. Polysome profiling can also be 
linked with variety of the methods to expand the information recovered 
(Northern, western blotting, qPCR, genome-wide microarrays) (Arava et al., 
2003; Kuhn et al., 2001; Mašek et al., 2011). However, this technique is 
laborious and limited in generating quantitative data and because of difficulties 
in resolving fractions that contain high amount of ribosomes, therefore 
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quantitative analysis of translation has always been problematic. In addition, 
polysome profiling data is unable to determine the exact positions of ribosomes 
on a transcript (Ingolia, 2014). Positions of ribosomes were historically studied 
by nuclease protection assay (Steitz, 1969), many data were generated this 
way, defining the specific sequences occupied by ribosomes. Before 
development of microarrays and NGS, this method could only be used in vitro 
on one specific sequence of template. For comprehensive analysis of in vivo 
translation another method had to be 
designed. Ribosome profiling combines 
the aforementioned techniques, taking 
the advantages that each of them 
provides. Nuclease protection allows for 
determination of sequences occupied by 
ribosomes, while NGS provides depth 
and scope of sequence analysis similar 
to RNAseq. Fragments of mRNA 
protected by ribosomes from 
ribonucleolytic cleavage (ribosome 
footprints, RFs) are deep sequenced and 
their sequences are then aligned with the 
genome (Fig. 5.1).  
Figure 5.1. Schematic overview of the 
ribosome profiling principle 
Cell lysate (A) is treated with ribonuclease, 
which digests mRNA, leaving fragments 
protected by translating ribosomes intact (B). 
Pieces of the mRNA protected by ribosomes 
(C) are isolated based on their size (∼ 30 nt) 
and converted into a cDNA library. Deep 
sequencing of the library and alignment with 
the reference genome results in ribosome 
profiles (D). 
 
This alignment is presented as histograms of footprint density, which 
corresponds to ribosome occupancy across each aligned transcript. Analysis of 
these histograms in combination with RNAseq data enables the intensity of 
translation and the exact positions of translating ribosomes to be defined. 
The first published ribosome profiling experiments were performed in yeast and 
provided a genome-wide, detailed measurement of translation in vivo 
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(Ingolia et al., 2009). The data generated provided insights into how ribosome 
densities change in position-specific manner. The resulting ribosome profiles 
allowed identification of characteristic ribosomal accumulation near the 
beginning of the transcript. Additionally, the data revealed the previously 
undetected presence of ribosomes on many short sequences upstream of 
known CDS. These upstream open reading frames (uORFs), many of which 
were uncharacterized, initiated from non-AUG codons and so it had previously 
been presumed that these were not translated. Finally, the ribosome profiling 
protocol was utilized to define changes in translation efficiency caused by 
starvation/nutrient deprivation and therefore it aided in characterizing regulatory 
and compensatory mechanisms invoked during this process. The complete 
methodology (Ingolia, 2010) included: 1) incubation of the cells with 
cyclohexamide to inhibit elongation and prevent ribosomes running off during 
the experiment, 2) treatment of the cell lysate with ribonuclease (RNase One) 
for the protection assay, 3) separation of ribosomes containing fragments of 
protected mRNA (ribosome footprints), 4) isolation and size separation of the 
ribosome footprints (∼ 30 nt), 5) conversion of isolated mRNA fragments into 
dsDNA sequencing library, 6) deep sequencing of the library on an Illumina 
platform and finally 7) alignment with the yeast genome and bioinformatics 
analyses to generate ribosome profiles. 
Since the first publication in 2009, ribosome profiling is progressively gaining 
more applications in a growing number of organisms including bacteria (Li et al., 
2012), C. elegans (Stadler and Fire, 2011) and D. melanogaster (Dunn et al., 
2013). The first published application in a mammalian genome was carried out 
on mouse embryonic stem cells (MESCs) by (Ingolia et al., 2011). Modification 
of the protocol allowed the authors to determine rates of translation elongation 
(pulse-chase experiments using inhibitory antibiotics) and to identify strong 
pause sites. This study, together with two others (Lee et al., 2012; Fritsch et al., 
2012) revealed many unannotated products of translation from uORFs, 
sprcRNAs (short polycistronic ribosome-associated coding RNAs) and 5’ end of 
long interspersed non-coding RNAs (lincRNAs) in mammalian cells. 
Various applications of ribosome profiling have generated results that have 
helped to expand knowledge on different aspects of translation. Among many 
others, ribosome profiling enabled investigation and characterization of different 
mechanisms of co-translational folding of proteins in bacteria (Oh et al., 
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2011) and mammals (Han et al., 2012). The genome-wide study by (Dunn et 
al., 2013) provided evidence of stop codon readthrough in Drosophila 
melanogaster, a phenomenon also observed in viruses. Investigations of 
different stress factors revealed a mechanism in which translation is affected in 
response to protein misfolding (Liu et al., 2013), heat shock (Shalgi et al., 2013) 
or oxidative stress (Gerashchenko et al., 2012). Ribosome profiling has also 
been successfully applied to medical purposes to investigate genomics of 
prostate cancer (Hsieh et al., 2012). It was used to characterize translation 
regulation of gene expression downstream of the mTOR oncogenic signalling 
and help to identify translationally controlled mRNAs regulating invasion and 
metastasis. 
The aim of my study was to optimize and apply ribosome profiling to human 
mitochondria. At the start of my project there were no published data on 
ribosome profiling in mitochondria so the available protocols required 
adjustments to accommodate the specifics of organellar translation. In addition, 
the essential steps that needed very careful optimization were purification of 
mitochondria and isolation of mitoribosomes protecting mRNAs. The final 
aspect that needed modification were the generated libraries, which had to be 
made compatible with IonTorrentTM sequencing as this was the NGS system 
available in our facility and for a small genome such as the human mtDNA 
would provide sufficient coverage to give meaningful results. Moreover, 
IonTorrent sequencing had been previously used for deep sequencing of 
mitochondrial DNA libraries with success (CLIP experiments by (Hornig-Do et 
al., 2014). This chapter will provide a detailed description of the methodology I 
had to develop in order to generate the profiles from the mitoribosome 
protected fragments. It will also present the preliminary results of deep 
sequencing. 
 
5.2. Optimization of mitoribosome footprints generation 
My initial protocol for mitoribosome profiling was based on the original 
publication by Ingolia (Ingolia et al., 2009) described later in greater detail in 
(Ingolia, 2010). Because the aim of this experiment was to capture and analyse 
fragments of mRNA protected only by mitochondrial, not cytosolic ribosomes, a 
number of changes to the protocol were considered necessary. The main 
adjustments included inhibition of mt-translation by chloramphenicol instead 
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of cyclohexamide, isolation and purification of mitochondria prior to RNase 
treatment and separation of mitoribosomes via sucrose gradient. The first part 
of optimization was focused on generating mitoribosomal footprints and 
investigating efficiency of the chosen protocol. Experiments were performed 
utilizing wild type HEK293 cell lines. For each mitoribosome profiling experiment 
2x 225cm2 flasks of HEK293 cells (at 80-95% confluence) were used. Prior to 
isolation of the mitochondria, cells were treated with chloramphenicol (final 
concentration 5 µg/ml, 1 h, 37°C). Next cells were harvested and the pellets 
were washed with Dulbecco’s A PBS, supplemented with chloramphenicol. 
Chloramphenicol was present in all the buffers used during generation of 
ribosome footprints in order to maintain inhibition of translation elongation 
throughout the whole of the procedure. Mitochondria from chloramphenicol-
treated cells were isolated as described in 2.5.2. The only difference was 
addition of chloramphenicol (50 µg/ml final) to the homogenisation buffer and 
lack of PMSF. To minimise contamination with cytosolic ribosomes the outer 
mitochondria membrane was “shaved” by treatment with DNase I and 
proteinase K (described below). DNase was added to reduce the viscosity of 
sample that was often observed after the mitochondria isolation. PMSF was 
omitted, as it would inhibit the activity of proteinase K. For the shaving 
procedure, mitochondrial pellets were resuspended in 250-300µl of 
homogenisation buffer (lacking BSA and PMSF) and the protein concentration 
was estimated by Bradford assay. Subsequently MgCl2 and CaCl2 were added 
to final concentrations of 10 mM and 1 mM respectively as the presence of Mg2+ 
and Ca2+ ions is necessary for DNase activity. For 4 - 5mg of mitochondrial 
protein 2U of DNase I (AMPD1, SIGMA) was used and incubated for 15 min at 
room temperature. Proteinase K (Invitrogen) was then added in proportion of 5 
µg of enzyme per 1 mg of mitochondrial proteins. After 30 min of incubation on 
ice, the reaction was quenched by addition of 1 mM PMSF and the sample was 
centrifuged (11000 g, 5 min, 4°C). Finally the pellet was washed with 
Homogenisation Buffer (-BSA, +PMSF, 2.5.2) and resuspended in 100 µl of the 
same buffer. A fraction (1/10) of mitochondrial solution was retained for RNA 
isolation (to estimate RNA contents in isolated mitochondria), the remaining 9/10 
was used for membrane lysis. To solubilize mitochondrial membranes, 
organellar solution was pelleted and, depending on the pellet volume, 
resuspended in 100-175µl of Lysis Buffer (2.5.2). The sample was 
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incubated for 30 min at 4°C, with agitation on a rotator and then centrifuged 
(12000 g, 5 min, 4°C). The supernatant was transferred into a new tube and 
protein concentration was determined by Bradford assay (2.5.3). The lysate 
was divided into aliquots of a maximum volume of 100µl, each containing 300-
700 µg of proteins. Each part had the same amount of proteins and an equal 
volume. 
The estimation of the RNA concentration in mitochondrial lysate was necessary 
to determine the amount of ribonuclease to be used in the protection assay. 
The 10µl of mitochondrial solution left before lysis was resuspended in 500µl of 
Trizol reagent (Invitrogen), and RNA isolated following manufacturer’s 
instructions. The final pellet was resuspended in 15 µl of DEPC-treated water 
followed by measurement of the RNA concentration by NanoDrop (Labtech). 
Based on these results, the amount of RNA in the remaining mitochondrial 
solution was calculated. 
For the ribonuclease protection assay 7U of RNase One (Promega) was used 
per 100 µg of mitochondrial RNA. Only one aliquot of mitochondrial lysate was 
treated with RNase, the second was left untreated as a control to compare the 
effect of the enzyme on ribosome composition. Reactions were performed in 
the presence of 5 mM EDTA, at 20°C for 10 min (shaking heatblock). The 
temperature used for this reaction was lower than the optimal 37°C and RNase 
activity was stopped by loading samples on sucrose gradient. 
Separation on an isokinetic 10% to 30% sucrose gradient was performed as in 
2.7. After centrifugation, aliquots (100 µl) of the samples were taken from the 
top (fraction 1, see Fig. 5.2), which partitioned into 11 fractions (volume of 
fraction 11 was equal to the volume of loaded sample). Samples from each 
fraction (12 µl with 3 µl of 5x SDS-PAGE loading buffer, 2.5.5) were then 
analysed via western blot (2.5.6). Immunoblotting of these samples with 
antibodies for mitoribosome proteins served as indicator of the monosome 
position within the gradient (Fig. 5.2). The positions of small and large 
mitoribosomal subunits were detected using DAP3 and MRPL3 antibodies, 
respectively. 
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Figure 5.2. Migration profile of mitoribosomal proteins is altered after 
RNase treatment. 
Equal amounts of cell lysate (300 - 700 µl) from HEK293 treated with RNase 
(“+RNase”) or untreated (“-RNase”) were separated on isokinetic sucrose gradients 
(10% - 30%). Western blotting was used to analyse each fraction (12 µl) for the 
presence of 28S small (DAP3) or 39S large (MRPL3) mitoribosomal subunit. Signals 
from each antibody indicated which fractions contained monosomes (55S). 
 
Prior to the RNase treatment (Fig. 5.2, sample ‘-RNase’, right panel) the signal 
from DAP3 antibodies representing the position of small subunit was present in 
fractions 4 and 5. The fractions containing the 55S monosome were identified 
as 7 and 8. However, after the RNase digestion (‘+RNase’ left panel) the 
positions of the subunits, as detected by antibody probing, shifted towards the 
less dense fractions of the gradient. The small subunit was identified in fractions 
2, 3 and 4 and monosome in fractions 6 – 7. The fraction 5 contains most likely 
free large subunits. The change in the position of small subunit and monosome 
was most likely caused by the digestion of mt-mRNA with RNase I. As observed 
in numerous experiments conducted in my host lab, mitochondrial transcripts 
are detected in sucrose gradient fractions corresponding to free mitoribosomal 
subunits as well as the whole monosome. The treatment with RNase would 
remove the unprotected parts of these mRNAs associated with mitoribosomes 
(free subunits and monosomes). This action would result in changing the 
molecular weight (MW) of mitoribosomal subunits and monosomes.  
The rest of each gradient fraction (~ 88 µl) was used directly after gradient 
separation to isolate RNA, using hot acid phenol: chloroform extraction (Ingolia, 
2010). This procedure allowed samples to be stored as precipitated in 
isopropanol. Only fractions that were identified to contain monosomes were 
processed further. Each of the samples was mixed with SDS (1% final volume) 
+ RNase  - RNase 
 1   2  3   4    5   6  7   8   9  10 11 1   2   3   4   5   6   7   8  9  10  11
DAP3
MRPL3
DAP3
MRPL3
28 S 55 S
1                      11
10%               30%
55 S28 S
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and heated to 65°C, then mixed with 1 volume of pre-heated (65°C) acid 
phenol: chloroform solution (5:1, pH 4.5) and incubated at 65°C for 5 min 
(thermomixer with maximum shaking). Samples were placed on ice for another 
5 min then centrifuged (16 000 g, 2 min, 4˚C). The aqueous phase was 
recovered, mixed with 1 volume of acid phenol: chloroform solution and 
incubated at room temperature (thermomixer with vigorous shaking). Next, 
samples were centrifuged (16 000 g, 2 min, 4˚C), the aqueous phase was again 
recovered and re-extracted by mixing with 1 volume of chloroform: isoamyl 
alcohol (24:1). After another centrifugation the final aqueous phase was 
transferred into new tubes and mixed with 2 volumes of 96% ethanol, NaOAc 
(300 mM final conc) and 2 µl linear acrylamide. At this point samples were 
stored at -80˚C until the western blot results were obtained that would indicate 
which fractions contained monosomes. Only these fractions were chosen for the 
next part of the experiment.  
 
5.3. Optimisation of library preparation 
Methodology used to optimize library preparation was based on Ingolia’s 
original protocol (Ingolia et al., 2009) further detailed in (Ingolia, 2010). 
According to this protocol the first step to create a sequencing library was 
polyadenylation of the 3’-end of the template. This was necessary to enable 
reverse transcription with a specific construct that served as a primer (RT 
primer, labelled “MITOPROF-RT”, Fig. 5.3). 
 
Figure 5.3. Sequence and features of the reverse transcription primer  
The RT primer (MITOPROF-RT) sequence was build of 4 parts (each bracketed). The 
5’ and 3’ adapters were separated by a flexible spacer sequence consisting of 2 
internal Sp18 modifications (polyethylene glycol) and 6-nt insert. The oligo-dT20 tract is 
added at 3’ end of the molecule. V and N stand for degenerate positions corresponding 
to A/C/ G or A/C/G/ T respectively. The 5’ end of the primer was phosphorylated. A 
simplified overview of the whole primer sequence is depicted below. 
T"T"T"T"T"3’ adapter5’ adapter5’ P 3’
3’ adapter
5’ adapter
5’  Phos - GATCGTCGGACTGTAGAACTCTGACCTGTCGGTGGTCGCCGTATCATT- iSp18- CACTCA- iSp18-
- CAAGCAGAAGACGGCATACGA - TTTTTTTTTTTTTTTTTTTTVN   3’
oligo-dT
spacer
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The reverse transcription primer contained an oligo-dT stretch of 20 dTs, which 
would be complementary to the poly(A) tail thus facilitating priming of the 
construct on the endogenous transcripts. The rest of the primer sequence 
included adapters for 3’ and 5’-end of library products. Both adapters were of 
defined sequence and served as priming sites for subsequent PCR 
amplification of cDNA. Between the two adapters there was a 6-nt sequence 
flanked by two polyethylene glycol modifications (Sp18 spacers). Sp18 spacers 
were introduced to form a hairpin loop (Durand et al., 1990) that would provide 
a full block to polymerases (Ingolia, 2010). The phosphorylation of the 5’ end 
facilitated internal ligation (explained in more depth in Fig. 5.4). Trialling this 
methodology with a synthetic RNA as the initial template is described in detail 
below.  
 
Figure 5.4. Schematic of methodology used to optimize library preparation 
A synthetic 40-nt long oligo-RNA (MT-ND3) was used as a test template for the 
sequencing library preparation. In vitro polyadenylation (A) of the template introduced a 
priming site for reverse transcription with oligo-dT containing RT primer (B). The primer 
sequence became part of the reverse transcribed cDNA, together with the MT-ND3 
sequence (C). In order to connect the 5’-adapter with the template in direct way, the 
cDNA molecule was circularized (D). PCR amplification of the circular cDNA generated 
double stranded DNA library (E).  
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The principle of this methodology is as follows: 
Reverse transcription using the RT (MITOPROF-RT, Fig. 5.3) primer generated 
a cDNA molecule that contained, starting from the 5’ end: 5’-adapter, spacer, 3’- 
adapter, oligo-dT tract followed by the template fragment (ribosome footprint, 
Fig. 5.4 C) Next, cDNA strands were circularized by CircLigase ssDNA II 
enzyme (Epicentre Biotechnology) to link the 5’-end adapter directly with the 
template and close the molecule (Fig. 5.4 D). The circularised cDNA molecules 
were then amplified via PCR using primers specific to each adapter sequence. 
Due to the presence of two internal Sp18 modifications to the 6-nt spacer a 
stable secondary structure was formed between the adapters (detailed in blue 
in Fig. 5.3 and 5.4). This structure blocked the progression of the DNA 
polymerase (Fig. 5.4 E). Thus, linear double stranded PCR products containing 
only one copy of the template were generated. These products were used as a 
sequencing library. 
As mentioned earlier, I decide to carry out the optimization using a synthetic 40-
nucleotide oligo-mt-mRNA (first 40 nucleotides of MT-ND3 transcript from 5’ 
end), to mimic a ribosome footprint. This oligo-RNA served as a test template 
for library preparation and was advantageous for optimization of this part of 
ribosome profiling protocol. This also allowed concurrent optimisation of actual 
mitoribosome footprint production. Availability of this synthetic oligo allowed for 
multiple repeats of the optimization experiments, which used the identical 
starting template and so could give confidence in the reproducibility of the 
technique. In addition, the possibility to control the initial concentration of the 
template was also beneficial to this stage of the project, as it permitted 
identification of the optimal and minimum amount of starting material necessary 
to successfully generate a library. First, the polyadenylation step was optimized. 
To do this different concentrations of E. coli poly(A) polymerase (PAP) were 
tested (0.2, 0.5, 1 and 2 U/µl of enzyme solution), different reaction times (5 and 
10 min) as well as the equipment (thermomixer and thermocycler). Further, to 
decrease the volume of the sample, the buffer used was more concentrated 
than in the original protocol (5x instead of 2x). Optimization of this reaction 
condition was very important to achieve the desirable poly(A) tail length, which 
according to (Ingolia, 2010) is between 25 – 35 nucleotides. This amount is long 
enough to facilitate priming via oligo-dT but the length of the poly(A) tail should 
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not exceed it. Following the initial experiments, optimal conditions were defined 
as given: 
 
5x PAP buffer 
12.5 µl 10x poly(A) polymerase reaction buffer (NEB) 
5 µl 10 mM ATP 
1.25 µl SUPERase-In (20 U/ µl, Ambion AM2694) 
6.25 µl DEPC H2O 
  
The 5x PAP buffer was used to dilute the enzyme (original concentration of 5 
U/µl) in two steps. First it was diluted to 1 U/µl of enzyme solution (1 U/µl PAP 
enzyme mix 1, as described below). This dilution was then used in second step 
to prepare 0.2, 0.5 U/µl of enzyme solution mixes. The original 5 U/µl enzyme 
concentration was also used to prepare the 2 U/µl of enzyme solution mix. 
Optimal enzyme concentration was 0.2U/µl (0.2 U/µl PAP enzyme mix 2, 
prepared as described below). 
 
1 U/µl PAP enzyme mix 1 
9 µl DEPC-treated H2O 
3 µl 5x PAP buffer  
3 µl E. coli poly(A) polymerase (PAP, NEB M0276S) 
 
0.2 U/µl PAP enzyme mix 2 
3 µl DEPC-treated H2O 
1 µl 5x PAP buffer 
1 µl 1 U/µl enzyme mix 1 
 
In order to denature samples, 1 µl of MT-ND3 oligo [125 ng/µl] was mixed with 6 
µl DEPC-treated H2O.and incubated for 2 min at 80°C, then placed on ice to 
cool down. Next, 2 µl of 5x PAP buffer and 1 µl 0.2 U/ µl PAP enzyme mix 2 
were added. Reactions were performed in the thermocycler at 37°C for 10 min 
and stopped by adding 40 µl of 10 mM EDTA. Finally samples were precipitated 
at -80°C over night, by addition of 110 µl 96% ethanol, 5 µl 3M sodium acetate 
and 2 µl linear acrylamide.  
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After precipitation samples were centrifuged for 30 min at 4°C, 16000 g. Pellets 
were resuspended in 10 µl DEPC-treated H2O, mixed with 15 µl denaturing 
loading dye (defined below) and denatured at 55°C for 5 min. In parallel, size 
marker samples were prepared. 0.5 µl of tRNAs (100 ng/µl, size approximately 
70 nt, the same as the desirable polyadenylation product), 1 µl of MT-ND3 (125 
ng/µl stock concentration) and 0.5 µl of ssRNA ladder (NEB, ND364S) were 
mixed with DEPC-treated H2O to final volume of 3 µl with 2 µl denaturing 
loading dye. These samples were denatured at 65°C for 5 min and kept on ice 
until loaded. 
All samples were loaded on 18% denaturing polyacrylamide gel and 
electrophoresed in 1x TBS buffer (defined below). Afterwards, the gel was 
stained with SybrGold (Invitrogen, SS-11494) 1:10000 in TBS for 20 min and 
visualized on a standard UV transilluminator, images were captured by CCD 
camera. 
 
18% denaturing PAG (15 ml stock solution)  
27 g urea 
33 ml 30% acrylamide: bisacrylamide (29:1) 
5.5 ml 10x TBE 
 
for 10 ml gel: 
10 ml stock solution 
72 µl 10% APS 
16 µl TEMED 
 
10x TBE (1 litre)   Denaturing loading dye (1 ml)  
108 g Tris base    900 µl formamide 
55 g Boric acid     100 µl 10x TBE 
40 ml 0.5M EDTA (pH 8.0)    Bromophenol blue 
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Figure 5.5. In vitro polyadenylation conditions were established to obtain 
optimal poly(A) extension of the ribosome profiling template 
A 40-nt long oligo-RNA fragment served as a template for initial optimisation of the in 
vitro polyadenylation assay. Different amounts of enzyme were used in order to obtain 
a poly(A) tail of the desired length (25- 35 residues). Products of the polyadenylation 
reactions were separated on 18% denaturing polyacrylamide gels. The expected size 
of the final product (depicted by the arrow) was approx. 70 nt, with the same 
anticipated migration as the tRNA mix used as a size marker. 
 
Comparison of product sizes revealed that under the optimal conditions (0.2U/µl 
of enzyme, 10 min, and reaction in thermocycler), the poly(A) tail length was 
approximately 30 residues, giving the desirable-sized end product of 70 nt (Fig. 
5.5 lane 3). Higher amounts of enzyme caused excessive elongation of the 
poly(A) tail.  
Next step of optimization focused on reverse transcription. In vitro 
polyadenylation assay was performed on MT-ND3 oligo using the optimal 
conditions defined above. After precipitation, the RNA pellets were 
resuspended in in 9µl DEPC-treated H2O and the entire sample was mixed 
with: 2.5 µl DEPC H2O, 1 µl 10 mM dNTP mix, 1 µl 50 mM RT primer 
“MITOPROF-RT” described earlier. Samples were then denatured at 65˚C for 5 
min and put on ice. Next 4 µl 5x First Strand Buffer, 1 µl SUPERase-In, 1 µl 0.1 
M DTT and 1 µl SuperScript III reverse transcriptase (200 U/µl; Invitrogen) were 
added. Reactions were performed at 48˚C for 30 min, and then stopped by 
adding 2.3 µl 1N NaOH and incubation at 98˚C for 15 min (procedure adapted 
from (Ingolia, 2010). Reaction products were loaded on 18% polyacrylamide gel 
(as in previous experiment) to separate the cDNA product from the unextended 
primer.  
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Figure 5.6. Reverse transcription using MITOPROF-RT primer generated 
correct sized cDNA products 
Products of polyadenylation of MT-ND3 oligo were reverse transcribed (8 identical 
repeats) using MITOPROF-RT primer. These samples (lanes 2 - 9) were separated by 
18% denaturing PAGE. Products of the desirable size (120-140 nt, depicted by the 
arrow) contained cDNA of MT-ND3 oligo with incorporated primer. The intense band of 
∼ 100 nt size corresponds to unincorporated primer. The untreated MT-ND3 oligo (lane 
1)  and molecular weight markers were electrophoresed alongside (lane 10) 
 
Bands of ~120-140 nt length (Fig. 5.6) were excised from gels and eluted as 
follows. Gel pieces, were transferred into 0.5 ml tubes with a hole in the bottom 
and the tube was put in 1.5 ml microcentrifuge tube. By centrifugation (16 000x 
g, 2 min, 4˚C), gel pieces were crumbled to facilitate elution. RNA/DNA elution 
buffer (400 µl, described below) was added to each tube and elution was 
performed overnight at 4˚C on rotating wheel. After incubation the elution was 
filtered from gel pieces by centrifugation through glass wool filled tubes (0.5 ml 
tube with a hole put in 1.5 ml tube) at 2000 g, 2 min, 4˚C. The DNA was 
precipitated in 2 volumes of 96% ethanol and 2 µl linear acrylamide at -80˚C for 
2 h minimum. DNA pelleted after precipitation was resuspended in 12 µl of 
DEPC-treated H2O, ready for circularisation as described below. 
 
RNA/DNA elution buffer 
300 mM NaOAc pH 5.5 
1 mM EDTA 
1 µl SUPERase-In (20 U/ µl concentrated) per 400 µl 
 
After the reverse transcription, the following step in optimization of library 
preparation was cDNA circularisation. It was necessary to internally ligate cDNA 
in order to introduce adapters on both ends of the target sequence in one 
reaction instead of two. The resuspended cDNA samples were mixed with: 2 µl 
10x CircLigase buffer, 2 µl 50 mM MnCl2, 4 µl 5M betaine, 1 µl CircLigase 
80#nt##
1#######2########3#########4#######5#######6########7########8#
150#nt##cDNA#
#1###########2##########3#########4##########5###########6##########7##########8###########9########10#
RT4PCR#products#
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ssDNA II enzyme (100 U/µl; Epicentre Biotechnology). Reaction was performed 
as described below (adapted from (Ingolia, 2010). 
 
Table 5.1. Conditions of circularization reaction 
 
 
Circularized cDNA samples were then amplified by PCR reaction with primers 
specific to the adapters sequences (Table 5.3). For each sample 5x reaction 
mix was prepared. As different cycle profiles needed to be tested 4 aliquots of 
mix (16.7 µl each) were prepared in separate tubes. All tubes were placed in 
thermocycler to perform PCR reaction. It was essential to prevent 
‘overamplification’ of the PCR products, which presented a risk of creating 
concatamers (Ingolia, 2010). Therefore 4 reactions were prepared and each 
aliquot was amplified through a different number of cycles (6, 8, 10 and 12). 
Comparison of the length of the PCR reaction products after different cycle 
profiles allowed the optimal number of cycles to be identified before undesirable 
overamplification occurred. In order to do that, at the end of 6th cycle the first of 
the 4 samples was removed from thermocycler and 4 µl of loading dye was 
added. The next were removed after the 8th, 10th and 12th cycle. All samples 
were analysed following electrophoresis on 10% nondenaturing polyacrylamide 
gels (Fig 5.7). 
 
 
Figure 5.7. Library PCR optimization generated correctly sized products 
Circularized cDNA samples were amplified via PCR with primers specific to both 
adapters. Different amount of reaction cycles were tested (6, 8, 10 and 12) for each of 
the experimental samples. Image contains results of only one, representative sample 
amplified in 4 separate reaction terminated after the 6th, 8th, 10th or 12th cycle (lanes 2-
5). A molecular marker (lane 1) was included in electrophoresis. The arrow depicts 
dsDNA product of the expected ~140 bp size.  
6th$$$$$$$8th$$$10th$$12th$
Library$PCR$
150$bp$
100$bp$
dsDNA$
6th$$$$$$$8th$$$10th$$12th$1$$$$$$$$$$$2$$$$$$$$$$3$$$$$$$$$$4$$$$$$$$$$$5$
Temperature Time 
60˚C 60 min 
80˚C 10 min 
4˚C ∞ 
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The expected size of this PCR reaction products was ~140 bp. The band 
present below the desirable product (~100 bp) contains unamplified cDNA 
template. The optimal number of PCR cycles was selected for each of the 
samples (based on the amount of the product). From all aliquots of PCR 
products only these with the bands of the highest intensity, ~140 bp length and 
no evidence of overamplification (multiple bands, bigger in size) were chosen. 
They were captured and eluted from gel as described previously. These purified 
DNA samples were ready for IonTorrentTM (Invitrogen) library preparation. 
 
Table 5.2. Composition of the library PCR reaction mix 
Components 5x reaction mix 
nH2O  57.6 µl 
5x Phusion buffer 16.7 µl 
10 mM dNTPs 1.7 µl 
50 mM LibraryFor primer 0.8 µl 
50 mM LibraryRev primer 0.8 µl 
Circularized product 0.8 µl 
Phusion DNA polymerase 
(2 U/µl; Finnzymes) 
5 µl 
 
Table 5.3. Sequence of library PCR primers 
Name Sequence 
LibraryFor  5’-AAT-GAT-ACG-GCG-ACC-ACC-GA-3’ 
LibraryRev 5’-CAA-GCA-GAA-GAC-GGC-ATA-CGA-3’ 
 
10% nondenaturing PAG (55 ml) 
5 ml 30% acrylamide: bisacrylamide (29:1) 
1.5 ml 10x TBE 
8.4 ml H2O 
150 µl 10% APS 
15 µl TEMED 
 
Nondenaturing loading dye (1.2 ml) 
600 µl glycerol 
600 µl 10x TBE 
Bromophenol blue 
Xylene cyanol  
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5.4. IonTorrent analysis of ND3 library 
In order to complete optimization, the generated library PCR products 
containing MT-ND3 fragment were next prepared for IonTorrentTM deep-
sequencing. The oligo RNA, which served as a template for these optimization 
experiments contained part of the sequence of one of actual mitochondrial 
transcripts. This allowed for the sequenced data to be aligned with the 
mitochondrial gnome and was predicted to generate a single accumulation of 
the reads at the beginning of MT-ND3. Because the adapter sequences used to 
generate the library were taken directly from (Ingolia, 2010) where the deep-
sequencing was performed on Illumina® platform not IonTorrentTM , amplified 
PCR products required an additional processing. The IonTorrentTM specific 
adapters had to be ligated to library products in order to facilitate additional 
amplification and sequencing. These procedures were planned according to 
manufacturer’s instructions. However, the protocols provided by IonTorrentTM 
(Ion Plus Fragmented Library Kit) lacked many details of the reaction mixes 
included in the kits, especially the information on how or if the template needs 
to be phosphorylated. To solve this problem and maximise the efficiency of the 
adapter ligation two strategies were used: 1) the library PCR on circular cDNA 
was repeated using phosphorylated primers and 2) the “end repair” step of the 
Ion Plus Fragmented Library Kit protocol was included prior to ligation. The end 
repair step is necessary for libraries generated from fragmented whole genomic 
DNA, which is a different method than the one used in ribosome profiling. 
However, it was possible that this step also included the phosphorylation of the 
template so it was decided to apply it to this library. As a result, two sets of 
libraries (amplified via un- and phosphorylated primers) containing MT-ND3 
fragment were converted into IonTorrentTM compatible libraries. This allowed for 
comparison between the two approaches and their efficiency. During the end 
repair step, library PCR products were resuspended in nuclease-free water to 
final volume 79 µl, and mixed with 20 µl of 5x end repair buffer and 1 µl End 
Repair Enzyme. Samples were incubated for 20 min at room temperature. Next 
the samples were purified using Qiagen Nucleotide Removal (Qiagen, #28304) 
kit according to the manufacturer’s instructions. The purified product was eluted 
with 35 µl elution buffer and used in ligation step. Reaction was prepared as 
described in Table 5.4. 
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Table 5.4. Components of ligation reaction 
Components N=1 
DNA (purified PCR products) 35 µl 
10x Ligase Buffer 10 µl 
Ion P1 Adapter  2 µl 
Ion XpressTM Barcode 2 µl 
dNTP mix 2 µl 
Nuclease-free Water 39 µl 
DNA Ligase 2 µl 
Nick repair polymerase 8 µl 
Total volume 100 µl 
 
The barcodes were used at this stage of processing in order to enable 
sequencing of the two libraries (amplified via un- and phosphorylated primers) 
on one chip. For the “unphosphorylated” sample the Ion XpressTM Barcode No 6 
was used whereas the “phosphorylated” sample was ligated with barcode No 
12. Ligation reaction was performed as described in Table 5.5. 
 
Table 5.5. Condition of the ligation reaction 
 
 
 
 
Products of the ligation were then purified with 400 µl Agencourt® AMPure® XP 
reagent (4x volume of the sample) according to the Ion Plus Fragment Library 
kit protocol. Pellets were resuspended in 25 µl of Low TE buffer and the 
samples were amplified with primers specific to IonTorrentTM adapters, as 
described in Tables 5.6. and 5.7. 
 
Table 5.6. Components of the amplification reaction 
Components N=1 
Platinium® PCR SuperMix High Fidelity 100 µl 
Library Amplification Primer Mix 5 µl 
Unamplified library  25 µl 
Total volume 130 µl 
 
 
 
Temperature Time 
25˚C 15 min 
72˚C 5 min 
4˚C ∞ 
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Table 5.7. Condition of the amplification reaction 
Stage Temperature Time 
Hold 95˚C 5 min 
9 cycles 95˚C 15 s 
58˚C 15 s 
70˚C 1 min 
Hold 4˚C ∞ 
 
The amplified libraries were purified using Agencourt® AMPure® XP reagent as 
described previously. Finally, pure libraries were resuspended in 20 µl of Low 
TE buffer and kept at -20˚C. The sequencing on IonTorrentTM was performed by 
Dr. Helen Tuppen according to the manufacturer’s instructions. 
The alignment of the sequencing results with the reference genome (mtDNA) 
was performed automatically by the IonTorrent software. The resulting *.bam 
files were then visualized with an open-access IGV software 
(http://www.broadinstitute.org/igv, (Thorvaldsdóttir et al., 2013). As the only 
template used in the sequenced library was a fragment of MTND3 transcript 
(first 40 nt from 5’ end), it was expected that all sequencing reads would be 
grouped at that region of mtDNA. However, the assessment of quality of the 
sequencing run (a built-in feature of the IonTorrent software) showed that in 
both samples (with and without phosphorylation of primers) only 4% of the 
reads were aligned to the mtDNA. The visual analysis of the alignment in the 
IGV software revealed that these reads were mostly localized to the beginning 
of MTND3. The number of the aligned reads was much lower than expected, 
especially considering that the library should have consisted of the 
homogenous population of a single sequence. The possible reason for this 
result was the presence of the 5’ and 3’ adapter sequences (from the RT primer 
“MITOPROF-RT”) that are not specific to IonTorrent application. The alignment 
step has a programmed specified number of the allowed mismatches between 
the sequencing read and the reference genome. Reads that contain more 
mismatches than the threshold value are being automatically excluded from the 
analysis. Having an unknown sequence (adapter sequences “5’ adapter” when 
sequencing from the 5’ end of the product or “3’ adapter” from the other end, 
Fig. 5.8 A) preceding the MTND3 sequence could possibly exceed the allowed 
mismatches number. As a result, these reads could have been filtered out by 
the software, even though they contained a fragment of an actual mtDNA 
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sequence. In order to test this hypothesis the alignment was repeated but this 
time the mtDNA genome was replaced with the exact sequence of the MTND3 
template with both adapters and poly(A) tract (Fig. 5.8 A labelled as “ND3 
construct”). In this setting, the majority of the reads should have been 
recognized and aligned giving the real representation of the content of the 
sequencing library. 
 
 
Figure 5.8. Alignment with predicted library product sequence 
Analysis of the sequencing results was performed by alignment to the exact library 
product sequence. The predicted library product sequence consisted of 4 parts (A, 
ND3 construct), starting from 5’ end: 5’ adapter, MT-ND3 oligo fragment, poly(A) tail 
and 3’ adapter. B. Screenshot of the alignment results of one of the samples visualized 
in the IGV software. Red arrow no. 1 depicts the position of the reference sequence 
and genome coordinates in the application window. Arrow no. 2 points at the histogram 
with the density of the reads aligning to reference sequence at each position (scale 0 ~ 
20000). Arrow no. 3 points at the data track for the “Unphosphorylated” sample that 
shows each of the aligning reads (grey horizontal bar) with possible mismatches (in 
colour or black). The data track for the “Phosphorylated” sample is depicted with arrow 
no. 4. C. Information about the quality of the alignment provided by the software. These 
metrics include data on the total number of aligned base pairs, the average coverage 
depth of the alignment to the reference sequence and what percentage of all base 
pairs was aligned.   
 
The visualisation of the alignment in IGV software showed reads covering the 
whole of the reference sequence. 81% of the reads aligned to the “ND3 
construct” sequence, which accounts for 6.4M aligned basepairs and 49344.6X 
coverage of the reference sequence (Fig. 5.8 C specifications taken from 
A.
B. C.
1.
2.
3.
5’  AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACGATC-ATAAACTTCGCCTTAATTTTAATAATCAACACCCTCCTAG-
     AAAAAAAAAAAAAAAAAAAA-TCGTATGCCGTCTTCTGCTTG  3’ 
3’ adapter
5’ adapter
Poly(A)
MT-ND3
4.
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the run information). The quality of the alignment was similar for both of the 
samples (Fig. 5.8 B arrow 3, Unphosphorylated; and arrow 4 Phosphorylated), 
which indicated that the 5’ end phosphorylation of the primers was not 
necessary for the successful preparation of libraries. There are areas where the 
coverage is more scarce mainly around position 90 bp of the “Phosphorylated” 
sample (Fig. 5.8.B arrow 4). This was most likely a result of the reads truncation 
due to the presence of the poly(A) sequence. When the polynucleotide 
sequence is long (as in case of this construct 20 nt) it is not easy for the system 
to detect the exact number of residues incorporated and also the quality of 
reads tends to decrease downstream of the polynucleotide tract. The uncovered 
space in this alignment was most likely caused by filtering out the reads that 
were sequenced from the 3’ end (indicated by the direction of the arrow at the 
end of the grey bars) the quality of which dropped after the poly(A) tail 
sequencing. However, regardless of the issues with the poly(A) presence, the 
high amount of the successfully aligned reads meant that the library preparation 
and sequencing methodology optimization was completed and can be used on 
real mitoribosome footprints.  
 
5.5. Generation of mitoribosome profiles from HEK293 WT cells 
After the successful optimization of each step of the ribosome profiling for 
human mitochondria, I performed the complete protocol on HEK293 wild type 
cells using methods described in detail in 5.2 for the generation of the ribosomal 
footprints and 5.3 for library preparation. Mitochondria were isolated from 2x 
225 cm2 confluent flasks of HEK293 that were first treated with the 
chloramphenicol. After the shaving step with DNase I and Proteinase K, 9/10 of 
the mitochondrial pellet volume was lysed and the protein concentration was 
estimated by Bradford measurement. The remaining 1/10 was used to Isolate 
and measure RNA concentration to adjust the amount of RNase One for the 
nuclease protection assay. The total mitochondrial lysate was divided into 4 
samples (40 µl of volume, each containing approx. 680 µg of protein and 70 µg 
RNA). The maximum of protein content loaded on the sucrose gradient was 700 
µg, hence the way the lysate was divided. All four samples were treated with 
RNase One as follows: 1.4 µl of RNase One (7U per reaction), 4 µl of 500 mM 
EDTA for 10 min at 20ºC in shaking thermoblock. Each sample was loaded on 
the 10-30 % sucrose gradient. RNA was isolated from each fraction and 
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those taken for further processing were chosen based on western blotting 
results with DAP3 and MRPL3 antibodies (Fig 5.9 A). DAP3 as a member of 
small mitoribosome subunit (SSU) is used as a marker for SSU position on the 
gradient, and MRPL3 as a marker for the large subunit, LSU. The highest 
accumulation together of both SSU and LSU marker proteins (fraction 5, 6 and 
7) pointed at the most likely position of the monosome and protected mt-mRNA 
fragments. Also the fraction 4 was included in further experiments, as it 
appeared to contain a lot of DAP3 and MRPL3. However, this was an unlikely 
place on a gradient for a monosome and there was a possibility that this fraction 
contained fragmented subunits rather than an intact 55S.   
 
Figure 5.9. Generation and size separation of the mitoribosome footprints 
from HEK293 WT 
The HEK293 mitochondrial lysate was treated with RNase One and ~680 µg separated 
on each 10-30% sucrose gradient (see 5.2). A. Western blot analysis of each fraction 
was used to confirm the position of the mitoribosomes and their RNA footprints (see 
5.2 and Fig. 5.2). Immunostaining with antibodies for mitoribosomal proteins DAP3 and 
MRPL3 allowed estimation of fractions containing 28S SSU (DAP3) and 55S 
monosomes (DAP3+MRPL3), both boxed. B. Total RNA was isolated from fractions 
chosen in A) (fractions 4, 5, 6 and 7, as described in 5.2). Size separation of the 
mitoribosomal footprints was performed by electrophoresis in denaturing 15% PAG 
with urea (see 5.2). Two molecular ladders were separated together with the samples 
(low range ssRNA and microRNA, lane 1 and 2 respectively). After the separation RNA 
fragments corresponding in size to ~30 nt were excised from each sample (left panel, 
lanes 3-6). The gel after the removal of the fragments is presented in the right panel. 
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Next, RNA was isolated from the chosen fractions and the RNA pellets were 
resuspended with 10 µl of DEPC-H2O. As the result of the prior RNase activity, 
the isolated RNA species contained a residual phosphate group on the 3’ end. 
The subsequent polyadenylation requires a free 3’ end of the molecule, hence 
3’-dephosphorylation was required (Ingolia, 2010). As described in (Ingolia, 
2010), a polynucleotide kinase (PNK) was used with a buffer devoid of ATP, to 
force the enzyme to catalyse the removal of the -(PO)3 group from the 3’ end of 
RNA. To each of the RNA samples 10 µl of the PNK reaction mix was added 
that consisted of: 6.75 µl of DEPC-H2O, 2 µl 10X PNK buffer without ATP 
(NEB), 0.25 µl SUPERase-In, 1 µl T4 PNK (10U/ µl, NEB: #M0236). Samples 
were incubated for 1 hour at 37°C. In order to terminate the reaction and to 
prepare the samples for the size selection, 30 µl of the denaturing loading dye 
was added to each of them. The mitoribosomal footprints were separated via 
electrophoresis on the 18% denaturing PAG (Fig. 5.9 B). Two types of size 
markers were used (ssRNA low range marker, NEB and microRNA, NEB 
#N2102) to facilitate accurate selection of the 25~30 nt range of fragments from 
each sample (Fig. 5.9 B, right panel). Excision and elution of the RNA 
fragments was performed as described earlier. Purified mixture of RNA that 
most likely contained mitoribosomal footprints was next polyadenylated and the 
products of this reaction served directly as the template for the reverse 
transcription with the RT primer (“MITOPROF-RT”). 
 
Figure 5.10. Mitoribosome footprints were converted into sequencing 
library 
The generation of the library from the size separated ribosomal footprints was 
performed as described in 5.3. Products of reverse transcription of the RNA fragments 
isolated from the picked fractions 4-7 (lanes 2-5) were separated on the 18% 
denaturing PAGE. RT-Primer (lane 1) and low range ssRNA ladder (lane 6) were 
electrophoresed alongside. The anticipated-size products (depicted with an arrow) 
were retrieved from the gel as presented in the right panel. 
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The results of the reverse transcription (Fig. 5.10 left panel) varied slightly from 
the ones obtained during optimization step. The space above the primer band 
was obscured by the intense signal from the un-extended RT primer. It was 
difficult to definitely state that the reverse transcription was unsuccessful, hence 
the region of the gel above the primer in all sample lanes was removed (Fig. 
5.10 right panel) and the cDNA was extracted as described previously.  
 
Figure 5.11. Selection of library PCR products based on the size and 
intensity of a signal 
After the circularization, cDNA was amplified in PCR reaction and the double stranded 
DNA products were separated on the10% non-denaturing PAGE. All 4 samples 
(amplified for 6, 8, 10 or 12 cycles) from each reaction mix (“Library 4-7”) were 
electrophoresed along the molecular weight markers (lanes 1, 10, 11 and 20).  
 
Next all 4 samples were circularized (as described in 5.3 and Table 5.1). The 
products of these reactions were immediately amplified according to library 
PCR protocol (5.3, Tables 5.2 and 5.3). The only change made to the original 
PCR protocol was to increase of the amount of cycles (maximum 14 cycles 
instead of 12). It was changed in order to improve the amount of the final 
product. As during the optimization step, each reaction mix (now labelled 
“Library 4-7”) was divided into 4 samples, each sample was placed in separate 
tube and amplified for different number of cycles (8, 10, 12 or 14). All 4 samples 
from each Library were separated on the 10% non-denaturing PAGE together 
with a size ladder (Fig. 5.11). Conditions of the electrophoresis were as 
described in 5.3. Amplification of cDNA was successful and resulted in the band 
of the expected size (about 140 bp depicted by the arrow). The lower-sized 
band of much greater intensity is the unamplified cDNA template. The very high 
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level of the template in comparison to the final product suggested that the 
amplification was weak and was a cause for the concern for quantity of the 
footprints in the libraries. For further steps of the procedure only the clearly 
visible bands of ~ 140 bp were chosen (Fig. 5.11, sample 8th, 10th and 12th from 
Library 4 and 5, sample 10th and 12th from Library 6 and 7, corresponding to 
lanes 3, 4, 5, 7, 8, 9, 14, 15, 18 and 19). Samples of DNA from one Library 
were pooled together and relabelled as 4 - 7. Next, the IonTorrent adapters 
were ligated to the purified samples. The conditions and components of the 
ligation were as described in 5.4 (detailed in Table 5.4. and 5.5). However, 
because of the low concentration of the template DNA (less than 5 ng/ µl) the 
Ion XpressTM Barcode adapters were diluted 1:9. Barcodes 4-7 were used and 
were assigned to the sample based on corresponding sample number (for 
sample 4 the barcode no. 4 was used and so on). Next the barcoded libraries 
were purified (as described in 5.4) using 400 µl of Agencourt AMPure reagent. 
After the purification, samples were amplified (conditions and reaction mix as 
described in Tables 5.6 and 5.7 but the number of PCR cycles was increased to 
10 and purified one more time (5.4). Final products were kept at -20ºC until 
sequencing on IonTorrent (performed by dr. Helen Tuppen). All 4 samples were 
analysed in the same sequencing run and the results were aligned to mtDNA 
sequence by the IonTorrent software. Unfortunately, the results of the 
alignment, when viewed in IGV, showed very low number of reads aligning to 
the reference genome. This observation was consistent to all 4 samples. 
Therefore, the data was not sufficient for any down stream analysis. However, 
given the previous difficulties with sequencing of the “ND3 construct” this was 
most likely caused by the lack of recognition by IonTorrent software of the 
Illumina-compatible adapters (parts of RT primer “ MITOPROF-RT”). In order to 
bypass the software’s built-in filters the analysis had to be performed manually. 
This was performed by Dr Matthew Bashton from the Bioinformatics Support 
Unit. The raw sequencing data was first processed with homerTools software 
(http://homer.salk.edu/homer/ngs/homerTools.html) to remove the adapter 
sequences from both ends. Next, the poly(A) stretches were removed and the 
remaining sequences were aligned with the mtDNA using bowtie2 (http://bowtie-
bio.sourceforge.net/bowtie2/index.shtml). Unfortunately, inspection of the data 
in IGV showed only very short sequences (4-5 bp) aligning to the genome. 
These results meant that the library products did not contain the expected-
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sized products (30 bp). Finally, this was a confirmation that the preparation of 
the mitoribosome footprints had not resulted in the sufficient amount of material 
to produce a functional library and later, a mitoribosome profile. 
 
5.6. Discussion 
At the beginning of this project there was no published evidence of the 
application of the ribosome profiling in mitochondria. The original published 
protocols (Ingolia, 2010; Ingolia et al., 2012) described the use of this technique 
for studying cytosolic ribosomes only, hence the necessity to optimize the 
methodology to human mitoribosomes. The other principle of adjusting the pre-
existing protocols was to change the sequencing platform from Illumina to 
IonTorrent. Although the IonTorrent is characterized by much lower throughput 
than the Illumina platform (10 Mb for 314 chip as opposed to 1500 Mb in MiSeq, 
Illumina benchtop sequencer(Loman et al., 2012), it would have been sufficient 
for the sequencing of a genome as small as the human mtDNA. The success of 
this approach was, however, dependent on reduction of the contamination with 
cytosolic ribosomal footprints. In that case even with low amount of reads, the 
majority of them would be derived from mitoribosomes and would form a 
complete ribosomal profile. In order to achieve that it was decided to isolate 
mitochondria prior to the RNase treatment.  
Despite the promising results of the trial sequencing with MT-ND3 fragment, the 
final experiment using the complete protocol did not yield sufficient amount of 
data to form mitoribosome profiles. It was most likely caused by too low an input 
of the ribosome footprints. This hypothesis is consistent with the observed low 
amounts of cDNA produced after reverse transcription (Fig. 5.10 A) and 
amplification (Fig. 5.11), which was not seen during the optimisation step (Fig. 
5.6 and 5.7). It is important to note that when the library preparation 
methodology was optimized, the concentration of the initial RNA template 
(fragment of the MT-ND3 transcript) was known and corresponded to the 
required amount described in (Ingolia, 2010). However, when the actual 
mitoribosome footprints were used the concentration of the initial template was 
unknown because the measurement step was omitted in order not to lose any 
of the material. The isolation of the mitoribosomes from the sucrose gradient is 
a crucial step, but it limits the size of the initial pool of mitoribosome footprints. 
The quality of the generated library depends on the correct digestion of the 
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mRNA and efficient isolation of the intact monosomes with protected mRNA 
fragments. The digested mitochondrial lysate separated on the sucrose gradient 
showed a shift in position of mitoribosomal subunits and monosomes in 
comparison to untreated samples (Fig. 5.2 and 5.9). A strong signal from the 
mt-SSU was detected, starting in fraction 2 after the RNase treatment, whereas 
in undigested sample it was fraction 4. Also the signal from mt-LSU was present 
in earlier fractions due to the enzymatic digestion, but there was only a ‘1 
fraction’ shift towards the top of the gradient. The change in the position of 
mitoribosomal could be explained by the activity of the RNase 1. The average 
molecular weight (MW) of mt-mRNAs could be estimated at approximately 0.5 
MDa. The difference in MW between the SSU and LSU is also approximately 
0.5 MDa, which results in the change of 1-2 fractions in position on a gradient 
(Fig. 5.2). Therefore, the shift in the position of where the mt-SSU and 
monosome were observed after the RNase digestion (2 fractions for SSU, 1 for 
monosome) was consistent with the loss of unprotected mt-mRNA. A difference 
in how big this shift was between mt-SSU and mt-LSU/monosome could be 
explained by a difference in ability to protect the transcript from the RNase. It is 
possible that, when bound with small mitoribosomal subunit, mRNA is more 
exposed than if associated with the LSU/ monosome and therefore more 
susceptible to the RNase activity. The evidence presented suggests that the 
RNase treatment was successful and resulted in removal of unprotected mRNA. 
However, the possibility of overdigestion cannot be completely excluded. Signal 
from the mt-SSU protein DAP3 was also present in the first fraction, although 
weaker than in the following ones. This signal represents free DAP3 proteins 
and could be interpreted as a result of disruption of the mitoribosome due to 
excessive RNase activity. The digestion with RNase requires further work, 
which should include investigation of the effect on mitoribosome composition 
over different time points. Comparison of the mitoribosomal subunits’ migration 
would allow to select optimal conditions for the digestion that accomplish the 
removal of the mRNA without causing damage to the structure of the 
mitoribosome. 
In order to continue the use of IonTorrent for deep sequencing, it would be 
advised to redesign the MITOPROF-RT primer so that it would contain the 
adapters suitable for sequencing with this platform. This would simplify the 
preparation of the library and ensure that the reads would not be discarded 
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by the software. The manual alignment of the data would provide an additional 
confirmation that viable sequencing reads are not being filtered out and 
discarded by the automated analysis pipeline. !  
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6.1. Introduction 
My first attempt to optimize the ribosome profiling protocol for the application in 
mitochondria did not yield sufficiently satisfying results. Thus, proceeding with 
this project required a completely new approach and re-evaluating the 
principals of the chosen methodology. The acquisition of data that 
corresponded to ribosome profiling in mitochondria by a group based at the 
Netherlands Cancer Institute in Amsterdam gave the opportunity to start a 
collaboration to successfully establish the technique in Newcastle. The group 
was a part of Division of Gene Regulation led by Prof. Reuven Agami and their 
results were later published as the first ribosome profiling application in 
mitochondria (Rooijers et al., 2013). The publication contained a description of 
methodology used to generate and analyse mitoribosome footprints, as well as 
the general characterisation of the mitoribosome profiles. The major difference 
observed by (Rooijers et al., 2013) between the mitochondrial and cytosolic 
ribosomes footprints was the size. Mitoribosomes generated two populations of 
footprints of 27 and 33 nt in size, both of which were distributed in the same 
way across the transcripts and showed no differences in periodicity. Based on 
these two features it was concluded that both sizes of footprints were indeed 
generated by mitoribosomes and were not artefactual. To test the efficiency of 
this method the authors compared the mitoribosome profiles of the cells 
containing a homoplasmic mutation in mitochondrial tRNATrp (m.5556G4A) 
relative to controls. The cell line harbouring the mutation was a 
transmitochondrial cybrid that was created by the transfer of mitochondria from 
a patient’s fibroblasts carrying the mentioned tRNATrp mutation into donor 
osteosarcoma cells devoid of their endogenous mtDNA (Smits et al., 2010a). 
Decrease in levels of aminoacylated-mt-tRNATrp, resulting from the destabilizing 
mutation was predicted to cause the stalling of mitoribosomes when translating 
tryptophan codons. Profiles of mitochondrial ribosome distribution in the mutant 
cell line were compared with control human osteosarcoma cells (143B). Results 
showed intensive stalling of mitoribosomes localized to tryptophan codons 
(represented by an increase in mitoribosome accumulation) due to reduction in 
tRNATrp levels.  
The basis of the collaboration with Prof. Agami’s group was to apply their 
ribosome profiling protocol to analyse one of the cell lines generated in my host 
group. The cell line, called T1V1, was a trans-mitochondrial cybrid cell line 
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with homoplasmic point mutation in mt-tRNAVal gene (1624C>T MTTV), which 
was transformed to inducibly express mitochondrial valyl-tRNA synthetase 
(VARS2) (Rorbach et al., 2008b). Mitochondria carrying the 1624C>T mutation 
were derived from a patient sample, where the biochemical phenotype included 
low activity of complex I and IV in skeletal and cardiac muscle (McFarland et al., 
2002). The uninduced T1V1 cybrids displayed reduced level of mt-tRNAVal that 
was a result of an accelerated degradation of the uncharged tRNAVal form. 
Overexpression of VARS2L partially restored the level of mt-tRNAVal. However, 
the trans-mitochondrial cybrids analysed in that study did not reflect the same 
severe biochemical defect as characterized patient skeletal muscles. In order to 
study cybrids with a phenotype more comparable to the patient’s a new 
selection process was performed (Hornig-Do et al., 2014). Impaired growth on 
galactose containing medium was chosen as indicator of the defect in 
respiratory function and served to identify more suitable cybrid clones. As 
described above, the selected cell lines were transformed with VARS2 gene 
and their mitochondrial function was investigated between un- and induced 
cells. Induction of VARS2 expression resulted in an increase in activity and 
levels of fully-assembled complex I and IV. In addition an overall increase in 
levels of de novo mt-translation was observed. These data suggested that 
indeed the VARS2 expression resulted in partial recovery of the mitochondrial 
defect caused by mt-tRNAVal mutation. The ability to induce the rescue of this 
T1V1 cell line phenotype was the reason for choosing it to conduct the first 
ribosome profiling experiments. Low levels of mt-tRNAVal in uninduced cells 
were expected to cause the stalling of the mitoribosomes on valine codons, 
similar to the observed stalling on tryptophan codons in (Rooijers et al., 2013). 
The rescue due to the overexpression of the valyl-tRNA synthetase was 
predicted to alleviate this effect and confirm that the mitoribosome stalling was 
caused by mt-tRNAVal deficiency. 
Changes to ribosome speed of translation are widely studied and the 
advantages provided by ribosome profiling contributed to expanding the 
knowledge about this phenomenon. Application of the ribosome profiling in 
different organisms and detailed analysis of the ribosome distribution allowed 
identifying different mechanisms that regulate the rate of their movement. The 
methods used for identification of the elongation speed involves detection of the 
shifts in ribosome densities where the increase in the ribosome footprint is 
! 154 
associated with lower speed (Ingolia, 2014). The elongation speed varies 
across the transcripts and its measurement is a source of valuable information 
about the translation process in vivo. By comparison between the regions of 
high and low ribosome density or investigating ribosome profiles from different 
conditions numerous factors that cause these changes were identified. The 
general tendency for the ribosomes to slow down at first 30-40 codons 
downstream from the initiation site was observed in yeast (Ingolia et al., 2009). 
The slowing of ribosome elongation was also shown to facilitate the mechanics 
of the protein synthesis. In C. elegans the wobble codon positions were 
reported to cause ribosomal pausing (Stadler and Fire, 2011). In mammalian 
cells the decrease in elongation rate was observed as a consequence of co-
translational folding of the nascent polypeptide (Han et al., 2012). Certain 
features of mRNA were proven to be affecting the speed of translation based on 
the ribosome profiling data. These included local folding of mRNA in mouse 
embryonic stem cells (Dana and Tuller, 2012) and Shine-Dalgarno-like 
sequences in bacterial genome (Li et al., 2012). Also the qualities of the 
nascent polypeptide chain, specifically positively charged residues, were 
identified as a cause for slowing of the ribosomes (Charneski and Hurst, 2013; 
Dana and Tuller, 2012). Different stress conditions were also shown to induce 
changes in ribosome progression. The heat shock (Shalgi et al., 2013), 
oxidative stress (Gerashchenko et al., 2012) and the accumulation of misfolded 
proteins (Liu et al., 2013) were reported to result in a characteristic ribosome 
arrest in the first 50 nt downstream from the start codon. 
The following part of my project was aimed at learning the mitochondria-
targeted ribosome profiling protocol from Prof. Agami’s group by applying it to a 
cell line with a specific defect in mt-translation. The data analysis on the 
generated ribosome profiles was planned to identify the regions with 
accumulation of mitoribosomes and linked them with mt-tRNAVal deficiency.  
 
6.2. Generation of mitoribosome footprints from T1V1 cell line 
As a part of collaboration with Prof. Agami’s group I spent 3 weeks in Division of 
Gene Regulation, NKI in Amsterdam in order to learn the ribosome profiling 
protocol optimized for mitochondria. One of the fundamental differences 
between this protocol and the one I previously used (optimized for IonTorrentTM, 
described in chapter 5) is the approach to generation of mitoribosome 
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footprints. This protocol does not require isolation of the mitochondria prior to 
the lysis and RNase treatment. Instead, the total cell lysate is subjected to 
RNase digestion and then separated on the sucrose gradient to enrich for 
mitoribosomes. As a result, the volume of the loaded samples exceeds the 
capacity of the gradients generally used in our lab. For this application a much 
bigger volume and also a different composition of the gradient was used. The 
gradient was prepared from two sucrose solutions (7% and 47%) in a buffer 
containing 20 mM Tris-HCl pH 7.8, 10 mM MgCl2, and 100 mM KCl. The buffer 
was additionally supplemented with chloramphenicol (final concentration 100 
µg/ml) and DTT (final concentration 2 mM). The solutions were combined in 
different proportions to give 5 different sucrose concentrations (Table 6.1). Each 
solution (2.3 ml) was carefully layered into the centrifuge tube without mixing, 
starting from the most dense and successively adding less concentrated 
sucrose solutions on top. Tubes were left overnight at 4ºC prior to the 
experiment to allow diffusing of the layers, which creates a linear sucrose 
gradient.  
 
Table 6.1. Sucrose gradient preparation !!!
 
 
The T1V1 cell line and the control 143B parental cultured in 225 cm2 flasks (see 
2.1.1) were seeded in 15 cm dishes (5 for ribosome profiling and 1 for parallel 
RNAseq analysis per condition). Three days prior to the experiment, expression 
of VARS2L was induced by addition of tetracycline (final concentration 1 µg/ml) 
to cells from 1 set of dishes. The second set of T1V1 cells, as well as the 143B 
parental control were left untreated. When the induction was completed, all cells 
were treated with chloramphenicol by adding the antibiotic to the medium to 
final concentration of 100 µg/ml and incubation left to proceed for 15 min. 
Similarly to the previously described protocol, chloramphenicol is used to inhibit 
elongation of mitochondrial translation and prevent the “run off” of 
mitoribosomes during the procedure. This allowed mitoribosomes to maintain 
the exact position they were occupying at the beginning of the experiment. 
Final concentration 7% sucrose (ml) 47% sucrose (ml) 
7% 12 0 
17% 8 4 
27% 6 6 
37% 4 8 
47% 0 12 
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Additionally, to maintain the effect of the initial treatment, all the buffers used in 
the following steps were supplemented with chloramphenicol (final 
concentration 100 µg/ml). To harvest cells after the treatment, plates were 
washed with PBS containing chloramphenicol and the cells were scraped off 
with a plastic scraper. Cells from the plates with the same experimental 
condition were pooled together and centrifuged. Cells collected from the plates 
designated for RNAseq analysis were resuspended in 5 ml Trizol reagent and 
stored at -20ºC. The cell pellets for ribosome profiling were resuspended in 1-
1.2 ml of lysis buffer (20 mM Tris-HCl pH 7.8, 10 mM MgCl2, 100 mM KCl, 1% 
Triton X-100, 1X complete protease inhibitor, 2mM DTT, 100 µg/ml 
chloramphenicol) depending on the size. Samples were incubated on ice for 15 
min and then sheared by passing 6 times through the needle (25G). The lysed 
samples were then centrifuged (10 min, 560 xg, 4ºC). The procedure was 
repeated in case the supernatant was cloudy after the first centrifugation. The 
clear supernatant was transferred to a new tube and treated with RNase 1 
(Ambion, final concentration 2.5 U/µl) for 45 min at room temperature with 
agitation. During this step the mRNA not protected by ribosomes was digested, 
allowing for generation of ribosome footprints. Depending on the volume of the 
lysis buffer used 1- 1.1 ml of each sample was designated for the sucrose 
gradient separation and the remaining part was stored at -20ºC.  
In order to separate the ribosome protected fragments of mitochondrial mRNA 
only, the lysate treated with ribonuclease was loaded on previously prepared 
sucrose gradient. Each tube was topped up with the lysis buffer (to the final 
volume 13.4 ml). Samples were centrifuged in the ultracentrifuge (SW40Ti rotor) 
at 221632 x g, 4ºC for 2 h, with maximum acceleration and minimum 
deceleration. Next, each sample was divided into 14 fractions of 935 µl. During 
the centrifugation mitoribosomes were separated from the cytosolic ones due to 
the difference in their density. They were retained in the different phases of the 
sucrose, with mitoribosomes located closer to the top in the lower sucrose 
density. To confirm the exact position of whole mitoribosomes, which were 
predicted to contain protected fragments, 20 µl of each fraction were subjected 
to western blotting, using antibodies that would detect small (DAP3) and large 
(MRPL3) subunit proteins. Until the presence of mitoribosomes was confirmed, 
the remaining parts of all fractions were prepared for the storage and RNA 
isolation following proteinase treatment. In order to facilitate RNA isolation, 
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ribosomal proteins were digested with 0.2 mg/ml of proteinase K (PCR grade, 
Roche) supplemented by 1% SDS for 30 min at 45ºC. For storage and 
subsequent RNA isolation, Trizol LS reagent was added in proportion of 3:1. 
 
 
Figure 6.1. Separation of mitoribosomes by isokinetic sucrose gradient 
centrifugation 
Cell lysate from 143B parental control cell line was separated on 7 - 47% sucrose 
gradient and after ultracentrifugation divided into 14 fractions. Each fraction was 
subjected to western blotting with antibodies specific to small and large mitoribosomal 
subunits (DAP3 and MRPL3 respectively). Fractions that contained monosomes were 
defined by presence of signal from both proteins (box labeled ‘55S’). 
 
Results of the western blot validation revealed the signals form DAP3 and 
MRPL3 (corresponding to the presence of small and large mitoribosome 
subunit respectively) coincided in fractions 3, 4 and 5. Both these proteins were 
detected with equally strong signals as these fractions contained the 
mitochondrial monosomes and most likely the 55S protected mRNA fragments.  
 
6.3. Library preparation and deep sequencing 
Size separation of mitoribosome footprints 
Based on the results of the western blot analysis that determined the position of 
mitoribosomes on the gradient, only fractions 3, 4 and 5 were chosen for RNA 
isolation. The procedure was performed according to the manufacturer’s 
instructions. RNA was precipitated in isopropanol with GlycoBlue. Pellets were 
washed with 75% ethanol and resuspended in 10 µl of loading dye (Gel loading 
buffer II, Ambion) to prepare the samples for size separation. According to the 
findings of Prof. Agami’s group, the size of mitoribosome footprints varies from 
their cytosolic equivalents (Rooijers et al., 2013). There are two populations of 
1                              14
7%                           47%
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ribosome-protected fragments in mitochondria with 27 and 33 nt in length. 
Therefore, it was necessary that the cutoff for the size separation included all 
RNA fragments between 25 and 35 nt, a pool that would most likely contain 
mitoribosome footprints. In order to separate these fragments total RNA isolated 
from the selected sucrose gradient fractions was loaded on 10% denaturing 
polyacrylamide gel. The gel was electrophoresed in 1x TBE buffer at 150 V, and 
subsequently stained with SYBRGold (Fig. 6.2; method as in chapter 5.3.).  
 
 
Figure 6.2. Size separation of the mitoribosome footprints  
Mitoribosome footprints were generated in all three cell lines: mt-tRNAVal mutant with 
(+Tet; lane 3), or without (-Tet; lane 2) VARS2L induction, and 143B control (Contr.; 
lane 6). Total RNA was isolated from the chosen sucrose gradient fractions that 
contained mitoribosomes, and loaded on 10% denaturing polyacrylamide gel. In 
addition to low range ssRNA ladder (lane 1), two oligo-RNA size markers were used 
(25 and 34-nt size, lane 7). The oligo-RNA fragments marked the borders of the area 
that was excised from each sample lane (2, 4 and 6) as it contained RNA fragments 
corresponding in size to the ribosome footprints.  
 
From each lane a fragment of the gel corresponding to 24-35 nt size was 
removed. This size range was predicted to contain the mitoribosome footprints. 
In order to facilitate the elution of mRNA fragments from the gel, the excised 
pieces were first triturated by centrifugation through a pierced tube (as 
described in Ch. 5.3.). Elution buffer (0.3 M NaCl) was then added and the gel 
fragments were incubated overnight at 37ºC with vigorous shaking. 
 
 
 
 
80 nt
50 nt
35 nt
24 nt             
    -Tet    +Tet    Contr.
Size of the excised 
fragment
1      2       3       4       5       6     7
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Table 6.2. Composition of 10% denaturing polyacrylamide gel 
Component Stock (30 ml) Final conc. 
urea 14.4 g 7M 
40% acrylamide:bisacrylamide (19:1) 7.5 ml 10% 
10x TBE 3 ml 1X 
H2O 8 ml n.a. 
The mixture was heated in the microwave oven to dissolve urea and then left at room 
temperature to cool down. For 1 gel, 10 ml of the stock solution was taken and 50 µl 
10% APS and 10 µl TEMED was added. The rest of the stock solution was kept at 
room temperature. 
 
Table 6.3. Sequences of the size markers 
Size marker Sequence 
24 nt 5′ GCGUGUACUCCGAAGAGGAUCCAA 3′ 
35 nt 5′ GGCAUUAACGCGAACUCGGCCUACAAUAGUGAUGA 3′ 
 
Dephosphorylation of the 3’ ends 
When the elution process was completed, the buffer was separated from the gel 
pieces by centrifugation through cellulose acetate filters (1 minute, 16000xg, 
4ºC). The RNA was then precipitated from the eluate by adding 1 ml of absolute 
ethanol with 3 µl glycogen (stock of 5 mg/ml concentration, Ambion AM9510, 
stored at -20ºC) and incubating at -20ºC for at least 2 h. After the incubation 
samples were centrifuged for 30 min, 21000xg at 4ºC. Pellets of RNA were 
resuspended in 25 µl 3’-dephosphorylation reaction mix (Table 6.4.). Residual 
phosphate moieties on 3’ ends were the result of RNase 1 activity and it was 
necessary to remove them in order to facilitate ligation of the 3’-linker (Fig. 6.3 
A). The reaction was performed by polynucleotide kinase, which in the absence 
of ATP (usage of the buffer devoid of this nucleotide) removed the phosphate 
group from the 3’ ends of the RNA fragments. Under the described conditions 
the enzyme efficiency is low, even at the optimal temperature of 37ºC, hence 
the reaction time was extended to 5 h. 
Table 6.4. Composition of the 3’-dephosphorylation reaction 
Components Volume 
1.5x MES-buffer (in Table 6.5 below) 16.67 µl 
T4 PNK [10 U/µl], NEB M0201S 1.25 µl 
Nuclease-free H2O 7.08 µl 
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Table 6.5. Composition of 1.5x MES-buffer (stored at -20ºC) 
Components Concentration 
MES-NaOH pH 5.5 150 mM 
NaCl 450 mM 
MgCl2 15 mM 
ß-mercapthoethanol  15 mM  
 
 !
Figure 6.3. Overview of the library preparation method 
A. The size separated mitoribosome footprints were first dephosphorylated at 3’ end in 
order to bare the free hydroxyl groups and facilitate ligation of the 3’-linker. After the 
ligation, successfully extended fragments were separated via electrophoresis in 10% 
denaturing polyacrylamide gel. B. Purified fragments were then phosphorylated at the 
5’ end and the 5’ linker was ligated. C. The size separation of the ligation products was 
repeated and the obtained RNA fragments were then reverse transcribed using a 
primer specific to the 3’-linker sequence. D. The cDNA was next amplified via PCR and 
the purified library was ready for sequencing. 
 
Samples containing dephosphorylated RNA fragments were next purified 
through isolation with Trizol® reagent. 725 µl of Trizol® was added to each 
sample, followed by 150 µl chloroform. RNA isolation was performed according 
to manufacturer’s instruction. Precipitated pellets were washed with 500 µl of 
75% ethanol and stored at -20ºC until the next step, ligation of the 3’-end linker 
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(Fig. 6.3 A).  
 
Ligation of the 3’ linker 
The sequence of this linker (Table 6.12 A) was designed to maximize the 
efficiency and specificity of the ligation. The first nucleotide at the 5’ end 
contained ribose (adenylated) so the ligation would occur between two RNA 
species. The rest of the sequence was build of deoxyribonucleotides with the 
dideoxy-modification of the 3’ end to prevent ligating on the 5’ end of ribosome 
footprints library. The reaction buffer applied lacked ATP (Table 6.7) to ensure 
the ligation occurred at the 3’ end only and with the linker in the right orientation 
as only its 5’ end was adenylated. The RNA pellets were resuspended in 15 µl 
of reaction mix (Table 6.6 and 6.7). Reaction was performed for 2.5 h at 37ºC 
with agitation. In addition to the experimental and control samples, both size 
marker oligos (24 and 35 nt, sequences in Table 6.3) were also subjected to 
ligation. These samples served as a positive control of the ligation and the right-
size markers for facilitating of the products selection. 
 
Table 6.6. Composition of the 3’ end ligation (15 µl) reaction. 
Components  [stock concentration] Volume 
3’ linker [100 µM] 1.5 µl 
10x T4 ligation buffer (custom) 1.5 µl 
T4 RNA ligase I [20U/µl], NEB M0204S 2.25 µl 
Nuclease-free H2O 9.75 µl 
Components of the positive control Volume 
3’ linker [100 µM] 1.5 µl 
10x T4 ligation buffer (custom) 1.5 µl 
24 nt marker [20 µM]  2.6 µl 
35 nt marker [20 µM]  1.3 µl 
T4 RNA ligase I [20U/µl], NEB M0204S 2.25 µl 
Nuclease-free H2O 5.85 µl 
 
Table 6.7. Composition of 10x T4 ligation buffer (custom, stored at -20ºC) 
Components Concentration 
Tris-HCl, pH 7.8  500 mM 
MgCl2 100 mM 
DTT 100 mM  
 
After the reaction was completed, the products were resuspended in loading 
dye (10 µl, Gel loading buffer II, Ambion 8546G) and separated on a 10% 
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denaturing polyacrylamide gel. The composition of the gel (Table 6.2) and the 
electrophoresis conditions were the same as those used for size separation of 
the RNA isolated from the ribosomes (see Fig. 6.2; method as in chapter 6.3, 
“Size separation of the mitoribosome footprints”). 
 
 
Figure 6.4. Size separation of the 3’ linker ligation products  
Ligation products of the 3’ linker and isolated RNA fragments (potential ribosome 
footprints) were separated by 10% denaturing SDS PAGE. Reactions were performed 
on RNA fragments from 3 cell lines: tRNAVal mutant with (+Tet) or without VARS2L 
induction (-Tet) and wild type control (C). In addition, a positive control of the ligation 
reaction (lane 8) facilitated selection of the correct sized products (depicted by 
brackets). ssRNA low range (lane 1) and oligo (lane 9) size markers were used. 
 
The expected product sizes of the 3’ linker ligation ranged between 44- 55 nt, 
extending the original 24-35 nt ribosomal footprints (Fig. 6.4). The main ligation 
products in experimental and control samples corresponded in size to the 
products in the positive control, which suggested that the reaction was 
successful. From each sample lane (Fig. 6.4 lanes 2, 4, 6 and 8) the gel area 
between 45 and 55 nt was excised. The products in the positive control 
samples were also included to serve the same purpose in following 5’ ligation 
step.  
 
Phosphorylation of 5’ ends and ligation of the 5’ linker 
RNA from gel pieces was eluted in the same way as described for size 
80 nt
50 nt
    -Tet    +Tet       C  
1    2       3      4       5       6       7      8      9
Ligation 
products
35 nt
24 nt
Lig
at
ion
 co
nt
ro
l
ss
RN
A 
m
ar
ke
r
Si
ze
 m
ar
ke
r
! 163 
separation of the footprints and prepared for the next step, which was 
phosphorylation of the 5’ end of the fragments (Fig. 6.3 B). Addition of the 
phosphate group at 5’ end was necessary for the ligation of the second linker 
(5’ linker). The pellets of the precipitated RNA were resuspended in 14 µl of 
phosphorylation reaction mix (Table 6.8). Reactions were performed for 30 min 
at 37ºC with agitation.  
 
Table 6.8. Composition of the 5’-phosphorylation reaction 
Components [stock concentration] Volume 
10x PNK buffer, NEB 1.5 µl 
ATP [4 mM] 3.6 µl 
T4 PNK [10 U/µl] NEB M0201S 1.5 µl 
Nuclease-free H2O 7.5 µl 
 
To purify the samples after phosphorylation, they were subjected to RNA 
isolation with Trizol®. As described previously (“Dephosphorylation of the 3’ 
ends”), the whole of the reaction sample was combined with 725 µl of Trizol® 
reagent and the isolation was carried according to the manufacturer’s 
instructions. Pellets were washed in 0.5 ml of 75% ethanol, dried and 
resuspended directly in 15 µl of 5’-ligation reaction mix (Table 6.9). The 5’-
ligation reaction was performed at 22ºC, overnight with agitation.  
 
Table 6.9. Composition of the 5’ end ligation reaction. 
Components Volume 
5’ linker [100 µM] sequence in Table 6.11 B. 3.9 µl 
10x T4 ligation buffer (custom), Table 6.7 1.5 µl 
4 mM ATP  0.9 µl 
T4 RNA ligase I [20U/µl], NEB M0204S 1.5 µl 
Nuclease-free H2O 7.2 µl 
 
As in case of the 3’ end ligation step, loading dye (10 µl) was added to the 
entire reaction product, which was then separated on 10 % denaturing 
polyacrylamide gels (Table 6.2). The preparation of the gels, conditions of 
electrophoresis and size markers were as described in “Size separation of the 
mitoribosome footprints”. The expected product size following successful 
ligation was between 65-75 nt.  
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Figure 6.5. Size separation of the 5’ linker ligation products  
Products of the ligation of the second linker (5’ linker) to the ribosome protected 
fragments were separated by 10% denaturing PAGE. The 5’ linker was ligated to RNA 
from all samples: uninduced tRNAVal mutant (-Tet; lane 2), tRNAVal mutant induced to 
express VARS2L (+Tet; lane 4), wild type control (C; lane 6) and positive control 
reaction (ligated size markers; lane 8). The latter served as a reference for the size of 
the expected products and aided in their excision (depicted by brackets). The size 
markers used were ssRNA low range marker (lane 1) and oligo size markers (lane 9). 
 
Results of the 5’ ligation in the positive sample (Fig. 6.5, lane 8) showed the 
presence of the expected-sized product indicated that the procedure had been 
successful. Similar sized products were detected in all of the experimental and 
control samples although of the much lower intensity. Taken together these 
results indicated that the ligation of the 5’ end linker was successful. The small 
amount of the final product was most likely due to the low levels of the template 
that was diminished after each size separation step. However, despite the low 
amount the ligation products, these were excised from gel and eluted as 
described above (“Size separation of the mitoribosome footprints”). Pellets of 
the precipitated samples were resuspended in 8 µl of water and prepared for 
reverse transcription (Fig. 6.3 C). The reaction was performed using 
SuperScript III kit (Invitrogen) with the conditions outlined in Table 6.10.  
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Table 6.10. Component and condition of the reverse transcription reaction  
Components  (all included in SuperScript III First-
Strand Synthesis System 18080-051) 
Volume 
RNA sample  8 µl 
dNTPs [10 mM] 1 µl 
mtRPRT primer [100 µM] sequence in Table 6.11 B 1 µl 
Samples were incubated for 5 min at 65ºC and then placed on ice 
10x buffer 2 µl 
MgCl2 [25 mM] 4 µl 
0.1 M DTT 2 µl 
SuperScript III [20 U/µl] Invitrogen 1 µl 
RNase Out 1 µl 
Temperature Time 
50ºC 50 min 
85ºC 5 min 
4ºC  
 
After the reverse transcription, samples were treated with 1 µl RNase H for 1 
hour at 37ºC. Then they were purified with illustra Microspin G-50 spin columns 
(GE Healthcare) according to the manufacturer’s instructions. Next, the purified 
samples were amplified in the PCR reaction (composition and conditions of the 
reaction in Tables 6.11. A and B) with primers specific to the linker sequences 
ligated to each end of the templates (Fig. 6.3 D). The forward primer (termed 
mtRPPCR RP1, Table 6.11 B) was universal for all samples, whereas three 
types of the reverse primers were used, each contained a different index 
sequence (one index sequence type per sample, Table 12 B). Use of the 
indexed primers allowed simultaneous sequencing of all libraries, since the 
reads originated from different samples they could easily be distinguished 
based on the index sequence. Index sequences embedded in primers were 
compatible with the Illumina platform and recognized by its software. After the 
sequencing, reads with one type of index were assigned to the specific sample. 
 
 
 
 
 
 
 
 
! 166 
Table 6.11. Component (A) and conditions (B) of the library PCR reaction 
 A. 
Components Volume 
2x Phusion master mix with HF buffer, 
Thermo Scientific 
50 µl 
mtRPPCR RP1 Forward primer [25 µM] 
Table 6.12 B 
1 µl 
mtRPPCR RPIX* Reverse primer [25 µM] 1 µl 
H2O 18 µl 
Template (cDNA) 30 µl 
* X= index number 
 B. 
Stage Temperature Time 
Hold 98˚C 30 s 
19 
cycles 
94˚C 30 s 
60˚C 30 s 
72˚C 15 s 
Hold 72˚C 10 min 
Hold 4˚C ∞ 
 
Table 6.12. Linker (A) and primer (B) sequences 
A. 
Type Name Sequence (5’-3’) 
5’ Linker 
(RNA) 
RP RNA 5’ 
adapter (RA5) 
GUUCAGAGUUCUACAGUCCGACGAUC 
3’ Linker 
(DNA*) 
RP RNA/DNA 3’ 
Adapter (RA3) 5rApp*/TGGAATTCTCGGGTGCCAAGG/3ddC** 
* 5rApp: adenylated ribonucleotide 
** 3ddC: dideoxy modification in the 3' nucleotide 
B. 
Type Name Sequence (5’-3’) Tm 
Reverse 
transcript
ion 
mtRPRTPrimer 
(RTP) 
GCCTTGGCACCCGAGAATTCCA 53.5 °C 
PCR 
Forward 
mtRPPCR 
(RP1) 
AATGATACGGCGACCACCGAGATCTAC
ACGTTCAGAGTTCTACAGTCCGA 
66.9 °C 
PCR 
Reverse 
Index 1 
mtRPPCR 
(RPI1) 
CAAGCAGAAGACGGCATACGAGAT[CG
TGAT]GTGACTGGAGTTCCTTGGCACC
CGAGAATTCCA 
70.7 °C 
PCR 
Reverse 
Index 2 
mtRPPCR 
(RPI2) 
CAAGCAGAAGACGGCATACGAGAT[AC
ATCG]GTGACTGGAGTTCCTTGGCACC
CGAGAATTCCA 
70.7 °C 
PCR 
Reverse 
Index 3 
mtRPPCR 
(RPI3) 
CAAGCAGAAGACGGCATACGAGAT[GC
CTAA]GTGACTGGAGTTCCTTGGCACC
CGAGAATTCCA 
70.7 °C 
PCR 
Reverse 
Index 4 
mtRPPCR 
(RPI4) 
CAAGCAGAAGACGGCATACGAGAT[TG
GTCA]GTGACTGGAGTTCCTTGGCACC
CGAGAATTCCA 
70.7 °C 
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PCR 
Reverse 
Index 5 
mtRPPCR 
(RPI5) 
CAAGCAGAAGACGGCATACGAGA[TCA
CTG]TGTGACTGGAGTTCCTTGGCACC
CGAGAATTCCA 
70.7 °C 
[ ] contain the index sequence 
The PCR products were purified using the Qiaquick PCR purification kit (Qiagen 
28106) according to the manufactures protocol. The elution was performed with 
25 µl of nuclease-free H2O. The purified DNA was finally size separated using 
E-GEL Invitrogen system (G6400EU) with E-GEL EX with SybrGold 2% 
SizeSelect precast gel  (Invitrogen G661002). Whole samples were loaded to 
the top row of wells, along the 10 µl 25 bp size marker (diluted to 200 µg/µl with 
nuclease-free water and stored at -20ºC, Invitrogen 10597-011). The E-Gel 
system utilizes precast gels set between two plastic plates, which allows 
omitting the running buffer. In addition, the real-time visualisation of the sample 
progress is possible as the gels are prestained with specific dyes (mainly 
SYBRGold) and placed on the transilluminator during the electrophoresis.  For 
the size selection these gels have two rows of wells- top one to load the sample 
and the one in the middle where the product of the desired size can be selected 
and retrieved.  For this purpose, the second row of wells was filled with 25 µl of 
the nuclease-free water so that the desired DNA species (approx. 130 bp) can 
be resuspended and removed from the gel. The samples were electrophoresed 
with the “2% select” pre-set program. When the expected size products 
(assessed based on the size marker) arrived in the second row of wells (after 
approx. 13 min) they were resuspended in the water and transferred in to a 
tube. These products contained purified, size selected library of potential 
mitochondrial ribosome footprints (RFs) and were stored at -20ºC prior to 
sequencing on HiSeq Illumina Platform. 
 
6.4. Bioinformatics analysis of sequencing results 
The library samples were sent to the Netherlands Cancer Institute, Amsterdam 
to be sequenced at the Genomics Core Facility. Samples were sequenced 
using mainly Illumina HiSeq2000 (samples from the first experiment were also 
sequenced in parallel on the MiSeq platform). As an additional control, data 
from a cell line used in published mitoribosome profiling study (Rooijers et al., 
2013) labeled SRR935452 or SRR935453 depending on the type of sequencer 
it was sequenced with (raw data available at NCBI Gene Expression Omnibus 
under accession code GSE48933) were included.  
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The bioinformatics analysis of the raw data (from the first experiment) was 
performed by Dr. Mathew Bashton from the Bioinformatics Support Unit, 
Newcastle University. The protocol described below was developed by him and 
then used by Dr. Fei Gao from my host lab to analyze data from the following 
experiments. First, the adaptors were removed using cutaddapt with the options 
listed in Table 6.13. 
Table 6.13. Adapter trimming options (based on the original methodology 
by (Rooijers et al., 2013)  
Option Function 
-a 
TGGAATTCTCGGGTGCCAAGGAACTC
CAGTCACATCACGATCTCGTATGCCG
TCTTCTGCTTG 
Removing the specified adapter 
adapter sequence from 3’ ends. 
Used in my samples and SRR935453  
-a TCGTATGCCGTCTTCTGCTTG Removing the specified adapter 
adapter sequence from 3’ ends. Used 
in SRR935452 
-O 12 minimum overlap length between the 
read and adaptor is set as 12 
-m 20 discards reads shorter than 20 
-o sample_name_trimmed.fastq The output file was named after the 
sample with _trimmed.fastq  
 
Next, the outputfiles (*_trimmed.fastq) were aligned to decoy tRNA / rRNA 
sequences from nuclear and mitochondrial genomes. This operation was 
facilitating filtering out reads that originated from other than mRNA fragments. It 
was performed with bowtie2 with the options as presented in Tab. 6.14. 
 
Table 6.14. Filtering out the tRNA / rRNA sequences (based on the original 
methodology by (Rooijers et al., 2013) 
Option Function 
-p 4 –D 20 –R 10 –N 1 –L 20 –i C/1 Technical parameters for the 
alignment 
--un sample_name_screened.fastq Output file for the fastq sequences that 
do not align to decoy tRNA/ rRNA, i.e. 
potential RFs mRNA sequences 
-x prescreen The bowtie index decoy file with tRNAs 
and rRNAs, created prior to this 
analysis 
-U sample_name _trimmed.fastq Input file 
-S sample_name _screened_out.sam Output *.sam file with the filtered out 
sequences aligned with the decoy 
index 
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Further analysis was conducted using the *_screened.fastq files which were 
devoid of rRNA and tRNA sequences. This file was aligned to the mitochondrial 
genome. This reference file was created by Dr. Bashton and labeled HumanMT. 
The alignment was performed with bowtie2 using the following parameters 
(Table 6.15): 
 
Table 6.15. Alignment with the mitochondrial genome (based on the 
original methodology by (Rooijers et al., 2013) 
Option Function 
-p 10 -D20 -R 10 -N 1 -L 20 -i C,1 Technical parameters for the 
alignment 
-x HumanMT The bowtie index for humen mt-
genome reference  
-U sample_name screened_out.sam Input file 
-S sample_name _.sam Output *.sam file with alignment to  
human mt-genome 
 
From the alignment output file (*.sam) multimapping reads were removed and 
the resulting file was converted into *bam file using the following pipeline 
command:  
samtools view -q 1 -bS sample_name_screened_out.sam -u | samtools sort - -f 
sample_name _screened.sorted.bam 
 
The final *bam file was then indexed (as it is required by the visualization 
software, namely IGV) using the following command: 
samtools index sample_name _screened.sorted.bam   
 
It is important to point that the quality of the data was rather low with only ∼ 1% 
of the reads originating in the mitochondrial mRNAs (approximately 1.5 x105, 
Appendix 1.4, Table A1, samples labeled ‘2553’). The retention of mitoribosome 
footprints was lower than expected and observed in Prof. Agami’s lab 
(approximately 5 x106,, Appendix 1.4, Table A1, samples labeled ‘SRR935452’). 
However, the quality of data did not render the data analysis impossible, hence 
the downstream analysis was commenced.  
Once the alignment was completed, the resulting *.bam files were visualized in 
the IGV software. The brief visual inspection of the ribosome profiles allowed 
identifying regions that in mt-tRNAVal mutant cell line would accumulated higher 
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amounts of ribosome footprints (RFs) associated with the presence of valine 
codons. However, in order to quantify the actual ribosomal occupancy over 
these codons and compare it between the mutant and control cell lines a 
different approach was needed. This part of the analysis was performed by Dr. 
John Grady using R. The first questions to be answered were : 1) is the mt-
tRNAVal mutation in T1V1 cell line resulting in an increase of the RFs 
accumulation over the mt-valine codons consistent with mitoribosome stalling? 
2) Is the mitoribosome stalling relieved to some extend in T1V1 cell line with 
VARS2 overexpression?  
  
Estimation of the A-site position in the mitoribosomal footprints 
First, it was important to establish methodology to identify the footprints 
generated by only these mitoribosomes that were actively translating valine 
codons. The presence of a valine codon in the footprint can be placed at any 
given position in a RF (Fig. 6.6 A position of the valine codon marked in blue). 
Valine codons at the 5’ end of the footprint represent these sequences that 
were already translated, whereas Val codons at the far 3’ end were not yet 
reached by the ribosome. Only the codons that were directly over the ribosomal 
A-site represent what sequence was currently translated by each ribosome at 
the time of experiment. In their publication (Rooijers et al., 2013) observed that 
in mt-tRNATrp mutant cell line there is a high concentration of RFs with Trp 
codon starting 15-18 nt from the 5’ end. After further investigation they 
estimated that on average the mitoribosomal A-site was placed 17 nt from the 5’ 
end of the RF. In order to test if the same relation is observed in my data, all 
RFs with valine codons were grouped according to the position at which these 
codons started (measured from the 5’ end per each nucleotide: 1 - 30). Number 
of RFs in each of the groups was counted. Then the numbers were used to 
calculate what percentage of all RFs with any amino acid codon starting at that 
particular position in a footprint it constituted. The results of these calculations 
were than plotted for all cell lines (Fig. 6.6 B wild type “Control”, uninduced 
T1V1  “Tet-“, T1V1 with VARS2 induction “Tet+”).  
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Figure 6.6. Estimation of the A-site position in ribosome footprints 
A. Schematic illustrating how RFs containing valine codons were grouped and 
quantified. B. Plots showing quantification of RFs with valine codons at various 
positions were generated for all 3 cell lines: wild type control (Control, in red), T1V1 
uninduced (Tet -, green), T1V1 induced (Tet+, blue). The x axis representing different 
offsets of all RFs containing valine codon which 5’ end starts at any possible position 
(1-30 nt, 5’ – 3’) in a predicted-sized footprint. The y axis represents a number of RFs 
with valine codon starting at each particular position. This number is presented as a 
percentage of all footprints with an amino acid codon starting at that position. C. The 
same types of plots as in A. were generated for the arginine-containing RFs. The 
original plots (in B and C) were generated by Dr. John Grady. 
 
Comparison of the percentage of the RFs containing valine between the 
analyzed cell lines showed the most striking difference in their number when the 
valine codon started 17 nt from the 5’ end. In both T1V1 cell lines (with and 
without Tetracycline) the number of RFs with valine codon beginning at 17 nt 
was higher than in control. Interestingly, in control cell line the position of the 
valine codon in a footprint did not change what the proportion of all amino acid-
encoding RFs they constitute. The position of the valine codon in RFs had an 
effect on their number only in T1V1 cell lines and when placed in the middle of 
RF. As a contrast, for arginine-containing RFs (Fig. 6.6 C), the position of this 
amino acid codon did not have an effect on their numbers, regardless of the cell 
line analysed. To investigate this further, number of RFs containing valine 17 nt 
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from 5’ end was compared between cell lines. Results, shown as % of RFs with 
all amino acid codons at that position, were presented on a graph (Fig. 6.7). 
 
 
Figure 6.7.  Proportion of RFs with valine codon beginning at 17 nt from 5’ 
end 
Number of RFs with valine codons beginning at the 17th nt from the 5’ end were 
compare between all 3 cell lines: wild type control (Control, in red), T1V1 with (T1V1 
Tet+, blue) and without (T1V1 Tet-, green) induction of VARS2 expression. Results 
were presented as percentage of RFs with aa-codons starting at that position. 
 
The result showed that approximately 14% (Fig. 6.7, ‘Tet-‘) and 12% (‘Tet+’) of 
all the footprints generated for these cell lines contained valine codon starting 
17 nt from the 5’ end. As opposed to control cell line where RFs with valine at 
that position constituted for only 5% of all RFs. Interestingly, there was very little 
variation between the induced and uninduced T1V1 cell lines. This result could 
have been explained by the failure to rescue the pathological phenotype, 
possibly caused by ineffective induction of VARS2L expression. This  was 
suggested in the correspondence with Koos Rooijers, who performed additional 
analysis of these ribosome profiling data and founf no evidence of the VARS2L 
overexpression. Until this result was definitively confirmed with 
immunodetection of VARS2L levels, it was assumed that the induction of T1V1 
was not successful and both samples (Tet- and Tet+) were treated as replicates 
of the mutant cell line. These results suggested that the estimation of the 
mitoribosomal A-site position at the 17th nt from the 5’ end was most likely 
correct and that the mutation in mt-tRNAVal was possibly causing the increase in 
ribosome accumulation over valine codons.  
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Is stalling depending on the type of valine codon? 
In human mitochondrial DNA there are 4 codons encoding valine, namely GTA, 
GTC, GTG and GTT. In the (Rooijers et al., 2013), stalling of mitoribosomes on 
tryptophan codons in mt-tRNATrp mutant was more profound on one of the Trp 
triplets than on the other. In order to investigate if the accumulation of the 
mitoribosomes on valine codons would also be dependent on their type in T1V1 
cells, the pool of RFs with valine in the A-site was divided into 4 categories 
based what Val codon they contained. The number of RFs in each category 
was calculated for all 3 cell lines and presented as a graph (Fig. 6.8, Control, 
T1V1 Tet- and T1V1 +Tet). 
 
 
Figure 6.8. Quantification of RFs with A-site valine codon based on the 
type of the coding triplet  
RFs with valine at the 17th nt from the 5’ end were grouped according to the type of 
valine codon (GTA, GTC, GTG or GTT) at that position. Number of RFs in each 
category was presented as % of all RFs with valine at 17 nt. Graphs were generated 
for each of the cell lines: wild type control (Control), uninduced T1V1 (Tet-) and 
induced T1V1 (Tet+).  
 
In wild type control majority (45%) of RFs with valine at A-site contained GTA 
codon at that position. The second most abundant codon was GTC. In both 
mutant cell lines, however, this proportion was different:  approximately 60% 
(63% in Tet- and 55% in Tet+) of RFs with A-site valine contained GTC codon 
at that position. GTA codon was present at the A-site of 20% (Tet-) or 25% 
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(Tet+). The proportion of RFs with GTG and GTT codons in the A-site varied to 
much smaller extent between the cell lines (4-13% for both codons). In order to 
explain the change of A-site valine codon usage between the cell lines, first the 
proportion, number and position of different valine codons in human mtDNA 
were determined. It was important to calculate which of the valine codon types 
is more abundant in mtDNA and how are they distributed across different ORFs. 
The position of valine codons was marked in all mitochondrial gene templates, 
distinguishing between the types of the triplets (Fig. 6.9 A).  
  
 
Figure 6.9. Position of valine codons in mtDNA 
A. Positions of each type of valine codons were marked in all mitochondrial polypeptide 
genes. Panels represent the position of each valine codon separately. The full length of 
each gene is presented as 100%. The Y-axis represents the number of valine codons 
in the certain area. Image enlarged in appendix 1.1. B. Representation of the 
occurrence of different types of valine codons in mtDNA when all transcripts were 
superimposed. The original plots were generated by Dr. John Grady. 
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By merging the distribution patterns of individual valine codons across each 
gene (which full length is represented as 100%) a general density map was 
created (Fig. 6.9 B). On average in human mitochondrial genes, the most 
represented type of valine codon is GTA. It is also the triplet that is fully 
complementary to the mt-tRNAVal anticodon (3’ CAT 5’). All other 3 valine 
codons require wobble (other than classical Watson:Crick) base pairing at their 
3rd position from 5’ end. In the wild type control cell line, the GTA codon is also 
the most abundant in the RFs with the valine codon at position 17. In T1V1 
cells, however, the proportion of valine codons in that position was shifted in 
favor of GTC, the second most abundant in the mtDNA. It is possible that the 
wobble base pairing of the 3rd (from 5’ end) nucleotide of this codon (C) with the 
corresponding nucleotide of the anticodon (T) increases the time required by a 
ribosome to translate it.  This also may be the reason why in the mutant T1V1 
cell line where the charged mt-tRNAVal level is lower than in the control, the time 
delay due to the wobble pairing is more prominent. 
 
Distribution of RFs across mt-transcripts 
In order to investigate if the potential staling on valine codons changes the 
distribution of mitochondrial ribosomes, the mitoribosome profiles were 
generated and compared between the cell lines. The number of RFs 
accumulating along the length of each mt-transcript was calculated and plotted 
to form histograms (Fig. 6.10 A). This resulted with separate mitoribosome 
profiles for each of the mt-transcripts. Regions in mt-genes with high 
concentration of valine codons, where identified by creating separate density 
maps, distinguishing between different types of these codons (as in Fig. 6.9 B). 
The valine codon density maps were created for each of the individual mt- 
transcripts (Fig. 6.10 B).  Comparison of these two sets of data facilitated 
determination if the higher accumulation of RFs is corresponding with the 
places in mtDNA sequence where valine codons are more abundant. 
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Figure 6.10. Distribution of mitoribosomes is not dependent on the 
position of valine codons 
A. Density of the RFs across each mt-transcript was calculated and plotted for all 3 cell 
lines: wild type control (in red), uninduced T1V1 (Tet-, in green), unsuccessfully 
induced T1V1 (Tet+, in blue). The full length of each transcript was presented as 
100%. B. Position of valine codons in mtDNA was marked for each type of codon 
separately. Amount of different Val codon was presented as density plots over the 
length of each mitochondrial transcript (length represented in %). Both images 
enlarged in appendix 1.2. The original plots were generated by Dr. John Grady. 
 
The pattern of RFs distribution between the two T1V1 samples (Fig. 6.10 A 
Tet+ and Tet-) was very similar, further confirming that the rescue experiment 
with VARS2L expression was most likely unsuccessful. If these two samples 
were to be treated as identical repeats of the same cell line the observed 
similarities in ribosome profiles could suggest reproducibility of this method.  
Comparison of the mitoribosome profiles between the control and T1V1 cell 
lines shows differences in distribution of RFs in most of mt-transcripts (Fig. 6.10 
A). These discrepancies in mitoribosome coverage were especially visible in 
COX1, COX2, COX3, ND3, ND4 and ND5. However, the regions with higher 
accumulation of RFs in T1V1 than control cells were not overlapping with the 
positions of valine codon-rich sequences in mtDNA (Fig. 6.10 B). For 
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example, the high number of valine codons in the 3’ region of COX2 and in the 
middle of ND4 did not generate a higher number of RFs in T1V1 cells than in 
control cell line. Similar, the valine codon-rich ND6 sequence did not generate a 
high number of mitoribosomal RFs. 
Finally the comparison of RFs profiles with valine triplets distribution was 
focused on GTC codons, which possibly had the highest stalling potential of all 
valine-encoding sequences in mutant cell lines (Fig. 6.8). The enrichment in 
GTC codons could have been a reason for the RFs accumulation visible as a 
peak approximately 25% in the COX2 transcript in T1V1 cell line. However, 
even higher number of GTC triplets in the second quarter of COX1 did not 
result in higher density of RFs. The changes of RFs distribution between control 
and T1V1 cell lines, visible in the general mitoribosome profiles were most likely 
caused by factors other than the presence of valine codons. 
 
Repeat of mitoribosome profiling on T1V1 cell line  
In addition to the samples analyzed in the preceding section, a second 
ribosome profiling experiment was performed on T1V1 cell line. This library 
included uninduced T1V1 and 143B wild type control. The sample from rescue 
experiment was omitted because of the concerns with possible lack of VARS2 
expression. Sequencing results were analysed as described in ‘Estimation of 
the A-site position in the mitoribosomal footprints’ and Fig. 6.6. The objective 
was to test if the estimation of the A-site position to be 17 nt from RFs’ 5’ end 
was correct and the new mutant sample would present similar valine codon-
induced stalling. Number of RFs with 17 nt valine codons was calculated for 
both cell lines distinguishing between 4 Val coding sequences. 
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Figure 6.11. Position of different valine codons in RFs 
Plots showing quantification of RFs with specific valine codon at various positions in 
T1V1 (upper panel) and control cell line (lower panel) were generated for each type of 
valine codon (GTA, GTC, GTG, GTT) separately. The x axis representing different 
offsets of all RFs containing one type of valine codon which 5’ end starts at any 
possible position (1-30 nt, 5’ – 3’) in a predicted-sized footprint. The y axis represents a 
number of RFs with specific valine codon starting at each particular position. This 
number is presented as a percentage of all footprints with an amino acid codon starting 
at that position. The original plots were generated by Dr. John Grady. 
 
Unlike in the first experiment (Fig. 6.6 B), for T1V1 cell line there was no strong 
enrichment in RFs with the valine codons beginning at 17th nt (Fig. 6.11 A). 
There was, however, a high accumulation of RFs with the GTA codon starting at 
19th nt. This observation was made in both cell lines, hence it was most likely 
caused by a factor other than tRNAVal level-induced stalling. To complete the 
investigation of potential stalling on valine codons, the RFs with Val sequences 
at the 17th position were then grouped based on the type of codon (as in 6.8). 
Quantification and comparison of the proportion of RFs with specific type of Val 
codon in the A-site is presented in Fig. 6.12. 
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Figure 6.12. Quantification of RFs with A-site valine codon based on the 
type of the coding triplet 
RFs with valine at the 17th nt from the 5’ end were grouped according to the type of 
valine codon (GTA, GTC, GTG or GTT) at that position. Number of RFs in each 
category was presented as % of all RFs with valine at 17 nt. Graphs were generated 
for each of the cell lines: wild type control (Control), uninduced T1V1 (Tet-) and 
induced T1V1 (Tet+).  
 
T1V1 sample analyzed in the first experiment (Fig. 6.8) was characterized with 
much higher proportion of A-site GTC-containing RFs than the control. 
Footprints of ribosomes translating valine, derived from wild type cells, were 
more enriched in GTA codons, which are also more abundant in mtDNA (Fig. 
6.9). Analysis of the data from the repeated experiment also showed a change 
in the proportion of Val codons in favor of GTC in T1V1 cell line (Fig. 6.12). 
However, the change is not as dramatic as in the first experiment. The 
proportion of GTA and GTC-containing RFs in the control cell line (Fig. 6.12) is 
similar to the control in first experiment (Fig. 6.8) 
 
Enrichment in RFs with valine codon at position 19 observed in both cell lines 
was unexpected, hence to investigate the matter further other amino acid 
coding sequences were analysed. The analysis was focused on finding other 
codons occupying a specific position within the footprint, which abundance was 
equally high in both cell lines. Such codons were identified, apart from valine, 
for methionine, alanine, histidine, glutamine and leucine (Fig. 6.13).  
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Figure 6.13. Comparison of different amino acids’ positions in RFs shows 
a dominant pattern 
Plots showing quantification of RFs with specific amino acid (M, A, H, Q, V, G and L) 
codons at various positions in T1V1 (left panel) and control cell line (right panel). A 
separate plot was generated for each of the coding triplets. The x axis representing 
different offsets of all RFs containing one type of valine codon which 5’ end starts at 
any given position (1-30 nt, in 5’ –> 3’ direction) in a predicted-sized footprint. The y 
axis represents a number of RFs with specified codon starting at each particular 
position. This number is presented as a percentage of all footprints with an amino acid 
codon starting at that position. The original plots were generated by Dr. John Grady. 
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When the results for these amino acids were put together it was observed that 
they form a pattern. High number of RFs with methionine-ATG codon starting at 
the very 5’ end prompted that the pattern may have been a specific polypeptide 
sequence. Indeed the MAHAAQVGL formed with the subsequent areas of high 
RFs densities is found at the beginning of COX2 sequence. To investigate 
participation of RFs from COX2 translation and compare it to other 
polypeptides, a number of RFs from each transcript was calculated. The results 
for each individual transcript were presented as percentage of all mt-transcripts 
(Fig. 6.14).  
 
 
Figure 6.14. The ribosome footprint (RFs) abundance on each mt-ORF 
from the T1V1 and control cell lines. 
The analysis was performed on data derived from T1V1 and control cell lines. The 
number of ribosome footprints (RFs) originating from mitochondrial ORF was 
calculated for each individual transcript. The results per ORF were presented as the 
percentage of the total number of mitochondrial RFs.  
 
When mitoribosome abundance was compared between the transcripts, those 
captured on COX2 were second most represented group in control cell line and 
fourth in T1V1. The most abundant group of RFs in both cell lines was COX1. 
There was also a high number of RFs generated from COX3 (in control), ND5 
(T1V1) and ND4 (T1V1). However, it was COX2 with its N-terminal sequence 
that seemed to have the most impact on the general population of RFs (Fig. 
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6.13). 
In order to investigate the distribution of RFs across COX2, detailed 
mitoribosome profiles were generated for this ORF in both T1V1 and control cell 
lines (Fig. 6.15). For the comparison, similar profiles were also generated with 
data from the first experiment. 
 
 
Figure 6.15. Distribution of RFs across MT-CO2 in T1V1 and control cell 
lines from both ribosome profiling experiments 
Distribution of the RFs across MT-CO1 experiment 2 (T1V1 and control cell line) and 
experiment 1 (T1V1 –Tet, T1V1 +Tet and control) was plotted as a number of RFs 
(represented as a percentage of all RFs in experiment, Y axis) aligning to each position 
within this mt-mRNAs. The X axis presents the full length of the transcript in 
nucleotides. The original plot weas generated by Dr. Fei Gao. 
 
In both cell lines analysed in the second experiment (Fig. 6.15, Control and 
T1V1) the majority of RFs was accumulated at the 5’ end of the MT-CO2 
transcript (approximately first 50 nt). This result confirmed the pattern observed 
for RFs separated based on specific amino-acid codons (Fig. 6.13). The 
participation of RFs originating from the beginning of this transcript was so high 
that it was visible on individual aminoacid-coding sequences distribution. The 
high abundance of RFs from COX2 observed in general population of RFs (Fig. 
6.14) was caused mainly by footprints from 5’ end sequence. As they are the 
most highly represented across the whole length of transcript, their contribution 
was the most important. It also explained why the valine codon distribution 
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was different in the repeated experiment than in the first one (Fig. 6.6 B). The 
proportion of the RFs at the beginning of MT-CO2 in all 3 cell lines from 
experiment 1 is much lower than in experiment 2 (Fig. 6.15). Therefore the 
pattern of valine-containing footprints distribution was a representation of all 
transcripts not just the COX2. 
 
6.5.  Complementary RNAseq analysis of T1V1 and control cell lines 
Ribosome profiling data provide information on the occupancy of ribosomes 
across the transcript. If this analysis is combined with the measurement of the 
transcript levels through RNAseq, it can be used to assess the efficiency with 
which each transcript was translated. For this purpose, while preparing cells for 
the ribosome profiling (repeated experiment on T1V1 cell line), an additional 
plate (1x diam. 15 cm per condition) was cultured in parallel for RNAseq 
analysis. Control 143B and T1V1 uninduced cell lines were treated with 
chloramphenicol (100 µg/ml, as described in 6.2.) then washed with PBS with 
chloramphenicol, stripped and resuspended in 5 ml Trizol. The Trizol samples 
were stored at -20°C and then sent to the Netherlands Cancer Institute, 
Amsterdam to be sequenced at the Genomics Core Facility. The RNA isolation 
and subsequently the sequencing library was prepared with TruSeq RNA 
Sample Preparation Kit v2 (Illumina, detailed in (Rooijers et al., 2013). The 
sequencing of the libraries was performed with Illumina HiSeq2000 (single-read 
sequencing).  
After receiving the raw data (Appendix 1.4, Table A2, samples ‘rp2’), the high 
quality of data was confirmed with FastQC software (http://www.bioinformatics. 
babraham.ac.uk/projects/fastqc/). Having established that the quality of these 
data was sufficient for the analysis, I proceeded to perform the alignment with 
the reference genome using TopHat2 software 
(http://ccb.jhu.edu/software/tophat/index.shtml). The reference sequence was 
provided from GRCh37 human genome. The alignment results 
(accepted_hits.bam file in the TopHat output directories) for each of the 
individual samples were assembled into transcripts using Cufflinks (http://cole-
trapnell-lab.github.io/cufflinks/). The output files of the transcriptome assembly 
(*.cuff) from both samples were then merged together into one file with 
Cuffmerge (http://cole-trapnell-lab.github.io/cufflinks/cuffmerge/). Finally, using 
Cuffdiff (http://cole-trapnell-lab.github.io/cufflinks/cuffdiff/) the differences in 
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transcript abundance between the two samples and their significance were 
calculated. The results (*_gene_exp.diff) were exported to excel for further 
analysis, i.e. comparison of the steady state levels of each mitochondrial 
transcript between the two cell lines. The level of individual mt-transcript 
expressed in FPKM, fragments per kb of transcript per million reads was 
presented on the plot (Fig. 6.16). 
 
 
Figure 6.16. RNAseq analysis shows no varition in mt-mRNAs expression 
between T1V1 and control cell lines 
Levels of each mt-mRNA expression (in FPKM), derived from the analysis with 
Cufflinks software, for both cell lines: T1V1 and Control are plotted pairwise to facilitate 
comparison. 
 
There was very little variation in levels of mt-mRNAs between the samples, 
which suggested that the mutation in 1624C>T MTTV does not affect the steady 
state levels of mt-transcripts. In both cell lines the most abundant transcript was 
RNA15, which corresponds to MT-ATP8, MT-ATP6 and MT-CO3.  Second most 
represented transcript was RNA7 (MT-ND4 and 4L), followed by MT-CO2. In 
order to compare the abundance of the specific templates with the number of 
RFs generated from it the RNAseq data (presented as % of all mt-transcript as 
in Fig. 6.16) was combined with RFs abundance data (Fig. 6.14). In RNAseq 
results the gene annotation for the mitochondrial transcripts in the reference 
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genome included two polycistronic transcripts (RNA15 and RNA7) unlike during 
the ribosome profiling analysis. Therefore the RFs from transcripts forming 
RNA15 and 7 were summed, including those aligning to the overlapping 
sequences, or spanning both transcripts. Having both ribosome profiling and 
RNAseq data sets prepared, they were utilized to calculate the translational 
efficiency (TE) ratio. For each transcript, the number of RFs originating from it 
(% of all RFs) was divided by this transcript’s level (% of all mt-transcripts) 
giving its TE ratio. TE ratio was calculated for all mt-transcripts in both T1V1 
(Fig. 6.17 A) and control (Fig. 6.17 B) cell lines. The higher the TE ratio value, 
the more mitoribosomes were captured translating it but with fewer of the 
available template. Therefore the high TE ratio value can be interpreted as high 
activity of translation of a particular transcript that would result in high level of 
synthesized protein. Alternatively, it can be caused by high level of stalling. The 
TE value that was close to 1 meant that the representation of RFs from this 
particular transcript is similar to how the level of this transcript is represented in 
the pool of all mt-transcripts.  
! 186 
 
Figure 6.17. Comparison of the translation efficiency ratio shows 
differences between the cell lines 
Translational efficiency (TE) values were calculated for each mt-ORF by dividing the 
RFs number originated from it  (presented as % of all RFs) by the mt-mRNA levels 
(presented as % of all mt-transcripts). TE values for all mt-ORFs were generated for 
T1V1 (panel A) and control (B) cell lines separately. 
 
In both cell lines the highest TE ratio value was observed in case of ND5, 
followed by COX1. In comparison ATP6-ATP8-COX3, ND4-ND4L and ND3 
were characterized with low TE value (	 1), meaning the proportion of RFs from 
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these ORFs was lower, or equal the proportion of the template. This 
observation was especially interesting in case of the two polycistronic 
templates. Even though these templates’ levels were high (Fig. 6.16) the 
amount of footprints originating from them was not proportional, which suggests 
low translational efficiency. 
The TE value for COX2, an ORF that was a source of high number of ribosome 
footprints (Fig. 6.14), were not as high as expected. However, in addition to 
very high proportion of RFs, the level of MT-COX2 was also relatively high (Fig. 
6.16), hence the TE ratio value was between 1 (T1V1) and 2 (Control). Another 
interesting result was obtained for ND6. As the only polypeptide translated from 
the anti-sense template the ND6 is though to be expressed at a very low level. 
However, the calculation of TE showed the value of 1 (control) or 2 (T1V1) 
which is higher than ND3 of both polycistronic templates. This suggested that 
translation of ND6 might be more effective than previously assumed. 
When comparing the results between the cell lines the most striking difference 
was observed in the ND5 TE value, which in T1V1 cells (Fig. 6.17 A) is 2x 
higher than in the control (Fig. 6. 17 B). In T1V1 cells, there was 10x more RFs 
generated from this transcript in comparison to what could be expected based 
on the transcript level. For some reason this template generated a very high 
amount of RFs, which was even higher in the T1V1 cell line. 
 
6.6. Validation of VARS2L overexpression via qPCR and screening of 
different T1V1 clones 
The comparison of the ribosome profiles of T1V1 samples did not show any 
significant changes between the induced and uninduced samples. It was an 
indication that the expression of the VARS2L protein, necessary for the rescue 
of low levels of mt-tRNAVal, might not have been successful. In order to 
investigate if the induction with tetracycline was successful in causing the 
overexpression of VARS2L, the remaining cell lysate (retained after RNase 
treatment) was analyzed by western blotting and antibodies specific to 
VARS2L. In the original study on the T1V1 cell line  the endogenous levels of 
VARS2L were very low and detection was only possible in samples where high 
amounts of mitochondrial proteins were used (100 µg of mitochondrial lysate). 
Since mitochondria were not isolated for the mitoribosomal profiling, such a blot 
could not been replicated in validation of the VARS2L induction as the only 
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remaining material from ribosome footprints generation was a total cell lysate. 
Thus, these total cell lysates from each sample (240 µg) were separated on the 
8% SDS-PAGE (2.5.5), unfortunately this proved to be insufficient material to 
detect endogenous levels of VARS2L protein. However, there was no signal in 
any of the cell line samples, which suggested that the induction to cause 
overexpression of VARS2L did not work. In the absence of the positive control it 
was not possible to confirm if the lack of detection was caused by the 
antibodies not working. Instead, in order to definitely confirm the lack of the 
VARS2L overexpression, other than the western blot method had to be chosen.  
It was decided to use a real-time quantitative PCR (qPCR) instead. This method 
allowed for the measurement of the VARS2L mRNA levels in RNA isolated from 
cells used in ribosome profiling experiments and stored in Trizol. First, the 
primers specific to VARS2L gene were designed using the PrimerQuest on-line 
tool (http://eu.idtdna.com/Primerquest/Home/Index).  
  
Table 6.16. VARS2L qPCR primer sequence 
Type Name Sequence 
Forward VARS2LqPCRFor 5’ CTGATGCAGAGGTTGTGGTAG 3’ 
Reverse VARS2LqPCRRev 5’ GCCCGTGTAGATGTGTGTATC 3’ 
 
The RNA was isolated from cells resuspended in the Trizol solution and stored 
(at -20°C) for RNAseq experiments.  From thawed samples, 1 ml of Trizol 
solution was taken and incubated at room temp for 5 min. The isolation was 
performed according to manufacturer’s instructions. From each samples 300 ng 
of RNA was taken and used as a template for cDNA synthesis. Reverse 
transcription was conducted with SuperScript VILO Master Mix (Invitrogen, 
Table 6.17).  
Table 6.17. Component and condition of the reverse transcription reaction 
Components Volume 
RNA sample (300 ng) 1 µl 
SuperScript VILO Master Mix 
(Invitrogen, Cat. No: 11755050)  
4 µl 
H2O 15 µl 
Temperature Time 
25ºC 10 min 
42ºC 60 min 
85ºC 5 min 
4ºC ∞ 
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To test the efficiency of the designed VARS2L primers, a qPCR reaction was 
performed on a dilution series of the 143B control cDNA template. The dilutions 
used were as follows: 10-3, 10-4, 10-5 and 10-6. The components and conditions 
of the reaction were as in 2.4.4.  
The averaged CT for each dilution was plotted and the slope of the standard 
curve was used to calculate the efficiency of the amplification: ! = 10! !!!"#$% 
For a 100% efficiency of the reaction (when the amount of PCR product 
doubles which each cycle, E=2) the optimal slope of the standard curve should 
be -3.32. The slope of the standard curve calculated for VARS2L primers on 4 
template dilutions was -3.33 (boxed in Fig 6.18), which corresponds with a 99% 
efficiency of the reaction. 
 
 
Figure 6.18. Calculation of the VARS2L primers amplification efficiency 
Efficiency of the amplification with VARS2L primers was determined using qPCR with 
serial dilution of the cDNA template (10-3 - 10-6). The averaged CT (from 3 technical 
replicates) was calculated for each template dilution and plotted against the log of its 
concentration to generate a standard curve. The equation with a calculated slope of the 
standard curve is boxed above the trendline.  
 
After the validation of the efficiency, primers were used for the actual 
experiment investigating the VARS2L overexpression in the cell samples used 
in ribosome profiling. The previously prepared cDNA samples (uninduced T1V1 
“-Tet”, induced “+Tet”, and 143B control) were used as templates without 
dilution. The 18S rRNA served as a reference gene. The conditions of the 
reaction were the same as described (2.4.4). The averaged CT for VARS2L was 
compared between uninduced and induced cell lines and normalized to the 
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reference gene. The difference in expression of VARS2L was calculated using 
the following equation (Livak and Schmittgen, 2001):  2!∆∆!!!! 
where: ∆∆!!! = !!!(!"#$!!)!! − !!!!(!"!) ∆!!!(!"#$!!) = !!!(!"#$!!,!!! !"#)!! − !!!!(!"#$!!,!!!–!"#) ∆!!!(!"!) = !!!(!"!,!!! !"#)!! − !!!!(!"!,!!! !"#) 
 
The difference in the VARS2L mRNA levels between the induced and 
uninduced T1V1 cell line in both ribosome profiling experiments was 1.08 and 
1.09 fold respectively. This indicated that in the supposedly induced cells the 
transcript levels were not significantly higher than endogenous levels. In order 
to identify the changes to mitoribosome profiles that could be caused by the mt-
tRNAVal deficiency, the T1V1 profiles had to be compared to 143B parental 
control. 
Since these results indicated that there was no increase in VARS2L expression 
in any of the induced samples it meant there was no potential for rescue of the 
deleterious phenotype. This meant that without the VARS2L overexpression 
both T1V1 cell lines used in ribosome profiling experiments could only be 
treated as replicates of the mutant cell line. The analysis of VARS2L expression 
was also conducted on samples (induced and uninduced T1V1 cell lines) from 
the second ribosome profiling experiment. Results confirmed the lack of VARS2 
overexpression in the induced sample. It was, therefore, excluded from the 
analysis and the uninduced T1V1 cells were compared against wild type 
control. It is not uncommon for cell lines to stop expressing proteins, particularly 
in lines that do not utilize the Flp-In cassette, as was the case with these lines. 
The cell line tested originated from one frozen aliquot that had been maintained 
in culture over an extended period of time. To investigate if other, previously 
preserved aliquots of T1V1 cells still retained the ability to inducibly express 
VARS2L, 3 more cell samples were tested. These were all aliquots of T1V1 
cells but handled and stored by different people prior to my experiments. For 
the sake of this experiment they were labeled: “DYG” (frozen by Dyg Pertiwi 
Kamal), “HTH” (Dr. Hue Tran Hornig-Do) and “MW” (myself; the aliquot frozen 
before the ribosome profiling experiments). After three days of induction with 
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tetracycline, the total RNA was isolated and converted to cDNA as described 
above. Levels of VARS2L expression were tested and calculated by qPCR. 
Comparison of the results between induced and uninduced cells showed that 
only the “DYG” sample displayed an increase in expression of VARS2L to a 
level of 150% of control (Fig. 6.19 A). In order to eliminate inactive tetracycline 
as the cause, a parallel 3-day induction of the HEK-C12orf65-FLAG cell line 
was performed using the same aliquot of the reagent. Total cell lysate from 
induced and uninduced cells was separated by 15% SDS-PAGE and analysed 
via western blotting with antibodies specific to FLAG. The strong signal from 
C12orf65-FLAG samples (Fig. 6.19 panel B, lanes 1 and 3) indicates that the 
activity of the tetracycline aliquot used in experiments was sufficient to induce 
overexpression. Absence or a very low level of VARS2L expression in tested 
cell aliquots was not caused by inactive tetracycline. 
 
Figure 6.19. Screening for the VARS2L expression in different T1V1 cell 
aliquots 
VARS2L induction was tested in three aliquots of T1V1 cell lines (DYG, HTH and MW), 
handled and stored in liquid nitrogen by different people, prior to the ribosome profiling 
experiments. Induction with 1 µg/mg tetracycline was conducted for 3 days, after which 
the levels of VARS2L transcript were measured with qPCR. A. Expression of VARS2L 
in induced cells was calculated based on the VARS2L levels normalized to 18S rRNA 
levels and represented in relation to endogenous expression in uninduced cells. B. 
Tetracycline activity was confirmed in a parallel experiment on HEK293 cell line stably 
transfected with C12orf65-FLAG. Total cell lysate (50 µg per lane) of both un- (lanes 2 
and 4) and induced cells (lanes 1 and 3), was subjected to western blot analysis with 
antibodies specific to the FLAG tag. Detection of porin served as a loading control. 
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6.7. Generation of a WARS2 in pcDNA5/FRT/TO construct as a part of 
the collaboration with Professor Agami 
The collaboration with Prof. Agami’s group also involved a contribution from my 
host laboratory that would further substantiate their mitoribosomal profiling data. 
The objective of this work was to assist in the generation of a cell system similar 
to T1V1, where low levels of a given mutant mt-tRNA could be rescued by 
inducibly overexpressing the cognate aa-tRNA synthetase. The chosen subject 
for this system was the cell line harboring the homoplasmic mutation in mt-
tRNATrp that had been used as the model for mitoribosome stalling in the 
publication (Rooijers et al., 2013). The potential rescue mechanism required 
generation of the construct containing mitochondrial tryptophanyl-tRNA 
synthetase (WARS2) in pcDNA5/FRT/TO vector. This construct could then be 
used for either transient or stable transfection of mammalian cells. The insert, 
comprising the full length WARS2 CDS (1082 bp), was generated via PCR from 
the pool of cDNA derived from 300 ng cell total RNA (2.3.1). Primers for this 
reaction were designed to include restriction sites for HindIII and XhoI enzymes 
at the 5’ and 3’ termini respectively (Fig 6.20). The FLAG encoding sequence 
was also added so that the resulting protein was tagged at C-terminus and was 
easily detected via western blotting.  
 
 
Figure 6.20 Primers for WARS2 cloning 
Primer sequences were designed to amplify full length WARS2 ORF. Highlighted are 
the digestion sites for the restriction enzymes (HindIII and XhoI) and the sequence 
encoding a protein tag (FLAG). 
 
The insert was cloned into pcDNA5/FRT/TO vector via the XhoI/HindIII sites 
(2.3.4). Transformation of E. coli α- select chemically competent cells (2.2.1) 
with the generated construct resulted in 5 clones (designated as clones 5, 
5’- CTCTCTAAGCTTATGGCGCTGCACTCAATGC- 3’
5’- CACACACTCGAGCTACTTATCGTCGTCATCCTTGTAATCCACCAATTTCTTCACCTCC - 3’
HindIII
XhoI FLAG
WARS2BOB-For
WARS2-Rev
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12, 13, 14, 16) that contained the full length of the insert (Fig 6.21 A lanes 7, 14, 
15, 16 and 18). The correct integration and orientation of the insert in all 5 
clones was confirmed by PCR amplification with the primers specific to the 
vector sequences flanking the insert (Fig. 6.10 C). Finally Sanger sequencing 
(2.3.9) of the isolated plasmids revealed that only clone 13 contained no 
mutations and therefore it was suitable for use in transfection of cell lines. The 
plasmid isolated from that clone was sent to the Netherlands Cancer Institute 
for future applications. 
 
 
Figure 6.21. Cloning of the WARS2 into pcDNA5/FRT/TO 
A. Plasmids isolated from 18 clones selected after transformation were digested with 
HindIII and XhoI enzymes (2.3.4) to confirm the presence of the insert (indicated by the 
arrow, (~1.1 kbp). An empty pcDNA5/FRT/TO vector digested with HindIII and XhoI 
was used as a negative control (lane 2).  B. PCR products generated with vector 
specific primers flanking the insert (CMV-For and BGM-Rev, see Table 6.18) were 
separated by agarose gel (1%) electrophoresis to confirm the expected size of the 
insert in plasmids from 5 positive clones. The product is indicated by the arrow (> 1.1 
kbp).  
 
Table 6.18. PCR primers for pcDNA5/FRT/TO vector 
Name Sequence (5’-3’) 
CMV Forward CGCAAATGGGCGGTAGGCGTG 
BGH Reverse TTAGAAGGCACAGTCGAGG3 
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6.8. Discussion 
The changes to the mitoribosome profiling protocol that was developed for the 
sequencing with the IonTorrent (Ch. 5) were necessary, as it did not yield 
satisfactory results. Therefore, as a result of a collaboration with Prof. Agami’s 
group, an entirely different protocol was introduced. This method characterized 
with simplified footprint generation step (6.2) and a library preparation method 
(6.3), with separate ligation reactions followed by electrophoresis, that allowed 
monitoring of the amount of product at most of the steps. Protocol was proven 
to be successful in analyzing mitochondrial translation including stalling of the 
mitoribosomes (Rooijers et al., 2013). The cell line selected to test this protocol, 
named T1V1, was characterized with lower level of aminoacetylated form of mt-
tRNAVal (Hornig-Do et al., 2014). This was a potential reason for mitoribosomes 
to stall on valine codons. The ability of T1V1 cell line to inducibly express 
VARS2L was an additional advantage as it provided the opportunity to perform 
the rescue experiment (Hornig-Do et al., 2014; Rorbach et al., 2008b). 
Therefore, this cell line was appropriate for first mitoribosome profiling 
application and to test the hypothesis of tRNA-induced stalling. The goal was to 
compare the mitoribosome profiles of uninduced T1V1 mutant cells with 
VARS2L-expressing cells and wild type control. Special focus was on the valine 
codons and the potential increase in mitochondrial ribosome footprints (RFs) 
accumulation. Unfortunately the rescue experiments (samples labeled ‘T1V1 
Tet+’) were not successful as the induction of VARS2L expression failed. The 
loss of expression of the introduced gene in stable cell lines is not uncommon. 
While T1V1 cell line was generated, the stable transfection of VARS2L was 
performed on trans-mitochondrial cybrids containing the mt-tRNAVal mutation 
(Rorbach et al., 2008b). This was not a Flp-In TRex cell line, which would 
contain the Flp cassette, hence it did not allow to control where the expression 
vector was integrated. With continuous passages of the cells, especially if the 
selection conditions (blastocidinS addition to the medium) were not rigorously 
kept it is possible for the cell line to cease the expression of the introduced 
gene. Careful handling and extended monitoring of the expression levels for 
these cell lines would be advised if they will be used in the future.  
However, even without the functional rescue system, the analysis of generated 
data was possible. Both mutant cell lines (Tet- and Tet+), treated as repeats of 
the same sample, were compared to the wild type control (ribosome 
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profiling data from (Rooijers et al., 2013). Investigation of the potential stalling 
due to the deficiency of the valyl-tRNA was commenced with identification of 
the footprints derived from mitoribosomes that were currently translating valine 
codons. This required estimation of the position of A-site in mitoribosomal 
footprints. In cytosolic ribosome profiling it was observed that within a given 
CDS the footprints’ 5’ ends would start abruptly 12 to 13 nt upstream of the start 
codon, corresponding to the position of the initiating ribosome. This observation 
led to the estimation of the A-site position within footprints as 15-16 nt from the 
5’ end (Ingolia et al., 2009). This method, however, could not be applied to the 
mitoribosome profiling data generated with the described protocol. Since human 
mitochondrial transcripts characterize with very short (maximum 3 nt) 5’ UTRs 
(Anderson et al., 1981), mitoribosomes at the initiation stage possibly overhang 
from the 5’ end of the mRNA. Therefore the fragment protected by the initiating 
mitoribosome is predicted to be much shorter (approximately 18 nt). The size 
selection step of the RNA fragments (6.2 and Fig. 6.2) includes only sequences 
between 25-35 nt so the footprints of the mitoribosome during initiation were 
most likely not selected. 
Different offsets of valine-coding sequences were tested (with 5’ at any possible 
position within RFs). The difference in the number of RFs between the mutant 
and control cell lines was visible when valine codons were positioned beginning 
at 17 nt, (Fig 6.6 B and 6.7). This position was assumed to be the beginning of 
the mitoribosomal A-site. The RFs with valine codon occupying it were treated 
as derived from the ribosomes in the state of translating and incorporating 
valine into the nascent polypeptide. The higher number of RFs with A-site valine 
codon suggested that the deficiency of charged tRNAVal was possibly causing 
mitoribosome stalling at Val sequences.  
It is also possible that the type of the valine codon was influencing the potential 
valine-related stalling. In mutant cell lines, higher proportion of RFs with A-site 
valine contained the GTC codon (Fig. 6.8), even though it was not the most 
abundant valine triplet in human mtDNA (Fig. 6.9 B). In control cell line majority 
of these RFs contained the GTA codon at A-site, which was consistent with its 
frequency in mtDNA. The possible explanation for this result was that with the 
lower levels of charged mt-tRNAVal the stalling time of the mitoribosome over 
valine codon would be increased because of the wobble base pairing of the 
GTC (5’-3’) and CAT (3’-5’) of tRNA’s anticodon. Similar situation was 
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observed in C. elegans where the G:U wobble base pairing caused 
accumulation of ribosomes higher than during G:C pairing (Stadler and Fire, 
2011). However, if the potential stalling of mitoribosomes on valine codons in 
T1V1 cell lines was visible analyzing the A-site valine RFs, it was not evident in 
the general mitoribosome profiles. The changes to the distribution of RFs (all 
aligned footprints, Fig. 6.10 A) across mt-transcripts between T1V1 and control 
did not coincide with the position of most-valine rich sequences (Fig. 6.10 B). 
The tRNA-induced staling, if present, was not affecting the global distribution of 
mitoribosome footprints.  
Interestingly in the repeated mitoribosome profiling experiment the valine 
codons had even less influence on stalling position of mitoribosomes. These 
samples (both T1V1 and control) had a very high abundance of RFs generated 
from the 5’ end of the COX2 open reading frame. It obscured the pattern of 
valine position in RFs from T1V1 that in first experiment contained valine at 
position 17 (estimated mitoribosomal A-site) at much higher level than control 
(Fig. 6.6). The preponderance of GTC A-site codons over GTA in T1V1 cells 
was, however, present but to a lower extent (Fig. 6.12). The usage of valine A-
site codons in control was as seen in the first experiment (Fig. 6.8). 
The prevalence of 5’ end of COX2 was visible when analysing the number of 
RFs with specific amino acids in regards to their position within footprints (Fig. 
6.13). This effect was shared by both T1V1 and control cell lines. The majority 
of RFs contained methionine codon at their very 5’ end (M), followed by the 
alanine starting 3 nt downstream (A), then histidine (H), finally forming a 
sequence that could be translated into first 9 codons of COX2 (MAHAAQVGL). 
The analysis of RFs originating from COX2 (Fig. 6.14) and their specific 
distribution across the template (Fig. 6.15) showed that indeed the number of 
RFs at the 5’ end of ORF surpasses those from other position. The general 
number of RFs from COX2 is high in comparison to other ORFs and vast 
majority of these footprints comes from the 5’ end sequence, which justifies the 
influence on amino acid coding sequences. None of the cell lines analysed in 
the first experiment showed such high proportion of RFs at the 5’ terminus of 
COX2 (Fig. 6.15). Therefore the imbalance in favor of COX2 RFs was not 
observed.  
The complementary RNAseq analysis allowed additional analysis of the 
translational efficiency. It enables comparison of the amount of ribosome 
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footprints between the ORFs eliminating the influence of the template levels. 
The most interesting results were obtained for ND5, which was characterized 
with the highest TE value in both cell lines (Fig. 6.17 A and B) due to high RFs 
abundance (Fig. 6.14) in comparison to low levels of MT-ND5 transcript (Fig. 
6.16). Therefore, it resulted in a very high TE value, which could be interpreted 
as though ND5 is translated at a very high rate. When comparing the TE value 
between T1V1 and control cell lines, the TE value for the former is 2x higher 
than in control, which would correspond to even grater efficiency of translation. 
However, analysis of de novo mt-protein synthesis in T1V1 cells performed by 
Hornig-Do and colleagues showed that levels of newly-synthesised ND5 are 
lower than in control (Hornig-Do et al., 2014). If ND5 is indeed translated at 
higher rate in T1V1 cells, its turnover rate must be very high. Alternatively, the 
high amount of ribosome footprints generated from ND5 ORF is a result of 
mitoribosome stalling. The later could be explained by the high number of valine 
codons present in MT-ND5, which could induce stalling in T1V1. 
In conclusion, the general pool of RFs in repeated experiment was dominated 
by COX2 5’-terminal sequences. This cell line- independent effect was not 
observed in the first experiment. It is possible that this result was caused by a 
bias during the ligation or amplification step. The higher than expected level of 
contamination with non-mRNA sequences and therefore smaller pool of 
mitoribosomal footprints in repeated experiment (approximately 5 x104, Table 
A1, samples ‘2934 1 and 2’) could be the one of the factors that makes it more 
prone to bias. In order to increase the reliability of the results the mitoribosome 
footprint retention should be improved, for example by depletion of rRNA from 
cDNA pool via hybridization to biotinylated complementary probes. After the 
removal of hybridized rRNA (through streptavidin affinity) the amplified pool 
would be enriched in mRNA, and increase the number of informative sequence 
data. !  
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! 199 
7.1. Introduction 
The questions that my project repeatedly posed referred to potential quality 
control and ribosome rescue systems that operate in human mitochondria. To 
obtain a better understanding of these mechanisms and to identify the potential 
factors involved (namely C12orf65) was a motivation to implement ribosome 
profiling on human mitochondria. However, quality control and rescue of stalled 
mitoribosomes are not the only aspects of mitochondrial translation that are still 
undefined. In fact the knowledge of the molecular mechanisms governing 
protein synthesis in human mitochondria is very superficial. Many basic steps of 
this process, which are well described in bacteria or in eukaryotic cytosol, 
remain unrevealed for mitochondria. There are various reasons for this, one of 
which is the lack of a well-established in vitro system to conduct the necessary 
investigations. So far, despite the numerous attempts, no reliable, complete in 
vitro system for mitochondrial translation has been established (Christian and 
Spremulli, 2012; Chrzanowska-Lightowlers et al., 2011). The knowledge 
generated up to now is based on in vitro experiments that used purified 
mitoribosomes and a few factors that may not constitute the actual components 
operating in vivo (Chrzanowska-Lightowlers et al., 2011). A further difficulty with 
working on mitochondrial gene expression is the lack of proven successful 
method of transforming human mitochondrial DNA. Without the ability to 
manipulate the mitochondrial genome scientists must rely on patient cell lines 
carrying a specific mtDNA mutation. However, access to such cell lines can be 
limited and the investigation is restricted to only the particular defects that arise 
and not those that might be designed to help determine molecular mechanisms, 
leaving no flexibility to the experiments. All of the factors mentioned above 
contribute to the fact that our understanding of the mechanisms regulating 
mitochondrial translation is very limited. That is why, in order to broaden our 
knowledge of mitochondrial protein synthesis, it was necessary to devise an 
alternative experimental approach. Ribosome profiling provides a suitable tool 
to thoroughly investigate mitochondrial protein synthesis as it provides a 
genome-wide analysis of translation in vivo, which has not yet been achieved 
with previous methods. The analysis of the ribosome profiling results usually 
focuses on 3 main themes: 1) identification of the sequences that were actively 
translated (rather than pre-selected candidates), 2) monitoring of the protein 
synthesis (speed of ribosome progression) and maturation in vivo, 3) 
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measuring the efficiency of the translation (and how it is regulated) (Ingolia, 
2014). These 3 approaches could be applied equally well to mitochondrial 
translation. The first and so far the only published data on ribosome profiling in 
mitochondria focuses on technical aspects of the methodology and general 
quality of data only (Rooijers et al., 2013). The characterisation of the typical 
features of mt-translation was not an objective of this study. Therefore the gap 
in our knowledge of mitochondrial gene expression in humans is still open. The 
analysis of mitoribosome profiles could potentially serve to characterize 
common features of mt-translation. For example it could identify regions within 
transcripts that accumulate high numbers of mitoribosomes. This would help 
understand what causes a decrease in mt-translation elongation. In addition to 
investigating local differences in mitoribosomal distribution a total number of 
ribosome footprints per transcript can be informative. When compared with the 
levels of mt-mRNAs expression, the abundance of mitochondrial ribosome 
footprints (RFs) could provide the information of each transcript’s translation 
efficiency. Finally, identification of unusual translational events is one of the 
most important features of ribosome profiling analysis (Ingolia, 2014). Since 
mitochondrial transcripts do not contain long sequences upstream the initiation 
codon (Anderson et al., 1981) they cannot be considered as templates for 
unanticipated translation as described in eukaryotic cytosol (Ingolia et al., 
2009). However, there are other regions in mitochondrial transcripts that can be 
investigated with this method, for example the overlapping sequences of the 
bicistronic transcripts including that which encodes MT-ATP8 and MT-ATP6. 
Detailed analysis of the mitoribosome profiles from this region could help shed 
new light on the mechanisms of translation from the bicistrons with overlapping 
open reading frames.  
In the final part of my project I applied the optimized ribosome profiling to the 
cell line after C12orf65 depletion. The protocol was proven successful in 
analysis of the stalled mitoribosomes in the mt-tRNAVal mutant cell line, as 
described in chapter 6. The mitoribosome profiles generated were compared 
between the two samples (C12orf65- depleted and control) and between 
individual transcripts. Although it was later discovered (chapter 3) that the 
depletion level obtained with siRNA treatment is not sufficient to generate 
visible changes to mitochondrial translation, mitoribosome profiling results were 
not discarded. The analysis was continued hoping that changes to 
! 201 
mitochondrial gene expression, not detected with metabolic labelling and 
northern blot, would be visible in mitoribosome profiles. Finally, in case there 
were no differences between the depleted and control samples, the generated 
data would be a valuable source of information about the normal distribution of 
mitoribosomes. 
In addition to the ribosome profiling, a parallel RNAseq experiment was 
performed on the same RNA samples. The ribosome profiling results were 
complemented with the corresponding RNAseq analysis in order to compare 
the efficiency of each mt-mRNA translation. 
 
7.2. Generation of the footprints and sequencing library 
For this experiment wild type HEK293 cells were seeded in 12x diam. 15 cm 
dishes. Out of these 12 dishes, 6 were treated with C12orf65 siRNA (siC12) and 
the other 6 with non-targeting siRNA (NT). The protocol was as described in 
(2.1.4) but scaled up for the much bigger volume of used dishes. Thus, 4.5 ml 
of OptiMEM, 66.6 µl of siRNA (20 µM) and 36 µl lipofectamine were used per 
dish. The treatment lasted 3 days and was followed by the preparation of the 
mitoribosome footprints, which was conducted as described in the previous 
chapter (6.2).  
Briefly: Cells were first treated with chloramphenicol (100 µg/ml) for 15 min in 
order to inhibit the translation elongation and secure ribosomes at the place 
they were currently translating. After the incubation the cells were washed with 
PBS-chloramphenicol, stripped and pelleted. For each condition 1 dish was 
used for the RNAseq analysis, where cell pellets were resuspended in 5 ml 
Trizol and stored at -20°C. Before freezing, from each sample 0.5 ml of the 
Trizol cell solution was taken and stored in a separate tube at -20°C for the 
qPCR to analyse C12orf65 depletion levels. For the ribosome profiling the 
remaining 5 dishes per conditions were used and these cells were lysed with 
the lysis buffer (1-1.2 ml, 20 mM Tris-HCl pH 7.8, 10 mM MgCl2, 100 mM KCl, 
1% Triton X-100, 1X complete protease inhibitor, 2 mM DTT, 100 µg/ml 
chloramphenicol) according to the protocol described in more details in 6.2. The 
clarified lysed (after centrifugation 10 min, 560 xg, 4ºC) was subjected to the 
RNase 1 digestion (Ambion, final concentration 2.5 U/µl) for 45 min at room 
temperature with agitation. This step was necessary to remove the mRNA, 
which was not protected by ribosomes, i.e. not actively translated. Samples 
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after the RNase treatment were separated on the 7 – 47% isokinetic sucrose 
gradient. The gradient samples were prepared prior to the experiment (details in 
6.3), the composition of the buffer was as follows: 20 mM Tris-HCl pH 7.8, 10 
mM MgCl2, 100 mM KCl, chloramphenicol (100 µg/ml) and DTT (2 mM). The 
whole of the lysate treated with RNase 1 was loaded on to the top of the 
gradient, tubes were then balanced and topped up with the lysis buffer to give a 
final and identical volume of 13.4 ml. The centrifugation was performed in the 
Beckman ultracentrifuge (SW40Ti rotor) at 35300 rpm (221632 xg), 4ºC for 2 h, 
with maximum acceleration and minimum deceleration. Next, samples of 935 µl 
were taken from top to bottom giving 14 fractions. From each fraction 20 µl was 
saved for the western blotting analysis in order to identify fractions containing 
the monosomes with protected mRNA fragments (ribosome footprints, RFs). 
Immunodetection with DAP3 (small subunit protein) and MRPL3 (large subunit 
protein) antibodies allowed confirmation of which sucrose gradient fractions 
contained mitoribosomes and therefore the RFs. Fractions 3 – 6, where the 
anticipated position of the mitoribosome was, were then treated with proteinase 
K (0.2 mg/ml proteinase K, 1% SDS for 30 min at 45ºC). For storage and 
subsequent RNA isolation, Trizol LS reagent was added to each sample in 
proportion of 3:1.  
 
Figure 7.1. Separation of mitoribosomes by isokinetic sucrose gradient 
centrifugation 
Cell lysates from HEK293 cells treated with C12orf65 siRNA (siC12orf65) or non-
targeting siRNA (siNT) were subjected to digestion with RNase 1. Both samples were 
separated on 7 - 47% sucrose gradient and after ultracentrifugation divided into 14 
fractions. Each fraction was subjected to western blotting with antibodies specific to 
small and large mitoribosomal subunits (DAP3 and MRPL3 respectively). Fractions that 
contained monosomes were defined by presence of signal from both proteins (box 
labelled “55S”). 
   2   3    4   5    6    7  8   9  10  11  12 13 14 
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The position of the mitoribosomes and potentially their RFs was estimated 
based on the presence of a strong signal from both mitoribosomal proteins (Fig. 
7.1, DAP3, MRPL3). All fractions taken from both samples were analysed, 
except for the fraction 1 from the siC12orf65 sample, which was unfortunately 
lost during the fractionation. The position of the monosome was assigned to 
fractions 4 – 6 (Fig. 7.1, boxed and labelled “55S”) in both samples. The RNA 
was isolated from these selected fractions. 
 
Library preparation 
The selected fractions from the sucrose gradient (3 – 6) were pooled and then 
RNA isolated (as described in 6.3, ‘Size separation of mitoribosome footprints’). 
The RNA pellets were resuspended in 10 µl Gel loading buffer II (Ambion) and 
separated on a 10% denaturing PAG along with the ssRNA low range marker 
and 24-35 nt oligo size markers (sequences tabulated in Table 6.3). The 
composition of the gel (Table 6.2) and the electrophoresis conditions were as 
described in 6.3. 
 
Figure 7.2. Isolation of mitoribosome footprints by size separation 
Mitoribosome footprints were generated from cells treated with C12orf65 (siC12, lane 
2) or non-targeting (NT, lane 4) siRNA. Total RNA was isolated from selected sucrose 
gradient fractions that contained mitoribosomes, and separated on 10% denaturing 
polyacrylamide gel. Low range ssRNA ladder (lane 1) and two  were used (24 and 35-
nt size, lane 5) as size markers. The RNA oligomers marked the borders of the area 
that was excised from each sample (lanes 2 and 4) as they spanned the expected size 
of the ribosome footprints.  
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From each sample (Fig. 7.2 lanes 2 and 4) a small area (Fig. 7.2, 25-35 nt, 
depicted by brackets and labelled “Predicted RFs size”) was excised and RNA 
extracted (as described in 6.3). RFs were predicted to be among these 
fragments, as it corresponded to their observed size (Rooijers et al., 2013) as 
described in 6.3. The eluted RNA was then precipitated in 96% ethanol 
supplemented with glycogen and the RNA pellet was resuspended in 25 µl of 
3’-dephosphorylation reaction mix (Table 6.4 and 6.5). This step was necessary 
to remove the residual phosphate moieties left on the 3’ ends by the RNase 1 
treatment and to facilitate the ligation of the first linker to the RNA fragments. 
The conditions of the dephosphorylation reaction as well as the subsequent 
purification of its products by Trizol isolation are described in 6.3. The RNA 
pellets precipitated after Trizol purification were resuspended in 15 µl of the 3’ 
end ligation mix (composition in Table 6.6). The reaction was performed for 2.5 
h at 37ºC with agitation. In parallel to the experimental (siC12) and control (NT) 
samples, both size marker oligos (24 and 35 nt) were also subjected to ligation 
(as described in Table 6.6). The products of their ligation served as a positive 
control and generated the correctly sized markers to facilitate the selection of 
correctly ligated sample products. The products of the 3’ ligation were size 
separated by denaturing 10% PAGE (as described earlier and in 6.3). The 
comparison with the positive control (Fig. 7.3 A, Contr.) showed that the ligation 
in both samples (Fig. 7.3 A, siC12 and NT) had been successful. The products 
that had increased in size to 45-55 nt (Fig. 7.3 A, depicted with brackets, 
labelled ‘Ligation products’) from both experimental samples (siC12 and NT) 
and positive control (Contr.) were extracted from the gel (as described in 6.3). 
The precipitated RNA from each of these 3 samples was then phosphorylated 
at the 5’ end by resuspension in 14 µl of phosphorylation reaction mix (Table 
6.8). Reactions were performed for 30 min at 37ºC with agitation. 
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Figure 7.3. Isolation of successful 3’ and 5’ linker ligation products by size 
separation 
A. The ligation reaction of the 3’ linker and isolated RNA fragments (potential ribosome 
footprints) was separated by 10% denaturing SDS PAGE. Reactions were performed 
on RNA fragments from C12orf65 siRNA treated (siC12, lane 2), non-targeting siRNA 
treated (NT, lane 4) and a positive control of the ligation reaction (Contr. lane 6), which 
facilitated selection of the correct sized products (depicted by brackets). Low range 
(lane 1 ssRNA) and oligo (lane 7) size markers were used. B. The reaction of the 
ligation of the second linker (5’ linker) was also separated by 10% denaturing SDS 
PAGE. Samples are as for A; siC12, lane 9; NT, lane 11 and the positive control, lane 
13. All were subjected to ligation and the correct sized product is depicted by brackets. 
The low range ssRNA marker (lane 8) and 25-25 oligo size markers (lane 14) were 
used as in A. 
 
After the phosphorylation step, the RNA was Trizol purified (details in 6.3) and 
then it was subjected to the ligation of the 5’ end linker (as described in 6.3 
‘Phosphorylation of 5’ ends and ligation of the 5’ linker’ and Tab.6.9). The 
products of the 5’ end ligation were also size separated by 10% denaturing 
PAGE. In the positive control sample (Fig. 7.3 B, Contr.) and both experimental 
samples (Fig. 7.3 B, siC12 and NT) the products of the expected 65-75 nt size 
were present (Fig. 7.3 B depicted by brackets and labelled ‘Ligation products’). 
This result confirmed that the ligation was successful, and the area of the gel 
with correctly sized products was extracted (Fig. 7.3 siC12 lane 9; NT lane 11). 
The RNA was eluted from the gel pieces and precipitated as described in 6.3. 
The pellets of the precipitated RNA were resuspended in 8 µl of the nuclease-
free H2O and used in the reverse transcription reaction (components and 
conditions listed in Table. 6.10). After the reverse transcription, samples were 
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treated with 1 µl RNase H for 1 hour at 37ºC and purified with illustra Microspin 
G-50 spin columns (GE Healthcare) according to the manufacturer’s 
instructions. Next, the resulting cDNA was amplified in the PCR reaction with 
primers specific to the linker sequences ligated to each end of the templates 
(reaction conditions in Tables 6.11 A and B, primer sequences in Table 6.12 B). 
A single forward primer (termed mtRPPCR RP1) was used for both samples, 
whereas 2 different reverse primers were added to each sample (termed 
mtRPPCR RPI3 and 4). The reverse primers varied in the embedded index 
sequence (depicted by brackets in Table 6.12 B). The PCR products were 
purified with Qiaquick PCR purification kits (Qiagen, 28106) as described in 6.3. 
The purified products were separated using the E-GEL Invitrogen system 
(G6400EU) with E-GEL EX with SybrGold 2% SizeSelect precast gel (Invitrogen 
G661002) according to the protocol described in 6.3. Samples were 
electrophoresed together with the 25 bp size marker (diluted to 200 µg/µl with 
nuclease-free water and stored at -20ºC, Invitrogen 10597-011). The size 
selected dsDNA library products (approximately 130 bp in length) were 
resuspended in 25 µl of nuclease free water (added to the second row of wells, 
see 6.3.) and stored at -20ºC for shipment to Netherlands Cancer Institute 
(NKI), Amsterdam. The sequencing of the samples was performed in NKI’s 
Genomics Core Facility with Illumina HiSeq2000 system. 
 
7.3. Bioinformatics analysis of results 
Before the sequencing results were obtained, the level of the C12orf65 
depletion was determined with qPCR following reverse transcription with 
random hexamer primers (SuperScript® III First-Strand Synthesis System, 
2.4.3) and analysed using C12orf65 –specific primers (C12RTFor and 
C12RTRev) as described in 3.5. 
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Figure 7.4. Determination of the level of C12orf65 depletion in the 
ribosome profling experiment 
RNA from cells cultivated and treated in parallel to the ribosome profiling experiment 
was isolated and analysed with qPCR to estimate the level of C12orf65 depletion. 
C12orf65 levels were normalized to 18S rRNA levels and represented in relation to the 
expression in NT cells.  
 
The results of the qPCR show that after 3 days of depletion with siC12orf65, 
approx. 30% (in comparison with NT control) of the C12orf65 still remained 
(Fig.7.4, ‘siC12’). Although, the experiments described in 3.6 and 3.7 clearly 
show that 70% of depletion may not be enough to induce changes to 
mitochondrial translation, these experiments were performed later than 
ribosome profiling. Therefore, at the time of this profiling experiment there was 
no cause for concern regarding depletion levels. In order to investigate if the 
level of depletion could cause changes to the mitoribosomal profiles, the 
sequenced data was analysed. 
The bioinformatics analysis of sequencing results was performed by Dr. Fei 
Gao according to the protocol developed by Dr. Bashton, as described in 6.4. 
The adapter sequences at the 3’ end were removed with Cutadapt, then the 
trimmed reads were aligned with the decoy collective tRNA / rRNA reference 
sequences using bowtie2. The reads that did not align to the decoy sequences 
(*_screened.fastq) were aligned with actual reference genome, human mtDNA 
(HumanMT) with bowtie2. The resulting *.sam files were devoid of multimapping 
reads (with samtools view) and next converted into *.bam files (samtools sort). 
Finally the *.bam files were indexed (samtools index). As observed in ribosome 
profling experiments on T1V1 cell line (6.4), the final number of reads that 
aligned to mt-mRNAs was low (approximately 2 x104, Appendix 1.4, Table A1 
‘2934_3_ siC12_RP1 and 4_siNT’). 
0
0.2
0.4
0.6
0.8
1
1.2
siC12 NT
C1
2o
rf6
5 
le
ve
l i
n 
re
la
tio
n 
to
 N
T
! 208 
The downstream analysis of the aligned reads, which contained a pool of the 
mitochondrial ribosome footprints (RFs) was collaboratively performed by Dr. 
John Grady and Dr. Fei Gao using R software.  
 
Amino acid position within RFs 
One of the interesting observations derived from the data obtained from 
ribosome profiling analysis of T1V1 cell line was unexpectedly high proportion 
of RFs from 5’ terminus of COX2 ORF, namely MAHAAQVGL sequence (Fig. 
6.13 and 6.15). It was determined by analysis of the position of different amino 
acid codons in RFs (Fig. 6.13). In order to investigate if the same pattern would 
be present in this experiment, a similar analysis (as in 6.4, ‘Repeat of 
mitoribosome profiling on T1V1 cell line’) was performed on siC12orf65 and NT 
cell lines (Fig. 7.5). The number of RFs with specific codons located at any 
given position was calculated for methionine, alanine, histidine, glutamine, 
valine, glycine and leucine encoding sequences (without distinguishing between 
particular triplets). Position of codons for each of these amino acids was plotted 
separately. Apart from siC12orf65 and NT cell lines, the plots were generated 
for the T1V1 and control cell lines (from both experiments) for comparison. 
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Figure 7.5. Comparison of different amino acids’ positions in RFs shows a 
dominant pattern  
Plots showing quantification of RFs with specific amino acid (M, A, H, Q, V, G and L) 
codons at various positions in siC12orf65 and non-targeting control cell lines. The 
T1V1 and control cell line data from previous experiments (6.4 and 6.5) were also 
included. The x axis representing different offsets of all RFs containing one type of 
valine codon which 5’ end starts at any given position (1-30 nt, in 5’ –> 3’ direction) in a 
predicted-sized footprint. The y axis represents a number of RFs with specified codon 
starting at each particular position. This number is presented as a percentage of all 
footprints with an amino acid codon starting at that position. The original plots were 
generated by Dr. John Grady. 
 
As in case of the results of repeated ribosome profiling on T1V1 there was a 
high number of RFs containing the MAHAAQVGL sequence. However their 
proportion in the total pool of all RFs was even higher in the siC12orf65 and NT 
cell lines than in the T1V1 and control. Therefore, the next step in analysis was 
to quantifiy the number of RFs originating from separate mt-ORFs. 
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Distribution of ribosomes between transcripts 
The comparison of the number of RFs aligning to each mitochondrial transcript 
was performed on data from both siC12orf65 and NT cell lines. For each of the 
mt-mRNAs including the overlapping fragments open reading frames of MT-
ATP6 / MT-ATP8 and MT-ND4 / MT-ND4L, the number of RFs that originated 
from it representing the number of actively translating mitoribosomes, was 
calculated and presented as the percentage of the total number of 
mitochondrial RFs. The results were calculated for each mt-transcript in both 
cell lines and presented as histograms (Fig. 7.6 siC12orf65 treated ‘siC12’ and 
non-targeting control ‘NT’). 
 
 
Figure 7.6. The Ribosome Footprint abundance on each mt-ORF from the 
C12orf65 depleted and control cell lines 
The analysis was performed on data derived from cells treated with siC12orf65 (siC12) 
or non-targeting control (NT) siRNAs. The number of ribosome footprints (RFs) 
originating from mitochondrial ORF was calculated for each individual transcript. The 
results per ORF were presented as the percentage of the total number of mitochondrial 
RFs.  
 
Comparing the RFs abundance between the two samples there were no striking 
differences in the number of mitoribosome footprints on each mt-transcript. It is 
important to remember that these were results of one experiment so the 
moderate variations (as seen in MT-CO2) may be sample-dependant. When 
examining the results for individual transcripts it was clear that the highest 
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number of RFs originated from MT-CO1 (25% and 22%) and MT-CO2 (29% 
and 37%). 
Interestingly, there was also a number of RFs aligning to the overlapping region 
of MT-ATP8 and MT-ATP6 (MT-ATP8/6, Fig. 7.6). This 45 nt sequence is 
shared between 3’ end of MT-ATP8 and 5’ end of MT-ATP6. The number of 
RFs aligning exclusively in that overlapping region (2%) was comparable to 
those from MT-ATP8 (full length excluding the overlap) even though the 
overlapping fragment is much shorter than the rest of the ORF.   
 
Distribution of RFs within each mt-transcript 
The next analytical step was focused on how the RFs were distributed within 
individual transcripts. In order to investigate this, a separate mitoribosome 
profile was prepared for each mt-mRNA. The profiles were represented as 
histograms of RFs density across the length of the transcript. The number of 
mitoribosome footprints found at each point in the transcript was again 
expressed as the percentage of all annotated RFs. Patterns of RFs distribution 
were divided into 4 major groups based on the position of the major 
accumulation of RFs within the transcript: 1) within first 100 nt near the 5’ 
terminus (Fig. 7.7 and 7.8), 2) 5’ terminus but further then 100 nt (Fig. 7.9), 3) at 
3’ terminus (Fig. 7.10 and 7.11), 4) diverse (Fig. 7.12). These also show the 
variation between siC12orf65 depleted and non-targeting control (Fig. 7.6 
siC12, NT).  
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Figure 7.7. RFs distribution patterns showing accumulation near 5’ 
terminus (first 100 nt) bigger in C12orf65 depleted cells 
Distribution of the RFs across each mitochondrial transcript (mitoribosome profile) was 
presented as a number of RFs (percentage of all RFs in experiment, Y axis) aligning to 
each nucleotide position within a particular mt-mRNA. The X axis presents the length 
of the transcript in nucleotides and includes the mt-genome coordinates for each 
transcript. In order to facilitate comparison between the profiles, the x axis are of equal 
length, even though transcripts vary in length. The original plots were generated by Dr. 
Fei Gao. 
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The profiles that belong to the first category characterise with the highest 
number of RFs accumulated in the first 100 nt from the 5’ terminus. This 
number was greater in either siC12orf65 cells (Fig. 7.7) or NT control (Fig. 7.8). 
However, the predominance of RFs in either cell line, even if present at the 5’ 
terminus of a particular transcript, it was not necessary consistent across its 
whole length. As in case of COX3, CYTB and ND3 (Fig. 7.7) even though there 
was more RFs at first 100 nt in siC12orf65 cells, this proportion changed at 
different parts of the transcript. 
The highest accumulation of RFs at 5’ terminus in siC12orf65 cells was 
observed at COX1 and COX3 (Fig. 7.7). RFs from these two mt-mRNAs were 
also among the 3 most represented in total RFs pool (Fig. 7.6).  
 
 
Figure 7.8. RFs distribution patterns showing accumulation near 5’ 
terminus (first 100 nt) bigger in non-targeting cells 
Distribution of the RFs across each mitochondrial transcript (mitoribosome profile) was 
presented as a number of RFs (percentage of all RFs in experiment, Y axis) aligning to 
each nucleotide position within a particular mt-mRNA. The X axis presents the length 
of the transcript in nucleotides and includes the mt-genome coordinates for each 
transcript. In order to facilitate comparison between the profiles, the x axis are of equal 
length, even though transcripts vary in length. The original plots were generated by Dr. 
Fei Gao. 
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mitoribosomes. As discussed in 6.8, the fraction of mitoribosome fragments is 
expected to contain smaller RNA species than these selected for the library 
preparation. Therefore the accumulation of RFs at 5’ terminus is a result of 
other features of mRNA like specific amino acid codons that would attract 
higher numbers of mitoribosomes. However, it is also possible that the arrest of 
mitoribosomes near the 5’ terminus of these ORFs is a form of regulation of 
translation. 
The highest accumulation of RFs was not only observed at first 100 nt from 5’ 
terminus. In ND1 and ND4 it was also present further downstream. This form of 
mitoribosomal footprints could be associated with potential interactions of the 
nascent polypeptide with the exit tunnel of the ribosome. Or, perhaps would 
signify the slower progression of the ribosome due to the interactions of the 
emerging peptide with the outside factors (as chaperons). 
 
 
Figure 7.9. RFs distribution patterns showing accumulation further from 5’ 
terminus (beyond 100 nt) bigger in C12orf65 depleted cells 
Distribution of the RFs across each mitochondrial transcript (mitoribosome profile) was 
presented as a number of RFs (percentage of all RFs in experiment, Y axis) aligning to 
each nucleotide position within a particular mt-mRNA. The X axis presents the length 
of the transcript in nucleotides and includes the mt-genome coordinates for each 
transcript. In order to facilitate comparison between the profiles, the x axis are of equal 
length, even though transcripts vary in length. The original plots were generated by Dr. 
Fei Gao. 
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The regions of the highest accumulation of RFs were also observed at the 3’ 
terminus of mRNAs (Fig. 7.10 and 7.11). The length of these regions varied 
from less than 100 nt (Fig. 7.10, ND6) to over 350 nt (Fig. 7.10 ND5) and 
increased with the length of the transcript. In majority cases the accumulation at 
3’ terminus was more profound in siC12orf65 treated cells (Fig. 7.10) but in ND2 
(Fig. 7.11) it was dominating in non-targeting cells. 
 
 
Figure 7.10. RFs distribution patterns showing accumulation near 3’ 
terminus bigger in C12orf65 depleted cells 
Distribution of the RFs across each mitochondrial transcript (mitoribosome profile) was 
presented as a number of RFs (percentage of all RFs in experiment, Y axis) aligning to 
each nucleotide position within a particular mt-mRNA. The X axis presents the length 
of the transcript in nucleotides and includes the mt-genome coordinates for each 
transcript. In order to facilitate comparison between the profiles, the x axis are of equal 
length, even though transcripts vary in length. The original plots were generated by Dr. 
Fei Gao. 
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Figure 7.11. RFs distribution pattern showing accumulation near 3’ 
terminus bigger in control cells 
Distribution of the RFs across each mitochondrial transcript (mitoribosome profile) was 
presented as a number of RFs (percentage of all RFs in experiment, Y axis) aligning to 
each nucleotide position within a particular mt-mRNA. The X axis presents the length 
of the transcript in nucleotides and includes the mt-genome coordinates for each 
transcript. In order to facilitate comparison between the profiles, the x axis are of equal 
length, even though transcripts vary in length. The original plot was generated by Dr. 
Fei Gao. 
 
Finally, the diverse pattern was observed in case of ND4L where there was not 
one dominating peak of RFs accumulation (Fig. 7.12). Instead there were two 
equally high peaks corresponding to two major accumulations of the RFs. This 
pattern was distinct from all presented above (Fig. 7.7- 7.11), possibly due to 
the small length of the transcript with low number of RFs. However, the 
distribution of RFs was similar in both siC12orf65 and NT treated cell lines 
suggesting that this is a normal pattern for this particular ORF.  
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Figure 7.12. Diverse RFs distribution pattern in C12orf65 depleted and 
control cell lines 
Distribution of the RFs across each mitochondrial transcript (mitoribosome profile) was 
presented as a number of RFs (percentage of all RFs in experiment, Y axis) aligning to 
each nucleotide position within a particular mt-mRNA. The X axis presents the length 
of the transcript in nucleotides and includes the mt-genome coordinates for each 
transcript. In order to facilitate comparison between the profiles, the x axis are of equal 
length, even though transcripts vary in length. The original plots were generated by Dr. 
Fei Gao. 
 
A representation of RFs from the junction of MT-ATP8 and MT-ATP6 (Fig. 7.12, 
RNA14) was also included in this category. The distribution pattern showed that 
there were two distinct accumulations of RFs. The gap between them (pointed 
with an arrow) represents the start of MT-ATP6 transcript, therefore the peak of 
RFs accumulation that starts after it is most likely composed of mitoribosomes 
that started translation of MT-ATP6 and/or finish synthesis of MT-ATP8. The 
peak before the gap represents mitoribosomes that are only translating the 
latter ORF. It is also very interesting that this peak contains higher number of 
RFs in siC12orf65 treated cells than in NT control. It is possible that these RFs 
originate from mitoribosomes that are stalled on MT-ATP8 as they wait for 
these initiating translation of MT-ATP6 to progress.  
In conclusion, the individual transcripts’ mitoribosome profiles presented various 
patterns of RFs distribution that differed between each other and in some 
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cases between the two samples. There was no single rule for the way these 
differences were manifested though. It is the fact that these are results of one 
experiment and were generated from a low number of reads (Table A1). It is 
also possible that the C12orf65 depletion was not sufficient to remove residual 
activity and therefore may not have generated strong changes to the 
mitoribosome profiles. Therefore, further analysis was focused on 
characterisation of the general features of mt-translation based on the obtained 
data in the cell lines examined. Mitoribosome profiles of all mt-ORFs (obtained 
as described in Fig. 7.7-7.12) were merged together to form one profile per cell 
line (Fig. 7.13). The length of each transcript was presented as their actual size 
and they were aligned at the 5’ ends. However, mt-ORFs vary in sizes, 
therefore not all of their 3’ end align at the same point. The merged 
mitoribosome profiles were not only generated for siC12orf65 treated cells and 
non-targeting control but also for the T1V1 and control cell lines from previous 
experiments (6.4 and 6.5). 
  
 
Figure 7.13. General mitoribosome profiles show similarities in RFs 
distribution in all tested cell lines 
RFs distribution profiles for every mt-ORF were merged together to form a singular 
profile per one cell line. The x-axis represents the maximum length of the my-mRNA in 
nt, the Y-axis shows the proportion of total RFs aligning at each point. The general 
mitoribosome profile was generated for each sample analysed with ribosome profiling 
including siC12orf65 and non-targeting control (NT), T1V1 mutants and 143B control 
cells (from both experiments, 6.4 and 6.5). The original plot was generated by Dr. John 
Grady. 
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On average, in all cell lines investigated in this analysis the highest number of 
RFs accumulated approximately at first 100 nt of mt-ORF. This was a consistent 
trend regardless of the type of cell line and experiment. This feature was most 
prominent in siC12orf65 and NT cell lines, where it was most likely caused by 
COX1 and COX2 abnormally high accumulation of RFs. This result further 
confirms that such domination of RFs from COX1 and COX2 was specific to the 
siRNA treatment experiment but not to the C12orf65 depletion. 
 
7.4.  Complementary RNAseq analysis of C12orf65-depleted and 
control cell lines 
In order to expand the analysis of mitoribosome distribution a complementary 
RNAseq experiment was conducted. The information on the level of each mt-
mRNA when compared with the RFs distribution leads to more accurate 
measurement of ribosome accumulation. By eliminating the level of template as 
a factor influencing the number of RFs per ORF it allows assessing how many 
ribosomes were associated with each transcript. These ribosome footprints 
represent either a number of ribosomes actively translating the template or 
accumulated as a result of stalling. 
HEK293 wild type (1x 15 cm dish per condition) cells were treated with 
siC12orf65 or NT siRNAs as in 7.2. The preparation of cell samples for the 
experiment was conducted as in 6.5. The library and sequencing was 
performed in Netherlands Cancer Institute, Amsterdam to be sequenced at the 
Genomics Core Facility with Illumina HiSeq2000 (single-read sequencing).  
After receiving the raw data, I first confirmed their quality with FastQC software 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, Appendix 1.4 Table 
A2, samples ‘rp1’). The quality value (Q) was generated per each bp of all 
reads. It represents the probability that the corresponding base call was 
incorrect on a scale of 0 – 40 (40 being the lowest probability of an error). The 
reports showed that both samples had a very high quality of sequencing across 
the whole length of reads, with Q ranged between 32 and 40 (Fig. 7.8). Having 
established that the raw data was of sufficient quality for the analysis, I 
proceeded to perform the alignment following the methodology as described in 
6.5. The resulting differential expression data were exported to excel for further 
analysis as described below. First, the expression of C12orf65 was investigated 
! 220 
in order to confirm the RT-qPCR estimate of the level of C12orf65 depletion 
(detailed in 7.4 and Fig. 7.4). 
 
 
Figure 7.14. Comparison of the levels of C12orf65 depletion as estimated 
by RT-PCR and RNAseq 
The level of C12orf65 depletion was estimated based on the RNAseq measurement of 
the C12orf65 transcript levels (RNAseq) in C12orf65 depleted cell line (siC12) and non-
targeting control (NT) as described in the text. This was compared with the previously 
derived estimate from RT-qPCR by evaluating the histograms depicted above.  
 
By analysing the levels of C12orf65 measured in control and depleted samples 
it was determined that approximately 30% of the transcript remained after 3 
days of days treatment (Fig. 7.14 ‘RNAseq”) which is consistent with previous 
observations from RT-PCR (Fig. 7.14 ‘RT-PCR’ and Fig. 7.4). With this level of 
depletion confirmed, however, the possibility existed that C12orf65 was not 
being removed to a sufficient extent to cause changes to phenotype. Therefore, 
the first feature investigated was the comparison of the mitochondrial transcripts 
levels between the C12orf65 (Fig. 7.15, siC12) depleted and control (Fig. 7.15, 
NT) cell line. The level of each mt-mRNA was presented as the percentage of a 
total number of mitochondrial transcripts. In previous experiments by Dr. Pajak 
it was observed that the C12orf65 depletion resulted in an increase in steady 
state levels of mt-transcripts (3.1). Therefore, the analysis with RNAseq was 
aimed to examine if the same effect would be observed in this experiment.  
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Figure 7.15. RNAseq analysis shows no varition in mt-mRNAs expression 
between siC12orf65-depleted and NT control cell lines 
Levels of each mt-mRNA expression (in FPKM), derived from the analysis with 
Cufflinks software, for both cell lines: C12orf65-depleted (siC12) and non-targeting 
control (NT) are plotted pairwise to facilitate comparison. 
 
Comparison of the mt-mRNAs between the two samples showed no changes to 
levels of ech mitochondrial transcript resulting from the C12orf65 depletion. As 
predicted after the confirmation of the percentage of depletion (Fig. 7.14) the 
remaining 30% of C12orf65 transcript (in comparison to NT control) was 
potentially sufficient to inhibit changes to mitochondrial gene expression.  
The next step in analysis was to test the efficiency of translation of each 
transcript. This was assessed by comparison of the abundance of the mt-mRNA 
(represented as % of all mt-transcripts) with the abundance of the RFs (also as 
% of all mitochondrial RFs) originating from it. The analysis was performed on 
both cell lines (C12orf65-depleted ‘siC12’ and non-targeting control ‘NT’, Fig. 
7.16). For each individual mt-ORF the number of RFs was divided by the level 
of the template mRNA. As described in 6.5, in order to merge the two data sets 
the annotation were first matched. The number of RFs from MT-ATP6, MT-
ATP8 and MT-CO3 with overlapping regions were added and presented as one 
sample. The same operation was performed on MT-ND4 and MT-ND4L.  
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Figure 7.16. Comparison of the translation efficiency ratio shows little 
difference between the cell lines 
Translational efficiency (RP/RNAseq ratio) values were calculated for each mt-ORF by 
dividing the RFs number originated from it  (presented as % of all RFs) by the mt-
mRNA levels (presented as % of all mt-transcripts). TE values for all mt-ORFs were 
generated for siC12orf65 treated (panel A) and non-targeting control (B) cell lines 
separately. 
 
Comparison of translational efficiency ratio between the cell lines showed only 
moderate changes with slight increase in COX1, COX2, ND5 and ND6. The 
higher the TE ratio the more ribosomes were accumulated over the transcript. 
The number of mitoribosomes can be a reflection of the translational activity or 
a measure of staling. Unfortunately without validated results of de novo mt-
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protein synthesis estimation (3.6) it is impossible to distinguish what is causing 
the increase in RFs number. 
Within each cell line the highest RP/RNAseq ratio was observed in COX1 and 
COX2, which was most likely a direct effect of the accumulation of RFs in the 5’ 
terminal region of these transcripts (Fig. 7.7 and 7.8). The disproportion in RFs 
accumulation between the beginning and the remaining part of COX1 and 
COX2 ORFs suggests that these footprints originated from mitoribosomes that 
did not complete translation. On the contrary, it seems that these mitoribosomes 
were arrested at the 5’ terminus. Therefore the high RP/RNAseq ratio was not a 
result of higher translational activity associated with these ORFs. Interestingly, 
comparison of results for siC12orf65 and NT treated cells with previously 
analysed T1V1 and control (Fig. 6.17) showed differences between these two 
experiments. In T1V1 and control cells the TE ratio for ND5 was the highest of 
all mt-ORFs but in the siC12orf65 and NT control cell lines it was COX1 and 
COX2 that dominated. This observation suggests that such high proportion of 
COX1 and COX2 RFs was specific to the experiment and was not caused by 
depletion of C12orf65. 
 
7.5. Discussion 
The purpose of the last part of my project was to compare the mitoribosome 
profiles from cells depleted of C12orf65 and control treated with non-targeting 
siRNA. The experiment and the generated initial data showed some potentially 
problematic features. First, efficiency of the siRNA knockdown of C12orf65 was 
questionable. However, it was possible that 70% of depletion would be 
sufficient to induce changes detectable with ribosome profiling. If not, it was 
decided to use the generated data to characterize the mitoribosome profiles of 
control cells. Second, the quality of deep sequencing data was lower than 
expected, resulting in low number of reads aligning to the mtDNA (Table A1). 
However, it was sufficient to perform the downstream analysis. Mitoribosome 
footprints (RFs) were grouped and quantified based on the ORF they originated 
from. There was very little variation in general RFs numbers between cell lines. 
The potential increase in mitoribosomal stalling, even if present, was not 
detectable in this presentation of data. Comparison of individual mitoribosome 
profiles showed variations in the distribution of RFs between the cell lines but 
they were not uniform. There was not one singular pattern that would show 
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specific mitoribosome stalling due to lack of C12orf65. One possible 
explanation of this observation would be insufficient silencing of C12orf65 and a 
failure to generate the pathological phenotype. The efficiency of depletion, 
calculated based on the results of RT-qPCR, was at the level of 70% (Fig. 7.4). 
The result was later confirmed with RNAseq analysis (Fig. 7.14). The residual 
30% of C12orf65 transcript could be the reason why there were very little 
differences in mitoribosomal occupancy between the cell lines. In addition, there 
was no difference between the levels of mt-transcripts as the increase observed 
by Dr. Pajak through Northern blot. As in my previous experiments on C12orf65 
depletion, where C12orf65 was not fully removed, there were no visible 
changes to the cellular phenotype (Fig. 3.7, 3.10 and 3.12). Steady state levels 
of mt-transcripts were unchanged, not displaying the anticipated increase in the 
same way it was observed on Northern blotting analysis of cells with 60% 
depletion (Fig. 3.12). This result confirms the necessity to increase the 
efficiency of depletion in order to observe the effect that lack of C12orf65 has 
on cells. 
Although there seemed to be no effect on accumulation of RFs in C12orf65 
depleted cells, the obtained data could be utilized as a source of information on 
normal mitoribosomes distribution. In general there was a tendency to 
accumulate high number of RFs in the first 100 nt (Fig. 7.13). As discussed in 
6.8, due to the method of mitoribosome footprints size selection, these RFs 
most likely do not represent the initiating ribosomes. However, other factors 
specific to the translated transcript or the nascent polypeptide could generate 
these mitoribosome profiles. The progression of ribosomes can be affected by 
codon adaptation, secondary structures in mRNA and positively charged amino 
acids (Charneski and Hurst, 2013; Dana and Tuller, 2012). It is possible that 
some of these factors or a combination contributes to the observed 
accumulation of RFs at 5’ terminus of majority of mt-transcripts. These could 
also explain the differences between individual mt-ORFs’ profiles (Fig. 7.7 -
7.12). If repeated it would be interesting to investigate if the same patterns of 
RFs distribution would occur and with the same proportion between the 
siC12orf65 and NT cells. 
The highest number of RFs was produced by mitoribosomes translating 
subunits of complex IV, namely COX1, COX2 and COX3 (Fig. 7.6). The 
detailed analysis of mitoribosomal profiles showed that in all 3 of these 
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ORFs the majority of RFs was accumulated at first 100 nt from 5’ terminus (Fig. 
7.7 and 7.8). In case of COX2, the high number of RFs at the 5’ end was also 
reflected in analysis of amino acid coding distribution within footprints (Fig. 7.5). 
As in repeated experiment on T1V1 and control cells (6.5, Fig. 6.13) the 
proportion of RFs from 5’ terminus of COX2 was so high it dominated the total 
pool of RFs. This was also a reason why footprints from COX2 were the most 
highly represented from all mt-ORFs (Fig. 7.6). This result confirmed that the 
unusually high number of COX2 5’end RFs was independent of the cell line. It 
was observed in HEK293 treated with both siC12orf65 and NT siRNAs as well 
as in 143B control and T1V1 cell lines. However, it was not observed in T1V1 
cell lines analysed in ribosome profiling experiment performed in Amsterdam, 
nor in the 143B control cells in (Rooijers et al., 2013) (Fig. 6.15). It may be 
caused by the handling of cells or the conditions in which they were kept. The 
fact that this effect was the strongest in siRNA treated cells (Fig. 7.5) suggests 
that it might be connected to process of siRNA transfection itself. As described 
in 7.2 and 2.1.4 these cells were kept for 3 days in medium containing siRNA 
and lipofectamine, which was not replaced with fresh media. Maybe these 
conditions or the downstream steps of preparing cells for lysis caused the arrest 
of translation near the 5’ terminus. This could be a form of regulation of 
translation that attenuates synthesis of proteins in conditions less than optimal. 
This and other curious aspects of the data presented in this chapter require 
further investigation. However, it is crucial that in the future experiments the 
issue of low quality of the data would be addressed. Higher number of reads 
generated from mt-mRNA would provide the confidence that obtained data fully 
reflect the natural course of mitochondrial protein synthesis. A possible solution 
to the problem of low quality would be a differential subhybridisation with probes 
against mitochondrial and cytosolic rRNA. This additional step, performed on 
cDNA samples before PCR amplification, would enrich the library in 
mitochondrial mRNA fragments.  
An increase in the number of the mitochondrial RFs is one of the ways to 
improve analysis of mitoribosomal stalling with ribosome profiling. Another 
approach should focus on finding a good model of stalling that would facilitate 
validation of different release factor candidates. The model used in this part of 
the project consisted of wild type cell line treated with siC12orf65. However, 
even if the depletion of C12orf65 was complete it is possible that the 
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changes to the level of mitoribosome stalling could only be moderate. In cells 
with wild type mtDNA the events of mitoribosome stalling could be sporadic and 
not easy to detect. It is also possible that in the absence of C12orf65 other 
factors as mtRF1 or ICT1 would act in its place. Therefore, in order to facilitate 
the analysis of mitoribosomal stalling, it should be performed on cells with pre-
existing mitoribosome progression defect. Depletion of C12orf65 in such cell 
lines would allow narrowing the analysis to the regions where the stalling would 
be anticipated. An example of a cell line that could be utilized in this type of 
experiment is derived from a patient harbouring µΔ9205 mutation in MT-ATP6 
(Temperley et al., 2003). As a result of this mutation 2 bp is removed from the 
MT-ATP6 stop codon rendering it non-functional. This mutation would 
potentially cause stalling at non-stop mRNA. This would be a great model to 
generate and investigate mitoribosome stalling. Comparison of the 
mitoribosomal footprints number over the 3’ terminus of MT-ATP6 between the 
cells with and without C12orf65 could provide the information on this protein’s 
potential to alleviate stalling. 
Finally, there is also a potential to improve the RNAseq data to make it more 
informative. In order to better characterize the common features of mt-
translation, especially these concerning levels of each transcript translation 
these experiments should be repeated. It is advised for RNAseq data to include 
at least 3 biological repeats (Trapnell et al., 2012). This would allow averaging 
the results and allowing to eliminate experimental variation. In addition, the 
RNAseq analysis results that were described in this chapter only referred to the 
levels of mitochondrial transcript. However, the analysis was performed on the 
total RNA. Differential expression profiles could be further analysed to compare 
which nuclear genes were upregulated as a result of the C12orf65 depletion. 
These results could answer the question if, for example, mtRF1 or ICT1 would 
be expressed at higher levels to compensate for the loss of C12orf65. !  
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Chapter 8 
 
Final discussion !  
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In my PhD project I focused on the characterisation of C12orf65 protein and 
exploring its putative role as a rescue factor for mitoribosomes. The second part 
of my project involved development of mitoribosome profiling, which was 
initiated to extend the investigation mentioned above. It was also designed to 
analyse general features on mitochondrial translation including mitoribosome 
distribution on mitochondrial transcripts. 
The following chapter will summarise and discuss the most important results  
I have obtained for each area of my PhD project. 
 
8.1. Characterisation of C12orf65 
The investigation into the function of C12orf65 was based on experiments using 
siRNA-mediated depletion in conjunction with the analysis of skin fibroblasts 
that harbour the c.210A mutation in C12orf65 gene from a patient presenting 
with mitochondrial disease. The panel of experiments using C12orf65 depletion 
were the continuation of work by Dr. Aleksandra Pajak whose most important 
observation was upregulation of mt-transcripts in the absence of C12orf65. This 
result was consistent with patient reports by (Antonicka et al., 2010) where the 
same effect was observed. My experiments, however, failed to repeat this 
result. In addition, none of the anticipated changes to phenotype (decrease in 
de novo mt-translation, loss of cell viability in GGQ mutants) were present. This 
was most likely caused by insufficient level of depletion (≤ 70%)as it was 
presented previously that ~90% of siRNA-mediated depletion can produce 
visibly negative effects on cells (Kogure et al., 2012).  
Even though my experiments failed to demonstrate a phenotype due to 
incomplete depletion of C12orf65, they revealed an important feature of this 
protein. Based on results of antibody validation, where I tested different 
combinations or conditions, the endogenous levels of C12orf65 appear to be 
very low. However, even with this little amount of protein it is necessary to 
remove over 70% of it in order to observe the negative effects of depletion. One 
explanation could be that C12orf65, if engaged in mitoribosome rescue, is not 
the primary factor, indispensable to the process. This hypothesis is in line with 
results of ICT1 overexpression that partially rescued the mitochondrial defect in 
patient cells with C12orf65 mutation (Antonicka et al., 2010). Another possibility 
would be that only small amounts of C12orf65 are required for its function. It 
may be that mitoribosome stalling in cells with wild type mtDNA would not 
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necessary be a very frequent event. Therefore, the low levels of the factor that 
could potentially alleviate it would be sufficient. 
The anticipated negative effects of C12orf65 absence on mitochondrial function 
were observed in the patient study. The c.210A mutation was predicted to result 
in a frameshift leading to a premature stop codon. The protein product of this 
mutated template would be truncated and devoid of the presumably 
catalytically-important GGQ motif. There is an indication that the truncation of 
C12orf65 does not trigger the nonsense-mediated decay as reflected by results 
of RT-qPCR (Antonicka et al., 2010) and western blotting (Haruo Shimazaki et 
al., 2012).  
The results of characterisation of the patient samples that I studied were as 
follows:  
• Impaired growth on galactose but not glucose containing medium 
• Decrease in complex IV activity 
• Disruption of complex I, IV and V assembly 
• Decrease in steady state levels of CI and CIV subunits 
• General decrease of de novo mt-protein synthesis 
• Increase in steady state levels of mitochondrial mRNAs and rRNAs 
These results clearly show disruption in mitochondrial protein synthesis, 
reflected in decrease of de novo translation, which leads to lower steady state 
levels of mitochondrial proteins and also of fully assembled complexes.  
As demonstrated in yeast cytosolic translation, ribosome rescue is part of a 
complicated process that in addition to recycling ribosomal subunits, includes 
degradation of nascent polypeptide and defective mRNA template 
(Defenouillère et al., 2013). It is possible that a similar mechanism could 
operate in mitochondria and involves C12orf65 to promote the release of the 
polypeptide. One explanation could be that the truncation of C12orf65 affects 
the downstream components of the rescue pathway, namely the mRNA 
degradation. This could lead to disruption of transcript turnover, which could be 
a reason for the increase in steady state levels of mt-mRNAs and rRNAs.  
Although it is not yet definitely confirmed, C12orf65 may associate with 
mitochondrial RNA processing granules (RPG). These distinct mitochondrial 
foci were shown to be sites of RNA processing, turnover and mitoribosome 
biogenesis (Antonicka et al., 2013; Antonicka and Shoubridge, 2015; Jourdain 
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et al., 2013). Recent publications on the composition of RNA granules did not 
list C12orf65 among proteins immunoprecipitated by GRSF1, a confirmed 
member of RNA granules (Antonicka and Shoubridge, 2015). However, when 
the IP of C12orf65 was performed GRSF1 was identified as a binding partner 
(Antonicka et al., 2013). This would suggest that the possible interaction 
between C12orf65 and the granules is weak and transient. C12orf65 may be 
directed to the processing granules to perform the mitoribosome rescue as all 
steps of this process can be implemented there.   
 
8.2. Mitoribosome profiling 
In order to facilitate the investigation of potential mitoribosome stalling, the 
method of ribosome profiling was selected. One of the objectives behind this 
choice was to design methodology to identify stalling of mitochondrial 
ribosomes. The developed protocol was validated on a T1V1 cell line where a 
defined mutation in mt-tRNAVal gene was expected to cause stalling on valine 
codons in mt-mRNAs. This cell line provided also a potential rescue mechanism 
via the stably inducible expression of mitochondrial valyl-tRNA synthetase 
(VARS2) (Hornig-Do et al., 2014). Although the rescue experiment was not 
successful due to the lack of VARS2 overexpression, the results derived from 
the uninduced mutant and wild type control cell lines were sufficient to provide 
informative data. 
 
The most important results of mitoribosome profiles’ analysis in these cell lines 
allowed me to conclude that there is : 
• Accumulation of ribosome footprints with A-site positioned valine is 
higher in the T1V1 mutant line than control cells 
• Higher proportion of RFs with A-site GTC codon in the T1V1 mutant line 
than in control cells 
• Dominance of ribosome footprints originating from the 5’ terminal 
sequence of COX2 in the experiment repeats 
• Higher ribosome footprints in the RNAseq ratio for ND5 in mutant cells. 
My data arising from the mitoribosome profiling suggest that there is an 
increase in ribosome occupancy of valine codons in mutant cells consistent with 
stalling. Differences in accumulation of RFs over particular valine codon types 
between the mutant and control cell lines could be caused by the wobble 
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base-pairing affecting the speed of translation more in the mutant cells. 
However, the potential stalling of mitoribosomes due to deficiency of mt-tRNAVal 
was not profound nor were all valine codon clusters associated with high 
density of RFs. 
Further, the mitoribosome profiles obtained in the experimental repeats showed 
more stalling at the 5’ terminus of COX2 than on valine codons. This could be a 
manifestation of a different physiological state of cells between the two 
experiments that triggered a regulatory mechanism as discussed in more detail 
below. 
There is also another factor that could potentially influence the results of the 
mitoribosome profiles derived from T1V1 cells. According to the recently 
published cryo-EM structures of mt-LSU, the position in central protuberance 
that is usually occupied by the 5S rRNA in eubacteria and eukaryotes  is taken 
up by a tRNA species in mitochondria. There is currently no consensus whether 
it is mt-tRNAPhe (Greber et al., 2014) or mt-tRNAVal (Brown et al., 2014). 
However, assuming that it is the latter it is possible that the shortage of mt-
tRNAVal could also affect the composition and/ or function of mitoribosome. If 
this were the case then mt-translation would be affected in a global way, which 
was indeed observed as a general decrease in de novo synthesis (Hornig-Do et 
al., 2014). In my experiments the potential effect of low mitoribosomal 
processivity was especially visible in ND5, where a very high ratio of RFs to 
transcript level did not result in higher levels of de novo synthesis. This protein 
is the largest of all those that are mitochondrially-encoded and it contains a high 
number of valines (third most enriched in valine residues). Both of these 
features could affect the function of potentially damaged mitoribosome in 
mitochondria with a shortage of tRNAVal.  
Final experiments were conducted on C12orf65 depleted cells and non-
targeting control.  Unfortunately, the level of depletion was again only 70%, 
which was previously proven to be insufficient to induce mitochondrial 
dysfunction. The mitoribosomal profiles of individual mt-ORFs varied in 
ribosomal distribution patterns as seen in the tRNAval cell line. However, there 
was no single significant feature that would suggest an increase in 
mitoribosome stalling in the absence of C12orf65. This could be partially 
caused by incomplete depletion. It is also possible that a different model needs 
to be used, namely a cell line with pre-existing mt-translational defect, or an 
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increased efficiency of C12orf65 depletion. In that case depletion of C12orf65 
would be more likely to cause a visible and easy to detect increase in 
mitoribosomal accumulation. 
Interestingly, as observed in the experimental repeat of T1V1, both siC12orf65 
and NT control cell lines were characterised by a high accumulation of RFs at 
the 5’ region of MT-CO1, MT-CO2 and MT-CO3. It is possible that cells were in 
less favourable physiological state at the day of experiment and this triggered a 
regulatory mechanism. This potential mechanism could repress protein 
synthesis by attenuation of translation at the 5’ end of the transcript. It seems 
that expression of complex IV subunits is more sensitive to changes in 
physiological state than other mt-ORFs and is a subject to this regulation. 
In conclusion the mitoribosome profiling protocol was proven successful in the 
analysis of patterns of translation in human mitochondria and also in 
mitoribosome stalling. However, there are certain aspects of the methodology 
that need further optimisation to produce higher quality and more extensive 
data. These include the removal of rRNA species from the library and 
optimisation of RNase treatment in order to reduce contamination with non-
mRNA fragments. When these issues are resolved the protocol presented here 
would serve as a powerful tool to study mitochondrial translation in control and 
diseased states with details and depth that have never been achieved before. !  
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Appendix 1.1. 
 
Figure A1. Position of valine codons in mtDNA (enlarged Fig. 6.9 A) 
Marked positions of valine codons in all mitochondrial polypeptide genes. Position of 
each valine codon type is represented in a separate panel. 
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Appendix 1.2. 
 
Figure A2. Distribution of mitoribosomes is not dependent on the position 
of valine codons (enlarged Fig. 6.10) 
A. Density of the RFs across each mt-transcript was calculated and plotted for all 3 cell 
lines: wild type control (in red), uninduced T1V1 (Tet-, in green), unsuccessfully 
induced T1V1 (Tet+, in blue). The full length of each transcript was presented as 
100%. B. Position of valine codons in mtDNA was marked for each type of codon 
separately. Amount of different Val codon was presented as density plots over the 
length of each mitochondrial transcript (length represented in %). 
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Appendix 1.3. 
 
List of all sequencing raw data files generated in this project. 
 
T1V1 ribosome profiling first experiment: 
2553_1_Tet_-_ATCACGA_L004_R1_001.fastq 
2553_2_Tet_Plus_CGATGTA_L004_R1_001.fastq 
(‘Tet-‘ uninduced T1V1, ‘Tet plus’ failed T1V1 rescue) 
 
T1V1 ribosome profiling second experiment: 
2934_1_RP2_-Tet__A_ATCACGA_L005_R1_001.fastq 
2934_2_RP2_Control__A_TTAGGCA_L005_R1_001.fastq 
(‘-Tet ‘ uninduced T1V1, ‘Control’ 143B parental) 
 
C12orf65 depletion ribosome profiling experiment: 
2934_3_siC12_RP1__A_TGACCAA_L005_R1_001.fastq 
2934_4_siNT_RP1__A_ACAGTGA_L005_R1_001.fastq 
 
T1V1 RNAseq experiment (complementary to the second T1V1 ribosome 
profiling experiment):  
3206_rp2_-tet_atcacga_l008_r1_001.fastq 
3206_rp2_control_ttaggca_l008_r1_001.fastq 
 
C12orf65 depletion RNAseq experiment (complementary to ribosome profiling 
experiment): 
3206_sint_rp1_gatcaga_l008_r1_001.fastq 
3206_sic12_rp1_acttgaa_l008_r1_001.fastq 
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Appendix 1.4. 
 
Table A1. Number of reads in mitoribosome profiling samples at various 
steps of alignment 
Sample Reads raw 
data 
Reads after screening Reads aligned to 
mt-mRNA 
SRR935452 183,299,160 43,210,341 (23.72%) 5,689,430 (13.17%) 
2553_1_Tet 62,039,090 4815136 (7,77%) 163,588 (3.4%) 
2553_2_Tet_Plus 50,296,184 3,341,448 (6.65%)  131,646 (3.9%) 
2934_1_RP2_Tet 33,452,085 7,597,643 (23.52%) 26,970 (0.35%) 
2934_2_RP2_Control 50,942,344 20,477,944 (42.68%) 76,575 (0.37%) 
2934_3_ siC12_RP1 40,484,160 6,075,251 (15.6%) 36,359 (0.6%) 
2934_4_ siNT_RP1 33,453,267 7,334,514 (22.6%) 12,489 (0.49%) 
 
Column 3 (‘Reads after screening’) presents number of reads that did not align 
to the decoy reference genome (containing tRNA and rRNA sequences) 
 
Percentage values are calculated in relation to the value in the preceeding 
column. 
 
Data in sample SRR935452 come from experiments described in (Rooijers et al., 
2013) 
  
 
Table A2. Number of reads in RNAseq samples (fastq) 
Sample Total reads 
3206_rp2_-tet 49,451,300 
3206_rp2_control 45,584,649 
3206_sint_rp1 48,447,645 
3206_sic12_rp1 48,167,239 
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Protein synthesis is central to life andmaintaining a highly accurate and efficientmechanism
is essential.What happens when a translating ribosome stalls on a messenger RNA?Many
highly intricate processes have been documented in the cytosol of numerous species, but
how does organellar protein synthesis resolve this stalling issue? Mammalianmitochondria
synthesize just thirteen highly hydrophobic polypeptides. These proteins are all integral
components of the machinery that couples oxidative phosphorylation. Consequently, it is
essential that stalled mitochondrial ribosomes can be efficiently recycled. To date, there
is no evidence to support any particular molecular mechanism to resolve this problem.
However, here we discuss the observation that there are four predicted members of
the mitochondrial translation release factor family and that only one member, mtRF1a,
is necessary to terminate the translation of all thirteen open reading frames in the
mitochondrion. Could the other members be involved in the process of recycling stalled
mitochondrial ribosomes?
Keywords: mitochondria, release factor, ICT1, ribosome rescue, ribosome stalling, protein synthesis, translation
INTRODUCTION
Maintaining the efficiency and accuracy of protein synthesis is
one of the most important aspects of cell survival. The transla-
tion of mRNAs into polypeptides is a complex multistep process
that involves many proteins and RNA species. Consequently there
are many points at which protein synthesis can be disrupted
with consequent detrimental effects on cell viability (Zaher and
Green, 2009). One step at which this process can fail is when
the ribosome ceases to progress along the open reading frame
within the transcript, termed stalling. The reasons for this are
multiple and varied. Elongation arrest can be an important reg-
ulatory step such as is seen in the binding of signal recognition
particles (SRP) to emergent nascent peptides. Docking of the
SRP to its receptor in the endoplasmic reticulum (ER) mem-
brane facilitates co-translational translocation and the nascent
peptide is immediately inserted into the ER membrane prior to
any folding event (Walter et al., 1981). Structural or sequence ele-
ments within the mRNA may cause pausing, as will the lack of
sufficient charged tRNAs. In bacteria, examples of each of the
events have been shown to trigger degradation of the mRNA on
which the ribosome has paused (reviewed in Deana, 2005). In
certain cases, however, there is potential for translational arrest
to be more harmful, or more specifically that not alleviating
the arrest or the cause of it, can be detrimental. For example,
stalled ribosomes sequester tRNAs within the A, P, and E-sites
thereby limiting their availability, impeding normal translation
(Manley, 1978; Jørgensen andKurland, 1990). Bacterial ribosomes
can also stall by colliding with the RNA polymerase ahead of
them, which has itself stalled on its template. The phenomenon
of translational arrest caused by ribosome stalling appears to
occur in bacteria and in the cytosol of eukaryotes, and although
under-researched it is also likely to affect mitochondrial pro-
tein synthesis. Because of the detrimental effects that can result
from stalling and the relative frequency of premature termination
events, organisms have developed different strategies to rescue
these ribosomes.
Eubacteria have developed a number of mechanisms (reviewed
in Janssen and Hayes, 2012) but the best characterized is trans-
translation promoted by tmRNA (reviewed in Moore and Sauer,
2007). This system, present in all eubacteria utilizes a molecule
that folds to present two very different domains. The 5′ domain
resembles a tRNA, which is recognized and aminoacylated by
alanyl-tRNA synthetase. Aborted nascent peptides are transferred
from the P-site tRNA to the alanine on this upstream tRNA-like
structure, resulting in an (peptidyl)-alanyl-tmRNA. The down-
stream element of the tmRNA then acts as an mRNA, where
the first triplet, or resume codon, generally encodes an alanine
(Kapoor et al., 2011). Protein synthesis is resumed with the addi-
tion of an approximately 10 amino acid tag, before terminating
in a conventional stop codon. The aberrantly translated peptide
is able to leave the ribosome through the conventional mecha-
nism, thereby rescuing the stalled components. This system is
found in all known bacterial genomes, either a single tmRNA or
as two pieces that bind to resemble tmRNA (Keiler et al., 2000).
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The elegance of this arrangement is that it relieves the stall and
tags the truncated/aberrant protein, effectively targeting it as
a substrate for degradation. Trans-translation also requires the
essential binding partner SmpB, which with tmRNA rescues ribo-
somes stalled on RNA templates that either lack a stop codon or
have stalled during the elongation phase for other reasons. Alter-
native rescue pathways identified in Escherichia coli require the
activity of protein factors ArfA or ArfB (YaeJ) that both utilize
translation terminationmechanisms to release arrested ribosomes
(Chadani et al., 2010; Handa et al., 2010b; Abo and Chadani,
2014). The two mechanisms differ. ArfA requires recruitment of
the translation termination factor RF2, whilst YaeJ retains the
GGQ motif characteristic of release factors (RFs) and directly
stimulates the ribosome dependent catalysis of the ester bond
between the peptide and the P-site tRNA (Chadani et al., 2012).
In eukaryotes, no homologs of the tmRNA system have been
found, but a different mechanism has been identified to tackle
the same problem. Characterized in the yeast cytosolic com-
partment, this system employs the protein Dom34, a homolog
of the eukaryotic release factor (eRF1) but lacking the charac-
teristic GGQ motif and codon recognition capability (Lee et al.,
2007; Graille et al., 2008). Dom34 can act in concert with either
a GTPase, Hbs1, or an ATPase, Rli1. In a codon-independent
manner, it releases ribosomes from truncated transcripts or those
that have failed to release the mRNA at the stop codon and have
migrated into the 3′UTR (Guydosh and Green, 2014). Although
mitoribosomes are likely to encounter similar issues that cause
stalls, similar to the eukaryote cytosol no tmRNA species has
been found in mammalian mitochondria. Curiously, a circularly
permuted gene resembling the upstream tRNA-like fragment was
identified in the primitive mitochondrial genome of Reclinomonas
americana (Keiler et al., 2000). However, since no accompany-
ing open reading frame for the tag peptide could be found,
it seems unlikely that any mitochondrial genome has retained
this apparatus. We are left, therefore, with no mechanistic data
on precisely how stalled ribosomal complexes are resolved in
mitochondria.
MITOCHONDRIAL RIBOSOMES, STALLING, AND PREDICTING
POTENTIAL RESCUE MECHANISMS
Our understanding of all the critical recognition elements and
trans-acting proteins responsible for mitochondrial translation
lags behind the characterization in bacteria and the eukaryotic
cytosol. Many of the aspects that are still unknown include the
mechanisms that exert quality control of protein synthesis and
rescue ribosome stalling. Given the presumed α-proteobacterial
origin (Gray et al., 1999) of the organelle, the prediction is often
that processes in mitochondria will strongly resemble those from
their bacteria origins (Smits et al., 2010). The existing models
of translation in mitochondria are, therefore, based on those of
bacteria. However, despite evident similarities between the two
processes, they are not identical and certain unique features of
mitochondrial translation make direct comparison more compli-
cated (reviewed in Christian and Spremulli, 2012).With respect
to the ribosome rescue mechanisms, one important consider-
ation is the structure and composition of the mitoribosome.
Mitochondrial ribosomes are often compared to their prokaryotic
counterparts (Sharma et al., 2003), however, mitoribosomes vary
enormously depending on their organism of origin (Rackham and
Filipovska, 2014). Although all consist of a small and a large sub-
unit there can be variations in their size, RNA to protein ratio, and
composition. Throughout their evolution, mitoribosomes have
acquired many distinct structural characteristics, including the
unusually high protein to rRNA ratio, caused by shortening of
rRNAand recruitment of additional proteins (Sharma et al., 2003).
Although many of the mitoribosome proteins (MRPs) have bac-
terial homologs, almost half of them are specific to mitochondria
(Sharma et al., 2003; Koc et al., 2010). These unique MRPs are
mostly situated on the outer surface of the mitoribosome some
of which compensate for the loss of rRNA domains or miss-
ing bacterial proteins (Sharma et al., 2003). These new protein
also form an extended peptide exit tunnel, the central protuber-
ance and line the mRNA entry site, which differs in structure
from the prokaryotic counterparts (Sharma et al., 2003; Greber
et al., 2013; Kaushal et al., 2014). Recent publications describing
high resolution cryo-electron microscopy (cryo-EM) structures
of both the mammalian 39S large (Greber et al., 2013) and 28S
small mitoribosomal subunits (Kaushal et al., 2014) confirm the
unique aspects of mitoribosome architecture derived from these
mitospecific RPs. Any potential ribosome rescue mechanism in
mitochondria might be predicted to reflect these global changes
to the structural features and composition of the mammalian 55S
particle. However, analysis of mitochondrial proteins that have
bacterial homologs with known function, and comparable struc-
tures may still be the best way to begin the search for potential
mitoribosome rescue factors. Other approaches include looking
for factors that transiently interact with the mitoribosome, or
through bioinformatics analyses. Use of the last twomethods have
helped to identify the most likely candidates, namely members of
the mitochondrial RF family (Rorbach et al., 2008; Richter et al.,
2010).
MITOCHONDRIAL RELEASE FACTOR FAMILY
There are two types of release factors: those that are capable of
mRNA sequence recognition (class 1 RFs) and those that are not
(class 2). Class 1 RFs effect translation termination by sampling
the ribosomal A-site and remaining transiently associated when
they recognize a cognate STOP codon. Their function is to release
the completed polypeptide from the ribosome by catalyzing the
cleavage of the ester bond between the P-site tRNA and the ter-
minal amino acid of the nascent peptide. Eubacteria utilize two
different RFs, RF1 and RF2, to recognize the 3 universal STOP
triplets (Oparina, 2005). In contrast, archaebacteria and eukary-
otic cytosol both contain a single, omnipotent class 1 RF (named
aRF1 and eRF1 respectively) that recognizes all three of the canoni-
cal STOP codons, UAA, UAG, and UGA (Ito et al., 2002; Seit-Nebi
et al., 2002). Large scale phylogenetic analysis has examined the
evolution and diversification of RF proteins and identified that
members are present in both plastids and mitochondria (Duarte
et al., 2012).
Human mitochondria use only UAA and UAG as terminating
triplets, as UGA has been recoded to tryptophan. In combination
with the altered characteristics of the mammalian mitoribosome
this might predict the need for a reduced number of RFs. It is
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perhaps a surprise, therefore, that bioinformatics classifies four
proteins as members of the human mitochondrial RF family,
namely mtRF1,mtRF1a, ICT1, and C12orf65. The first to be iden-
tified solely bydatabase searcheswasmtRF1 (Zhang andSpremulli,
1998). The sequence recognition domains differed from the con-
sensus, supporting the assumption that mtRF1 functioned as a
single RF that recognized the four codons that at the time were
assumed to function as stop codons. This premise was absorbed
into the literature until mtRF1a was identified, with decoding
domains thatmore closely resembled the consensus, and biochem-
ical characterization confirming its recognition of UAA and UAG
as stop codons (Soleimanpour-Lichaei et al., 2007). The second
confounding assumption that had been accepted in the literature
was thatAGAandAGGwere also stop codons. Since these followed
the final coding triplet in mitochondrial transcripts MTCO1 and
MTND6 respectively, this was not an unreasonable interpreta-
tion of the human mitochondrial genome (Anderson et al., 1981).
More recent investigations in whole cells have shown that physio-
logically neither of these are stop codons. Although both codons
are unassigned, they function to promote a -1 frameshift, to posi-
tion UAG in the A-site for conventional termination by mtRF1a
(Temperley et al., 2010).
Since mtRF1a is sufficient to terminate translation of all 13
open reading frames, what are the functions of the remain-
ing 3 mitochondrial RF family members? Is there any evidence
that they can still function as RFs? These proteins were grouped
together due to similarities in their sequence and structures that
they share with RFs from bacteria and the eukaryotic cytosol
(Duarte et al., 2012). In particular all four family members dis-
play high conservation of the GGQ domain that is critical for
catalyzing peptidyl-tRNA hydrolysis (PTH; Frolova et al., 1999).
For the RF to trigger ester bond cleavage the GGQ domain must
be positioned in the peptidyl transferase center of the ribosome
(PTC), which occurs when the RF undergoes a major conforma-
tional change from a closed to open conformation (Vestergaard
et al., 2001; Petry et al., 2005; Laurberg et al., 2008). In order
to prevent RFs from displaying PTH activity too early, the con-
formational change that promotes peptidyl-tRNA hydrolysis is
dependent on stop codon recognition (Shaw and Green, 2007;
Laurberg et al., 2008). The required sequence specificity is dic-
tated by another conserved domain, which comprises amino
acid stretches that come together in space. This domain devi-
ates from the consensus in mtRF1, both in amino acid content
and by being extended in length. The hypothesis predicated on
these changes, is that the extra bulk of the sequence recogni-
tion domain can fill the space in the A-site normally occupied
by the mRNA. Three dimensional modeling shows that mtRF1
could occupy this cavity and synchronously extend the GGQ
motif into the PTC to rescue ribosomes that have stalled with
an incomplete peptide anchored to a mis-processed or partially
degraded mRNA lacking a termination codon (Huynen et al.,
2012). In contrast the codon recognition domain is absent in
both ICT1 and C12orf65, the two remaining members of the
mitochondrial RF family. Despite this, the retention of the
GGQ motif in all family members strongly suggests they have
all retained the ribosome dependent ability to release peptides
from a P-site anchored tRNA. That they play an important role in
translation is further substantiated as intra-organellar protein syn-
thesis is impaired when ICT1 or C12orf65 are depleted ormutated
(Antonicka et al., 2010; Richter et al., 2010). These observations
suggest that mtRF1, C12orf65, and ICT1 are likely to function
on stalled ribosomes or large subunits with peptidyl-tRNA still
anchored within, allowing them to be recycled for a new round of
translation.
ICT1 is intriguing as it has been incorporated into themitoribo-
some as a permanent fixture. This would appear to be dangerous,
as ICT1 displays codon independent PTH activity, which a priori
could cause premature peptide release (Richter et al., 2010). Since
this does not occur physiologically, the associated PTH activity
of ICT1 must be carefully controlled with an as yet undefined
specificity. The current hypothesis is that ICT1 must function in
ribosome rescue but whether this occurs at stalling events within
ORFs or on truncated transcripts is not yet clear. ICT1 does, how-
ever, have a bacterial homolog, YaeJ, which has been shown to be
involved in release of arrested ribosomes (Gagnon et al., 2012).
Below we will compare and contrast and see if there are useful
parallels to be drawn to elucidate the potential role of ICT1 in
mitochondrial ribosome rescue.
YaeJ
ArfB or YaeJ, is conserved among eukaryotes and is present in
many Gram-negative species (Handa et al., 2010b). Its potential
role in ribosome rescue was indicated by its structural similarity
to RF1 and RF2 and the presence of the GGQ motif, character-
istic of ribosome dependent PTH activity (Frolova et al., 1999).
Convincing evidence for its function in ribosome rescue derived
from studies in E. coli where YaeJ overexpression in strains lack-
ing tmRNA and ArfA suppressed the lethal phenotype (Chadani
et al., 2011). Subsequently YaeJ was shown to have direct PTH
activity on stalled ribosomes both in vitro (Handa et al., 2010b)
and in vivo (Handa et al., 2010b; Chadani et al., 2011), which
was lost when the GGQ was mutated to GAQ (Chadani et al.,
2011). This indicated that no auxiliary factors were required, in
contrast to ArfA that needs to co-opt RF2 for activity. As with
ICT1, the protein lacks domains 2 and 4 of a standard RF, thereby
losing codon-recognition consistent with its ability to rescue ribo-
somes stalled on mRNA lacking STOP codons (Chadani et al.,
2011). Structural analysis by the Steitz group has detailed the
critical interactions that drive ribosomal rescue. The N-terminal
globular domain is bound in the A-site and is joined to the C-
terminus via a flexible linker (Gagnon et al., 2012). Although
the C-terminus was thought to be an unstructured, it has a
basic residue-rich tail that was necessary to facilitate interaction
with the ribosome (Handa et al., 2010b; Chadani et al., 2011;
Gagnon et al., 2012; Kogure et al., 2014). Gagnon et al. (2012)
have shown that once positioned within the mRNA entry chan-
nel, it forms an α-helix. Their data suggest that the YaeJ tail
can sample the mRNA channel and thereby determine whether
or not the ribosome has stalled on a non-stop transcript or is
still translating (Gagnon et al., 2012). If the ribosome is stalled
on non-stop mRNA or an endonucleolytically cleaved transcript,
the basic residues of the YaeJ tail could interact with negatively
charged rRNA nucleotides lining the tunnel. Such binding to
the ribosome would cause structural rearrangements within YaeJ,
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similar to those following codon recognition of a standard RF,
placing the GGQ domain within the PTC, facilitating peptidyl-
tRNA hydrolysis (Gagnon et al., 2012). The data is clear that
YaeJ is an important protein in ribosome rescue, but does it
follow that the human mitochondrial ortholog plays a similar
role?
ICT1
First reported, under the name of DS-1, as a transcript down-
regulated during in vitro differentiation of a colon carcinoma
cell line, immature colon carcinoma transcript-1 (ICT1; Van
Belzen et al., 1995, 1998) had no connection to any potential
mitochondrial function. Subsequent research by our group inves-
tigating ribosome recycling in human mitochondria, identified
ICT1 as associated with mtRRF (Rorbach et al., 2008). Sub-
sequently, the available data and bioinformatic analyses classi-
fied ICT1 in the prokaryote/mitochondrial RF family (uniprot
Q14197). At ∼175 amino acids post-maturation ICT1 is smaller
than standard RFs due mainly to the loss of the codon recog-
nition elements. It does, however, retain the GGQ motif that
has been confirmed as functional, as GSQ and AGQ mutations
affect growth and activity (Richter et al., 2010). As mentioned
above, this work confirmed that ICT1 is not just mitochon-
drial but has actually become an integrated component of the
FIGURE 1 | ICT1 as a mitochondrial translation rescue factor and its
possible orthologs. (A) Alignment of human ICT1 (14197) with the Pth4
ortholog from S. pombe (Q9HDZ3) and YaeJ ortholog from E. coli (E2QFB9).
Identity is indicated by (*), high levels of similarity by (:) and lower levels by
(·). The conserved GGQ region is boxed and the YaeJ residues that are
required for PTH activity and are highly conserved between bacterial
species are indicated by arrows. (B) Release activity of recombinant YaeJ
and ICT1. PTH activity was tested on 70S ribosomes primed with either no
RNA or UAA triplet in the A-site. (C) Mitochondrial targetted YaeJ-FLAG
shows interaction with human mitochondrial ribosomal proteins. FLAG tag
mediated immunoprecipitations of ICT1 and mitochondrially targeted YaeJ
were performed on lysates of HEK293 cell lines induced for 3 days. The
elution fractions (10%) were separated by SDS PAGE and analyzed by silver
staining (left panel, FLAG protein indicated by *) or western blot (right
panel). Antibodies against MRPL3, MRPL12, ICT1, DAP3, and MRPS18B
were used to determine the relative levels of coimmunoprecipitated
ribosomal proteins. The presence of FLAG tagged protein in each elution
was confirmed by anti-FLAG antibodies. (D) Mitochondrially-targeted
YaeJ-FLAG does not co-migrate with the 39S LSU. Lysate (700 µg) of
mtYaeJ-FLAG expressing cells was separated on an isokinetic sucrose
gradient. Fractions were analyzed by western blot using antibodies against
the 39S LSU (MRPL3) and the 28S SSU (DAP3). The distribution of
mtYaeJ-FLAG was determined by applying FLAG antibodies. Methods for
panels (B–D) were essentially as described in Richter et al. (2010), except a
YaeJ-FLAG construct was used to generate a HEK293T overexpression line
instead of the ICT1 FLAG.
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large ribosomal subunit. Recent cryo-EM coupled with cross-
linked mass spectroscopy confirmed this observation and posi-
tions ICT1 at the central protruberance, close to MRPL15,
-18, and -49 (Greber et al., 2013). Perhaps not surprisingly,
depletion of ICT1 causes disruption of the mitoribosomal
structure and subsequent de novo synthesis of mitochondri-
ally encoded proteins (Richter et al., 2010). The combination
of these characteristics make ICT1 a codon-independent but
ribosome-dependent and ribosome-integrated peptidyl-tRNA
hydrolase.
Analysis of ICT1 solution structure may provide more insight
into the role of the protein (Handa et al., 2010a). The three dis-
tinct regions are the N-terminal mitochondrial targeting signal,
the structured catalytic domain containing the GGQ motif, and
an unstructured C-terminal extension rich in positively charged
amino acids. The topology of the GGQ domain is β1-β2-α1-β3-
α2, which follows the bacterial RF2 pattern with the exception of
the α1 inserted between β2 and β3 that is not present in the lat-
ter (Handa et al., 2010a). Loss of the codon recognition domain
appears to be replaced by a C-terminal extension, somewhat
reminiscent of YaeJ.
YaeJ vs. ICT1
Comparisons of ICT1 and YaeJ structure and sequence alignment
show both similarities and differences (Figure 1A; Handa et al.,
2010a; Gagnon et al., 2012; Kogure et al., 2014). Identity and sim-
ilarity are strong in the GGQ domains. The N-termini differ as
would be expected, as ICT1 is a mitochondrially destined pro-
tein. Although an inserted region (αi) is common to both the
structure that follows differs, in YaeJ this is a β-strand in con-
trast to a 310 helix in ICT1 (Kogure et al., 2014). The inserted
α-helices share structure but differ in amino acid sequence, they
are a characteristic and conserved feature for these two pro-
teins that distinguish them from class I RFs (Kogure et al., 2014).
An important feature for ribosome binding and activity in YaeJ
was the length and amino acid composition of the linker and
C-terminal region and critical residues for PTH activity are con-
served between ICT1 andYaeJ (Kogure et al., 2014). The conserved
similarities that link these two proteins whilst simultaneously dis-
tinguishing them from other RFs, suggest a conserved function
and mechanism. As with Kogure et al. (2014) we could show
codon-independent release activity by using recombinant YaeJ in
in vitro assays with 70S ribosomes (Figure 1B). We, therefore,
looked to see whether the similarities in these proteins were suf-
ficient for YaeJ to substitute for ICT1 in the mitoribosome. To
test this hypothesis, we generated cell lines that could inducibly
express a mitochondrially targeted YaeJ (reported here) or the
potential yeastmitochondrial RF,Schizosaccharomyces pombe Pth4
(reported in Dujeancourt et al., 2013). Each was generated with
a C-terminal FLAG tag to facilitate efficient immunoprecipita-
tion (IP). The immunoprecipitated protein was specifically and
competitively eluted using FLAG peptide and in ach case demon-
strated an association with the mitoribosome, but neither was
as efficient as ICT1 at immunoprecipitating MRPs (Figure 1C).
Each cell line was induced to express either YaeJ or Pth4 and
the cell lysates were separated by isokinetic sucrose gradient (as
in Richter et al., 2010). In neither case did the expressed protein
migrate in fractions with the mt-LSU polypeptides (Figure1D).
Similar results were derived for mtRRF-FLAG (Rorbach et al.,
2008), supportive of an interaction with mitoribosome mediated
by transient A-site entry, akin toYaeJ interaction with the bacterial
ribosome (Figure 2; Gagnon et al., 2012; Kogure et al., 2014) rather
than mitoribosome integration. This suggests that these proteins
may take part in ribosome rescue but by different mechanisms.
The integration of ICT1 into the mitoribosome and the cryo-EM
data positioning it near the central protuberance would preclude
unrestricted access of the GGQ motif to the PTC (Greber et al.,
2013). This might indicate the pathway in which ICT1 is involved,
as without significant conformational changes in the mitoribo-
some it would not be able to exert PTH activity (Figure 2). Such
structural rearrangements of the 55S might potentially occur to
release tRNA from prematurely discharged peptidyl-tRNA com-
plexes, or if subunit dissociation occurs prior to release of the
peptide. Further data is required to confirm the substrate and
mechanism of ICT1 in the rescue of stalled translation in human
mitochondria.
DISCUSSION
This “perspective” aims to highlight how perplexing post-
transcriptional gene expression in mitochondria can be. Transla-
tion will not be an error free process but the exact nature of those
errors, have yet to be determined. Mitochondrial ribosomes from
different organisms can vary dramatically, and those in mammals
are currently the most significantly different from the norm. This
FIGURE 2 | Schematic of a composite ribosome to show relative
positions occupied by ICT1 andYaeJ.Truncated mRNA lacking an A-site
codon allows ingress of YaeJ such that the C-terminal α-helix aligns within
the mRNA entry channel in the small subunit (SSU). This positions the GGQ
motif at the peptidyl transferase centre (PTC) allowing cleavage of the ester
bond between the P-site tRNA and the truncated polypeptide (as described
in Kogure et al., 2014). The aborted product is then released via the
polypeptide exit site in the large subunit (LSU). ICT1 by contrast is located
at the central protuberance (CP) precluding its interaction with the nascent
peptide without a large scale conformational change of the ribosome (as
described in Greber et al., 2013).
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alone would be enough to stymie progress but the lack of a robust
transfection mechanism and the lack of a robust in vitro transla-
tion systemmakes study of mammalianmitochondrial translation
processes a technical quagmire.
Lessons that we learnt from bacterial studies are unfortunately
limited, as described above. Despite similarities between YaeJ and
ICT1 and their common divergence from standard RFs, we can-
not assume a similar mechanism using the bacterial paradigm, as
the integration of ICT1 into the mitoribosome excludes a sim-
ilar mechanism of action. Since bacteria have more than one
rescue pathway, it seems probable that mitochondria will too.
Thus far bioinformatics has narrowed the plausible candidates
for mitochondrial rescue factors to members of mitochondrial
RF family. In addition to ICT1, the feature conferring ribosome
dependent PTH activity, the GGQ motif, is present in mtRF1 and
C12orf65, neither of which have characterized functions. The lat-
ter shares sequence similarities with ICT1 (Kogure et al., 2012),
moreover, evidence for its importance comes from clinical data
where patients harboring mutations in C12orf65 manifest clear
defects in mt-protein synthesis (Antonicka et al., 2010; Shimazaki
et al., 2012; Spiegel et al., 2014). However, as discussed above,
sharing similarities is not sufficient to infer function and confirma-
tion of mtRF1 and C12orf65 as mitoribosome rescue factors will
require evidence of their direct involvement in relieving ribosome
stalling. This cannot be accomplished without initially develop-
ing a method to analyse stalled mammalian mitoribosomes. A
promising approach to allow precisely such analyses comes from
recent data using a patient cell line with a mutation inMT-TY, the
gene encoding mitochondrial tRNATrp. Greater accumulation of
mitoribosomes on Trp codons was detected, inferring mitoribo-
some arrest due to the shortage of the aminoacylated wild type
mt-tRNATrp (Rooijers et al., 2013). We are currently analysing
mitoribosome distribution in the absence of the potential res-
cue factors, to confirm whether or not they indeed play a role in
alleviating mitoribosome stalling.
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